,source,target,Unnamed: 0,value,type,source layer,target layer,normalized value,unique,fan_in,fan_out,fan_tot,nodes_in_SG,log(Nodes in SG),weighted_val_log
0,1433B,Activation of BH3-only proteins,3570.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
1,1433B,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,3608.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
2,1433B,FOXO-mediated transcription,3578.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
3,1433B,G2/M DNA damage checkpoint,3596.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
4,1433B,Paradoxical activation of RAF signaling by kinase inactive BRAF,3590.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
5,1433B,RAF/MAP kinase cascade,3580.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
6,1433B,RHO GTPase Effectors,3574.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
7,1433B,Rap1 signalling,3600.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
8,1433B,SARS-CoV-2 Infection,3598.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
9,1433B,Signaling by BRAF and RAF1 fusions,3588.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
10,1433B,Signaling by Hippo,3602.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
11,1433B,Signaling by MRAS-complex mutants,3594.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
12,1433B,Signaling by NTRK1 (TRKA),3572.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
13,1433B,Signaling by RAF1 mutants,3592.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
14,1433B,Signaling by RAS mutants,3582.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
15,1433B,Signaling by high-kinase activity BRAF mutants,3586.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
16,1433B,Signaling by moderate kinase activity BRAF mutants,3584.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
17,1433B,Transcriptional Regulation by TP53,3576.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
18,1433B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,3606.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
19,1433B,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",3610.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
20,1433B,mTORC1-mediated signalling,3604.5,0.0004945811008734,0.5,0.0,1.0,0.00027087584564434997,True,0,21,21,51,5.672425341971495,7.412313746882129e-05
21,1433E,Activation of BH3-only proteins,4106.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
22,1433E,Anchoring of the basal body to the plasma membrane,4134.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
23,1433E,"Cell death signalling via NRAGE, NRIF and NADE",4108.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
24,1433E,G2/M DNA damage checkpoint,4122.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
25,1433E,G2/M Transition,4118.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
26,1433E,HSF1 activation,4116.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
27,1433E,Mitotic Prometaphase,4120.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
28,1433E,Neurodegenerative Diseases,4124.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
29,1433E,RAB GEFs exchange GTP for GDP on RABs,4126.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
30,1433E,RHO GTPase Effectors,4110.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
31,1433E,Regulation of HSF1-mediated heat shock response,4114.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
32,1433E,SARS-CoV-2 Infection,4128.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
33,1433E,Signaling by Hippo,4130.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
34,1433E,Transcriptional Regulation by TP53,4112.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
35,1433E,Translocation of SLC2A4 (GLUT4) to the plasma membrane,4132.5,0.0086068667833063,0.5,0.0,1.0,0.0047138726371853505,True,0,15,15,47,5.554588851677638,0.0013131055170765417
36,1433F,Activation of BH3-only proteins,4532.5,0.0051724622995227,0.5,0.0,1.0,0.0028328925164596,True,0,6,6,25,4.643856189774724,0.0009164766297365844
37,1433F,G2/M DNA damage checkpoint,4538.5,0.0051724622995227,0.5,0.0,1.0,0.0028328925164596,True,0,6,6,25,4.643856189774724,0.0009164766297365844
38,1433F,RHO GTPase Effectors,4534.5,0.0051724622995227,0.5,0.0,1.0,0.0028328925164596,True,0,6,6,25,4.643856189774724,0.0009164766297365844
39,1433F,SARS-CoV-2 Infection,4540.5,0.0051724622995227,0.5,0.0,1.0,0.0028328925164596,True,0,6,6,25,4.643856189774724,0.0009164766297365844
40,1433F,Transcriptional Regulation by TP53,4536.5,0.0051724622995227,0.5,0.0,1.0,0.0028328925164596,True,0,6,6,25,4.643856189774724,0.0009164766297365844
41,1433F,Translocation of SLC2A4 (GLUT4) to the plasma membrane,4542.5,0.0051724622995227,0.5,0.0,1.0,0.0028328925164596,True,0,6,6,25,4.643856189774724,0.0009164766297365844
42,1433G,Activation of BH3-only proteins,4086.5,0.010821769167645299,0.5,0.0,1.0,0.005926946803015649,True,0,10,10,34,5.087462841250339,0.0017777142053852033
43,1433G,Anchoring of the basal body to the plasma membrane,4104.5,0.010821769167645299,0.5,0.0,1.0,0.005926946803015649,True,0,10,10,34,5.087462841250339,0.0017777142053852033
44,1433G,FOXO-mediated transcription,4092.5,0.010821769167645299,0.5,0.0,1.0,0.005926946803015649,True,0,10,10,34,5.087462841250339,0.0017777142053852033
45,1433G,G2/M DNA damage checkpoint,4098.5,0.010821769167645299,0.5,0.0,1.0,0.005926946803015649,True,0,10,10,34,5.087462841250339,0.0017777142053852033
46,1433G,G2/M Transition,4094.5,0.010821769167645299,0.5,0.0,1.0,0.005926946803015649,True,0,10,10,34,5.087462841250339,0.0017777142053852033
47,1433G,Mitotic Prometaphase,4096.5,0.010821769167645299,0.5,0.0,1.0,0.005926946803015649,True,0,10,10,34,5.087462841250339,0.0017777142053852033
48,1433G,RHO GTPase Effectors,4088.5,0.010821769167645299,0.5,0.0,1.0,0.005926946803015649,True,0,10,10,34,5.087462841250339,0.0017777142053852033
49,1433G,SARS-CoV-2 Infection,4100.5,0.010821769167645299,0.5,0.0,1.0,0.005926946803015649,True,0,10,10,34,5.087462841250339,0.0017777142053852033
50,1433G,Transcriptional Regulation by TP53,4090.5,0.010821769167645299,0.5,0.0,1.0,0.005926946803015649,True,0,10,10,34,5.087462841250339,0.0017777142053852033
51,1433G,Translocation of SLC2A4 (GLUT4) to the plasma membrane,4102.5,0.010821769167645299,0.5,0.0,1.0,0.005926946803015649,True,0,10,10,34,5.087462841250339,0.0017777142053852033
52,1433T,Activation of BH3-only proteins,3192.5,0.0049779659393006,0.5,0.0,1.0,0.0027263693073097,True,0,7,7,26,4.700439718141092,0.0008732599914106117
53,1433T,FOXO-mediated transcription,3198.5,0.0049779659393006,0.5,0.0,1.0,0.0027263693073097,True,0,7,7,26,4.700439718141092,0.0008732599914106117
54,1433T,G2/M DNA damage checkpoint,3200.5,0.0049779659393006,0.5,0.0,1.0,0.0027263693073097,True,0,7,7,26,4.700439718141092,0.0008732599914106117
55,1433T,RHO GTPase Effectors,3194.5,0.0049779659393006,0.5,0.0,1.0,0.0027263693073097,True,0,7,7,26,4.700439718141092,0.0008732599914106117
56,1433T,SARS-CoV-2 Infection,3202.5,0.0049779659393006,0.5,0.0,1.0,0.0027263693073097,True,0,7,7,26,4.700439718141092,0.0008732599914106117
57,1433T,Transcriptional Regulation by TP53,3196.5,0.0049779659393006,0.5,0.0,1.0,0.0027263693073097,True,0,7,7,26,4.700439718141092,0.0008732599914106117
58,1433T,Translocation of SLC2A4 (GLUT4) to the plasma membrane,3204.5,0.0049779659393006,0.5,0.0,1.0,0.0027263693073097,True,0,7,7,26,4.700439718141092,0.0008732599914106117
59,1433Z,Activation of BH3-only proteins,4266.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
60,1433Z,Deactivation of the beta-catenin transactivating complex,4270.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
61,1433Z,FOXO-mediated transcription,4274.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
62,1433Z,G2/M DNA damage checkpoint,4278.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
63,1433Z,GP1b-IX-V activation signalling,4292.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
64,1433Z,"Interleukin-3, Interleukin-5 and GM-CSF signaling",4276.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
65,1433Z,KSRP (KHSRP) binds and destabilizes mRNA,4290.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
66,1433Z,NOTCH4 Activation and Transmission of Signal to the Nucleus,4280.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
67,1433Z,Negative regulation of NOTCH4 signaling,4282.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
68,1433Z,RHO GTPase Effectors,4268.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
69,1433Z,Rap1 signalling,4286.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
70,1433Z,SARS-CoV-2 Infection,4284.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
71,1433Z,Transcriptional Regulation by TP53,4272.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
72,1433Z,Translocation of SLC2A4 (GLUT4) to the plasma membrane,4288.5,0.0034212978922820002,0.5,0.0,1.0,0.00187380180548035,True,0,14,14,45,5.491853096329675,0.0005270140654008812
73,4F2,Amino acid transport across the plasma membrane,2312.5,0.0038054514880797,0.5,0.0,1.0,0.00208419789610175,True,0,4,4,16,4.0,0.00076109029761594
74,4F2,Basigin interactions,2316.5,0.0038054514880797,0.5,0.0,1.0,0.00208419789610175,True,0,4,4,16,4.0,0.00076109029761594
75,4F2,Defective SLC7A7 causes lysinuric protein intolerance (LPI),2314.5,0.0038054514880797,0.5,0.0,1.0,0.00208419789610175,True,0,4,4,16,4.0,0.00076109029761594
76,4F2,Tryptophan catabolism,2318.5,0.0038054514880797,0.5,0.0,1.0,0.00208419789610175,True,0,4,4,16,4.0,0.00076109029761594
77,A1AG1,Neutrophil degranulation,1336.5,0.0023734829038278,0.5,0.0,1.0,0.00129992672093885,True,0,2,2,9,3.169925001442312,0.0005691907895242358
78,A1AG1,Platelet degranulation ,1334.5,0.0023734829038278,0.5,0.0,1.0,0.00129992672093885,True,0,2,2,9,3.169925001442312,0.0005691907895242358
79,A1AG2,Neutrophil degranulation,2878.5,0.0055065989947648,0.5,0.0,1.0,0.00301589498000835,True,0,2,2,9,3.169925001442312,0.0013205510873361397
80,A1AG2,Platelet degranulation ,2876.5,0.0055065989947648,0.5,0.0,1.0,0.00301589498000835,True,0,2,2,9,3.169925001442312,0.0013205510873361397
81,A1AT,COPII-mediated vesicle transport,260.5,0.005116449412906799,0.5,0.0,1.0,0.0028022149632690504,True,0,6,6,18,4.169925001442312,0.0009896564092282587
82,A1AT,Cargo concentration in the ER,262.5,0.005116449412906799,0.5,0.0,1.0,0.0028022149632690504,True,0,6,6,18,4.169925001442312,0.0009896564092282587
83,A1AT,Neutrophil degranulation,266.5,0.005116449412906799,0.5,0.0,1.0,0.0028022149632690504,True,0,6,6,18,4.169925001442312,0.0009896564092282587
84,A1AT,Platelet degranulation ,264.5,0.005116449412906799,0.5,0.0,1.0,0.0028022149632690504,True,0,6,6,18,4.169925001442312,0.0009896564092282587
85,A1AT,Post-translational protein phosphorylation,270.5,0.005116449412906799,0.5,0.0,1.0,0.0028022149632690504,True,0,6,6,18,4.169925001442312,0.0009896564092282587
86,A1AT,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),268.5,0.005116449412906799,0.5,0.0,1.0,0.0028022149632690504,True,0,6,6,18,4.169925001442312,0.0009896564092282587
87,A1BG,Neutrophil degranulation,1564.5,0.007801443415438,0.5,0.0,1.0,0.00427275239322985,True,0,2,2,9,3.169925001442312,0.0018708833882478946
88,A1BG,Platelet degranulation ,1562.5,0.007801443415438,0.5,0.0,1.0,0.00427275239322985,True,0,2,2,9,3.169925001442312,0.0018708833882478946
89,A2AP,Dissolution of Fibrin Clot,2422.5,0.0004141555595871,0.5,0.0,1.0,0.00022682778867475,True,0,2,2,7,2.807354922057604,0.00010877776515862052
90,A2AP,Platelet degranulation ,2420.5,0.0004141555595871,0.5,0.0,1.0,0.00022682778867475,True,0,2,2,7,2.807354922057604,0.00010877776515862052
91,A2GL,Neutrophil degranulation,1278.5,0.0014570354039073002,0.5,0.0,1.0,0.00079799995687285,True,0,1,1,5,2.321928094887362,0.00043861136132048166
92,A2MG,HDL assembly,288.5,0.0109732076100764,0.5,0.0,1.0,0.0060098877323882995,True,0,3,3,12,3.584962500721156,0.00239330367660596
93,A2MG,Intrinsic Pathway of Fibrin Clot Formation,290.5,0.0109732076100764,0.5,0.0,1.0,0.0060098877323882995,True,0,3,3,12,3.584962500721156,0.00239330367660596
94,A2MG,Platelet degranulation ,286.5,0.0109732076100764,0.5,0.0,1.0,0.0060098877323882995,True,0,3,3,12,3.584962500721156,0.00239330367660596
95,AACT,Neutrophil degranulation,274.5,0.0037265003157711998,0.5,0.0,1.0,0.00204095733246945,True,0,2,2,9,3.169925001442312,0.0008936612323920121
96,AACT,Platelet degranulation ,272.5,0.0037265003157711998,0.5,0.0,1.0,0.00204095733246945,True,0,2,2,9,3.169925001442312,0.0008936612323920121
97,AATC,Aspartate and asparagine metabolism,2822.5,0.0027993239371813,0.5,0.0,1.0,0.0015331544965574,True,0,3,3,10,3.321928094887362,0.0006477025706403512
98,AATC,Gluconeogenesis,2820.5,0.0027993239371813,0.5,0.0,1.0,0.0015331544965574,True,0,3,3,10,3.321928094887362,0.0006477025706403512
99,AATC,Methionine salvage pathway,2818.5,0.0027993239371813,0.5,0.0,1.0,0.0015331544965574,True,0,3,3,10,3.321928094887362,0.0006477025706403512
100,ABC transporter disorders,Disorders of transmembrane transporters,6422.5,0.00030133804793201546,0.5,2.0,3.0,0.0056814736845193,True,2,1,3,16,4.0,6.0267609586403095e-05
101,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,5912.5,0.0042069020690242,0.5,1.0,2.0,0.05264023795984515,False,2,2,4,5,2.321928094887362,0.0012664037115971485
102,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,6602.5,0.0032734612257622002,0.5,2.0,3.0,0.06171833905174505,True,2,2,4,5,2.321928094887362,0.0009854100185974057
103,ABC-family proteins mediated transport,Transport of small molecules,6732.5,0.0018049094437355999,0.5,3.0,4.0,0.061843530859182955,True,1,1,2,5,2.321928094887362,0.0005433318820216063
104,ACTA,NOTCH4 Intracellular Domain Regulates Transcription,4136.5,0.0082882082188145,0.5,0.0,1.0,0.00453934735108745,True,0,2,2,8,3.0,0.002072052054703625
105,ACTA,Smooth Muscle Contraction,4138.5,0.0082882082188145,0.5,0.0,1.0,0.00453934735108745,True,0,2,2,8,3.0,0.002072052054703625
106,ACTB,Adherens junctions interactions,3926.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
107,ACTB,B-WICH complex positively regulates rRNA expression,3928.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
108,ACTB,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,3924.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
109,ACTB,DNA Damage Recognition in GG-NER,3934.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
110,ACTB,EPH-Ephrin signaling,3920.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
111,ACTB,Gap junction trafficking,3910.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
112,ACTB,HATs acetylate histones,3952.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
113,ACTB,L1CAM interactions,3922.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
114,ACTB,Paradoxical activation of RAF signaling by kinase inactive BRAF,3944.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
115,ACTB,Parasite infection,3948.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
116,ACTB,RAF/MAP kinase cascade,3930.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
117,ACTB,RHO GTPase Effectors,3914.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
118,ACTB,RHO GTPase cycle,3916.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
119,ACTB,Regulation of actin dynamics for phagocytic cup formation,3918.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
120,ACTB,Sensory processing of sound by inner hair cells of the cochlea,3954.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
121,ACTB,Sensory processing of sound by outer hair cells of the cochlea,3956.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
122,ACTB,Signaling by BRAF and RAF1 fusions,3942.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
123,ACTB,Signaling by RAF1 mutants,3946.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
124,ACTB,Signaling by RAS mutants,3936.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
125,ACTB,Signaling by high-kinase activity BRAF mutants,3940.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
126,ACTB,Signaling by moderate kinase activity BRAF mutants,3938.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
127,ACTB,Translocation of SLC2A4 (GLUT4) to the plasma membrane,3950.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
128,ACTB,UCH proteinases,3932.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
129,ACTB,VEGFA-VEGFR2 Pathway,3912.5,0.0481663808605488,0.5,0.0,1.0,0.0263801207207214,True,0,24,24,65,6.022367813028454,0.006858994308328126
130,ACTN1,Nephrin family interactions,2636.5,0.0061296420266406006,0.5,0.0,1.0,0.0033571278088288,True,0,5,5,18,4.169925001442312,0.0011856346126743705
131,ACTN1,Platelet degranulation ,2634.5,0.0061296420266406006,0.5,0.0,1.0,0.0033571278088288,True,0,5,5,18,4.169925001442312,0.0011856346126743705
132,ACTN1,RHO GTPase cycle,2630.5,0.0061296420266406006,0.5,0.0,1.0,0.0033571278088288,True,0,5,5,18,4.169925001442312,0.0011856346126743705
133,ACTN1,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,2632.5,0.0061296420266406006,0.5,0.0,1.0,0.0033571278088288,True,0,5,5,18,4.169925001442312,0.0011856346126743705
134,ACTN1,Syndecan interactions,2638.5,0.0061296420266406006,0.5,0.0,1.0,0.0033571278088288,True,0,5,5,18,4.169925001442312,0.0011856346126743705
135,ACTN4,Nephrin family interactions,72.5,0.0015361491240753,0.5,0.0,1.0,0.0008413295459225,True,0,2,2,8,3.0,0.000384037281018825
136,ACTN4,Platelet degranulation ,70.5,0.0015361491240753,0.5,0.0,1.0,0.0008413295459225,True,0,2,2,8,3.0,0.000384037281018825
137,ACY1,Aflatoxin activation and detoxification,4520.5,0.0006034456578647,0.5,0.0,1.0,0.00033049959366795,True,0,3,3,11,3.4594316186372973,0.00013531896202707096
138,ACY1,Defective ACY1 causes encephalopathy,4518.5,0.0006034456578647,0.5,0.0,1.0,0.00033049959366795,True,0,3,3,11,3.4594316186372973,0.00013531896202707096
139,ACY1,Paracetamol ADME,4522.5,0.0006034456578647,0.5,0.0,1.0,0.00033049959366795,True,0,3,3,11,3.4594316186372973,0.00013531896202707096
140,ADH1A,Abacavir metabolism,2094.5,0.023454085746449,0.5,0.0,1.0,0.0128455076410411,True,0,3,3,13,3.700439718141092,0.00498976418225921
141,ADH1A,Ethanol oxidation,2090.5,0.023454085746449,0.5,0.0,1.0,0.0128455076410411,True,0,3,3,13,3.700439718141092,0.00498976418225921
142,ADH1A,RA biosynthesis pathway,2092.5,0.023454085746449,0.5,0.0,1.0,0.0128455076410411,True,0,3,3,13,3.700439718141092,0.00498976418225921
143,ADH1B,Ethanol oxidation,112.5,0.00020158609200027604,0.5,0.0,1.0,0.00011040616603481478,True,0,1,1,6,2.584962500721156,5.6231018304856665e-05
144,ADIPO,AMPK inhibits chREBP transcriptional activation activity,4752.5,0.0014008704559810002,0.5,0.0,1.0,0.00076723912161605,True,0,2,2,7,2.807354922057604,0.000367937973910751
145,ADIPO,Transcriptional regulation of white adipocyte differentiation,4750.5,0.0014008704559810002,0.5,0.0,1.0,0.00076723912161605,True,0,2,2,7,2.807354922057604,0.000367937973910751
146,AK1C1,Bile acid and bile salt metabolism,4528.5,0.0021543719074192,0.5,0.0,1.0,0.0011799223852751,True,0,2,2,11,3.4594316186372973,0.00048310459530659383
147,AK1C1,Retinoid metabolism and transport,4530.5,0.0021543719074192,0.5,0.0,1.0,0.0011799223852751,True,0,2,2,11,3.4594316186372973,0.00048310459530659383
148,AL1A1,Ethanol oxidation,116.5,0.0035044206295996,0.5,0.0,1.0,0.00191932708277745,True,0,3,3,13,3.700439718141092,0.0007455516589383071
149,AL1A1,Fructose catabolism,120.5,0.0035044206295996,0.5,0.0,1.0,0.00191932708277745,True,0,3,3,13,3.700439718141092,0.0007455516589383071
150,AL1A1,RA biosynthesis pathway,118.5,0.0035044206295996,0.5,0.0,1.0,0.00191932708277745,True,0,3,3,13,3.700439718141092,0.0007455516589383071
151,ALAT1,Alanine metabolism,2972.5,0.0012676362536237,0.5,0.0,1.0,0.0006942684254682,True,0,1,1,5,2.321928094887362,0.00038159653593184783
152,ALBU,Aspirin ADME,1374.5,0.007520769170743,0.5,0.0,1.0,0.0041190306411288,True,0,10,10,30,4.906890595608519,0.0012732196489866124
153,ALBU,Bile acid and bile salt metabolism,1356.5,0.007520769170743,0.5,0.0,1.0,0.0041190306411288,True,0,10,10,30,4.906890595608519,0.0012732196489866124
154,ALBU,Cytoprotection by HMOX1,1362.5,0.007520769170743,0.5,0.0,1.0,0.0041190306411288,True,0,10,10,30,4.906890595608519,0.0012732196489866124
155,ALBU,HDL remodeling,1360.5,0.007520769170743,0.5,0.0,1.0,0.0041190306411288,True,0,10,10,30,4.906890595608519,0.0012732196489866124
156,ALBU,Heme biosynthesis,1364.5,0.007520769170743,0.5,0.0,1.0,0.0041190306411288,True,0,10,10,30,4.906890595608519,0.0012732196489866124
157,ALBU,Heme degradation,1366.5,0.007520769170743,0.5,0.0,1.0,0.0041190306411288,True,0,10,10,30,4.906890595608519,0.0012732196489866124
158,ALBU,Platelet degranulation ,1358.5,0.007520769170743,0.5,0.0,1.0,0.0041190306411288,True,0,10,10,30,4.906890595608519,0.0012732196489866124
159,ALBU,Post-translational protein phosphorylation,1372.5,0.007520769170743,0.5,0.0,1.0,0.0041190306411288,True,0,10,10,30,4.906890595608519,0.0012732196489866124
160,ALBU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1370.5,0.007520769170743,0.5,0.0,1.0,0.0041190306411288,True,0,10,10,30,4.906890595608519,0.0012732196489866124
161,ALBU,Scavenging of heme from plasma,1368.5,0.007520769170743,0.5,0.0,1.0,0.0041190306411288,True,0,10,10,30,4.906890595608519,0.0012732196489866124
162,ALDH2,Ethanol oxidation,1774.5,0.00194336911478,0.5,0.0,1.0,0.0010643588107905,True,0,3,3,12,3.584962500721156,0.00042385714484564116
163,ALDH2,Serotonin clearance from the synaptic cleft,1772.5,0.00194336911478,0.5,0.0,1.0,0.0010643588107905,True,0,3,3,12,3.584962500721156,0.00042385714484564116
164,ALDH2,Smooth Muscle Contraction,1776.5,0.00194336911478,0.5,0.0,1.0,0.0010643588107905,True,0,3,3,12,3.584962500721156,0.00042385714484564116
165,ALDOA,Gluconeogenesis,1472.5,0.0065313996083804,0.5,0.0,1.0,0.0035771653810401,True,0,4,4,14,3.807354922057604,0.0013586264618017604
166,ALDOA,Glycolysis,1470.5,0.0065313996083804,0.5,0.0,1.0,0.0035771653810401,True,0,4,4,14,3.807354922057604,0.0013586264618017604
167,ALDOA,Neutrophil degranulation,1476.5,0.0065313996083804,0.5,0.0,1.0,0.0035771653810401,True,0,4,4,14,3.807354922057604,0.0013586264618017604
168,ALDOA,Platelet degranulation ,1474.5,0.0065313996083804,0.5,0.0,1.0,0.0035771653810401,True,0,4,4,14,3.807354922057604,0.0013586264618017604
169,ALDOB,Fructose catabolism,1760.5,0.012226286363435701,0.5,0.0,1.0,0.00669618319813845,True,0,4,4,13,3.700439718141092,0.0026010941734342452
170,ALDOB,Gluconeogenesis,1766.5,0.012226286363435701,0.5,0.0,1.0,0.00669618319813845,True,0,4,4,13,3.700439718141092,0.0026010941734342452
171,ALDOB,Glycolysis,1764.5,0.012226286363435701,0.5,0.0,1.0,0.00669618319813845,True,0,4,4,13,3.700439718141092,0.0026010941734342452
172,ALDOB,Hereditary fructose intolerance,1762.5,0.012226286363435701,0.5,0.0,1.0,0.00669618319813845,True,0,4,4,13,3.700439718141092,0.0026010941734342452
173,ALK mutants bind TKIs,Signaling by ALK in cancer,5752.5,1.6029557772753002e-06,0.5,1.0,2.0,2.005750839226237e-05,True,1,1,2,6,2.584962500721156,4.471332062616687e-07
174,ALS,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),3688.5,0.0058277652622305,0.5,0.0,1.0,0.00319179370347065,True,0,1,1,4,2.0,0.0019425884207435
175,AMBP,Scavenging of heme from plasma,1332.5,0.0016375013210886001,0.5,0.0,1.0,0.0008968388689140001,True,0,1,1,5,2.321928094887362,0.0004929370155870648
176,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,5828.5,0.00037395964539614624,0.5,1.0,2.0,0.004679292362420149,False,2,2,4,5,2.321928094887362,0.00011257307043210585
177,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,6598.5,0.0002413404087535,0.5,2.0,3.0,0.00455026901101235,True,2,2,4,5,2.321928094887362,7.265070220060955e-05
178,AMPN,Metabolism of Angiotensinogen to Angiotensins,2744.5,0.0005500541730706001,0.5,0.0,1.0,0.0003012577492702,True,0,2,2,8,3.0,0.00013751354326765002
179,AMPN,Neutrophil degranulation,2742.5,0.0005500541730706001,0.5,0.0,1.0,0.0003012577492702,True,0,2,2,8,3.0,0.00013751354326765002
180,ANGI,Adherens junctions interactions,1424.5,0.0013438970485745,0.5,0.0,1.0,0.0007360355032747499,True,0,2,2,9,3.169925001442312,0.0003222832660322828
181,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",1426.5,0.0013438970485745,0.5,0.0,1.0,0.0007360355032747499,True,0,2,2,9,3.169925001442312,0.0003222832660322828
182,ANGT,Class A/1 (Rhodopsin-like receptors),276.5,0.011125804771058501,0.5,0.0,1.0,0.0060934632773312,True,0,5,5,16,4.0,0.0022251609542117004
183,ANGT,G alpha (i) signalling events,280.5,0.011125804771058501,0.5,0.0,1.0,0.0060934632773312,True,0,5,5,16,4.0,0.0022251609542117004
184,ANGT,G alpha (q) signalling events,278.5,0.011125804771058501,0.5,0.0,1.0,0.0060934632773312,True,0,5,5,16,4.0,0.0022251609542117004
185,ANGT,Metabolism of Angiotensinogen to Angiotensins,284.5,0.011125804771058501,0.5,0.0,1.0,0.0060934632773312,True,0,5,5,16,4.0,0.0022251609542117004
186,ANGT,PPARA activates gene expression,282.5,0.011125804771058501,0.5,0.0,1.0,0.0060934632773312,True,0,5,5,16,4.0,0.0022251609542117004
187,ANT3,Common Pathway of Fibrin Clot Formation,254.5,0.0304123568268809,0.5,0.0,1.0,0.01665646515600865,True,0,4,4,10,3.321928094887362,0.007036756780580707
188,ANT3,Intrinsic Pathway of Fibrin Clot Formation,252.5,0.0304123568268809,0.5,0.0,1.0,0.01665646515600865,True,0,4,4,10,3.321928094887362,0.007036756780580707
189,ANT3,Post-translational protein phosphorylation,258.5,0.0304123568268809,0.5,0.0,1.0,0.01665646515600865,True,0,4,4,10,3.321928094887362,0.007036756780580707
190,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),256.5,0.0304123568268809,0.5,0.0,1.0,0.01665646515600865,True,0,4,4,10,3.321928094887362,0.007036756780580707
191,APC/C-mediated degradation of cell cycle proteins,Regulation of mitotic cell cycle,5286.5,0.0010304739535289,0.5,1.0,2.0,0.01289414234873475,True,9,1,10,14,3.807354922057604,0.00021435362485943625
192,APOA,LDL remodeling,2382.5,0.0009255574499644999,0.5,0.0,1.0,0.0005069161690748,True,0,1,1,6,2.584962500721156,0.00025817772146244583
193,APOA1,ABC transporters in lipid homeostasis,1060.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
194,APOA1,Amyloid fiber formation,1064.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
195,APOA1,Chylomicron assembly,1040.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
196,APOA1,Chylomicron remodeling,1044.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
197,APOA1,Defective ABCA1 causes TGD,1036.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
198,APOA1,HDL assembly,1042.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
199,APOA1,HDL clearance,1048.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
200,APOA1,HDL remodeling,1046.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
201,APOA1,Heme signaling,1058.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
202,APOA1,PPARA activates gene expression,1034.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
203,APOA1,Platelet degranulation ,1038.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
204,APOA1,Post-translational protein phosphorylation,1066.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
205,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1062.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
206,APOA1,Retinoid metabolism and transport,1056.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
207,APOA1,Scavenging by Class A Receptors,1054.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
208,APOA1,Scavenging by Class B Receptors,1052.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
209,APOA1,Scavenging of heme from plasma,1050.5,0.0475390154997471,0.5,0.0,1.0,0.026036520606736002,True,0,17,17,44,5.459431618637297,0.007359628262428465
210,APOA2,Chylomicron assembly,1094.5,0.0111271724422225,0.5,0.0,1.0,0.00609421233361835,True,0,6,6,21,4.392317422778761,0.002063523262784568
211,APOA2,Chylomicron remodeling,1096.5,0.0111271724422225,0.5,0.0,1.0,0.00609421233361835,True,0,6,6,21,4.392317422778761,0.002063523262784568
212,APOA2,PPARA activates gene expression,1092.5,0.0111271724422225,0.5,0.0,1.0,0.00609421233361835,True,0,6,6,21,4.392317422778761,0.002063523262784568
213,APOA2,Post-translational protein phosphorylation,1102.5,0.0111271724422225,0.5,0.0,1.0,0.00609421233361835,True,0,6,6,21,4.392317422778761,0.002063523262784568
214,APOA2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1100.5,0.0111271724422225,0.5,0.0,1.0,0.00609421233361835,True,0,6,6,21,4.392317422778761,0.002063523262784568
215,APOA2,Retinoid metabolism and transport,1098.5,0.0111271724422225,0.5,0.0,1.0,0.00609421233361835,True,0,6,6,21,4.392317422778761,0.002063523262784568
216,APOA4,Amyloid fiber formation,2026.5,0.0420469347883424,0.5,0.0,1.0,0.0230285771078408,True,0,5,5,17,4.087462841250339,0.008264814132383634
217,APOA4,Assembly of active LPL and LIPC lipase complexes,2020.5,0.0420469347883424,0.5,0.0,1.0,0.0230285771078408,True,0,5,5,17,4.087462841250339,0.008264814132383634
218,APOA4,Chylomicron assembly,2018.5,0.0420469347883424,0.5,0.0,1.0,0.0230285771078408,True,0,5,5,17,4.087462841250339,0.008264814132383634
219,APOA4,Chylomicron remodeling,2022.5,0.0420469347883424,0.5,0.0,1.0,0.0230285771078408,True,0,5,5,17,4.087462841250339,0.008264814132383634
220,APOA4,Retinoid metabolism and transport,2024.5,0.0420469347883424,0.5,0.0,1.0,0.0230285771078408,True,0,5,5,17,4.087462841250339,0.008264814132383634
221,APOB,Cargo recognition for clathrin-mediated endocytosis,1480.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
222,APOB,Chylomicron assembly,1484.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
223,APOB,Chylomicron clearance,1490.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
224,APOB,Chylomicron remodeling,1486.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
225,APOB,Heme signaling,1506.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
226,APOB,LDL clearance,1492.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
227,APOB,LDL remodeling,1488.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
228,APOB,Platelet sensitization by LDL,1510.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
229,APOB,Post-translational protein phosphorylation,1512.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
230,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1508.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
231,APOB,Regulation of TLR by endogenous ligand,1478.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
232,APOB,Retinoid metabolism and transport,1504.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
233,APOB,Scavenging by Class A Receptors,1498.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
234,APOB,Scavenging by Class B Receptors,1496.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
235,APOB,Scavenging by Class F Receptors,1500.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
236,APOB,Scavenging by Class H Receptors,1502.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
237,APOB,VLDL assembly,1482.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
238,APOB,VLDL clearance,1494.5,0.0786938387797176,0.5,0.0,1.0,0.04309962529666135,True,0,18,18,43,5.426264754702098,0.012245657747315394
239,APOC1,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,1108.5,0.010140408544702401,0.5,0.0,1.0,0.0055537741633768,True,0,3,3,12,3.584962500721156,0.0022116666260863518
240,APOC1,VLDL assembly,1104.5,0.010140408544702401,0.5,0.0,1.0,0.0055537741633768,True,0,3,3,12,3.584962500721156,0.0022116666260863518
241,APOC1,VLDL clearance,1106.5,0.010140408544702401,0.5,0.0,1.0,0.0055537741633768,True,0,3,3,12,3.584962500721156,0.0022116666260863518
242,APOC2,Assembly of active LPL and LIPC lipase complexes,1112.5,0.0135029614206599,0.5,0.0,1.0,0.00739540206260355,True,0,6,6,20,4.321928094887363,0.0025372310899186784
243,APOC2,Chylomicron assembly,1110.5,0.0135029614206599,0.5,0.0,1.0,0.00739540206260355,True,0,6,6,20,4.321928094887363,0.0025372310899186784
244,APOC2,Chylomicron remodeling,1114.5,0.0135029614206599,0.5,0.0,1.0,0.00739540206260355,True,0,6,6,20,4.321928094887363,0.0025372310899186784
245,APOC2,HDL remodeling,1116.5,0.0135029614206599,0.5,0.0,1.0,0.00739540206260355,True,0,6,6,20,4.321928094887363,0.0025372310899186784
246,APOC2,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,1118.5,0.0135029614206599,0.5,0.0,1.0,0.00739540206260355,True,0,6,6,20,4.321928094887363,0.0025372310899186784
247,APOC2,Retinoid metabolism and transport,1120.5,0.0135029614206599,0.5,0.0,1.0,0.00739540206260355,True,0,6,6,20,4.321928094887363,0.0025372310899186784
248,APOC3,Chylomicron assembly,1122.5,0.0137554408134021,0.5,0.0,1.0,0.0075336818490654,True,0,4,4,15,3.9068905956085187,0.0028032907083179515
249,APOC3,Chylomicron remodeling,1124.5,0.0137554408134021,0.5,0.0,1.0,0.0075336818490654,True,0,4,4,15,3.9068905956085187,0.0028032907083179515
250,APOC3,HDL remodeling,1126.5,0.0137554408134021,0.5,0.0,1.0,0.0075336818490654,True,0,4,4,15,3.9068905956085187,0.0028032907083179515
251,APOC3,Retinoid metabolism and transport,1128.5,0.0137554408134021,0.5,0.0,1.0,0.0075336818490654,True,0,4,4,15,3.9068905956085187,0.0028032907083179515
252,APOD,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,1770.5,0.0020807893955939,0.5,0.0,1.0,0.0011396221694357,True,0,2,2,10,3.321928094887362,0.0004814493323142919
253,APOD,Transport of fatty acids,1768.5,0.0020807893955939,0.5,0.0,1.0,0.0011396221694357,True,0,2,2,10,3.321928094887362,0.0004814493323142919
254,APOE,Amyloid fiber formation,1088.5,0.009786750633534801,0.5,0.0,1.0,0.0053600801755007005,True,0,12,12,36,5.169925001442312,0.0015862025277855083
255,APOE,Chylomicron assembly,1072.5,0.009786750633534801,0.5,0.0,1.0,0.0053600801755007005,True,0,12,12,36,5.169925001442312,0.0015862025277855083
256,APOE,Chylomicron clearance,1078.5,0.009786750633534801,0.5,0.0,1.0,0.0053600801755007005,True,0,12,12,36,5.169925001442312,0.0015862025277855083
257,APOE,Chylomicron remodeling,1074.5,0.009786750633534801,0.5,0.0,1.0,0.0053600801755007005,True,0,12,12,36,5.169925001442312,0.0015862025277855083
258,APOE,HDL remodeling,1076.5,0.009786750633534801,0.5,0.0,1.0,0.0053600801755007005,True,0,12,12,36,5.169925001442312,0.0015862025277855083
259,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,1080.5,0.009786750633534801,0.5,0.0,1.0,0.0053600801755007005,True,0,12,12,36,5.169925001442312,0.0015862025277855083
260,APOE,Nuclear signaling by ERBB4,1068.5,0.009786750633534801,0.5,0.0,1.0,0.0053600801755007005,True,0,12,12,36,5.169925001442312,0.0015862025277855083
261,APOE,Post-translational protein phosphorylation,1090.5,0.009786750633534801,0.5,0.0,1.0,0.0053600801755007005,True,0,12,12,36,5.169925001442312,0.0015862025277855083
262,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1086.5,0.009786750633534801,0.5,0.0,1.0,0.0053600801755007005,True,0,12,12,36,5.169925001442312,0.0015862025277855083
263,APOE,Retinoid metabolism and transport,1084.5,0.009786750633534801,0.5,0.0,1.0,0.0053600801755007005,True,0,12,12,36,5.169925001442312,0.0015862025277855083
264,APOE,Scavenging by Class A Receptors,1082.5,0.009786750633534801,0.5,0.0,1.0,0.0053600801755007005,True,0,12,12,36,5.169925001442312,0.0015862025277855083
265,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,1070.5,0.009786750633534801,0.5,0.0,1.0,0.0053600801755007005,True,0,12,12,36,5.169925001442312,0.0015862025277855083
266,APOF,LDL remodeling,4676.5,0.0003150848783678,0.5,0.0,1.0,0.00017256802317535,True,0,1,1,6,2.584962500721156,8.78907041020421e-05
267,APOH,Platelet degranulation ,1276.5,0.0053432413938002,0.5,0.0,1.0,0.0029264260774854002,True,0,1,1,6,2.584962500721156,0.0014904594937116765
268,APOL1,Post-translational protein phosphorylation,60.5,0.0064125699916242,0.5,0.0,1.0,0.00351208389517335,True,0,3,3,9,3.169925001442312,0.0015378142267321816
269,APOL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),58.5,0.0064125699916242,0.5,0.0,1.0,0.00351208389517335,True,0,3,3,9,3.169925001442312,0.0015378142267321816
270,APOL1,Scavenging of heme from plasma,56.5,0.0064125699916242,0.5,0.0,1.0,0.00351208389517335,True,0,3,3,9,3.169925001442312,0.0015378142267321816
271,APOM,Retinoid metabolism and transport,92.5,0.0091293472602129,0.5,0.0,1.0,0.0050000286200257,True,0,1,1,8,3.0,0.002282336815053225
272,ARLY,Urea cycle,1606.5,0.0013760947750149,0.5,0.0,1.0,0.00075366979290275,True,0,1,1,5,2.321928094887362,0.0004142458041559625
273,ARPC3,EPH-Ephrin signaling,66.5,0.0006057698207888,0.5,0.0,1.0,0.0003317725084566,True,0,4,4,18,4.169925001442312,0.00011717187785505623
274,ARPC3,Parasite infection,68.5,0.0006057698207888,0.5,0.0,1.0,0.0003317725084566,True,0,4,4,18,4.169925001442312,0.00011717187785505623
275,ARPC3,RHO GTPase Effectors,62.5,0.0006057698207888,0.5,0.0,1.0,0.0003317725084566,True,0,4,4,18,4.169925001442312,0.00011717187785505623
276,ARPC3,Regulation of actin dynamics for phagocytic cup formation,64.5,0.0006057698207888,0.5,0.0,1.0,0.0003317725084566,True,0,4,4,18,4.169925001442312,0.00011717187785505623
277,ASSY,Urea cycle,250.5,0.0001574678333800243,0.5,0.0,1.0,8.624315092765133e-05,True,0,1,1,5,2.321928094887362,4.7402541199605236e-05
278,ATF6 (ATF6-alpha) activates chaperones,Unfolded Protein Response (UPR),5434.5,0.0074033305036578,0.5,1.0,2.0,0.09263659410505826,True,3,1,4,8,3.0,0.00185083262591445
279,AUF1 (hnRNP D0) binds and destabilizes mRNA,AUF1 (hnRNP D0) binds and destabilizes mRNA,5934.5,0.0040020787208691,0.5,1.0,2.0,0.050077318830824946,False,11,2,13,14,3.807354922057604,0.0008324907949913054
280,AUF1 (hnRNP D0) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,6364.5,0.0038773102485068,0.5,2.0,3.0,0.0731034009637406,True,11,2,13,14,3.807354922057604,0.000806537131410149
281,Abacavir ADME,Drug ADME,6688.5,0.0056508391162469005,0.5,3.0,4.0,0.19362070738717063,True,1,1,2,5,2.321928094887362,0.00170107207466166
282,Abacavir metabolism,Abacavir ADME,6050.5,0.0063386700150963,0.5,2.0,3.0,0.11951025478780405,True,2,2,4,5,2.321928094887362,0.001908129807159847
283,Abacavir metabolism,Abacavir metabolism,5866.5,0.0079461986711366,0.5,1.0,2.0,0.09942940958971655,False,2,2,4,5,2.321928094887362,0.0023920441515173836
284,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,5956.5,0.0028660928245177,0.5,1.0,2.0,0.0358629237910004,False,2,2,4,5,2.321928094887362,0.0008627799105371309
285,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Diseases of metabolism,6408.5,0.0024340063700483998,0.5,2.0,3.0,0.04589112869842605,True,2,2,4,5,2.321928094887362,0.0007327089270217724
286,Activation of BH3-only proteins,Intrinsic Pathway for Apoptosis,5156.5,0.0018522902557314,0.5,1.0,2.0,0.023177387596051098,True,6,1,7,11,3.4594316186372973,0.0004153646505061599
287,Activation of C3 and C5,Complement cascade,5250.5,0.0018379815840854,0.5,1.0,2.0,0.02299834566258655,True,7,1,8,12,3.584962500721156,0.00040087167207939194
288,Activation of HOX genes during differentiation,Developmental Biology,6660.5,0.002705368845071,0.5,3.0,4.0,0.0926969285003783,True,1,1,2,7,2.807354922057604,0.0007105638692620074
289,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,5798.5,0.0019942445005284,0.5,1.0,2.0,0.024953636508652698,False,13,2,15,16,4.0,0.00039884890010568003
290,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,6130.5,0.0020666698865631,0.5,2.0,3.0,0.0389653104069494,True,13,2,15,16,4.0,0.00041333397731262
291,Activation of NMDA receptors and postsynaptic events,Neurotransmitter receptors and postsynaptic signal transmission,5164.5,0.0061118150620246,0.5,1.0,2.0,0.0764760847656639,True,5,1,6,10,3.321928094887362,0.0014141408482141549
292,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of HOX genes during differentiation,6118.5,0.0034403913842896,0.5,2.0,3.0,0.0648656658142788,True,4,2,6,7,2.807354922057604,0.00090361719742963
293,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of anterior HOX genes in hindbrain development during early embryogenesis,5952.5,0.0031863993434424,0.5,1.0,2.0,0.0398708638617794,False,4,2,6,7,2.807354922057604,0.0008369063059979651
294,Adaptive Immune System,Immune System,6826.5,0.0056091838852096,0.5,3.0,4.0,0.19219342992732646,True,6,1,7,89,6.475733430966398,0.0007503188733261846
295,Adherens junctions interactions,Cell-cell junction organization,5456.5,0.0058124744766965,0.5,1.0,2.0,0.07273048779569115,True,5,1,6,10,3.321928094887362,0.0013448799584547427
296,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,5836.5,0.0001314375012097414,0.5,1.0,2.0,0.0016446547190799498,False,4,2,6,7,2.807354922057604,3.452199857918914e-05
297,Advanced glycosylation endproduct receptor signaling,Innate Immune System,6286.5,0.0002347076928772,0.5,2.0,3.0,0.00442521477054545,True,4,2,6,7,2.807354922057604,6.1645866403849e-05
298,Aflatoxin activation and detoxification,Aflatoxin activation and detoxification,5860.5,0.0012071509390528998,0.5,1.0,2.0,0.015104870910375351,False,2,2,4,5,2.321928094887362,0.0003633886419488653
299,Aflatoxin activation and detoxification,Biological oxidations,6134.5,0.0007702939963628,0.5,2.0,3.0,0.014523240923979951,True,2,2,4,5,2.321928094887362,0.00023188159838508445
300,Aggrephagy,Selective autophagy,5744.5,0.0006815222146456001,0.5,1.0,2.0,0.0085277695951192,True,7,1,8,12,3.584962500721156,0.00014864292009769009
301,Alanine metabolism,Alanine metabolism,5992.5,0.0010052494693494,0.5,1.0,2.0,0.0125785127410492,False,2,2,4,5,2.321928094887362,0.0003026102433994693
302,Alanine metabolism,Metabolism of amino acids and derivatives,6348.5,0.0003783391491986,0.5,2.0,3.0,0.0071332642351228,True,2,2,4,5,2.321928094887362,0.00011389143244276889
303,Amino acid transport across the plasma membrane,Transport of inorganic cations/anions and amino acids/oligopeptides,5464.5,0.0006448642711132,0.5,1.0,2.0,0.008069075088092199,True,1,1,2,6,2.584962500721156,0.0001798803393294848
304,Amyloid fiber formation,Amyloid fiber formation,6186.5,0.01998835577412275,0.5,1.5,2.5,0.3070510696316426,False,18,2,20,20,4.321928094887363,0.0037558485228924915
305,Amyloid fiber formation,Metabolism of proteins,6758.5,0.0114428975189391,0.5,3.0,4.0,0.3920801612995449,True,18,2,20,20,4.321928094887363,0.0021501413237679768
306,Anchoring fibril formation,Assembly of collagen fibrils and other multimeric structures,5336.5,0.0020095263193517,0.5,1.0,2.0,0.0251448552644312,True,2,1,3,7,2.807354922057604,0.0005278011534227268
307,Anchoring of the basal body to the plasma membrane,Anchoring of the basal body to the plasma membrane,5948.5,0.0010727884043672,0.5,1.0,2.0,0.01342361575332645,False,7,2,9,10,3.321928094887362,0.0002482198641009919
308,Anchoring of the basal body to the plasma membrane,Cilium Assembly,6162.5,0.0005416000757328,0.5,2.0,3.0,0.0102114107359706,True,7,2,9,10,3.321928094887362,0.00012531445777024552
309,Antagonism of Activin by Follistatin,Signaling by Activin,5202.5,0.00012788887649115024,0.5,1.0,2.0,0.0016002513917498002,True,1,1,2,6,2.584962500721156,3.567369992445498e-05
310,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",Class I MHC mediated antigen processing & presentation,5764.5,0.0035841201304206,0.5,1.0,2.0,0.0448474752790664,True,6,1,7,11,3.4594316186372973,0.0008037168045007106
311,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),5768.5,0.004237079365025,0.5,1.0,2.0,0.05301784124520875,True,28,1,29,33,5.044394119358453,0.000700993231307478
312,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,5194.5,0.007753464359855499,0.5,1.0,2.0,0.09701775848817029,True,22,1,23,27,4.754887502163468,0.001347283392931781
313,Antigen processing: Ubiquitination & Proteasome degradation,Class I MHC mediated antigen processing & presentation,5762.5,6.950081163756692e-05,0.5,1.0,2.0,0.0008696516350931501,True,10,1,11,15,3.9068905956085187,1.4163921180506352e-05
314,Antimicrobial peptides,Innate Immune System,6550.5,0.005560427591746299,0.5,2.0,3.0,0.10483715300466764,True,2,1,3,13,3.700439718141092,0.001182959026213256
315,Antiviral mechanism by IFN-stimulated genes,Interferon Signaling,5168.5,0.00020558317094020184,0.5,1.0,2.0,0.0025724266601109,True,2,1,3,7,2.807354922057604,5.399632425891589e-05
316,Apoptosis,Programmed Cell Death,6682.5,0.0107887400719596,0.5,3.0,4.0,0.36966606933529145,True,4,1,5,28,4.807354922057604,0.0018577717767828527
317,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,5158.5,0.0022691233848974,0.5,1.0,2.0,0.028393148445445097,True,1,1,2,6,2.584962500721156,0.0006329559610291432
318,Apoptotic execution phase,Apoptosis,6290.5,0.002332834129805,0.5,2.0,3.0,0.0439836117934361,True,1,1,2,6,2.584962500721156,0.0006507276238832968
319,Arachidonic acid metabolism,Fatty acid metabolism,5372.5,0.0008899440725462001,0.5,1.0,2.0,0.0111357162541837,True,4,1,5,9,3.169925001442312,0.00021341968314499235
320,Aryl hydrocarbon receptor signalling,Phase I - Functionalization of compounds,5354.5,9.011274721673045e-06,0.5,1.0,2.0,0.00011275652199348782,True,1,1,2,6,2.584962500721156,2.5136315149350445e-06
321,Asparagine N-linked glycosylation,Post-translational protein modification,6484.5,0.007198499277115701,0.5,2.0,3.0,0.13572160731652316,True,1,1,2,9,3.169925001442312,0.0017262898672340274
322,Aspartate and asparagine metabolism,Aspartate and asparagine metabolism,5988.5,0.0009126242398936,0.5,1.0,2.0,0.011419509265416902,False,2,2,4,5,2.321928094887362,0.00027472727097801455
323,Aspartate and asparagine metabolism,Metabolism of amino acids and derivatives,6152.5,0.0003192071754032,0.5,2.0,3.0,0.0060183809492652,True,2,2,4,5,2.321928094887362,9.609093462753698e-05
324,Aspirin ADME,Aspirin ADME,6279.5,0.00101611651388605,0.5,1.5,2.5,0.015704169296912825,False,4,2,6,6,2.584962500721156,0.000283438533508132
325,Aspirin ADME,Drug ADME,6800.5,0.0006415778679879,0.5,3.0,4.0,0.02198306447738465,True,4,2,6,6,2.584962500721156,0.00017896362036111656
326,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,5672.5,0.002584129326598,0.5,1.0,2.0,0.03233476331021125,True,2,1,3,7,2.807354922057604,0.0006787203661069407
327,Assembly of collagen fibrils and other multimeric structures,Collagen formation,6262.5,0.0050825660279543005,0.5,2.0,3.0,0.09582747792991614,True,2,1,3,9,3.169925001442312,0.0012188626956591113
328,Assembly of the ORC complex at the origin of replication,Assembly of the pre-replicative complex,5602.5,0.0020523883781583003,0.5,1.0,2.0,0.02568118079281445,True,3,1,4,8,3.0,0.0005130970945395751
329,Assembly of the pre-replicative complex,DNA Replication Pre-Initiation,6190.5,0.0016213978388402999,0.5,2.0,3.0,0.03057008305696745,True,1,1,2,8,3.0,0.00040534945971007496
330,Atorvastatin ADME,Atorvastatin ADME,6249.5,0.00914785566430205,0.5,1.5,2.5,0.14116694217057513,False,3,2,5,5,2.321928094887362,0.0027537789509595725
331,Atorvastatin ADME,Drug ADME,6662.5,0.0058666580715155,0.5,3.0,4.0,0.2010155416634647,True,3,2,5,5,2.321928094887362,0.0017660400538303716
332,Autophagy,root,6878.5,0.0093393159871725,0.5,4.0,5.0,0.778328293659774,True,3,1,4,21,4.392317422778761,0.0017319670291886821
333,Axon guidance,Nervous system development,6322.5,0.0081220994743397,0.5,2.0,3.0,0.1531353068196396,True,6,1,7,47,5.554588851677638,0.0012391470553123802
334,B-WICH complex positively regulates rRNA expression,Positive epigenetic regulation of rRNA expression,5500.5,0.0015594298959554,0.5,1.0,2.0,0.019512876567585997,True,4,1,5,9,3.169925001442312,0.00037397072978914903
335,B2MG,Amyloid fiber formation,4080.5,0.0187030376884261,0.5,0.0,1.0,0.010243418402004049,True,0,10,10,25,4.643856189774724,0.003313875665774651
336,B2MG,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",4074.5,0.0187030376884261,0.5,0.0,1.0,0.010243418402004049,True,0,10,10,25,4.643856189774724,0.003313875665774651
337,B2MG,Antigen processing-Cross presentation,4062.5,0.0187030376884261,0.5,0.0,1.0,0.010243418402004049,True,0,10,10,25,4.643856189774724,0.003313875665774651
338,B2MG,DAP12 signaling,4066.5,0.0187030376884261,0.5,0.0,1.0,0.010243418402004049,True,0,10,10,25,4.643856189774724,0.003313875665774651
339,B2MG,Host Interactions of HIV factors,4064.5,0.0187030376884261,0.5,0.0,1.0,0.010243418402004049,True,0,10,10,25,4.643856189774724,0.003313875665774651
340,B2MG,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,4076.5,0.0187030376884261,0.5,0.0,1.0,0.010243418402004049,True,0,10,10,25,4.643856189774724,0.003313875665774651
341,B2MG,Interferon gamma signaling,4068.5,0.0187030376884261,0.5,0.0,1.0,0.010243418402004049,True,0,10,10,25,4.643856189774724,0.003313875665774651
342,B2MG,Modulation by Mtb of host immune system,4070.5,0.0187030376884261,0.5,0.0,1.0,0.010243418402004049,True,0,10,10,25,4.643856189774724,0.003313875665774651
343,B2MG,Neutrophil degranulation,4078.5,0.0187030376884261,0.5,0.0,1.0,0.010243418402004049,True,0,10,10,25,4.643856189774724,0.003313875665774651
344,B2MG,SARS-CoV-2 Infection,4072.5,0.0187030376884261,0.5,0.0,1.0,0.010243418402004049,True,0,10,10,25,4.643856189774724,0.003313875665774651
345,B3AT,Bicarbonate transporters,1248.5,0.005446867695253,0.5,0.0,1.0,0.0029831808988635,True,0,4,4,13,3.700439718141092,0.0011587996063923784
346,B3AT,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",1250.5,0.005446867695253,0.5,0.0,1.0,0.0029831808988635,True,0,4,4,13,3.700439718141092,0.0011587996063923784
347,B3AT,Erythrocytes take up carbon dioxide and release oxygen,1252.5,0.005446867695253,0.5,0.0,1.0,0.0029831808988635,True,0,4,4,13,3.700439718141092,0.0011587996063923784
348,B3AT,Erythrocytes take up oxygen and release carbon dioxide,1254.5,0.005446867695253,0.5,0.0,1.0,0.0029831808988635,True,0,4,4,13,3.700439718141092,0.0011587996063923784
349,B4GT1,Diseases associated with N-glycosylation of proteins,2758.5,0.0180296772461154,0.5,0.0,1.0,0.00987462736063135,True,0,7,7,22,4.459431618637297,0.0033024824753855424
350,B4GT1,Diseases associated with glycosaminoglycan metabolism,2756.5,0.0180296772461154,0.5,0.0,1.0,0.00987462736063135,True,0,7,7,22,4.459431618637297,0.0033024824753855424
351,B4GT1,Interaction With Cumulus Cells And The Zona Pellucida,2760.5,0.0180296772461154,0.5,0.0,1.0,0.00987462736063135,True,0,7,7,22,4.459431618637297,0.0033024824753855424
352,B4GT1,Keratan sulfate/keratin metabolism,2752.5,0.0180296772461154,0.5,0.0,1.0,0.00987462736063135,True,0,7,7,22,4.459431618637297,0.0033024824753855424
353,B4GT1,Lactose synthesis,2764.5,0.0180296772461154,0.5,0.0,1.0,0.00987462736063135,True,0,7,7,22,4.459431618637297,0.0033024824753855424
354,B4GT1,Neutrophil degranulation,2762.5,0.0180296772461154,0.5,0.0,1.0,0.00987462736063135,True,0,7,7,22,4.459431618637297,0.0033024824753855424
355,B4GT1,Pre-NOTCH Processing in Golgi,2754.5,0.0180296772461154,0.5,0.0,1.0,0.00987462736063135,True,0,7,7,22,4.459431618637297,0.0033024824753855424
356,BASP1,RHO GTPase cycle,4448.5,0.0007689086440610001,0.5,0.0,1.0,0.0004211215891902,True,0,1,1,6,2.584962500721156,0.0002144816421109915
357,BGH3,Amyloid fiber formation,4748.5,0.0019145286659904,0.5,0.0,1.0,0.00104856325988725,True,0,1,1,4,2.0,0.0006381762219968
358,BHMT1,Choline catabolism,4840.5,0.0012944967275145,0.5,0.0,1.0,0.00070897956903345,True,0,1,1,5,2.321928094887362,0.00038968234427072784
359,BIP,ATF6 (ATF6-alpha) activates chaperones,2534.5,0.0079540353213471,0.5,0.0,1.0,0.0043563250600354,True,0,6,6,18,4.169925001442312,0.0015385204464529124
360,BIP,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",2542.5,0.0079540353213471,0.5,0.0,1.0,0.0043563250600354,True,0,6,6,18,4.169925001442312,0.0015385204464529124
361,BIP,IRE1alpha activates chaperones,2536.5,0.0079540353213471,0.5,0.0,1.0,0.0043563250600354,True,0,6,6,18,4.169925001442312,0.0015385204464529124
362,BIP,PERK regulates gene expression,2538.5,0.0079540353213471,0.5,0.0,1.0,0.0043563250600354,True,0,6,6,18,4.169925001442312,0.0015385204464529124
363,BIP,Platelet degranulation ,2540.5,0.0079540353213471,0.5,0.0,1.0,0.0043563250600354,True,0,6,6,18,4.169925001442312,0.0015385204464529124
364,BIP,Regulation of HSF1-mediated heat shock response,2532.5,0.0079540353213471,0.5,0.0,1.0,0.0043563250600354,True,0,6,6,18,4.169925001442312,0.0015385204464529124
365,BLMH,Antigen processing: Ubiquitination & Proteasome degradation,4678.5,0.0002035310062729935,0.5,0.0,1.0,0.0001114713711091,True,0,1,1,6,2.584962500721156,5.67735384211274e-05
366,BLVRB,Cytoprotection by HMOX1,3532.5,0.0025477832653628997,0.5,0.0,1.0,0.00139538883573375,True,0,2,2,9,3.169925001442312,0.0006109901891476852
367,BLVRB,Heme degradation,3534.5,0.0025477832653628997,0.5,0.0,1.0,0.00139538883573375,True,0,2,2,9,3.169925001442312,0.0006109901891476852
368,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",6184.5,0.00254490155874985,0.5,1.5,2.5,0.038090946942979424,False,3,2,5,5,2.321928094887362,0.0007660917051957264
369,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",Circadian Clock,6838.5,0.0009207648643145,0.5,3.0,4.0,0.0315491453036155,True,3,2,5,5,2.321928094887362,0.0002771778431121402
370,BST1,Neutrophil degranulation,4648.5,0.0004636197750091554,0.5,0.0,1.0,0.000253918717054202,True,0,3,3,12,3.584962500721156,0.00010111746277886327
371,BST1,Nicotinate metabolism,4646.5,0.0004636197750091554,0.5,0.0,1.0,0.000253918717054202,True,0,3,3,12,3.584962500721156,0.00010111746277886327
372,BST1,Post-translational modification: synthesis of GPI-anchored proteins,4650.5,0.0004636197750091554,0.5,0.0,1.0,0.000253918717054202,True,0,3,3,12,3.584962500721156,0.00010111746277886327
373,BTD,Biotin transport and metabolism,3752.5,0.0089509662722248,0.5,0.0,1.0,0.00490233159746905,True,0,2,2,10,3.321928094887362,0.002071058582120645
374,BTD,Defects in biotin (Btn) metabolism,3754.5,0.0089509662722248,0.5,0.0,1.0,0.00490233159746905,True,0,2,2,10,3.321928094887362,0.002071058582120645
375,Base Excision Repair,DNA Repair,6744.5,0.00028641170124979996,0.5,3.0,4.0,0.0098136285707584,True,1,1,2,9,3.169925001442312,6.868509653068931e-05
376,"Base-Excision Repair, AP Site Formation",Base Excision Repair,6444.5,0.0005249532021429196,0.5,2.0,3.0,0.0098975480330038,True,2,1,3,9,3.169925001442312,0.00012589032223873244
377,Basigin interactions,Basigin interactions,5852.5,0.001037652204215,0.5,1.0,2.0,0.01298396255801265,False,3,2,5,6,2.584962500721156,0.0002894457624051198
378,Basigin interactions,Cell surface interactions at the vascular wall,6268.5,0.0008778791215895,0.5,2.0,3.0,0.01655166734412685,True,3,2,5,6,2.584962500721156,0.0002448781881018015
379,Beta-catenin independent WNT signaling,Signaling by WNT,6274.5,0.000372038485812,0.5,2.0,3.0,0.00701447056312705,True,1,1,2,15,3.9068905956085187,7.581960073553716e-05
380,Bicarbonate transporters,Transport of inorganic cations/anions and amino acids/oligopeptides,5466.5,0.000438065819927,0.5,1.0,2.0,0.00548144183645985,True,1,1,2,6,2.584962500721156,0.0001221953701995148
381,Bile acid and bile salt metabolism,Metabolism of steroids,5294.5,0.0003127602124138,0.5,1.0,2.0,0.0039135144426257,True,2,1,3,7,2.807354922057604,8.214632436861847e-05
382,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,6630.5,0.019010845262842,0.5,3.0,4.0,0.6513887994504022,True,5,1,6,60,5.906890595608519,0.002752446270819653
383,Biological oxidations,Metabolism,6738.5,0.0007346169625796,0.5,3.0,4.0,0.02517096187437845,True,3,1,4,21,4.392317422778761,0.00013623399829475142
384,Biosynthesis of DHA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),5708.5,0.0002708554751142761,0.5,1.0,2.0,0.00338916771268065,True,1,1,2,6,2.584962500721156,7.555322407411248e-05
385,Biosynthesis of EPA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),5710.5,0.0009171557520012,0.5,1.0,2.0,0.01147621129264565,True,1,1,2,6,2.584962500721156,0.00025583412708409187
386,Biosynthesis of specialized proresolving mediators (SPMs),Metabolism of lipids,6114.5,0.00031371025610960003,0.5,2.0,3.0,0.005914741191436651,True,2,1,3,7,2.807354922057604,8.239585290358535e-05
387,Biotin transport and metabolism,Metabolism of water-soluble vitamins and cofactors,5310.5,0.0011600414381049001,0.5,1.0,2.0,0.014515397873117751,True,1,1,2,6,2.584962500721156,0.0003235853758223537
388,Branched-chain amino acid catabolism,Branched-chain amino acid catabolism,5982.5,0.0003289271488324,0.5,1.0,2.0,0.004115808521782199,False,2,2,4,5,2.321928094887362,9.901693818678307e-05
389,Branched-chain amino acid catabolism,Metabolism of amino acids and derivatives,6260.5,0.00011729946497792017,0.5,2.0,3.0,0.00221158206888785,True,2,2,4,5,2.321928094887362,3.531065743369062e-05
390,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,5932.5,0.00038530852790299996,0.5,1.0,2.0,0.00482129896631475,False,2,2,4,5,2.321928094887362,0.00011598942448393507
391,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,6436.5,0.0003062197410961,0.5,2.0,3.0,0.00577351387472535,True,2,2,4,5,2.321928094887362,9.218132733438443e-05
392,C-type lectin receptors (CLRs),Innate Immune System,6392.5,0.001394779310246,0.5,2.0,3.0,0.0262973826281021,True,2,1,3,16,4.0,0.0002789558620492
393,C163A,Leishmania parasite growth and survival,4820.5,0.0070593148991185,0.5,0.0,1.0,0.00386629794302985,True,0,2,2,9,3.169925001442312,0.0016929117182387676
394,C163A,Scavenging of heme from plasma,4822.5,0.0070593148991185,0.5,0.0,1.0,0.00386629794302985,True,0,2,2,9,3.169925001442312,0.0016929117182387676
395,C1QA,Initial triggering of complement,1260.5,0.0012225163899139,0.5,0.0,1.0,0.00066955684385675,True,0,2,2,7,2.807354922057604,0.00032109336138623425
396,C1QA,Regulation of Complement cascade,1262.5,0.0012225163899139,0.5,0.0,1.0,0.00066955684385675,True,0,2,2,7,2.807354922057604,0.00032109336138623425
397,C1QB,Initial triggering of complement,1264.5,0.0019932012454777,0.5,0.0,1.0,0.0010916512417370001,True,0,2,2,7,2.807354922057604,0.0005235133803602729
398,C1QB,Regulation of Complement cascade,1266.5,0.0019932012454777,0.5,0.0,1.0,0.0010916512417370001,True,0,2,2,7,2.807354922057604,0.0005235133803602729
399,C1QC,Initial triggering of complement,1268.5,0.0018380727465873,0.5,0.0,1.0,0.0010066893148735,True,0,2,2,7,2.807354922057604,0.00048276895225569163
400,C1QC,Regulation of Complement cascade,1270.5,0.0018380727465873,0.5,0.0,1.0,0.0010066893148735,True,0,2,2,7,2.807354922057604,0.00048276895225569163
401,C1R,Initial triggering of complement,172.5,0.0011098712589275,0.5,0.0,1.0,0.00060786252302695,True,0,2,2,7,2.807354922057604,0.00029150717010845254
402,C1R,Regulation of Complement cascade,174.5,0.0011098712589275,0.5,0.0,1.0,0.00060786252302695,True,0,2,2,7,2.807354922057604,0.00029150717010845254
403,C1S,Initial triggering of complement,2448.5,0.0008289791757799001,0.5,0.0,1.0,0.00045402146354640003,True,0,2,2,7,2.807354922057604,0.00021773099507410668
404,C1S,Regulation of Complement cascade,2450.5,0.0008289791757799001,0.5,0.0,1.0,0.00045402146354640003,True,0,2,2,7,2.807354922057604,0.00021773099507410668
405,C1TC,Metabolism of folate and pterines,2592.5,0.0007016055165452,0.5,0.0,1.0,0.0003842605131237,True,0,1,1,6,2.584962500721156,0.0001957079094702006
406,C4BPA,Regulation of Complement cascade,1440.5,0.0007083962828053,0.5,0.0,1.0,0.0003879797303563,True,0,1,1,6,2.584962500721156,0.0001976021458140212
407,C4BPB,Regulation of Complement cascade,2888.5,0.0020789411816727003,0.5,0.0,1.0,0.00113860992592705,True,0,1,1,6,2.584962500721156,0.0005799059770512237
408,CAD13,Adherens junctions interactions,3892.5,0.00010990230692713049,0.5,0.0,1.0,6.01921106054727e-05,True,0,1,1,6,2.584962500721156,3.065647322810835e-05
409,CADH5,Adherens junctions interactions,3622.5,0.0097983453232501,0.5,0.0,1.0,0.0053664304411619995,True,0,2,2,10,3.321928094887362,0.0022671236328158915
410,CADH5,VEGFA-VEGFR2 Pathway,3620.5,0.0097983453232501,0.5,0.0,1.0,0.0053664304411619995,True,0,2,2,10,3.321928094887362,0.0022671236328158915
411,CAH1,Erythrocytes take up carbon dioxide and release oxygen,240.5,0.0074585874099468,0.5,0.0,1.0,0.00408497447317255,True,0,4,4,12,3.584962500721156,0.0016267499262586464
412,CAH1,Erythrocytes take up oxygen and release carbon dioxide,242.5,0.0074585874099468,0.5,0.0,1.0,0.00408497447317255,True,0,4,4,12,3.584962500721156,0.0016267499262586464
413,CAH1,Interleukin-12 family signaling,236.5,0.0074585874099468,0.5,0.0,1.0,0.00408497447317255,True,0,4,4,12,3.584962500721156,0.0016267499262586464
414,CAH1,Reversible hydration of carbon dioxide,238.5,0.0074585874099468,0.5,0.0,1.0,0.00408497447317255,True,0,4,4,12,3.584962500721156,0.0016267499262586464
415,CAH2,Erythrocytes take up carbon dioxide and release oxygen,246.5,0.013493228027701,0.5,0.0,1.0,0.00739007120575505,True,0,3,3,8,3.0,0.00337330700692525
416,CAH2,Erythrocytes take up oxygen and release carbon dioxide,248.5,0.013493228027701,0.5,0.0,1.0,0.00739007120575505,True,0,3,3,8,3.0,0.00337330700692525
417,CAH2,Reversible hydration of carbon dioxide,244.5,0.013493228027701,0.5,0.0,1.0,0.00739007120575505,True,0,3,3,8,3.0,0.00337330700692525
418,CAH3,Reversible hydration of carbon dioxide,2142.5,0.0030449479042733,0.5,0.0,1.0,0.0016676796526522999,True,0,1,1,4,2.0,0.0010149826347577667
419,CALR,ATF6 (ATF6-alpha) activates chaperones,3210.5,0.0586202185374074,0.5,0.0,1.0,0.0321055560759077,True,0,7,7,23,4.523561956057013,0.010612756587825687
420,CALR,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",3214.5,0.0586202185374074,0.5,0.0,1.0,0.0321055560759077,True,0,7,7,23,4.523561956057013,0.010612756587825687
421,CALR,Antigen processing-Cross presentation,3206.5,0.0586202185374074,0.5,0.0,1.0,0.0321055560759077,True,0,7,7,23,4.523561956057013,0.010612756587825687
422,CALR,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,3212.5,0.0586202185374074,0.5,0.0,1.0,0.0321055560759077,True,0,7,7,23,4.523561956057013,0.010612756587825687
423,CALR,Scavenging by Class A Receptors,3216.5,0.0586202185374074,0.5,0.0,1.0,0.0321055560759077,True,0,7,7,23,4.523561956057013,0.010612756587825687
424,CALR,Scavenging by Class F Receptors,3218.5,0.0586202185374074,0.5,0.0,1.0,0.0321055560759077,True,0,7,7,23,4.523561956057013,0.010612756587825687
425,CALR,Virus Assembly and Release,3208.5,0.0586202185374074,0.5,0.0,1.0,0.0321055560759077,True,0,7,7,23,4.523561956057013,0.010612756587825687
426,CAMP,Neutrophil degranulation,3864.5,0.0046009855533401,0.5,0.0,1.0,0.0025199018934557,True,0,1,1,5,2.321928094887362,0.0013850346611720104
427,CAP1,Neutrophil degranulation,4508.5,0.00035482413321850004,0.5,0.0,1.0,0.00019433271301884999,True,0,3,3,13,3.700439718141092,7.548743404772866e-05
428,CAP1,Platelet degranulation ,4506.5,0.00035482413321850004,0.5,0.0,1.0,0.00019433271301884999,True,0,3,3,13,3.700439718141092,7.548743404772866e-05
429,CAP1,Signaling by ROBO receptors,4504.5,0.00035482413321850004,0.5,0.0,1.0,0.00019433271301884999,True,0,3,3,13,3.700439718141092,7.548743404772866e-05
430,CATA,Detoxification of Reactive Oxygen Species,1454.5,0.0079245180556985,0.5,0.0,1.0,0.0043401588250548,True,0,3,3,13,3.700439718141092,0.001685909942662226
431,CATA,FOXO-mediated transcription,1452.5,0.0079245180556985,0.5,0.0,1.0,0.0043401588250548,True,0,3,3,13,3.700439718141092,0.001685909942662226
432,CATA,Neutrophil degranulation,1456.5,0.0079245180556985,0.5,0.0,1.0,0.0043401588250548,True,0,3,3,13,3.700439718141092,0.001685909942662226
433,CATB,Collagen degradation,2178.5,0.0080792523889806,0.5,0.0,1.0,0.004424904872374451,True,0,4,4,12,3.584962500721156,0.001762119622071028
434,CATB,MHC class II antigen presentation,2176.5,0.0080792523889806,0.5,0.0,1.0,0.004424904872374451,True,0,4,4,12,3.584962500721156,0.001762119622071028
435,CATB,Neutrophil degranulation,2180.5,0.0080792523889806,0.5,0.0,1.0,0.004424904872374451,True,0,4,4,12,3.584962500721156,0.001762119622071028
436,CATB,Trafficking and processing of endosomal TLR,2174.5,0.0080792523889806,0.5,0.0,1.0,0.004424904872374451,True,0,4,4,12,3.584962500721156,0.001762119622071028
437,CATD,Collagen degradation,2104.5,0.0011851207998332999,0.5,0.0,1.0,0.00064907574971755,True,0,5,5,17,4.087462841250339,0.00023294927880830168
438,CATD,Estrogen-dependent gene expression,2100.5,0.0011851207998332999,0.5,0.0,1.0,0.00064907574971755,True,0,5,5,17,4.087462841250339,0.00023294927880830168
439,CATD,MHC class II antigen presentation,2102.5,0.0011851207998332999,0.5,0.0,1.0,0.00064907574971755,True,0,5,5,17,4.087462841250339,0.00023294927880830168
440,CATD,Metabolism of Angiotensinogen to Angiotensins,2108.5,0.0011851207998332999,0.5,0.0,1.0,0.00064907574971755,True,0,5,5,17,4.087462841250339,0.00023294927880830168
441,CATD,Neutrophil degranulation,2106.5,0.0011851207998332999,0.5,0.0,1.0,0.00064907574971755,True,0,5,5,17,4.087462841250339,0.00023294927880830168
442,CATZ,COPII-mediated vesicle transport,5104.5,0.0262675088686102,0.5,0.0,1.0,0.014386384083802248,True,0,5,5,15,3.9068905956085187,0.005353188206828704
443,CATZ,Cargo concentration in the ER,5106.5,0.0262675088686102,0.5,0.0,1.0,0.014386384083802248,True,0,5,5,15,3.9068905956085187,0.005353188206828704
444,CATZ,Lysosome Vesicle Biogenesis,5108.5,0.0262675088686102,0.5,0.0,1.0,0.014386384083802248,True,0,5,5,15,3.9068905956085187,0.005353188206828704
445,CATZ,Metabolism of Angiotensinogen to Angiotensins,5112.5,0.0262675088686102,0.5,0.0,1.0,0.014386384083802248,True,0,5,5,15,3.9068905956085187,0.005353188206828704
446,CATZ,Neutrophil degranulation,5110.5,0.0262675088686102,0.5,0.0,1.0,0.014386384083802248,True,0,5,5,15,3.9068905956085187,0.005353188206828704
447,CBG,Metabolism of steroid hormones,2310.5,0.0026487424591738,0.5,0.0,1.0,0.0014506829158164,True,0,1,1,6,2.584962500721156,0.0007388480238331573
448,CBPB2,Metabolism of Angiotensinogen to Angiotensins,4924.5,0.0017572515698586,0.5,0.0,1.0,0.0009624245733504499,True,0,2,2,9,3.169925001442312,0.00042141083334851204
449,CBPB2,Regulation of Complement cascade,4922.5,0.0017572515698586,0.5,0.0,1.0,0.0009624245733504499,True,0,2,2,9,3.169925001442312,0.00042141083334851204
450,CBPN,Regulation of Complement cascade,2750.5,0.0033784091308368,0.5,0.0,1.0,0.00185031217050525,True,0,1,1,6,2.584962500721156,0.0009423833945702903
451,CBS,Cysteine formation from homocysteine,3638.5,0.0003557500112023,0.5,0.0,1.0,0.0001948398047403,True,0,2,2,8,3.0,8.8937502800575e-05
452,CBS,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",3640.5,0.0003557500112023,0.5,0.0,1.0,0.0001948398047403,True,0,2,2,8,3.0,8.8937502800575e-05
453,CCN2,Transcriptional regulation by RUNX3,3518.5,0.0022146567521465,0.5,0.0,1.0,0.00121293963616925,True,0,2,2,7,2.807354922057604,0.0005816785662182594
454,CCN2,YAP1- and WWTR1 (TAZ)-stimulated gene expression,3516.5,0.0022146567521465,0.5,0.0,1.0,0.00121293963616925,True,0,2,2,7,2.807354922057604,0.0005816785662182594
455,CD14,Antigen processing-Cross presentation,2386.5,0.0610640311104218,0.5,0.0,1.0,0.033444001471703254,True,0,10,10,23,4.523561956057013,0.011055190762087925
456,CD14,Caspase activation via Death Receptors in the presence of ligand,2398.5,0.0610640311104218,0.5,0.0,1.0,0.033444001471703254,True,0,10,10,23,4.523561956057013,0.011055190762087925
457,CD14,IRAK4 deficiency (TLR2/4),2402.5,0.0610640311104218,0.5,0.0,1.0,0.033444001471703254,True,0,10,10,23,4.523561956057013,0.011055190762087925
458,CD14,MyD88 deficiency (TLR2/4),2400.5,0.0610640311104218,0.5,0.0,1.0,0.033444001471703254,True,0,10,10,23,4.523561956057013,0.011055190762087925
459,CD14,Neutrophil degranulation,2404.5,0.0610640311104218,0.5,0.0,1.0,0.033444001471703254,True,0,10,10,23,4.523561956057013,0.011055190762087925
460,CD14,Regulation of TLR by endogenous ligand,2396.5,0.0610640311104218,0.5,0.0,1.0,0.033444001471703254,True,0,10,10,23,4.523561956057013,0.011055190762087925
461,CD14,Toll Like Receptor 2 (TLR2) Cascade,2394.5,0.0610640311104218,0.5,0.0,1.0,0.033444001471703254,True,0,10,10,23,4.523561956057013,0.011055190762087925
462,CD14,Toll Like Receptor 4 (TLR4) Cascade,2388.5,0.0610640311104218,0.5,0.0,1.0,0.033444001471703254,True,0,10,10,23,4.523561956057013,0.011055190762087925
463,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,2392.5,0.0610640311104218,0.5,0.0,1.0,0.033444001471703254,True,0,10,10,23,4.523561956057013,0.011055190762087925
464,CD14,Toll Like Receptor 9 (TLR9) Cascade,2390.5,0.0610640311104218,0.5,0.0,1.0,0.033444001471703254,True,0,10,10,23,4.523561956057013,0.011055190762087925
465,CD209 (DC-SIGN) signaling,C-type lectin receptors (CLRs),5544.5,0.0028173984359324998,0.5,1.0,2.0,0.035253619328862604,True,1,1,2,6,2.584962500721156,0.0007858934187918975
466,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),5766.5,0.005969362663039501,0.5,1.0,2.0,0.0746936025358668,True,28,1,29,33,5.044394119358453,0.0009875866042423262
467,CD36,Antigen processing-Cross presentation,2786.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
468,CD36,Free fatty acids regulate insulin secretion,2796.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
469,CD36,IRAK4 deficiency (TLR2/4),2802.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
470,CD36,Interleukin-4 and Interleukin-13 signaling,2798.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
471,CD36,MyD88 deficiency (TLR2/4),2800.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
472,CD36,Neutrophil degranulation,2808.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
473,CD36,PPARA activates gene expression,2794.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
474,CD36,Platelet degranulation ,2804.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
475,CD36,Regulation of TLR by endogenous ligand,2792.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
476,CD36,Scavenging by Class B Receptors,2810.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
477,CD36,Toll Like Receptor 2 (TLR2) Cascade,2790.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
478,CD36,Toll Like Receptor 4 (TLR4) Cascade,2788.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
479,CD36,Transcriptional regulation of white adipocyte differentiation,2806.5,0.0042141346579421,0.5,0.0,1.0,0.0023080285257833,True,0,13,13,36,5.169925001442312,0.0006830122986838548
480,CD44,Hyaluronan metabolism,2778.5,0.0167437340480439,0.5,0.0,1.0,0.00917033245204495,True,0,4,4,14,3.807354922057604,0.0034829411016063247
481,CD44,Integrin cell surface interactions,2782.5,0.0167437340480439,0.5,0.0,1.0,0.00917033245204495,True,0,4,4,14,3.807354922057604,0.0034829411016063247
482,CD44,Interferon gamma signaling,2780.5,0.0167437340480439,0.5,0.0,1.0,0.00917033245204495,True,0,4,4,14,3.807354922057604,0.0034829411016063247
483,CD44,Neutrophil degranulation,2784.5,0.0167437340480439,0.5,0.0,1.0,0.00917033245204495,True,0,4,4,14,3.807354922057604,0.0034829411016063247
484,CD59,COPI-mediated anterograde transport,2678.5,0.0004652144868625,0.5,0.0,1.0,0.0002547921206701,True,0,5,5,13,3.700439718141092,9.897254613584977e-05
485,CD59,COPII-mediated vesicle transport,2674.5,0.0004652144868625,0.5,0.0,1.0,0.0002547921206701,True,0,5,5,13,3.700439718141092,9.897254613584977e-05
486,CD59,Cargo concentration in the ER,2676.5,0.0004652144868625,0.5,0.0,1.0,0.0002547921206701,True,0,5,5,13,3.700439718141092,9.897254613584977e-05
487,CD59,Neutrophil degranulation,2680.5,0.0004652144868625,0.5,0.0,1.0,0.0002547921206701,True,0,5,5,13,3.700439718141092,9.897254613584977e-05
488,CD59,Regulation of Complement cascade,2672.5,0.0004652144868625,0.5,0.0,1.0,0.0002547921206701,True,0,5,5,13,3.700439718141092,9.897254613584977e-05
489,CDK-mediated phosphorylation and removal of Cdc6,Switching of origins to a post-replicative state,5610.5,0.0034136114052366,0.5,1.0,2.0,0.04271392909219225,True,9,1,10,14,3.807354922057604,0.0007100810030842354
490,CERU,Defective CP causes aceruloplasminemia (ACERULOP),130.5,0.0049376243652112,0.5,0.0,1.0,0.00270427473479815,True,0,5,5,15,3.9068905956085187,0.0010062633900234472
491,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),128.5,0.0049376243652112,0.5,0.0,1.0,0.00270427473479815,True,0,5,5,15,3.9068905956085187,0.0010062633900234472
492,CERU,Metal ion SLC transporters,126.5,0.0049376243652112,0.5,0.0,1.0,0.00270427473479815,True,0,5,5,15,3.9068905956085187,0.0010062633900234472
493,CERU,Post-translational protein phosphorylation,134.5,0.0049376243652112,0.5,0.0,1.0,0.00270427473479815,True,0,5,5,15,3.9068905956085187,0.0010062633900234472
494,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),132.5,0.0049376243652112,0.5,0.0,1.0,0.00270427473479815,True,0,5,5,15,3.9068905956085187,0.0010062633900234472
495,CFAB,Activation of C3 and C5,232.5,0.0068867396309131,0.5,0.0,1.0,0.0037717806401449004,True,0,3,3,8,3.0,0.001721684907728275
496,CFAB,Initial triggering of complement,230.5,0.0068867396309131,0.5,0.0,1.0,0.0037717806401449004,True,0,3,3,8,3.0,0.001721684907728275
497,CFAB,Regulation of Complement cascade,234.5,0.0068867396309131,0.5,0.0,1.0,0.0037717806401449004,True,0,3,3,8,3.0,0.001721684907728275
498,CFAD,Initial triggering of complement,208.5,0.0004933614436202,0.5,0.0,1.0,0.00027020785471364996,True,0,3,3,11,3.4594316186372973,0.0001106332568388974
499,CFAD,Neutrophil degranulation,212.5,0.0004933614436202,0.5,0.0,1.0,0.00027020785471364996,True,0,3,3,11,3.4594316186372973,0.0001106332568388974
500,CFAD,Platelet degranulation ,210.5,0.0004933614436202,0.5,0.0,1.0,0.00027020785471364996,True,0,3,3,11,3.4594316186372973,0.0001106332568388974
501,CFAH,Regulation of Complement cascade,2406.5,0.001662055950472,0.5,0.0,1.0,0.00091028713045695,True,0,1,1,6,2.584962500721156,0.0004636187826616481
502,CFAI,Regulation of Complement cascade,1854.5,0.000142283308974811,0.5,0.0,1.0,7.79267779774901e-05,True,0,1,1,6,2.584962500721156,3.968892532242362e-05
503,CH3L1,Neutrophil degranulation,3694.5,0.0034434590281842,0.5,0.0,1.0,0.00188593918076085,True,0,1,1,5,2.321928094887362,0.0010365844563233867
504,CH60,Mitochondrial protein import,2524.5,0.0007531111859584,0.5,0.0,1.0,0.0004124695201665,True,0,2,2,8,3.0,0.0001882777964896
505,CH60,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,2522.5,0.0007531111859584,0.5,0.0,1.0,0.0004124695201665,True,0,2,2,8,3.0,0.0001882777964896
506,CHLE,Aspirin ADME,1888.5,0.00029299448568407497,0.5,0.0,1.0,0.00016046939306545,True,0,3,3,11,3.4594316186372973,6.570220394445863e-05
507,CHLE,Glycerophospholipid biosynthesis,1884.5,0.00029299448568407497,0.5,0.0,1.0,0.00016046939306545,True,0,3,3,11,3.4594316186372973,6.570220394445863e-05
508,CHLE,"Synthesis, secretion, and deacylation of Ghrelin",1886.5,0.00029299448568407497,0.5,0.0,1.0,0.00016046939306545,True,0,3,3,11,3.4594316186372973,6.570220394445863e-05
509,CHM4A,Endosomal Sorting Complex Required For Transport (ESCRT),5052.5,0.0014540413660123,0.5,0.0,1.0,0.0007963601599917001,True,0,8,8,23,4.523561956057013,0.0002632434247284637
510,CHM4A,HCMV Late Events,5046.5,0.0014540413660123,0.5,0.0,1.0,0.0007963601599917001,True,0,8,8,23,4.523561956057013,0.0002632434247284637
511,CHM4A,HIV Life Cycle,5042.5,0.0014540413660123,0.5,0.0,1.0,0.0007963601599917001,True,0,8,8,23,4.523561956057013,0.0002632434247284637
512,CHM4A,Late endosomal microautophagy,5056.5,0.0014540413660123,0.5,0.0,1.0,0.0007963601599917001,True,0,8,8,23,4.523561956057013,0.0002632434247284637
513,CHM4A,Mitotic Metaphase and Anaphase,5044.5,0.0014540413660123,0.5,0.0,1.0,0.0007963601599917001,True,0,8,8,23,4.523561956057013,0.0002632434247284637
514,CHM4A,Pyroptosis,5054.5,0.0014540413660123,0.5,0.0,1.0,0.0007963601599917001,True,0,8,8,23,4.523561956057013,0.0002632434247284637
515,CHM4A,SARS-CoV-1 Infection,5048.5,0.0014540413660123,0.5,0.0,1.0,0.0007963601599917001,True,0,8,8,23,4.523561956057013,0.0002632434247284637
516,CHM4A,SARS-CoV-2 Infection,5050.5,0.0014540413660123,0.5,0.0,1.0,0.0007963601599917001,True,0,8,8,23,4.523561956057013,0.0002632434247284637
517,CLEC7A (Dectin-1) signaling,C-type lectin receptors (CLRs),5524.5,0.0006774737083897,0.5,1.0,2.0,0.00847711133657225,True,9,1,10,14,3.807354922057604,0.00014092442088709634
518,CLUS,Platelet degranulation ,2530.5,0.0050076885781671,0.5,0.0,1.0,0.0027426480226175,True,0,3,3,11,3.4594316186372973,0.0011229432372588633
519,CLUS,Regulation of Complement cascade,2528.5,0.0050076885781671,0.5,0.0,1.0,0.0027426480226175,True,0,3,3,11,3.4594316186372973,0.0011229432372588633
520,CLUS,Terminal pathway of complement,2526.5,0.0050076885781671,0.5,0.0,1.0,0.0027426480226175,True,0,3,3,11,3.4594316186372973,0.0011229432372588633
521,CO1A1,Anchoring fibril formation,1002.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
522,CO1A1,Collagen chain trimerization,1000.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
523,CO1A1,Collagen degradation,1014.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
524,CO1A1,Crosslinking of collagen fibrils,1004.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
525,CO1A1,ECM proteoglycans,1018.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
526,CO1A1,GP1b-IX-V activation signalling,1026.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
527,CO1A1,GPVI-mediated activation cascade,1024.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
528,CO1A1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1012.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
529,CO1A1,Integrin cell surface interactions,1016.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
530,CO1A1,MET promotes cell motility,1008.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
531,CO1A1,Platelet Adhesion to exposed collagen,1010.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
532,CO1A1,Scavenging by Class A Receptors,1020.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
533,CO1A1,Syndecan interactions,1022.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
534,CO1A1,Transcriptional regulation by RUNX2,1006.5,0.0475588539681809,0.5,0.0,1.0,0.026047385886270098,True,0,14,14,34,5.087462841250339,0.007812590435198864
535,CO1A2,Anchoring fibril formation,2284.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
536,CO1A2,Collagen chain trimerization,2280.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
537,CO1A2,Collagen degradation,2296.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
538,CO1A2,Crosslinking of collagen fibrils,2286.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
539,CO1A2,ECM proteoglycans,2300.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
540,CO1A2,GP1b-IX-V activation signalling,2308.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
541,CO1A2,GPVI-mediated activation cascade,2306.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
542,CO1A2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,2294.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
543,CO1A2,Integrin cell surface interactions,2298.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
544,CO1A2,Interleukin-4 and Interleukin-13 signaling,2288.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
545,CO1A2,MET promotes cell motility,2290.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
546,CO1A2,Platelet Adhesion to exposed collagen,2292.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
547,CO1A2,Scavenging by Class A Receptors,2302.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
548,CO1A2,Syndecan interactions,2304.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
549,CO1A2,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,2282.5,0.0066380860629634,0.5,0.0,1.0,0.00363559620978165,True,0,15,15,39,5.285402218862249,0.0010561115791512532
550,CO2,Activation of C3 and C5,1996.5,0.0014920181882022,0.5,0.0,1.0,0.00081715958764355,True,0,3,3,8,3.0,0.00037300454705055
551,CO2,Initial triggering of complement,1994.5,0.0014920181882022,0.5,0.0,1.0,0.00081715958764355,True,0,3,3,8,3.0,0.00037300454705055
552,CO2,Regulation of Complement cascade,1998.5,0.0014920181882022,0.5,0.0,1.0,0.00081715958764355,True,0,3,3,8,3.0,0.00037300454705055
553,CO3,Activation of C3 and C5,294.5,0.0043226021827642,0.5,0.0,1.0,0.0023674348242837,True,0,10,10,25,4.643856189774724,0.000765895167668462
554,CO3,Cell recruitment (pro-inflammatory response),302.5,0.0043226021827642,0.5,0.0,1.0,0.0023674348242837,True,0,10,10,25,4.643856189774724,0.000765895167668462
555,CO3,Class A/1 (Rhodopsin-like receptors),298.5,0.0043226021827642,0.5,0.0,1.0,0.0023674348242837,True,0,10,10,25,4.643856189774724,0.000765895167668462
556,CO3,G alpha (i) signalling events,300.5,0.0043226021827642,0.5,0.0,1.0,0.0023674348242837,True,0,10,10,25,4.643856189774724,0.000765895167668462
557,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,304.5,0.0043226021827642,0.5,0.0,1.0,0.0023674348242837,True,0,10,10,25,4.643856189774724,0.000765895167668462
558,CO3,Initial triggering of complement,292.5,0.0043226021827642,0.5,0.0,1.0,0.0023674348242837,True,0,10,10,25,4.643856189774724,0.000765895167668462
559,CO3,Neutrophil degranulation,306.5,0.0043226021827642,0.5,0.0,1.0,0.0023674348242837,True,0,10,10,25,4.643856189774724,0.000765895167668462
560,CO3,Post-translational protein phosphorylation,310.5,0.0043226021827642,0.5,0.0,1.0,0.0023674348242837,True,0,10,10,25,4.643856189774724,0.000765895167668462
561,CO3,Regulation of Complement cascade,296.5,0.0043226021827642,0.5,0.0,1.0,0.0023674348242837,True,0,10,10,25,4.643856189774724,0.000765895167668462
562,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),308.5,0.0043226021827642,0.5,0.0,1.0,0.0023674348242837,True,0,10,10,25,4.643856189774724,0.000765895167668462
563,CO4A,Activation of C3 and C5,2462.5,0.0013434763385158,0.5,0.0,1.0,0.0007358050856694,True,0,5,5,12,3.584962500721156,0.0002930179556113029
564,CO4A,Initial triggering of complement,2460.5,0.0013434763385158,0.5,0.0,1.0,0.0007358050856694,True,0,5,5,12,3.584962500721156,0.0002930179556113029
565,CO4A,Post-translational protein phosphorylation,2468.5,0.0013434763385158,0.5,0.0,1.0,0.0007358050856694,True,0,5,5,12,3.584962500721156,0.0002930179556113029
566,CO4A,Regulation of Complement cascade,2464.5,0.0013434763385158,0.5,0.0,1.0,0.0007358050856694,True,0,5,5,12,3.584962500721156,0.0002930179556113029
567,CO4A,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2466.5,0.0013434763385158,0.5,0.0,1.0,0.0007358050856694,True,0,5,5,12,3.584962500721156,0.0002930179556113029
568,CO4B,Activation of C3 and C5,2472.5,0.0004572364849733,0.5,0.0,1.0,0.0002504226694224,True,0,3,3,8,3.0,0.000114309121243325
569,CO4B,Initial triggering of complement,2470.5,0.0004572364849733,0.5,0.0,1.0,0.0002504226694224,True,0,3,3,8,3.0,0.000114309121243325
570,CO4B,Regulation of Complement cascade,2474.5,0.0004572364849733,0.5,0.0,1.0,0.0002504226694224,True,0,3,3,8,3.0,0.000114309121243325
571,CO5,Activation of C3 and C5,314.5,0.003664784258866,0.5,0.0,1.0,0.0020071562246743,True,0,5,5,14,3.807354922057604,0.000762328623179216
572,CO5,Class A/1 (Rhodopsin-like receptors),318.5,0.003664784258866,0.5,0.0,1.0,0.0020071562246743,True,0,5,5,14,3.807354922057604,0.000762328623179216
573,CO5,G alpha (i) signalling events,320.5,0.003664784258866,0.5,0.0,1.0,0.0020071562246743,True,0,5,5,14,3.807354922057604,0.000762328623179216
574,CO5,Regulation of Complement cascade,316.5,0.003664784258866,0.5,0.0,1.0,0.0020071562246743,True,0,5,5,14,3.807354922057604,0.000762328623179216
575,CO5,Terminal pathway of complement,312.5,0.003664784258866,0.5,0.0,1.0,0.0020071562246743,True,0,5,5,14,3.807354922057604,0.000762328623179216
576,CO6,Regulation of Complement cascade,2666.5,0.0023335555469637,0.5,0.0,1.0,0.0012780590099896,True,0,2,2,7,2.807354922057604,0.0006129072793934797
577,CO6,Terminal pathway of complement,2664.5,0.0023335555469637,0.5,0.0,1.0,0.0012780590099896,True,0,2,2,7,2.807354922057604,0.0006129072793934797
578,CO6A1,Collagen chain trimerization,2594.5,0.0227297030878016,0.5,0.0,1.0,0.01244877237379235,True,0,6,6,17,4.087462841250339,0.004467787539105711
579,CO6A1,Collagen degradation,2598.5,0.0227297030878016,0.5,0.0,1.0,0.01244877237379235,True,0,6,6,17,4.087462841250339,0.004467787539105711
580,CO6A1,ECM proteoglycans,2602.5,0.0227297030878016,0.5,0.0,1.0,0.01244877237379235,True,0,6,6,17,4.087462841250339,0.004467787539105711
581,CO6A1,Integrin cell surface interactions,2600.5,0.0227297030878016,0.5,0.0,1.0,0.01244877237379235,True,0,6,6,17,4.087462841250339,0.004467787539105711
582,CO6A1,NCAM signaling for neurite out-growth,2596.5,0.0227297030878016,0.5,0.0,1.0,0.01244877237379235,True,0,6,6,17,4.087462841250339,0.004467787539105711
583,CO6A1,Signaling by PDGF,2604.5,0.0227297030878016,0.5,0.0,1.0,0.01244877237379235,True,0,6,6,17,4.087462841250339,0.004467787539105711
584,CO6A3,Collagen chain trimerization,2606.5,0.0080778785360159,0.5,0.0,1.0,0.00442415243039275,True,0,6,6,17,4.087462841250339,0.001587800990017769
585,CO6A3,Collagen degradation,2610.5,0.0080778785360159,0.5,0.0,1.0,0.00442415243039275,True,0,6,6,17,4.087462841250339,0.001587800990017769
586,CO6A3,ECM proteoglycans,2614.5,0.0080778785360159,0.5,0.0,1.0,0.00442415243039275,True,0,6,6,17,4.087462841250339,0.001587800990017769
587,CO6A3,Integrin cell surface interactions,2612.5,0.0080778785360159,0.5,0.0,1.0,0.00442415243039275,True,0,6,6,17,4.087462841250339,0.001587800990017769
588,CO6A3,NCAM signaling for neurite out-growth,2608.5,0.0080778785360159,0.5,0.0,1.0,0.00442415243039275,True,0,6,6,17,4.087462841250339,0.001587800990017769
589,CO6A3,Signaling by PDGF,2616.5,0.0080778785360159,0.5,0.0,1.0,0.00442415243039275,True,0,6,6,17,4.087462841250339,0.001587800990017769
590,CO7,Regulation of Complement cascade,2520.5,0.0019135273055717,0.5,0.0,1.0,0.0010480148273861,True,0,2,2,7,2.807354922057604,0.0005025870570893808
591,CO7,Terminal pathway of complement,2518.5,0.0019135273055717,0.5,0.0,1.0,0.0010480148273861,True,0,2,2,7,2.807354922057604,0.0005025870570893808
592,CO8A,Regulation of Complement cascade,2112.5,0.0013539736695409,0.5,0.0,1.0,0.00074155434178415,True,0,2,2,7,2.807354922057604,0.00035562055475752015
593,CO8A,Terminal pathway of complement,2110.5,0.0013539736695409,0.5,0.0,1.0,0.00074155434178415,True,0,2,2,7,2.807354922057604,0.00035562055475752015
594,CO8B,Regulation of Complement cascade,2116.5,0.0005402738330302,0.5,0.0,1.0,0.00029590118009585,True,0,2,2,7,2.807354922057604,0.0001419026710381444
595,CO8B,Terminal pathway of complement,2114.5,0.0005402738330302,0.5,0.0,1.0,0.00029590118009585,True,0,2,2,7,2.807354922057604,0.0001419026710381444
596,CO8G,Regulation of Complement cascade,2130.5,0.0012223741153684,0.5,0.0,1.0,0.0006694789218784,True,0,2,2,7,2.807354922057604,0.00032105599304301104
597,CO8G,Terminal pathway of complement,2128.5,0.0012223741153684,0.5,0.0,1.0,0.0006694789218784,True,0,2,2,7,2.807354922057604,0.00032105599304301104
598,CO9,Regulation of Complement cascade,1274.5,0.0007113238498086,0.5,0.0,1.0,0.00038958312196650004,True,0,2,2,7,2.807354922057604,0.0001868288784130953
599,CO9,Terminal pathway of complement,1272.5,0.0007113238498086,0.5,0.0,1.0,0.00038958312196650004,True,0,2,2,7,2.807354922057604,0.0001868288784130953
600,COIA1,Activation of Matrix Metalloproteinases,3732.5,0.0094682956977184,0.5,0.0,1.0,0.005185666414266101,True,0,5,5,11,3.4594316186372973,0.0021232068360791906
601,COIA1,Collagen chain trimerization,3728.5,0.0094682956977184,0.5,0.0,1.0,0.005185666414266101,True,0,5,5,11,3.4594316186372973,0.0021232068360791906
602,COIA1,Collagen degradation,3730.5,0.0094682956977184,0.5,0.0,1.0,0.005185666414266101,True,0,5,5,11,3.4594316186372973,0.0021232068360791906
603,COIA1,Integrin cell surface interactions,3734.5,0.0094682956977184,0.5,0.0,1.0,0.005185666414266101,True,0,5,5,11,3.4594316186372973,0.0021232068360791906
604,COIA1,Laminin interactions,3736.5,0.0094682956977184,0.5,0.0,1.0,0.005185666414266101,True,0,5,5,11,3.4594316186372973,0.0021232068360791906
605,COL10,Initial triggering of complement,5154.5,0.0008256445876467,0.5,0.0,1.0,0.00045219515158485,True,0,1,1,6,2.584962500721156,0.00023030773333908297
606,COL11,Initial triggering of complement,5036.5,0.0009560810231372999,0.5,0.0,1.0,0.000523633546024,True,0,2,2,9,3.169925001442312,0.00022928014839753864
607,COL11,Scavenging by Class A Receptors,5038.5,0.0009560810231372999,0.5,0.0,1.0,0.000523633546024,True,0,2,2,9,3.169925001442312,0.00022928014839753864
608,COMP,ECM proteoglycans,3860.5,0.003199578245004,0.5,0.0,1.0,0.0017523687445599998,True,0,2,2,5,2.321928094887362,0.0009631690252201227
609,COMP,Integrin cell surface interactions,3858.5,0.003199578245004,0.5,0.0,1.0,0.0017523687445599998,True,0,2,2,5,2.321928094887362,0.0009631690252201227
610,COPI-mediated anterograde transport,ER to Golgi Anterograde Transport,5322.5,0.0027495980262792,0.5,1.0,2.0,0.034405244529696,True,6,1,7,11,3.4594316186372973,0.0006165803764739453
611,COPII-mediated vesicle transport,ER to Golgi Anterograde Transport,5318.5,0.0063932706131667,0.5,1.0,2.0,0.07999788939627919,True,5,1,6,10,3.321928094887362,0.001479263530721309
612,CPN2,Regulation of Complement cascade,2906.5,0.0002184630877197,0.5,0.0,1.0,0.00011964948422745001,True,0,1,1,6,2.584962500721156,6.0938737204574294e-05
613,CPSM,Urea cycle,3568.5,0.0013067581036232002,0.5,0.0,1.0,0.0007156949704435001,True,0,1,1,5,2.321928094887362,0.00039337338626756424
614,CRIS3,Neutrophil degranulation,3880.5,0.00021569974669479998,0.5,0.0,1.0,0.0001181360371192,True,0,1,1,5,2.321928094887362,6.493209381225749e-05
615,CRP,Initial triggering of complement,1256.5,0.0016035904007385,0.5,0.0,1.0,0.0008782662845387,True,0,1,1,6,2.584962500721156,0.0004473102299998729
616,CSF1R,Other interleukin signaling,2098.5,0.0023040350638554,0.5,0.0,1.0,0.00126189101284675,True,0,2,2,10,3.321928094887362,0.0005331035161322942
617,CSF1R,Transcriptional Regulation by VENTX,2096.5,0.0023040350638554,0.5,0.0,1.0,0.00126189101284675,True,0,2,2,10,3.321928094887362,0.0005331035161322942
618,CSPG2,Chondroitin sulfate/dermatan sulfate metabolism,2648.5,0.0260055380729192,0.5,0.0,1.0,0.01424290597537555,True,0,6,6,17,4.087462841250339,0.00511169101070581
619,CSPG2,Diseases associated with glycosaminoglycan metabolism,2650.5,0.0260055380729192,0.5,0.0,1.0,0.01424290597537555,True,0,6,6,17,4.087462841250339,0.00511169101070581
620,CSPG2,ECM proteoglycans,2652.5,0.0260055380729192,0.5,0.0,1.0,0.01424290597537555,True,0,6,6,17,4.087462841250339,0.00511169101070581
621,CSPG2,Heparan sulfate/heparin (HS-GAG) metabolism,2646.5,0.0260055380729192,0.5,0.0,1.0,0.01424290597537555,True,0,6,6,17,4.087462841250339,0.00511169101070581
622,CSPG2,Post-translational protein phosphorylation,2656.5,0.0260055380729192,0.5,0.0,1.0,0.01424290597537555,True,0,6,6,17,4.087462841250339,0.00511169101070581
623,CSPG2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2654.5,0.0260055380729192,0.5,0.0,1.0,0.01424290597537555,True,0,6,6,17,4.087462841250339,0.00511169101070581
624,CTRB1,Activation of Matrix Metalloproteinases,2826.5,0.00042333666395930004,0.5,0.0,1.0,0.0002318561640138,True,0,2,2,9,3.169925001442312,0.00010152140957280394
625,CTRB1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",2824.5,0.00042333666395930004,0.5,0.0,1.0,0.0002318561640138,True,0,2,2,9,3.169925001442312,0.00010152140957280394
626,CTRB2,Activation of Matrix Metalloproteinases,4766.5,0.0011978789104067,0.5,0.0,1.0,0.0006560632063435,True,0,2,2,9,3.169925001442312,0.0002872662961545765
627,CTRB2,"Cobalamin (Cbl, vitamin B12) transport and metabolism",4764.5,0.0011978789104067,0.5,0.0,1.0,0.0006560632063435,True,0,2,2,9,3.169925001442312,0.0002872662961545765
628,CXCL7,Class A/1 (Rhodopsin-like receptors),1378.5,0.0022918026534355,0.5,0.0,1.0,0.00125519147557995,True,0,4,4,15,3.9068905956085187,0.00046705802967903474
629,CXCL7,G alpha (i) signalling events,1380.5,0.0022918026534355,0.5,0.0,1.0,0.00125519147557995,True,0,4,4,15,3.9068905956085187,0.00046705802967903474
630,CXCL7,Neutrophil degranulation,1384.5,0.0022918026534355,0.5,0.0,1.0,0.00125519147557995,True,0,4,4,15,3.9068905956085187,0.00046705802967903474
631,CXCL7,Platelet degranulation ,1382.5,0.0022918026534355,0.5,0.0,1.0,0.00125519147557995,True,0,4,4,15,3.9068905956085187,0.00046705802967903474
632,CYTC,Amyloid fiber formation,338.5,0.0099949746408327,0.5,0.0,1.0,0.0054741218442193006,True,0,4,4,10,3.321928094887362,0.002312619372972976
633,CYTC,Neutrophil degranulation,334.5,0.0099949746408327,0.5,0.0,1.0,0.0054741218442193006,True,0,4,4,10,3.321928094887362,0.002312619372972976
634,CYTC,Post-translational protein phosphorylation,340.5,0.0099949746408327,0.5,0.0,1.0,0.0054741218442193006,True,0,4,4,10,3.321928094887362,0.002312619372972976
635,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),336.5,0.0099949746408327,0.5,0.0,1.0,0.0054741218442193006,True,0,4,4,10,3.321928094887362,0.002312619372972976
636,Carboxyterminal post-translational modifications of tubulin,Carboxyterminal post-translational modifications of tubulin,5970.5,0.0029653584326278003,0.5,1.0,2.0,0.037105017176206595,False,6,2,8,9,3.169925001442312,0.0007111299199870811
637,Carboxyterminal post-translational modifications of tubulin,Post-translational protein modification,6254.5,0.001920240675317,0.5,2.0,3.0,0.03620451164274145,True,6,2,8,9,3.169925001442312,0.0004604976527522242
638,Cardiac conduction,Muscle contraction,6672.5,0.0023109504376416,0.5,3.0,4.0,0.0791825513464687,True,1,1,2,5,2.321928094887362,0.0006956654002229263
639,Cargo concentration in the ER,ER to Golgi Anterograde Transport,5320.5,0.006021663062276901,0.5,1.0,2.0,0.0753480283855982,True,5,1,6,10,3.321928094887362,0.001393281639599753
640,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,5650.5,0.0115084039721849,0.5,1.0,2.0,0.1440026683992556,True,3,1,4,8,3.0,0.002877100993046225
641,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,5508.5,0.0160669182514954,0.5,1.0,2.0,0.20104256913122326,True,1,1,2,6,2.584962500721156,0.004481753504608028
642,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,6100.5,0.0134628955714932,0.5,2.0,3.0,0.2538314940040785,True,1,1,2,6,2.584962500721156,0.0037553797477058648
643,Catecholamine biosynthesis,Metabolism of amine-derived hormones,5350.5,1.303159459863069e-05,0.5,1.0,2.0,0.0001630620892553988,True,1,1,2,6,2.584962500721156,3.635071383873398e-06
644,Cell Cycle,root,6850.5,0.0012395596192316999,0.5,4.0,5.0,0.10330353150608754,True,4,1,5,59,5.882643049361842,0.0001800993615885153
645,Cell Cycle Checkpoints,Cell Cycle,6742.5,0.0011106747233996,0.5,3.0,4.0,0.0380562286764461,True,2,1,3,25,4.643856189774724,0.00019679359041994529
646,"Cell Cycle, Mitotic",Cell Cycle,6626.5,0.0018880109803874,0.5,3.0,4.0,0.06469092714502316,True,5,1,6,39,5.285402218862249,0.0003003802962237726
647,"Cell death signalling via NRAGE, NRIF and NADE",p75 NTR receptor-mediated signalling,5292.5,0.0011305057255759,0.5,1.0,2.0,0.01414582261076645,True,1,1,2,6,2.584962500721156,0.0003153465971676094
648,Cell junction organization,Cell-Cell communication,6822.5,0.0047586602663913,0.5,3.0,4.0,0.16305103508341445,True,3,1,4,18,4.169925001442312,0.0009204505413644731
649,Cell recruitment (pro-inflammatory response),Leishmania infection,5738.5,0.0033528905694990997,0.5,1.0,2.0,0.04195413977694385,True,2,1,3,7,2.807354922057604,0.0008806351491095296
650,Cell surface interactions at the vascular wall,Hemostasis,6634.5,0.0006073328218677,0.5,3.0,4.0,0.0208096900602575,True,2,1,3,8,3.0,0.000151833205466925
651,Cell-Cell communication,root,6864.5,0.0030305612445958,0.5,4.0,5.0,0.25256363159545586,True,2,1,3,20,4.321928094887363,0.0005694479877522548
652,Cell-cell junction organization,Cell junction organization,6312.5,0.0046094544733359,0.5,2.0,3.0,0.0869073602552567,True,1,1,2,10,3.321928094887362,0.0010665273396817194
653,Cell-extracellular matrix interactions,Cell junction organization,6304.5,7.060360978898173e-05,0.5,2.0,3.0,0.00133117126695725,True,2,1,3,8,3.0,1.7650902447245434e-05
654,Cellular Senescence,Cellular responses to stress,6150.5,0.0003165397315131,0.5,2.0,3.0,0.00596808855382915,True,3,1,4,10,3.321928094887362,7.324039747157101e-05
655,Cellular response to chemical stress,Cellular responses to stress,6282.5,0.0034380316809857,0.5,2.0,3.0,0.06482117560696254,True,3,1,4,31,4.954196310386875,0.0005774132228371746
656,Cellular response to heat stress,Cellular responses to stress,6090.5,0.0034946571595632003,0.5,2.0,3.0,0.06588880104828759,True,3,1,4,16,4.0,0.0006989314319126401
657,Cellular response to hypoxia,Cellular responses to stress,6048.5,1.1465279819131048e-05,0.5,2.0,3.0,0.0002161681408141,True,1,1,2,14,3.807354922057604,2.384945568825148e-06
658,Cellular responses to stimuli,root,6902.5,0.006512432824381601,0.5,4.0,5.0,0.5427389687571165,True,2,1,3,74,6.20945336562895,0.0009033185311149395
659,Cellular responses to stress,Cellular responses to stimuli,6766.5,0.0076578624600238,0.5,3.0,4.0,0.262389481647147,True,7,1,8,70,6.129283016944966,0.0010741420198668646
660,Chaperone Mediated Autophagy,Autophagy,6748.5,0.0089208333494364,0.5,3.0,4.0,0.30566399574796327,True,8,2,10,10,3.321928094887362,0.0020640864802885838
661,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,6099.5,0.015273271041288351,0.5,1.5,2.5,0.2365627099635096,False,8,2,10,10,3.321928094887362,0.0035339021626379936
662,Chaperonin-mediated protein folding,Protein folding,6226.5,0.0008663449172307,0.5,2.0,3.0,0.016334199689490802,True,1,1,2,11,3.4594316186372973,0.00019427249733127105
663,Choline catabolism,Choline catabolism,5978.5,0.0008537831887537001,0.5,1.0,2.0,0.01068324136970965,False,2,2,4,5,2.321928094887362,0.0002570143496085064
664,Choline catabolism,Metabolism of amino acids and derivatives,6184.5,0.00038513969398789997,0.5,2.0,3.0,0.00726148274760755,True,2,2,4,5,2.321928094887362,0.00011593860041120457
665,Chondroitin sulfate/dermatan sulfate metabolism,Glycosaminoglycan metabolism,5230.5,0.0008044528009944,0.5,1.0,2.0,0.0100659787599079,True,2,1,3,7,2.807354922057604,0.00021128915414054714
666,Chromatin modifying enzymes,Chromatin organization,6762.5,0.001769251381152,0.5,3.0,4.0,0.06062174075695825,True,5,1,6,12,3.584962500721156,0.00038588131983058083
667,Chromatin organization,root,6886.5,0.0011532455203543,0.5,4.0,5.0,0.09611020970498114,True,1,1,2,12,3.584962500721156,0.0002515277977023605
668,Chromosome Maintenance,Cell Cycle,6782.5,0.0002843290631662732,0.5,3.0,4.0,0.0097422689282915,True,2,1,3,11,3.4594316186372973,6.375903646060568e-05
669,Chylomicron assembly,Plasma lipoprotein assembly,5668.5,0.0044126774432489,0.5,1.0,2.0,0.0552150696264112,True,8,1,9,13,3.700439718141092,0.0009387797116551479
670,Chylomicron clearance,Plasma lipoprotein clearance,5682.5,0.0011405677612158,0.5,1.0,2.0,0.01427172712239035,True,2,1,3,7,2.807354922057604,0.0002995695921617426
671,Chylomicron remodeling,Plasma lipoprotein remodeling,5674.5,0.0106683652718921,0.5,1.0,2.0,0.1334914094363985,True,7,1,8,12,3.584962500721156,0.0023268162542690596
672,Cilium Assembly,Organelle biogenesis and maintenance,6696.5,0.0015269422192339,0.5,3.0,4.0,0.05231924437158115,True,2,1,3,14,3.807354922057604,0.0003176262714092162
673,Circadian Clock,root,6862.5,0.00024555585376876603,0.5,4.0,5.0,0.0204643540195641,True,1,1,2,5,2.321928094887362,7.391967759527684e-05
674,Citric acid cycle (TCA cycle),Pyruvate metabolism and Citric Acid (TCA) cycle,5628.5,0.0005464267919266,0.5,1.0,2.0,0.0068373439368721,True,2,1,3,7,2.807354922057604,0.0001435187428313868
675,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,5418.5,0.0041763198305277,0.5,1.0,2.0,0.052257567699072596,True,10,1,11,15,3.9068905956085187,0.0008511132965274074
676,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,6146.5,0.0043769306548848,0.5,2.0,3.0,0.08252332058744974,True,3,1,4,31,4.954196310386875,0.0007351001590675482
677,Clathrin-mediated endocytosis,Membrane Trafficking,6256.5,0.009778844442905901,0.5,2.0,3.0,0.18437183007139546,True,1,1,2,8,3.0,0.0024447111107264753
678,"Cobalamin (Cbl, vitamin B12) transport and metabolism",Metabolism of water-soluble vitamins and cofactors,5306.5,0.0001988117515749131,0.5,1.0,2.0,0.0024876970607843,True,4,1,5,9,3.169925001442312,4.76775365279105e-05
679,Collagen biosynthesis and modifying enzymes,Collagen formation,6480.5,0.0047292212179415,0.5,2.0,3.0,0.08916546079193555,True,1,1,2,10,3.321928094887362,0.0010942387550445245
680,Collagen chain trimerization,Collagen biosynthesis and modifying enzymes,5240.5,0.0055241972028303,0.5,1.0,2.0,0.0691233241285182,True,5,1,6,10,3.321928094887362,0.0012781788779330147
681,Collagen degradation,Collagen degradation,5796.5,0.0080713698394707,0.5,1.0,2.0,0.10099565476935504,False,12,2,14,15,3.9068905956085187,0.0016449051965198227
682,Collagen degradation,Degradation of the extracellular matrix,6548.5,0.006581718809178801,0.5,2.0,3.0,0.1240927339573288,True,12,2,14,15,3.9068905956085187,0.001341321694653064
683,Collagen formation,Extracellular matrix organization,6652.5,0.0044990689229777,0.5,3.0,4.0,0.15415638094278877,True,2,1,3,14,3.807354922057604,0.0009358720119320929
684,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,5792.5,0.0107441637635716,0.5,1.0,2.0,0.1344398628526041,False,16,2,18,19,4.247927513443585,0.002047315580493126
685,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),6530.5,0.0074098081483641,0.5,2.0,3.0,0.1397056571221884,True,16,2,18,19,4.247927513443585,0.0014119494084821938
686,Complement cascade,Innate Immune System,6200.5,0.0077334698480071,0.5,2.0,3.0,0.1458080243533708,True,4,1,5,80,6.321928094887363,0.001056206746062844
687,Constitutive Signaling by Overexpressed ERBB2,Signaling by ERBB2 in Cancer,5178.5,4.421226723188923e-05,0.5,1.0,2.0,0.00055322045287605,True,1,1,2,6,2.584962500721156,1.2332700055578105e-05
688,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,Chaperonin-mediated protein folding,5448.5,0.0007122540501412001,0.5,1.0,2.0,0.0089123117372679,True,6,1,7,11,3.4594316186372973,0.00015971857201811944
689,Cristae formation,Cristae formation,5824.5,0.000338097318541,0.5,1.0,2.0,0.0042305532692653,False,2,2,4,5,2.321928094887362,0.0001017774343344009
690,Cristae formation,Mitochondrial biogenesis,6178.5,0.000248676128796806,0.5,2.0,3.0,0.00468857779966035,True,2,2,4,5,2.321928094887362,7.485897397343814e-05
691,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,5338.5,0.0068379760659485,0.5,1.0,2.0,0.08556241181025276,True,3,1,4,8,3.0,0.001709494016487125
692,Cyclin A:Cdk2-associated events at S phase entry,S Phase,5612.5,0.00015957704494829142,0.5,1.0,2.0,0.0019967599628377,True,9,1,10,14,3.807354922057604,3.319435480332511e-05
693,Cysteine formation from homocysteine,Sulfur amino acid metabolism,5220.5,1.1167927195749703e-05,0.5,1.0,2.0,0.0001397423413848796,True,1,1,2,6,2.584962500721156,3.1152145087997846e-06
694,Cytokine Signaling in Immune system,Immune System,6812.5,0.0045340103456792,0.5,3.0,4.0,0.15535361605095835,True,3,1,4,60,5.906890595608519,0.0006564473959616468
695,Cytoprotection by HMOX1,Cellular response to chemical stress,5758.5,0.0033337254411436,0.5,1.0,2.0,0.041714329840651446,True,5,1,6,10,3.321928094887362,0.0007713514357370362
696,DAG1,Diseases associated with O-glycosylation of proteins,4720.5,0.0102767833126802,0.5,0.0,1.0,0.00562846490779735,True,0,4,4,13,3.700439718141092,0.0021863450929957705
697,DAG1,ECM proteoglycans,4722.5,0.0102767833126802,0.5,0.0,1.0,0.00562846490779735,True,0,4,4,13,3.700439718141092,0.0021863450929957705
698,DAG1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,4724.5,0.0102767833126802,0.5,0.0,1.0,0.00562846490779735,True,0,4,4,13,3.700439718141092,0.0021863450929957705
699,DAG1,Signaling by ROBO receptors,4718.5,0.0102767833126802,0.5,0.0,1.0,0.00562846490779735,True,0,4,4,13,3.700439718141092,0.0021863450929957705
700,DAP12 interactions,Innate Immune System,6362.5,0.0016818476129139,0.5,2.0,3.0,0.0317098123510006,True,1,1,2,6,2.584962500721156,0.0004691395272825245
701,DAP12 signaling,DAP12 interactions,5374.5,0.0031194642722184003,0.5,1.0,2.0,0.0390333168927088,True,1,1,2,6,2.584962500721156,0.0008701525529460586
702,DCXR,Essential pentosuria,4812.5,0.001513458850222,0.5,0.0,1.0,0.00082890236844435,True,0,2,2,9,3.169925001442312,0.0003629462999211061
703,DCXR,Formation of xylulose-5-phosphate,4814.5,0.001513458850222,0.5,0.0,1.0,0.00082890236844435,True,0,2,2,9,3.169925001442312,0.0003629462999211061
704,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,6138.5,8.583757227245791e-05,0.5,2.0,3.0,0.00161839472763465,True,1,1,2,7,2.807354922057604,2.2545198446082566e-05
705,DEF1,Defensins,3894.5,0.0053388436874209,0.5,0.0,1.0,0.0029240175090378,True,0,2,2,7,2.807354922057604,0.0014022448121373552
706,DEF1,Neutrophil degranulation,3896.5,0.0053388436874209,0.5,0.0,1.0,0.0029240175090378,True,0,2,2,7,2.807354922057604,0.0014022448121373552
707,DHE3,Glutamate and glutamine metabolism,124.5,0.00040219947996187325,0.5,0.0,1.0,0.00022027959430712308,True,0,2,2,8,3.0,0.00010054986999046831
708,DHE3,Transcriptional activation of mitochondrial biogenesis,122.5,0.00040219947996187325,0.5,0.0,1.0,0.00022027959430712308,True,0,2,2,8,3.0,0.00010054986999046831
709,DHSO,Formation of xylulose-5-phosphate,4502.5,0.0023874321182466,0.5,0.0,1.0,0.00130756653015335,True,0,2,2,7,2.807354922057604,0.0006270579357903316
710,DHSO,Fructose biosynthesis,4500.5,0.0023874321182466,0.5,0.0,1.0,0.00130756653015335,True,0,2,2,7,2.807354922057604,0.0006270579357903316
711,DMBT1,Surfactant metabolism,5116.5,0.0005859808066806,0.5,0.0,1.0,0.00032093431443425,True,0,1,1,4,2.0,0.00019532693556019998
712,DNA Damage Recognition in GG-NER,Global Genome Nucleotide Excision Repair (GG-NER),5576.5,0.0096224998124081,0.5,1.0,2.0,0.1204046758357786,True,1,1,2,6,2.584962500721156,0.00268412844220056
713,DNA Damage/Telomere Stress Induced Senescence,Cellular Senescence,5398.5,2.7897843744475662e-05,0.5,1.0,2.0,0.0003490808935365,True,3,1,4,8,3.0,6.9744609361189154e-06
714,DNA Double Strand Break Response,DNA Double-Strand Break Repair,6510.5,0.00015686506192986272,0.5,2.0,3.0,0.0029575578905198497,True,1,1,2,7,2.807354922057604,4.1200535579459016e-05
715,DNA Double-Strand Break Repair,DNA Repair,6658.5,0.0014953172281395,0.5,3.0,4.0,0.0512356436848804,True,3,1,4,10,3.321928094887362,0.00034598382835392155
716,DNA Repair,root,6860.5,0.0028406134754057,0.5,4.0,5.0,0.2367335940122645,True,3,1,4,19,4.247927513443585,0.0005412829098970816
717,DNA Replication,root,6892.5,0.0024911062173451,0.5,4.0,5.0,0.20760604461125753,True,2,1,3,21,4.392317422778761,0.0004619732152306025
718,DNA Replication Pre-Initiation,DNA Replication,6756.5,0.0015091281576331,0.5,3.0,4.0,0.051708862242903546,True,1,1,2,8,3.0,0.000377282039408275
719,DNA methylation,DNA methylation,5864.5,0.0007500919250167,0.5,1.0,2.0,0.0093857705211094,False,4,2,6,7,2.807354922057604,0.0001970112953407897
720,DNA methylation,Epigenetic regulation of gene expression,6374.5,0.0001829866497844918,0.5,2.0,3.0,0.00345005830662255,True,4,2,6,7,2.807354922057604,4.8061358483910545e-05
721,DOPO,Catecholamine biosynthesis,2444.5,0.000336079560659721,0.5,0.0,1.0,0.00018406654649101372,True,0,1,1,6,2.584962500721156,9.374702262356015e-05
722,DSC2,Formation of the cornified envelope,4510.5,0.0006261567192859,0.5,0.0,1.0,0.0003429381562355,True,0,1,1,5,2.321928094887362,0.0001884919544916072
723,Deactivation of the beta-catenin transactivating complex,TCF dependent signaling in response to WNT,5330.5,4.650925129357957e-05,0.5,1.0,2.0,0.0005819622171514,True,1,1,2,6,2.584962500721156,1.2973427555859707e-05
724,Death Receptor Signalling,Signal Transduction,6654.5,0.0011812404281492,0.5,3.0,4.0,0.04047409642844095,True,1,1,2,6,2.584962500721156,0.0003294986845501396
725,Defective ABCA1 causes TGD,ABC transporter disorders,5534.5,0.001147729061543,0.5,1.0,2.0,0.014361335234758549,True,1,1,2,6,2.584962500721156,0.0003201509252362113
726,Defective ACY1 causes encephalopathy,Metabolic disorders of biological oxidation enzymes,5518.5,0.0005521893782144,0.5,1.0,2.0,0.00690945018238815,True,1,1,2,6,2.584962500721156,0.00015402933171639057
727,Defective AHCY causes HMAHCHD,Metabolic disorders of biological oxidation enzymes,5514.5,0.00018360342573474128,0.5,1.0,2.0,0.0022973979099932002,True,1,1,2,6,2.584962500721156,5.1214880406087194e-05
728,Defective CFTR causes cystic fibrosis,ABC transporter disorders,5532.5,0.00020526508462099263,0.5,1.0,2.0,0.0025684465010152,True,9,1,10,14,3.807354922057604,4.269813399447046e-05
729,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,5540.5,0.0001112137266727471,0.5,1.0,2.0,0.0013915981262222,True,1,1,2,6,2.584962500721156,3.102228451493571e-05
730,Defective CSF2RA causes SMDP4,Diseases associated with surfactant metabolism,5564.5,0.0004460141750074,0.5,1.0,2.0,0.0055808982288245,True,1,1,2,6,2.584962500721156,0.0001244125077787227
731,Defective CSF2RB causes SMDP5,Diseases associated with surfactant metabolism,5562.5,0.0024314293147981,0.5,1.0,2.0,0.030424054473700897,True,1,1,2,6,2.584962500721156,0.0006782300552122903
732,Defective GSS causes GSS deficiency,Metabolic disorders of biological oxidation enzymes,5516.5,1.59840906246873e-05,0.5,1.0,2.0,0.00020000616136285,True,1,1,2,6,2.584962500721156,4.458649322404884e-06
733,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,6094.5,0.0015353470460416998,0.5,2.0,3.0,0.0289476682368928,True,1,1,2,8,3.0,0.00038383676151042495
734,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),5728.5,0.0012313132115264,0.5,1.0,2.0,0.01540720924670585,True,3,1,4,8,3.0,0.0003078283028816
735,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,5536.5,2.5867330386138137e-05,0.5,1.0,2.0,0.00032367343108319997,True,1,1,2,6,2.584962500721156,7.21550933404035e-06
736,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",SLC transporter disorders,5538.5,0.00031552429844370527,0.5,1.0,2.0,0.0039481009730384,True,1,1,2,6,2.584962500721156,8.801327723239336e-05
737,Defective SLC7A7 causes lysinuric protein intolerance (LPI),SLC transporter disorders,5542.5,0.00038017113957497474,0.5,1.0,2.0,0.00475701571473405,True,1,1,2,6,2.584962500721156,0.00010604605752459028
738,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),5732.5,0.0036507950250553,0.5,1.0,2.0,0.04568176670347475,True,5,1,6,10,3.321928094887362,0.0008447144295098336
739,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),5734.5,0.0039156043477907,0.5,1.0,2.0,0.04899527995718655,True,2,1,3,7,2.807354922057604,0.001028431661336841
740,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),5730.5,0.0018184002476629999,0.5,1.0,2.0,0.0227533277867407,True,4,1,5,9,3.169925001442312,0.00043607504860016514
741,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),5726.5,0.0027580069028938,0.5,1.0,2.0,0.0345104633483662,True,3,1,4,8,3.0,0.00068950172572345
742,Defective pro-SFTPB causes SMDP1 and RDS,Diseases associated with surfactant metabolism,5560.5,0.0010758759551397,0.5,1.0,2.0,0.01346224974211715,True,1,1,2,6,2.584962500721156,0.00030010800808189073
743,Defective pyroptosis,Defective pyroptosis,6028.5,6.154714529207949e-05,0.5,1.0,2.0,0.0007701287837859,False,4,2,6,7,2.807354922057604,1.6165329093831273e-05
744,Defective pyroptosis,Diseases of programmed cell death,6430.5,3.924350893993884e-05,0.5,2.0,3.0,0.0007399031249473,True,4,2,6,7,2.807354922057604,1.0307289376302885e-05
745,Defects in biotin (Btn) metabolism,Defects in vitamin and cofactor metabolism,5406.5,0.0055890440494733,0.5,1.0,2.0,0.06993474150458914,True,1,1,2,6,2.584962500721156,0.0015590244105340015
746,Defects in vitamin and cofactor metabolism,Diseases of metabolism,6300.5,0.0045812168683567,0.5,2.0,3.0,0.08637496412836729,True,1,1,2,6,2.584962500721156,0.0012778981279260623
747,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,6160.5,0.0082250640469762,0.5,2.0,3.0,0.15507661663394015,True,5,1,6,19,4.247927513443585,0.0015672975714519878
748,Defensins,Antimicrobial peptides,5198.5,0.0007528064608446001,0.5,1.0,2.0,0.00941973703841595,True,3,1,4,8,3.0,0.00018820161521115002
749,Degradation of AXIN,TCF dependent signaling in response to WNT,5332.5,0.0007116493182684,0.5,1.0,2.0,0.008904744831937851,True,9,1,10,14,3.807354922057604,0.00014803344662636347
750,Degradation of DVL,TCF dependent signaling in response to WNT,5334.5,0.0021524349501816998,0.5,1.0,2.0,0.0269330462443915,True,9,1,10,14,3.807354922057604,0.000447737890186904
751,Degradation of GLI1 by the proteasome,Hedgehog 'off' state,5526.5,0.00041699661882099997,0.5,1.0,2.0,0.00521780656716915,True,9,1,10,14,3.807354922057604,8.674138389651508e-05
752,Degradation of GLI2 by the proteasome,Hedgehog 'off' state,5528.5,0.0004898993745896,0.5,1.0,2.0,0.006130026140770101,True,9,1,10,14,3.807354922057604,0.00010190622130722925
753,Degradation of beta-catenin by the destruction complex,Degradation of beta-catenin by the destruction complex,5842.5,0.0010897403722613,0.5,1.0,2.0,0.01363573279555705,False,10,2,12,13,3.700439718141092,0.0002318379635963644
754,Degradation of beta-catenin by the destruction complex,Signaling by WNT,6486.5,0.0004137797929233,0.5,2.0,3.0,0.00780146755716,True,10,2,12,13,3.700439718141092,8.80300179845599e-05
755,Degradation of the extracellular matrix,Extracellular matrix organization,6772.5,0.0039769050565834005,0.5,3.0,4.0,0.136264925337091,True,2,1,3,23,4.523561956057013,0.0007199892185915316
756,Deposition of new CENPA-containing nucleosomes at the centromere,Nucleosome assembly,5646.5,0.0011947921990088,0.5,1.0,2.0,0.01495022813378205,True,3,1,4,8,3.0,0.0002986980497522
757,Depurination,"Base-Excision Repair, AP Site Formation",5636.5,0.00040395502003258616,0.5,1.0,2.0,0.0050546192972168,True,3,1,4,8,3.0,0.00010098875500814654
758,Depyrimidination,"Base-Excision Repair, AP Site Formation",5638.5,0.00015052813735552732,0.5,1.0,2.0,0.00188353254723825,True,3,1,4,8,3.0,3.763203433888183e-05
759,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,5756.5,0.0027269155921872,0.5,1.0,2.0,0.034121423155078046,True,7,1,8,12,3.584962500721156,0.0005947519945382958
760,Deubiquitination,Post-translational protein modification,6224.5,0.0006464481650882,0.5,2.0,3.0,0.01218823266281605,True,3,1,4,19,4.247927513443585,0.0001231816109182525
761,Developmental Biology,root,6882.5,0.0039383077145837,0.5,4.0,5.0,0.3282142212137654,True,6,1,7,77,6.266786540694901,0.0005419600111450488
762,Disease,root,6876.5,0.0183406449206701,0.5,4.0,5.0,1.528489119045941,True,8,1,9,229,7.839203788096944,0.0020749204747794133
763,Diseases associated with N-glycosylation of proteins,Diseases of glycosylation,5428.5,0.0007798125089801,0.5,1.0,2.0,0.009757659047741549,True,1,1,2,6,2.584962500721156,0.00021752319831050724
764,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,5430.5,0.0020953821224187,0.5,1.0,2.0,0.0262191540785063,True,3,1,4,8,3.0,0.000523845530604675
765,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,5416.5,0.0037455199674459004,0.5,1.0,2.0,0.04686704352389175,True,4,1,5,9,3.169925001442312,0.0008982223819733889
766,Diseases associated with glycosylation precursor biosynthesis,Diseases of glycosylation,5432.5,0.0004699432699688,0.5,1.0,2.0,0.0058803188552778,True,1,1,2,6,2.584962500721156,0.00013108736001402123
767,Diseases associated with surfactant metabolism,Diseases of metabolism,6576.5,0.002194312957191,0.5,2.0,3.0,0.0413719124001604,True,3,1,4,8,3.0,0.00054857823929775
768,Diseases associated with the TLR signaling cascade,Diseases of Immune System,6472.5,0.014180565529607999,0.5,2.0,3.0,0.2673625532552446,True,2,1,3,13,3.700439718141092,0.0030168593535789584
769,Diseases associated with visual transduction,Diseases of the neuronal system,6382.5,0.0007801994646937,0.5,2.0,3.0,0.0147100001402197,True,2,1,3,8,3.0,0.000195049866173425
770,Diseases of Immune System,Disease,6668.5,0.009268818669408,0.5,3.0,4.0,0.31758738666870645,True,1,1,2,13,3.700439718141092,0.0019719045930182864
771,Diseases of carbohydrate metabolism,Diseases of metabolism,6202.5,0.0019463424588013001,0.5,2.0,3.0,0.03669663866421405,True,3,1,4,10,3.321928094887362,0.00045034124031441706
772,Diseases of glycosylation,Diseases of metabolism,6198.5,0.0041248199720725996,0.5,2.0,3.0,0.077769987180622,True,4,1,5,16,4.0,0.0008249639944145199
773,Diseases of hemostasis,Disease,6830.5,0.0050253316175521,0.5,3.0,4.0,0.1721882790554073,True,1,1,2,19,4.247927513443585,0.0009575840376374744
774,Diseases of metabolism,Disease,6712.5,0.0057628160399783,0.5,3.0,4.0,0.1974574917545719,True,6,1,7,40,5.321928094887363,0.0009115598838649833
775,Diseases of programmed cell death,Disease,6806.5,0.0012546413403828,0.5,3.0,4.0,0.0429891099082379,True,2,1,3,12,3.584962500721156,0.0002736426612399689
776,Diseases of signal transduction by growth factor receptors and second messengers,Disease,6628.5,0.0031790431520684,0.5,3.0,4.0,0.10892693478887215,True,5,1,6,52,5.700439718141092,0.0004744529144052003
777,Diseases of the neuronal system,Disease,6754.5,7.290956300988099e-06,0.5,3.0,4.0,0.000249817785905,True,1,1,2,8,3.0,1.8227390752470248e-06
778,Disorders of transmembrane transporters,Disease,6784.5,0.0008777495427308,0.5,3.0,4.0,0.0300752656156277,True,2,1,3,24,4.584962500721156,0.00015716301454440579
779,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,5981.5,0.0051219481061813,0.5,1.5,2.5,0.07957817631170047,False,5,2,7,7,2.807354922057604,0.0013452772885731525
780,Dissolution of Fibrin Clot,Hemostasis,6792.5,0.0033487700543007,0.5,3.0,4.0,0.11474246805690605,True,5,2,7,7,2.807354922057604,0.0008795528977085562
781,Downregulation of ERBB2 signaling,Signaling by ERBB2,5174.5,0.00011862851312109404,0.5,1.0,2.0,0.0014843780665817,True,1,1,2,6,2.584962500721156,3.309058688821168e-05
782,Downstream TCR signaling,TCR signaling,5340.5,0.00015173000464510408,0.5,1.0,2.0,0.0018985713047566998,True,9,1,10,14,3.807354922057604,3.156205587170624e-05
783,Downstream signaling events of B Cell Receptor (BCR),Signaling by the B Cell Receptor (BCR),5166.5,0.0002935629893996,0.5,1.0,2.0,0.0036733029114192502,True,10,1,11,15,3.9068905956085187,5.9826683248721245e-05
784,Drug ADME,root,6896.5,0.0028991306836881,0.5,4.0,5.0,0.241610353609511,True,4,1,5,14,3.807354922057604,0.000603061502779004
785,Drug resistance in ERBB2 KD mutants,Signaling by ERBB2 in Cancer,5182.5,5.1884896727868846e-05,0.5,1.0,2.0,0.0006492267386938001,True,1,1,2,6,2.584962500721156,1.4472925928076404e-05
786,Drug resistance in ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,5188.5,3.4351505826959146e-05,0.5,1.0,2.0,0.00042983445094295,True,1,1,2,6,2.584962500721156,9.582110222923935e-06
787,Drug-mediated inhibition of ERBB2 signaling,Signaling by ERBB2,5176.5,3.77359517851091e-05,0.5,1.0,2.0,0.00047218343784025,True,1,1,2,6,2.584962500721156,1.0526177547887344e-05
788,E3 ubiquitin ligases ubiquitinate target proteins,Protein ubiquitination,5648.5,0.0001717505201205967,0.5,1.0,2.0,0.00214908455213345,True,1,1,2,6,2.584962500721156,4.7908595999552895e-05
789,ECM proteoglycans,ECM proteoglycans,6149.5,0.00943174823559205,0.5,1.5,2.5,0.14635114621690612,False,18,2,20,20,4.321928094887363,0.001772242703664652
790,ECM proteoglycans,Extracellular matrix organization,6774.5,0.0068342948510191,0.5,3.0,4.0,0.23417070922126254,True,18,2,20,20,4.321928094887363,0.0012841764731065474
791,ECM1,Platelet degranulation ,4754.5,0.00019945563327185918,0.5,0.0,1.0,0.00010923934059679604,True,0,1,1,6,2.584962500721156,5.56367418715639e-05
792,EF1A2,Eukaryotic Translation Elongation,4544.5,2.3683990334783106e-05,0.5,0.0,1.0,1.2971423491186883e-05,True,0,1,1,5,2.321928094887362,7.129591507785532e-06
793,EGR2 and SOX10-mediated initiation of Schwann cell myelination,EGR2 and SOX10-mediated initiation of Schwann cell myelination,6034.5,0.0045897442242365995,0.5,1.0,2.0,0.0574306756312683,False,3,2,5,6,2.584962500721156,0.001280276773693817
794,EGR2 and SOX10-mediated initiation of Schwann cell myelination,Nervous system development,6572.5,0.0034277655451964003,0.5,2.0,3.0,0.064627616311253,True,3,2,5,6,2.584962500721156,0.000956151018178535
795,ENOA,Gluconeogenesis,2030.5,0.0019657120238906,0.5,0.0,1.0,0.00107659574097005,True,0,3,3,11,3.4594316186372973,0.0004407987815476982
796,ENOA,Glycolysis,2028.5,0.0019657120238906,0.5,0.0,1.0,0.00107659574097005,True,0,3,3,11,3.4594316186372973,0.0004407987815476982
797,ENOA,Response of Mtb to phagocytosis,2032.5,0.0019657120238906,0.5,0.0,1.0,0.00107659574097005,True,0,3,3,11,3.4594316186372973,0.0004407987815476982
798,ENOG,Gluconeogenesis,2434.5,0.000736242868702,0.5,0.0,1.0,0.00040323095505885,True,0,2,2,7,2.807354922057604,0.00019337384713902984
799,ENOG,Glycolysis,2432.5,0.000736242868702,0.5,0.0,1.0,0.00040323095505885,True,0,2,2,7,2.807354922057604,0.00019337384713902984
800,ENPL,ATF6 (ATF6-alpha) activates chaperones,2710.5,0.0030127742003746,0.5,0.0,1.0,0.001650058519868,True,0,6,6,20,4.321928094887363,0.0005661057696869098
801,ENPL,Interleukin-4 and Interleukin-13 signaling,2712.5,0.0030127742003746,0.5,0.0,1.0,0.001650058519868,True,0,6,6,20,4.321928094887363,0.0005661057696869098
802,ENPL,Post-translational protein phosphorylation,2718.5,0.0030127742003746,0.5,0.0,1.0,0.001650058519868,True,0,6,6,20,4.321928094887363,0.0005661057696869098
803,ENPL,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2716.5,0.0030127742003746,0.5,0.0,1.0,0.001650058519868,True,0,6,6,20,4.321928094887363,0.0005661057696869098
804,ENPL,Scavenging by Class A Receptors,2714.5,0.0030127742003746,0.5,0.0,1.0,0.001650058519868,True,0,6,6,20,4.321928094887363,0.0005661057696869098
805,ENPL,Trafficking and processing of endosomal TLR,2708.5,0.0030127742003746,0.5,0.0,1.0,0.001650058519868,True,0,6,6,20,4.321928094887363,0.0005661057696869098
806,EPH-Ephrin signaling,Axon guidance,5400.5,0.0022251294916353,0.5,1.0,2.0,0.02784266046828195,True,8,1,9,13,3.700439718141092,0.0004733875179906112
807,ER to Golgi Anterograde Transport,Membrane Trafficking,6326.5,0.010544147393809,0.5,2.0,3.0,0.19880096906024813,True,3,1,4,17,4.087462841250339,0.0020725748222305595
808,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,Positive epigenetic regulation of rRNA expression,5498.5,0.0007488637560484,0.5,1.0,2.0,0.009370402655234051,True,3,1,4,8,3.0,0.0001872159390121
809,ESR-mediated signaling,Signaling by Nuclear Receptors,6376.5,0.0011404768099474,0.5,2.0,3.0,0.021502724358863752,True,2,1,3,13,3.700439718141092,0.00024263194048543832
810,EST1,Aspirin ADME,2956.5,0.007442075233235101,0.5,0.0,1.0,0.00407593096175995,True,0,3,3,10,3.321928094887362,0.0017219340696664359
811,EST1,Metabolism of Angiotensinogen to Angiotensins,2952.5,0.007442075233235101,0.5,0.0,1.0,0.00407593096175995,True,0,3,3,10,3.321928094887362,0.0017219340696664359
812,EST1,Physiological factors,2954.5,0.007442075233235101,0.5,0.0,1.0,0.00407593096175995,True,0,3,3,10,3.321928094887362,0.0017219340696664359
813,EZRI,L1CAM interactions,2766.5,0.0003210954840990839,0.5,0.0,1.0,0.0001758599563030952,True,0,4,4,11,3.4594316186372973,7.200367929337225e-05
814,EZRI,Netrin-1 signaling,2768.5,0.0003210954840990839,0.5,0.0,1.0,0.0001758599563030952,True,0,4,4,11,3.4594316186372973,7.200367929337225e-05
815,EZRI,Sensory processing of sound by inner hair cells of the cochlea,2770.5,0.0003210954840990839,0.5,0.0,1.0,0.0001758599563030952,True,0,4,4,11,3.4594316186372973,7.200367929337225e-05
816,EZRI,Sensory processing of sound by outer hair cells of the cochlea,2772.5,0.0003210954840990839,0.5,0.0,1.0,0.0001758599563030952,True,0,4,4,11,3.4594316186372973,7.200367929337225e-05
817,Elastic fibre formation,Extracellular matrix organization,6638.5,0.0043322852928807006,0.5,3.0,4.0,0.14844169613657793,True,1,1,2,12,3.584962500721156,0.0009448900164830764
818,Endosomal Sorting Complex Required For Transport (ESCRT),Endosomal Sorting Complex Required For Transport (ESCRT),5846.5,0.0022018742722489,0.5,1.0,2.0,0.0275516719303452,False,2,2,4,5,2.321928094887362,0.0006628302026277182
819,Endosomal Sorting Complex Required For Transport (ESCRT),Membrane Trafficking,6238.5,0.0026596786204202997,0.5,2.0,3.0,0.050145987852830254,True,2,2,4,5,2.321928094887362,0.0008006430435727064
820,Epigenetic regulation of gene expression,Gene expression (Transcription),6740.5,0.0006044299236061,0.5,3.0,4.0,0.020710224971391702,True,4,1,5,15,3.9068905956085187,0.0001231798247442162
821,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,5808.5,0.0025554733071616,0.5,1.0,2.0,0.03197619549537595,False,6,2,8,9,3.169925001442312,0.0006128343570394435
822,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,6462.5,0.0013616933923217,0.5,2.0,3.0,0.025673575666768297,True,6,2,8,9,3.169925001442312,0.0003265510511221932
823,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,5810.5,0.0065223181406467,0.5,1.0,2.0,0.0816126387874511,False,6,2,8,9,3.169925001442312,0.0015641332010505541
824,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,6336.5,0.0046468296412999,0.5,2.0,3.0,0.08761203739343809,True,6,2,8,9,3.169925001442312,0.0011143676780020345
825,Essential pentosuria,Diseases of carbohydrate metabolism,5552.5,0.0012163590505907,0.5,1.0,2.0,0.015220090417403,True,1,1,2,6,2.584962500721156,0.00033929477654118153
826,Estrogen-dependent gene expression,ESR-mediated signaling,5656.5,0.0019781253622891,0.5,1.0,2.0,0.0247519405198459,True,6,1,7,11,3.4594316186372973,0.0004435823960214847
827,Ethanol oxidation,Phase I - Functionalization of compounds,5352.5,0.0018186727532055,0.5,1.0,2.0,0.0227567376014621,True,4,1,5,9,3.169925001442312,0.00043614039882646557
828,Eukaryotic Translation Elongation,Eukaryotic Translation Elongation,6002.5,2.318183591939815e-05,0.5,1.0,2.0,0.0002900703033066,False,2,2,4,5,2.321928094887362,6.978427966299549e-06
829,Eukaryotic Translation Elongation,Translation,6488.5,2.199729431198149e-06,0.5,2.0,3.0,4.147403543024261e-05,True,2,2,4,5,2.321928094887362,6.621845411355107e-07
830,Events associated with phagocytolytic activity of PMN cells,ROS and RNS production in phagocytes,5172.5,0.0056275347647194995,0.5,1.0,2.0,0.07041636916707356,True,1,1,2,6,2.584962500721156,0.0015697611240249952
831,Extra-nuclear estrogen signaling,ESR-mediated signaling,5654.5,0.0002814773224368,0.5,1.0,2.0,0.0035220770510625,True,2,1,3,7,2.807354922057604,7.392988786153973e-05
832,Extracellular matrix organization,root,6854.5,0.015623226192889701,0.5,4.0,5.0,1.3020224394242725,True,8,1,9,68,6.087462841250339,0.002204346822386094
833,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,5788.5,0.0103762763676686,0.5,1.0,2.0,0.12983655149782974,False,4,2,6,7,2.807354922057604,0.0027253241633855775
834,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),6330.5,0.0077897317007532,0.5,2.0,3.0,0.146868793937604,True,4,2,6,7,2.807354922057604,0.002045969409267315
835,F13A,Common Pathway of Fibrin Clot Formation,144.5,0.008283352331979299,0.5,0.0,1.0,0.00453668784296935,True,0,3,3,12,3.584962500721156,0.0018066346956330467
836,F13A,Interleukin-4 and Interleukin-13 signaling,140.5,0.008283352331979299,0.5,0.0,1.0,0.00453668784296935,True,0,3,3,12,3.584962500721156,0.0018066346956330467
837,F13A,Platelet degranulation ,142.5,0.008283352331979299,0.5,0.0,1.0,0.00453668784296935,True,0,3,3,12,3.584962500721156,0.0018066346956330467
838,F13B,Common Pathway of Fibrin Clot Formation,1856.5,0.0023556124124204,0.5,0.0,1.0,0.0012901392776591,True,0,1,1,5,2.321928094887362,0.0007091099942969333
839,F16P1,Gluconeogenesis,2446.5,0.0002607641694487,0.5,0.0,1.0,0.0001428172544167,True,0,1,1,6,2.584962500721156,7.273832554629074e-05
840,FA10,Common Pathway of Fibrin Clot Formation,206.5,0.0476481473465747,0.5,0.0,1.0,0.02609629074603965,True,0,7,7,17,4.087462841250339,0.00936579761531276
841,FA10,Defective factor IX causes hemophilia B,198.5,0.0476481473465747,0.5,0.0,1.0,0.02609629074603965,True,0,7,7,17,4.087462841250339,0.00936579761531276
842,FA10,Defective factor IX causes thrombophilia,200.5,0.0476481473465747,0.5,0.0,1.0,0.02609629074603965,True,0,7,7,17,4.087462841250339,0.00936579761531276
843,FA10,Defective factor VIII causes hemophilia A,196.5,0.0476481473465747,0.5,0.0,1.0,0.02609629074603965,True,0,7,7,17,4.087462841250339,0.00936579761531276
844,FA10,Extrinsic Pathway of Fibrin Clot Formation,202.5,0.0476481473465747,0.5,0.0,1.0,0.02609629074603965,True,0,7,7,17,4.087462841250339,0.00936579761531276
845,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",194.5,0.0476481473465747,0.5,0.0,1.0,0.02609629074603965,True,0,7,7,17,4.087462841250339,0.00936579761531276
846,FA10,Intrinsic Pathway of Fibrin Clot Formation,204.5,0.0476481473465747,0.5,0.0,1.0,0.02609629074603965,True,0,7,7,17,4.087462841250339,0.00936579761531276
847,FA11,Defective factor IX causes hemophilia B,1428.5,0.002701263272439,0.5,0.0,1.0,0.0014794479043734499,True,0,2,2,9,3.169925001442312,0.0006477966082134991
848,FA11,Intrinsic Pathway of Fibrin Clot Formation,1430.5,0.002701263272439,0.5,0.0,1.0,0.0014794479043734499,True,0,2,2,9,3.169925001442312,0.0006477966082134991
849,FA12,Defective SERPING1 causes hereditary angioedema,226.5,0.0010259664349375,0.5,0.0,1.0,0.0005619089067003,True,0,3,3,10,3.321928094887362,0.00023738628047772708
850,FA12,Defective factor XII causes hereditary angioedema,224.5,0.0010259664349375,0.5,0.0,1.0,0.0005619089067003,True,0,3,3,10,3.321928094887362,0.00023738628047772708
851,FA12,Intrinsic Pathway of Fibrin Clot Formation,228.5,0.0010259664349375,0.5,0.0,1.0,0.0005619089067003,True,0,3,3,10,3.321928094887362,0.00023738628047772708
852,FA5,COPII-mediated vesicle transport,2618.5,0.0071534149970035,0.5,0.0,1.0,0.00391783538258185,True,0,6,6,17,4.087462841250339,0.0014060869278497599
853,FA5,Cargo concentration in the ER,2620.5,0.0071534149970035,0.5,0.0,1.0,0.00391783538258185,True,0,6,6,17,4.087462841250339,0.0014060869278497599
854,FA5,Common Pathway of Fibrin Clot Formation,2624.5,0.0071534149970035,0.5,0.0,1.0,0.00391783538258185,True,0,6,6,17,4.087462841250339,0.0014060869278497599
855,FA5,Platelet degranulation ,2622.5,0.0071534149970035,0.5,0.0,1.0,0.00391783538258185,True,0,6,6,17,4.087462841250339,0.0014060869278497599
856,FA5,Post-translational protein phosphorylation,2628.5,0.0071534149970035,0.5,0.0,1.0,0.00391783538258185,True,0,6,6,17,4.087462841250339,0.0014060869278497599
857,FA5,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2626.5,0.0071534149970035,0.5,0.0,1.0,0.00391783538258185,True,0,6,6,17,4.087462841250339,0.0014060869278497599
858,FA7,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",2428.5,0.0017072571130584998,0.5,0.0,1.0,0.0009350432384402001,True,0,3,3,11,3.4594316186372973,0.00038284186395489556
859,FA7,Extrinsic Pathway of Fibrin Clot Formation,2426.5,0.0017072571130584998,0.5,0.0,1.0,0.0009350432384402001,True,0,3,3,11,3.4594316186372973,0.00038284186395489556
860,FA7,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",2424.5,0.0017072571130584998,0.5,0.0,1.0,0.0009350432384402001,True,0,3,3,11,3.4594316186372973,0.00038284186395489556
861,FA9,Defective factor IX causes hemophilia B,186.5,0.020100406877904098,0.5,0.0,1.0,0.01100873992401275,True,0,6,6,16,4.0,0.00402008137558082
862,FA9,Defective factor IX causes thrombophilia,188.5,0.020100406877904098,0.5,0.0,1.0,0.01100873992401275,True,0,6,6,16,4.0,0.00402008137558082
863,FA9,Defective factor VIII causes hemophilia A,184.5,0.020100406877904098,0.5,0.0,1.0,0.01100873992401275,True,0,6,6,16,4.0,0.00402008137558082
864,FA9,Extrinsic Pathway of Fibrin Clot Formation,190.5,0.020100406877904098,0.5,0.0,1.0,0.01100873992401275,True,0,6,6,16,4.0,0.00402008137558082
865,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",182.5,0.020100406877904098,0.5,0.0,1.0,0.01100873992401275,True,0,6,6,16,4.0,0.00402008137558082
866,FA9,Intrinsic Pathway of Fibrin Clot Formation,192.5,0.020100406877904098,0.5,0.0,1.0,0.01100873992401275,True,0,6,6,16,4.0,0.00402008137558082
867,FAAA,Tyrosine catabolism,2812.5,0.000580009842036,0.5,0.0,1.0,0.0003176640922309,True,0,1,1,6,2.584962500721156,0.00016178965384416836
868,FABPL,Cytoprotection by HMOX1,2058.5,0.0075421251535656,0.5,0.0,1.0,0.0041307270441988,True,0,4,4,14,3.807354922057604,0.0015688721294448305
869,FABPL,Heme degradation,2060.5,0.0075421251535656,0.5,0.0,1.0,0.0041307270441988,True,0,4,4,14,3.807354922057604,0.0015688721294448305
870,FABPL,PPARA activates gene expression,2054.5,0.0075421251535656,0.5,0.0,1.0,0.0041307270441988,True,0,4,4,14,3.807354922057604,0.0015688721294448305
871,FABPL,Triglyceride catabolism,2056.5,0.0075421251535656,0.5,0.0,1.0,0.0041307270441988,True,0,4,4,14,3.807354922057604,0.0015688721294448305
872,FBLN1,Molecules associated with elastic fibres,2958.5,0.0003749031806184,0.5,0.0,1.0,0.00020532975462555,True,0,1,1,5,2.321928094887362,0.00011285710283596971
873,FBLN3,Molecules associated with elastic fibres,4652.5,0.0055621202669304,0.5,0.0,1.0,0.0030463032821504,True,0,1,1,5,2.321928094887362,0.0016743650398366003
874,FBLN5,Molecules associated with elastic fibres,5114.5,0.0016731970805372001,0.5,0.0,1.0,0.000916388987205,True,0,1,1,5,2.321928094887362,0.0005036825098990994
875,FBN1,Integrin cell surface interactions,3646.5,0.008566176966730801,0.5,0.0,1.0,0.00469158733664605,True,0,5,5,14,3.807354922057604,0.00178188985536029
876,FBN1,Molecules associated with elastic fibres,3648.5,0.008566176966730801,0.5,0.0,1.0,0.00469158733664605,True,0,5,5,14,3.807354922057604,0.00178188985536029
877,FBN1,Post-translational protein phosphorylation,3652.5,0.008566176966730801,0.5,0.0,1.0,0.00469158733664605,True,0,5,5,14,3.807354922057604,0.00178188985536029
878,FBN1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),3650.5,0.008566176966730801,0.5,0.0,1.0,0.00469158733664605,True,0,5,5,14,3.807354922057604,0.00178188985536029
879,FBN1,TGF-beta receptor signaling activates SMADs,3644.5,0.008566176966730801,0.5,0.0,1.0,0.00469158733664605,True,0,5,5,14,3.807354922057604,0.00178188985536029
880,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,5384.5,0.0005072312670608,0.5,1.0,2.0,0.006346897113522749,True,26,1,27,31,4.954196310386875,8.518887195169462e-05
881,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,5382.5,0.0010975795121188,0.5,1.0,2.0,0.0137338225967292,True,26,1,27,31,4.954196310386875,0.00018433713886861829
882,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,5386.5,0.0007050734922745,0.5,1.0,2.0,0.0088224626586383,True,35,1,36,40,5.321928094887363,0.00011152823659046413
883,FCG3A,FCGR activation,2408.5,0.0004665920762721,0.5,0.0,1.0,0.0002555466090555,True,0,6,6,15,3.9068905956085187,9.508915415592968e-05
884,FCG3A,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,2418.5,0.0004665920762721,0.5,0.0,1.0,0.0002555466090555,True,0,6,6,15,3.9068905956085187,9.508915415592968e-05
885,FCG3A,Leishmania parasite growth and survival,2416.5,0.0004665920762721,0.5,0.0,1.0,0.0002555466090555,True,0,6,6,15,3.9068905956085187,9.508915415592968e-05
886,FCG3A,Parasite infection,2414.5,0.0004665920762721,0.5,0.0,1.0,0.0002555466090555,True,0,6,6,15,3.9068905956085187,9.508915415592968e-05
887,FCG3A,Regulation of actin dynamics for phagocytic cup formation,2410.5,0.0004665920762721,0.5,0.0,1.0,0.0002555466090555,True,0,6,6,15,3.9068905956085187,9.508915415592968e-05
888,FCG3A,Role of phospholipids in phagocytosis,2412.5,0.0004665920762721,0.5,0.0,1.0,0.0002555466090555,True,0,6,6,15,3.9068905956085187,9.508915415592968e-05
889,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,5342.5,0.0030679504788868,0.5,1.0,2.0,0.03838873370662675,True,31,1,32,36,5.169925001442312,0.0004972427506281876
890,FCN2,Initial triggering of complement,4746.5,0.00018671946668407058,0.5,0.0,1.0,0.0001022639024155552,True,0,1,1,6,2.584962500721156,5.208407804726265e-05
891,FCN3,Initial triggering of complement,78.5,0.0029985213642089,0.5,0.0,1.0,0.0016422524208432,True,0,1,1,6,2.584962500721156,0.0008364163819302749
892,FETUA,Neutrophil degranulation,1340.5,0.016954667808956,0.5,0.0,1.0,0.009285858218721299,True,0,4,4,13,3.700439718141092,0.003607038665663635
893,FETUA,Platelet degranulation ,1338.5,0.016954667808956,0.5,0.0,1.0,0.009285858218721299,True,0,4,4,13,3.700439718141092,0.003607038665663635
894,FETUA,Post-translational protein phosphorylation,1344.5,0.016954667808956,0.5,0.0,1.0,0.009285858218721299,True,0,4,4,13,3.700439718141092,0.003607038665663635
895,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1342.5,0.016954667808956,0.5,0.0,1.0,0.009285858218721299,True,0,4,4,13,3.700439718141092,0.003607038665663635
896,FHR1,Regulation of Complement cascade,4524.5,0.0008048607727707,0.5,0.0,1.0,0.00044081211769965,True,0,1,1,6,2.584962500721156,0.00022451023479570374
897,FHR2,Regulation of Complement cascade,3706.5,0.00045418299931880004,0.5,0.0,1.0,0.00024875031375139997,True,0,1,1,6,2.584962500721156,0.00012669114369465119
898,FHR3,Regulation of Complement cascade,4516.5,0.0036101906926301,0.5,0.0,1.0,0.0019772560153966503,True,0,1,1,6,2.584962500721156,0.0010070372261645328
899,FHR5,Regulation of Complement cascade,5040.5,0.0016165277924031,0.5,0.0,1.0,0.0008853519311625,True,0,1,1,6,2.584962500721156,0.0004509190241398388
900,FIBA,Amyloid fiber formation,1168.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
901,FIBA,Antigen processing-Cross presentation,1130.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
902,FIBA,Common Pathway of Fibrin Clot Formation,1158.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
903,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,1162.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
904,FIBA,IRAK4 deficiency (TLR2/4),1140.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
905,FIBA,Integrin cell surface interactions,1160.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
906,FIBA,MyD88 deficiency (TLR2/4),1138.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
907,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,1152.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
908,FIBA,Platelet degranulation ,1156.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
909,FIBA,Post-translational protein phosphorylation,1170.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
910,FIBA,RAF/MAP kinase cascade,1142.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
911,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1166.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
912,FIBA,Regulation of TLR by endogenous ligand,1136.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
913,FIBA,Signaling by BRAF and RAF1 fusions,1150.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
914,FIBA,Signaling by RAF1 mutants,1154.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
915,FIBA,Signaling by RAS mutants,1144.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
916,FIBA,Signaling by high-kinase activity BRAF mutants,1148.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
917,FIBA,Signaling by moderate kinase activity BRAF mutants,1146.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
918,FIBA,Toll Like Receptor 2 (TLR2) Cascade,1134.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
919,FIBA,Toll Like Receptor 4 (TLR4) Cascade,1132.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
920,FIBA,p130Cas linkage to MAPK signaling for integrins,1164.5,0.0175567374723226,0.5,0.0,1.0,0.00961560419751675,True,0,21,21,44,5.459431618637297,0.00271800036115661
921,FIBB,Antigen processing-Cross presentation,1172.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
922,FIBB,Common Pathway of Fibrin Clot Formation,1200.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
923,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,1204.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
924,FIBB,IRAK4 deficiency (TLR2/4),1182.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
925,FIBB,Integrin cell surface interactions,1202.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
926,FIBB,MyD88 deficiency (TLR2/4),1180.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
927,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,1194.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
928,FIBB,Platelet degranulation ,1198.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
929,FIBB,RAF/MAP kinase cascade,1184.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
930,FIBB,Regulation of TLR by endogenous ligand,1178.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
931,FIBB,Signaling by BRAF and RAF1 fusions,1192.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
932,FIBB,Signaling by RAF1 mutants,1196.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
933,FIBB,Signaling by RAS mutants,1186.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
934,FIBB,Signaling by high-kinase activity BRAF mutants,1190.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
935,FIBB,Signaling by moderate kinase activity BRAF mutants,1188.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
936,FIBB,Toll Like Receptor 2 (TLR2) Cascade,1176.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
937,FIBB,Toll Like Receptor 4 (TLR4) Cascade,1174.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
938,FIBB,p130Cas linkage to MAPK signaling for integrins,1206.5,0.0017122828002405,0.5,0.0,1.0,0.0009377957440717499,True,0,18,18,39,5.285402218862249,0.0002724221522533603
939,FIBG,Antigen processing-Cross presentation,1208.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
940,FIBG,Common Pathway of Fibrin Clot Formation,1236.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
941,FIBG,GRB2:SOS provides linkage to MAPK signaling for Integrins ,1240.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
942,FIBG,IRAK4 deficiency (TLR2/4),1218.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
943,FIBG,Integrin cell surface interactions,1238.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
944,FIBG,MyD88 deficiency (TLR2/4),1216.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
945,FIBG,Paradoxical activation of RAF signaling by kinase inactive BRAF,1230.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
946,FIBG,Platelet degranulation ,1234.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
947,FIBG,Post-translational protein phosphorylation,1246.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
948,FIBG,RAF/MAP kinase cascade,1220.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
949,FIBG,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1244.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
950,FIBG,Regulation of TLR by endogenous ligand,1214.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
951,FIBG,Signaling by BRAF and RAF1 fusions,1228.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
952,FIBG,Signaling by RAF1 mutants,1232.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
953,FIBG,Signaling by RAS mutants,1222.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
954,FIBG,Signaling by high-kinase activity BRAF mutants,1226.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
955,FIBG,Signaling by moderate kinase activity BRAF mutants,1224.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
956,FIBG,Toll Like Receptor 2 (TLR2) Cascade,1212.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
957,FIBG,Toll Like Receptor 4 (TLR4) Cascade,1210.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
958,FIBG,p130Cas linkage to MAPK signaling for integrins,1242.5,0.0018156554299261,0.5,0.0,1.0,0.00099441163261485,True,0,20,20,43,5.426264754702098,0.00028253666775829376
959,FINC,ALK mutants bind TKIs,1302.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
960,FINC,ECM proteoglycans,1310.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
961,FINC,Fibronectin matrix formation,1306.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
962,FINC,G alpha (s) signalling events,1280.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
963,FINC,GRB2:SOS provides linkage to MAPK signaling for Integrins ,1316.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
964,FINC,Integrin cell surface interactions,1308.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
965,FINC,Interleukin-4 and Interleukin-13 signaling,1282.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
966,FINC,MET promotes cell motility,1298.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
967,FINC,Molecules associated with elastic fibres,1312.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
968,FINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,1294.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
969,FINC,Platelet degranulation ,1300.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
970,FINC,Post-translational protein phosphorylation,1322.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
971,FINC,RAF/MAP kinase cascade,1284.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
972,FINC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1320.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
973,FINC,Signaling by ALK fusions and activated point mutants,1304.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
974,FINC,Signaling by BRAF and RAF1 fusions,1292.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
975,FINC,Signaling by RAF1 mutants,1296.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
976,FINC,Signaling by RAS mutants,1286.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
977,FINC,Signaling by high-kinase activity BRAF mutants,1290.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
978,FINC,Signaling by moderate kinase activity BRAF mutants,1288.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
979,FINC,Syndecan interactions,1314.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
980,FINC,p130Cas linkage to MAPK signaling for integrins,1318.5,0.004180467904800899,0.5,0.0,1.0,0.0022895896687159497,True,0,22,22,47,5.554588851677638,0.0006377925449482487
981,FLNA,Antiviral mechanism by IFN-stimulated genes,2890.5,0.0043400035784603,0.5,0.0,1.0,0.0023769653497450003,True,0,4,4,15,3.9068905956085187,0.0008844712336452821
982,FLNA,GP1b-IX-V activation signalling,2896.5,0.0043400035784603,0.5,0.0,1.0,0.0023769653497450003,True,0,4,4,15,3.9068905956085187,0.0008844712336452821
983,FLNA,Platelet degranulation ,2894.5,0.0043400035784603,0.5,0.0,1.0,0.0023769653497450003,True,0,4,4,15,3.9068905956085187,0.0008844712336452821
984,FLNA,RHO GTPase Effectors,2892.5,0.0043400035784603,0.5,0.0,1.0,0.0023769653497450003,True,0,4,4,15,3.9068905956085187,0.0008844712336452821
985,FLNB,Antiviral mechanism by IFN-stimulated genes,74.5,0.00020167780116164596,0.5,0.0,1.0,0.00011045639398855424,True,0,1,1,6,2.584962500721156,5.6256599928472383e-05
986,FOXO-mediated transcription,Generic Transcription Pathway,5370.5,0.0033519216322388003,0.5,1.0,2.0,0.041942015632594296,True,7,1,8,12,3.584962500721156,0.0007310684943904308
987,FSTL1,Post-translational protein phosphorylation,4656.5,0.0099173313867167,0.5,0.0,1.0,0.0054315976109234505,True,0,3,3,9,3.169925001442312,0.0023782997016220794
988,FSTL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4654.5,0.0099173313867167,0.5,0.0,1.0,0.0054315976109234505,True,0,3,3,9,3.169925001442312,0.0023782997016220794
989,FSTL1,Signaling by BMP,4658.5,0.0099173313867167,0.5,0.0,1.0,0.0054315976109234505,True,0,3,3,9,3.169925001442312,0.0023782997016220794
990,FSTL3,Antagonism of Activin by Follistatin,100.5,0.0003035398661724,0.5,0.0,1.0,0.0001662449652666,True,0,3,3,10,3.321928094887362,7.023251185772235e-05
991,FSTL3,Post-translational protein phosphorylation,104.5,0.0003035398661724,0.5,0.0,1.0,0.0001662449652666,True,0,3,3,10,3.321928094887362,7.023251185772235e-05
992,FSTL3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),102.5,0.0003035398661724,0.5,0.0,1.0,0.0001662449652666,True,0,3,3,10,3.321928094887362,7.023251185772235e-05
993,FUCO,Neutrophil degranulation,1458.5,0.0033121737045812,0.5,0.0,1.0,0.00181403586098405,True,0,1,1,5,2.321928094887362,0.0009970636359284313
994,FUCO2,Neutrophil degranulation,5030.5,0.007731291072190101,0.5,0.0,1.0,0.0042343308375585,True,0,3,3,9,3.169925001442312,0.0018540599817780817
995,FUCO2,Post-translational protein phosphorylation,5034.5,0.007731291072190101,0.5,0.0,1.0,0.0042343308375585,True,0,3,3,9,3.169925001442312,0.0018540599817780817
996,FUCO2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),5032.5,0.007731291072190101,0.5,0.0,1.0,0.0042343308375585,True,0,3,3,9,3.169925001442312,0.0018540599817780817
997,FUMH,Citric acid cycle (TCA cycle),2252.5,0.0030025141535272998,0.5,0.0,1.0,0.0016444392213117499,True,0,1,1,6,2.584962500721156,0.0008375301423441138
998,Factors involved in megakaryocyte development and platelet production,Hemostasis,6706.5,0.0005632987819536,0.5,3.0,4.0,0.019300904943233402,True,1,1,2,9,3.169925001442312,0.00013508607031511688
999,Fatty acid metabolism,Metabolism of lipids,6338.5,0.000729762930665,0.5,2.0,3.0,0.01375906200681985,True,4,1,5,14,3.807354922057604,0.00015180134242151046
1000,Fc epsilon receptor (FCERI) signaling,Innate Immune System,6342.5,0.0015292488691127,0.5,2.0,3.0,0.028832692275565702,True,4,1,5,43,5.426264754702098,0.00023796854432331762
1001,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,6596.5,0.0057233786731553,0.5,2.0,3.0,0.1079094576380917,True,3,1,4,43,5.426264754702098,0.0008906229188530559
1002,Fertilization,Reproduction,6674.5,0.0033029103982568997,0.5,3.0,4.0,0.1131711299138314,True,1,1,2,5,2.321928094887362,0.000994275102865793
1003,Fibronectin matrix formation,Extracellular matrix organization,6788.5,0.0025289670635396,0.5,3.0,4.0,0.08665268674762869,True,2,2,4,4,2.0,0.0008429890211798666
1004,Fibronectin matrix formation,Fibronectin matrix formation,6004.5,0.0021377135467679003,0.5,1.5,2.5,0.0334288158013077,False,2,2,4,4,2.0,0.0007125711822559668
1005,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,6648.5,0.0124477169753157,0.5,3.0,4.0,0.42650935843960125,True,3,1,4,32,5.0,0.00207461949588595
1006,Formation of the beta-catenin:TCF transactivating complex,TCF dependent signaling in response to WNT,5328.5,8.220772060252009e-05,0.5,1.0,2.0,0.00102865098917235,True,3,1,4,8,3.0,2.055193015063002e-05
1007,Formation of the cornified envelope,Formation of the cornified envelope,5974.5,0.004307263047925201,0.5,1.0,2.0,0.05389603753030145,False,17,2,19,20,4.321928094887363,0.0008093425862072574
1008,Formation of the cornified envelope,Keratinization,6582.5,0.0033455081517022997,0.5,2.0,3.0,0.0630767228223577,True,17,2,19,20,4.321928094887363,0.000628627086284056
1009,Formation of xylulose-5-phosphate,Formation of xylulose-5-phosphate,5996.5,0.0007356270850558001,0.5,1.0,2.0,0.009204774480531,False,3,2,5,6,2.584962500721156,0.00020519798600621912
1010,Formation of xylulose-5-phosphate,Metabolism of carbohydrates,6072.5,0.0005952544101561999,0.5,2.0,3.0,0.0112230177705914,True,3,2,5,6,2.584962500721156,0.00016604201858079622
1011,Free fatty acids regulate insulin secretion,Regulation of insulin secretion,5454.5,5.945805767464027e-05,0.5,1.0,2.0,0.0007439883917595156,True,1,1,2,6,2.584962500721156,1.6585405750458925e-05
1012,Fructose biosynthesis,Fructose metabolism,5546.5,0.00027817696022350324,0.5,1.0,2.0,0.0034807801895208497,True,1,1,2,6,2.584962500721156,7.759550069702118e-05
1013,Fructose catabolism,Fructose metabolism,5548.5,0.0026307132037186,0.5,1.0,2.0,0.032917659307428,True,3,1,4,8,3.0,0.00065767830092965
1014,Fructose metabolism,Metabolism of carbohydrates,6594.5,0.0014806751421162,0.5,2.0,3.0,0.0279168757911111,True,2,1,3,10,3.321928094887362,0.0003425959686529189
1015,G alpha (i) signalling events,GPCR downstream signalling,5446.5,0.0015297885732685,0.5,1.0,2.0,0.019141979823597298,True,8,1,9,13,3.700439718141092,0.00032545648173390327
1016,G alpha (q) signalling events,GPCR downstream signalling,5442.5,0.0099274084123853,0.5,1.0,2.0,0.12421994441000575,True,5,1,6,10,3.321928094887362,0.0022969860197648725
1017,G alpha (s) signalling events,GPCR downstream signalling,5444.5,0.0005474421320336,0.5,1.0,2.0,0.0068500487120168995,True,1,1,2,6,2.584962500721156,0.00015270512088298713
1018,G1/S DNA Damage Checkpoints,Cell Cycle Checkpoints,6234.5,0.0015030426938569,0.5,2.0,3.0,0.02833859703565435,True,2,1,3,15,3.9068905956085187,0.0003063126565736082
1019,G1/S Transition,Mitotic G1 phase and G1/S transition,5492.5,0.0011758853864742,0.5,1.0,2.0,0.014713650458678201,True,9,1,10,14,3.807354922057604,0.00024460132558111757
1020,G2/M Checkpoints,Cell Cycle Checkpoints,6358.5,0.0009575010857909,0.5,2.0,3.0,0.01805287204570375,True,1,1,2,13,3.700439718141092,0.00020370457727507415
1021,G2/M DNA damage checkpoint,G2/M Checkpoints,5616.5,0.0012131803001449002,0.5,1.0,2.0,0.0151803152628756,True,8,1,9,13,3.700439718141092,0.0002580993211045121
1022,G2/M Transition,Mitotic G2-G2/M phases,5490.5,0.0025054454755735,0.5,1.0,2.0,0.03135020589157705,True,19,1,20,24,4.584962500721156,0.0004486056039319844
1023,G3P,Gluconeogenesis,1604.5,0.00030616899611169996,0.5,0.0,1.0,0.000167684906652,True,0,2,2,7,2.807354922057604,8.041514447154231e-05
1024,G3P,Glycolysis,1602.5,0.00030616899611169996,0.5,0.0,1.0,0.000167684906652,True,0,2,2,7,2.807354922057604,8.041514447154231e-05
1025,G6PI,Gluconeogenesis,2042.5,0.0017618386773022,0.5,0.0,1.0,0.0009649368743778,True,0,4,4,14,3.807354922057604,0.0003664881636299307
1026,G6PI,Glycolysis,2040.5,0.0017618386773022,0.5,0.0,1.0,0.0009649368743778,True,0,4,4,14,3.807354922057604,0.0003664881636299307
1027,G6PI,Neutrophil degranulation,2044.5,0.0017618386773022,0.5,0.0,1.0,0.0009649368743778,True,0,4,4,14,3.807354922057604,0.0003664881636299307
1028,G6PI,Transcriptional Regulation by TP53,2038.5,0.0017618386773022,0.5,0.0,1.0,0.0009649368743778,True,0,4,4,14,3.807354922057604,0.0003664881636299307
1029,"GABA synthesis, release, reuptake and degradation",Neurotransmitter release cycle,5160.5,0.0016607578925381,0.5,1.0,2.0,0.020780776263036947,True,1,1,2,6,2.584962500721156,0.00046325669855794017
1030,GANAB,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,4734.5,0.010765885695493499,0.5,0.0,1.0,0.00589634012849875,True,0,3,3,11,3.4594316186372973,0.0024141833794467543
1031,GANAB,SARS-CoV-1 Infection,4736.5,0.010765885695493499,0.5,0.0,1.0,0.00589634012849875,True,0,3,3,11,3.4594316186372973,0.0024141833794467543
1032,GANAB,SARS-CoV-2 Infection,4738.5,0.010765885695493499,0.5,0.0,1.0,0.00589634012849875,True,0,3,3,11,3.4594316186372973,0.0024141833794467543
1033,GELS,Amyloid fiber formation,1990.5,0.0070319797561732,0.5,0.0,1.0,0.0038513268291963,True,0,4,4,14,3.807354922057604,0.0014627544398497275
1034,GELS,Apoptotic cleavage of cellular proteins,1986.5,0.0070319797561732,0.5,0.0,1.0,0.0038513268291963,True,0,4,4,14,3.807354922057604,0.0014627544398497275
1035,GELS,Neutrophil degranulation,1988.5,0.0070319797561732,0.5,0.0,1.0,0.0038513268291963,True,0,4,4,14,3.807354922057604,0.0014627544398497275
1036,GELS,Sensory processing of sound by outer hair cells of the cochlea,1992.5,0.0070319797561732,0.5,0.0,1.0,0.0038513268291963,True,0,4,4,14,3.807354922057604,0.0014627544398497275
1037,GFAP,Chaperone Mediated Autophagy,2684.5,0.00020156275149175906,0.5,0.0,1.0,0.0001103933827319971,True,0,2,2,8,3.0,5.0390687872939765e-05
1038,GFAP,Nuclear signaling by ERBB4,2682.5,0.00020156275149175906,0.5,0.0,1.0,0.0001103933827319971,True,0,2,2,8,3.0,5.0390687872939765e-05
1039,GLI3 is processed to GLI3R by the proteasome,Hedgehog 'off' state,5530.5,0.00012192231444460366,0.5,1.0,2.0,0.0015255928328437,True,9,1,10,14,3.807354922057604,2.536162118698311e-05
1040,GLU2B,Advanced glycosylation endproduct receptor signaling,2696.5,0.013115177461688301,0.5,0.0,1.0,0.007183017667752549,True,0,6,6,16,4.0,0.0026230354923376603
1041,GLU2B,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,2690.5,0.013115177461688301,0.5,0.0,1.0,0.007183017667752549,True,0,6,6,16,4.0,0.0026230354923376603
1042,GLU2B,Post-translational protein phosphorylation,2700.5,0.013115177461688301,0.5,0.0,1.0,0.007183017667752549,True,0,6,6,16,4.0,0.0026230354923376603
1043,GLU2B,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2698.5,0.013115177461688301,0.5,0.0,1.0,0.007183017667752549,True,0,6,6,16,4.0,0.0026230354923376603
1044,GLU2B,SARS-CoV-1 Infection,2692.5,0.013115177461688301,0.5,0.0,1.0,0.007183017667752549,True,0,6,6,16,4.0,0.0026230354923376603
1045,GLU2B,SARS-CoV-2 Infection,2694.5,0.013115177461688301,0.5,0.0,1.0,0.007183017667752549,True,0,6,6,16,4.0,0.0026230354923376603
1046,GOLM1,Post-translational protein phosphorylation,4832.5,0.017390628714943998,0.5,0.0,1.0,0.00952462852124365,True,0,2,2,6,2.584962500721156,0.004850993200471602
1047,GOLM1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4830.5,0.017390628714943998,0.5,0.0,1.0,0.00952462852124365,True,0,2,2,6,2.584962500721156,0.004850993200471602
1048,GP1BA,Defective factor IX causes hemophilia B,2120.5,0.0008688298093952,0.5,0.0,1.0,0.00047584715413775003,True,0,5,5,16,4.0,0.00017376596187904
1049,GP1BA,GP1b-IX-V activation signalling,2126.5,0.0008688298093952,0.5,0.0,1.0,0.00047584715413775003,True,0,5,5,16,4.0,0.00017376596187904
1050,GP1BA,Intrinsic Pathway of Fibrin Clot Formation,2124.5,0.0008688298093952,0.5,0.0,1.0,0.00047584715413775003,True,0,5,5,16,4.0,0.00017376596187904
1051,GP1BA,Platelet Adhesion to exposed collagen,2122.5,0.0008688298093952,0.5,0.0,1.0,0.00047584715413775003,True,0,5,5,16,4.0,0.00017376596187904
1052,GP1BA,Transcriptional regulation by RUNX1,2118.5,0.0008688298093952,0.5,0.0,1.0,0.00047584715413775003,True,0,5,5,16,4.0,0.00017376596187904
1053,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,6006.5,3.974178971123134e-05,0.5,1.0,2.0,0.00049728214087815,False,8,2,10,11,3.4594316186372973,8.911850906097209e-06
1054,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",6140.5,3.3490055696945455e-05,0.5,2.0,3.0,0.00063142663676565,True,8,2,10,11,3.4594316186372973,7.509938162742647e-06
1055,GPCR downstream signalling,Signaling by GPCR,6450.5,0.008424988315594401,0.5,2.0,3.0,0.15884601939886095,True,3,1,4,18,4.169925001442312,0.001629615190402953
1056,GPCR ligand binding,Signaling by GPCR,6060.5,0.0036472741087447,0.5,2.0,3.0,0.0687662643707488,True,1,1,2,15,3.9068905956085187,0.0007432963987436101
1057,GPIX,Defective factor IX causes hemophilia B,2720.5,0.0007258143266299,0.5,0.0,1.0,0.0003975193737881,True,0,4,4,12,3.584962500721156,0.00015830321982256967
1058,GPIX,GP1b-IX-V activation signalling,2726.5,0.0007258143266299,0.5,0.0,1.0,0.0003975193737881,True,0,4,4,12,3.584962500721156,0.00015830321982256967
1059,GPIX,Intrinsic Pathway of Fibrin Clot Formation,2724.5,0.0007258143266299,0.5,0.0,1.0,0.0003975193737881,True,0,4,4,12,3.584962500721156,0.00015830321982256967
1060,GPIX,Platelet Adhesion to exposed collagen,2722.5,0.0007258143266299,0.5,0.0,1.0,0.0003975193737881,True,0,4,4,12,3.584962500721156,0.00015830321982256967
1061,GPVI-mediated activation cascade,GPVI-mediated activation cascade,6004.5,0.0054878478253443,0.5,1.0,2.0,0.06866849065506114,False,3,2,5,6,2.584962500721156,0.0015307964376866864
1062,GPVI-mediated activation cascade,"Platelet activation, signaling and aggregation",6456.5,0.0045326488972451,0.5,2.0,3.0,0.08545925616624875,True,3,2,5,6,2.584962500721156,0.0012643504349998936
1063,GPX3,Detoxification of Reactive Oxygen Species,2900.5,0.0024680950661331,0.5,0.0,1.0,0.00135174461173055,True,0,1,1,6,2.584962500721156,0.000688457707894187
1064,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,5904.5,0.00014848254407783917,0.5,1.0,2.0,0.0018579363923613501,False,10,2,12,13,3.700439718141092,3.1589075274123576e-05
1065,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,6104.5,0.00020834208239794218,0.5,2.0,3.0,0.00392811351452345,True,10,2,12,13,3.700439718141092,4.43239558192518e-05
1066,GRHPR,Glyoxylate metabolism and glycine degradation,5102.5,9.262347212094451e-05,0.5,0.0,1.0,5.072871020135533e-05,True,0,1,1,5,2.321928094887362,2.788244341095081e-05
1067,GRN,Neutrophil degranulation,3514.5,0.0002498834084579,0.5,0.0,1.0,0.00013685799853449998,True,0,1,1,5,2.321928094887362,7.522240136458249e-05
1068,GRP75,Cristae formation,3724.5,0.0025354376683829,0.5,0.0,1.0,0.00138862730761215,True,0,4,4,15,3.9068905956085187,0.0005167096390231363
1069,GRP75,Interleukin-12 family signaling,3722.5,0.0025354376683829,0.5,0.0,1.0,0.00138862730761215,True,0,4,4,15,3.9068905956085187,0.0005167096390231363
1070,GRP75,Mitochondrial protein import,3726.5,0.0025354376683829,0.5,0.0,1.0,0.00138862730761215,True,0,4,4,15,3.9068905956085187,0.0005167096390231363
1071,GRP75,Regulation of HSF1-mediated heat shock response,3720.5,0.0025354376683829,0.5,0.0,1.0,0.00138862730761215,True,0,4,4,15,3.9068905956085187,0.0005167096390231363
1072,GSHB,Defective GSS causes GSS deficiency,3758.5,5.637586042526143e-05,0.5,0.0,1.0,3.087634937859832e-05,True,0,2,2,10,3.321928094887362,1.3044145850540972e-05
1073,GSHB,Glutathione conjugation,3756.5,5.637586042526143e-05,0.5,0.0,1.0,3.087634937859832e-05,True,0,2,2,10,3.321928094887362,1.3044145850540972e-05
1074,GSTO1,Glutathione conjugation,4412.5,0.00043653401072849993,0.5,0.0,1.0,0.0002390841847773,True,0,4,4,14,3.807354922057604,9.080544661380198e-05
1075,GSTO1,Interleukin-12 family signaling,4416.5,0.00043653401072849993,0.5,0.0,1.0,0.0002390841847773,True,0,4,4,14,3.807354922057604,9.080544661380198e-05
1076,GSTO1,Methylation,4410.5,0.00043653401072849993,0.5,0.0,1.0,0.0002390841847773,True,0,4,4,14,3.807354922057604,9.080544661380198e-05
1077,GSTO1,Vitamin C (ascorbate) metabolism,4414.5,0.00043653401072849993,0.5,0.0,1.0,0.0002390841847773,True,0,4,4,14,3.807354922057604,9.080544661380198e-05
1078,Galactose catabolism,Galactose catabolism,5998.5,0.0002554315825747061,0.5,1.0,2.0,0.0031961712130636,False,2,2,4,5,2.321928094887362,7.689256819490764e-05
1079,Galactose catabolism,Metabolism of carbohydrates,6126.5,0.0002869808053551,0.5,2.0,3.0,0.0054107800351689,True,2,2,4,5,2.321928094887362,8.638983059169158e-05
1080,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,6368.5,0.0070949190525850005,0.5,2.0,3.0,0.13376868990716695,True,1,1,2,12,3.584962500721156,0.0015474322966587098
1081,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",5216.5,0.009355783989869599,0.5,1.0,2.0,0.11706730687978159,True,7,1,8,12,3.584962500721156,0.0020405366430800804
1082,Gap junction trafficking,Gap junction trafficking and regulation,5214.5,0.0024451511263267,0.5,1.0,2.0,0.03059575312802165,True,6,1,7,11,3.4594316186372973,0.0005483100393574111
1083,Gap junction trafficking and regulation,Membrane Trafficking,6600.5,0.0020398139096526003,0.5,2.0,3.0,0.03845896370716865,True,1,1,2,11,3.4594316186372973,0.00045741567179270303
1084,Gene Silencing by RNA,Gene expression (Transcription),6752.5,0.0009538150706955,0.5,3.0,4.0,0.03268157965666475,True,3,1,4,11,3.4594316186372973,0.000213887139049116
1085,Gene expression (Transcription),root,6874.5,0.0036398929055555,0.5,4.0,5.0,0.3033446601631792,True,4,1,5,69,6.108524456778169,0.0005120461957593413
1086,Generic Transcription Pathway,RNA Polymerase II Transcription,6180.5,0.0116782346365117,0.5,2.0,3.0,0.22018322354016195,True,9,1,10,49,5.614709844115208,0.001765494619072561
1087,Global Genome Nucleotide Excision Repair (GG-NER),Nucleotide Excision Repair,6076.5,0.0088924454020514,0.5,2.0,3.0,0.16765952686521912,True,1,1,2,6,2.584962500721156,0.002480484914490063
1088,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,Regulation of insulin secretion,5458.5,0.0007741650842344458,0.5,1.0,2.0,0.009686993798683501,True,1,1,2,6,2.584962500721156,0.00021594788901661136
1089,Gluconeogenesis,Glucose metabolism,5624.5,0.0011145798797925,0.5,1.0,2.0,0.013946545257030051,True,12,1,13,17,4.087462841250339,0.00021908364042587703
1090,Glucose metabolism,Metabolism of carbohydrates,6400.5,0.0021983097876496,0.5,2.0,3.0,0.0414472692534609,True,2,1,3,18,4.169925001442312,0.00042521115626170837
1091,Glucuronidation,Phase II - Conjugation of compounds,5206.5,0.0044797388053744,0.5,1.0,2.0,0.0560541968516893,True,1,1,2,6,2.584962500721156,0.0012495915381188086
1092,Glutamate and glutamine metabolism,Glutamate and glutamine metabolism,5990.5,0.00032370222404922886,0.5,1.0,2.0,0.00405042994167905,False,2,2,4,5,2.321928094887362,9.744407910196044e-05
1093,Glutamate and glutamine metabolism,Metabolism of amino acids and derivatives,6578.5,1.0073780385406502e-05,0.5,2.0,3.0,0.00018993259748005,True,2,2,4,5,2.321928094887362,3.0325100657388183e-06
1094,Glutathione conjugation,Phase II - Conjugation of compounds,5208.5,0.0017934206838903,0.5,1.0,2.0,0.022440762825742297,True,2,1,3,7,2.807354922057604,0.000471041108749873
1095,Glycerophospholipid biosynthesis,Phospholipid metabolism,5200.5,0.0014065632376929,0.5,1.0,2.0,0.0176000825127125,True,2,1,3,7,2.807354922057604,0.00036943318038044974
1096,Glycogen breakdown (glycogenolysis),Glycogen metabolism,5698.5,3.198355556249105e-05,0.5,1.0,2.0,0.00040020469884664996,True,3,1,4,8,3.0,7.995888890622763e-06
1097,Glycogen metabolism,Metabolism of carbohydrates,6580.5,0.0006788319010975999,0.5,2.0,3.0,0.0127988005788371,True,2,1,3,10,3.321928094887362,0.00015706691231180504
1098,Glycogen synthesis,Glycogen metabolism,5696.5,0.0020858632325433,0.5,1.0,2.0,0.026100045855891853,True,2,1,3,7,2.807354922057604,0.0005478510081786752
1099,Glycolysis,Glucose metabolism,5622.5,0.0019486830200909,0.5,1.0,2.0,0.0243835335842966,True,8,1,9,13,3.700439718141092,0.000414574622150788
1100,Glycosaminoglycan metabolism,Metabolism of carbohydrates,6566.5,0.007289471619721899,0.5,2.0,3.0,0.13743681379006134,True,4,1,5,13,3.700439718141092,0.001550806319585076
1101,Glycosphingolipid metabolism,Sphingolipid metabolism,5470.5,0.0008601785860397431,0.5,1.0,2.0,0.010763265869795249,True,1,1,2,6,2.584962500721156,0.00023994074857594977
1102,Glyoxylate metabolism and glycine degradation,Glyoxylate metabolism and glycine degradation,5976.5,0.00017700632772886017,0.5,1.0,2.0,0.00221484956368655,False,2,2,4,5,2.321928094887362,5.3284214068716014e-05
1103,Glyoxylate metabolism and glycine degradation,Metabolism of amino acids and derivatives,6586.5,4.5062874093632046e-05,0.5,2.0,3.0,0.000849622326383,True,2,2,4,5,2.321928094887362,1.3565276793012586e-05
1104,Golgi Associated Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,5326.5,0.0050795360199523,0.5,1.0,2.0,0.06355935565619535,True,3,1,4,8,3.0,0.001269884004988075
1105,Golgi-to-ER retrograde transport,Intra-Golgi and retrograde Golgi-to-ER traffic,5600.5,0.0032974378075031003,0.5,1.0,2.0,0.041260268957251045,True,5,1,6,10,3.321928094887362,0.0007629552679055013
1106,H2A1B,Activation of anterior HOX genes in hindbrain development during early embryogenesis,1748.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1107,H2A1B,Amyloid fiber formation,1746.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1108,H2A1B,Assembly of the ORC complex at the origin of replication,1708.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1109,H2A1B,B-WICH complex positively regulates rRNA expression,1696.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1110,H2A1B,DNA Damage/Telomere Stress Induced Senescence,1692.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1111,H2A1B,DNA methylation,1738.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1112,H2A1B,Defective pyroptosis,1750.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1113,H2A1B,Deposition of new CENPA-containing nucleosomes at the centromere,1720.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1114,H2A1B,Depurination,1716.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1115,H2A1B,Depyrimidination,1718.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1116,H2A1B,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,1694.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1117,H2A1B,Estrogen-dependent gene expression,1722.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1118,H2A1B,Formation of the beta-catenin:TCF transactivating complex,1684.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1119,H2A1B,HATs acetylate histones,1742.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1120,H2A1B,HCMV Early Events,1724.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1121,H2A1B,HCMV Late Events,1726.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1122,H2A1B,HDACs deacetylate histones,1740.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1123,H2A1B,Inhibition of DNA recombination at telomere,1678.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1124,H2A1B,Meiotic recombination,1732.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1125,H2A1B,Meiotic synapsis,1730.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1126,H2A1B,Metalloprotease DUBs,1706.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1127,H2A1B,Mitotic Prophase,1710.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1128,H2A1B,NoRC negatively regulates rRNA expression,1700.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1129,H2A1B,Oxidative Stress Induced Senescence,1688.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1130,H2A1B,PRC2 methylates histones and DNA,1736.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1131,H2A1B,Packaging Of Telomere Ends,1676.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1132,H2A1B,Pre-NOTCH Transcription and Translation,1680.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1133,H2A1B,RHO GTPase Effectors,1682.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1134,H2A1B,RMTs methylate histone arginines,1744.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1135,H2A1B,RNA Polymerase I Promoter Escape,1714.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1136,H2A1B,RNA Polymerase I Promoter Opening,1712.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1137,H2A1B,SIRT1 negatively regulates rRNA expression,1698.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1138,H2A1B,Senescence-Associated Secretory Phenotype (SASP),1690.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1139,H2A1B,Transcriptional regulation by RUNX1,1686.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1140,H2A1B,Transcriptional regulation by small RNAs,1734.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1141,H2A1B,Transcriptional regulation of granulopoiesis,1728.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1142,H2A1B,UCH proteinases,1702.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1143,H2A1B,Ub-specific processing proteases,1704.5,0.013046462712856598,0.5,0.0,1.0,0.0071453834644538,True,0,38,38,86,6.426264754702098,0.001756800106621024
1144,H2B1A,Activation of anterior HOX genes in hindbrain development during early embryogenesis,4916.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1145,H2B1A,Amyloid fiber formation,4914.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1146,H2B1A,Assembly of the ORC complex at the origin of replication,4874.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1147,H2B1A,B-WICH complex positively regulates rRNA expression,4862.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1148,H2B1A,DNA Damage/Telomere Stress Induced Senescence,4858.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1149,H2B1A,DNA methylation,4908.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1150,H2B1A,Defective pyroptosis,4920.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1151,H2B1A,Deposition of new CENPA-containing nucleosomes at the centromere,4888.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1152,H2B1A,Depurination,4884.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1153,H2B1A,Depyrimidination,4886.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1154,H2B1A,E3 ubiquitin ligases ubiquitinate target proteins,4890.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1155,H2B1A,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,4860.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1156,H2B1A,Estrogen-dependent gene expression,4892.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1157,H2B1A,Formation of the beta-catenin:TCF transactivating complex,4850.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1158,H2B1A,G2/M DNA damage checkpoint,4878.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1159,H2B1A,HATs acetylate histones,4912.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1160,H2B1A,HCMV Early Events,4894.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1161,H2B1A,HCMV Late Events,4896.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1162,H2B1A,HDACs deacetylate histones,4910.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1163,H2B1A,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),4870.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1164,H2B1A,Inhibition of DNA recombination at telomere,4844.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1165,H2B1A,Meiotic recombination,4902.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1166,H2B1A,Meiotic synapsis,4900.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1167,H2B1A,Mitotic Prophase,4876.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1168,H2B1A,NoRC negatively regulates rRNA expression,4866.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1169,H2B1A,Nonhomologous End-Joining (NHEJ),4918.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1170,H2B1A,Oxidative Stress Induced Senescence,4854.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1171,H2B1A,PRC2 methylates histones and DNA,4906.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1172,H2B1A,Packaging Of Telomere Ends,4842.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1173,H2B1A,Pre-NOTCH Transcription and Translation,4846.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1174,H2B1A,RHO GTPase Effectors,4848.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1175,H2B1A,RNA Polymerase I Promoter Escape,4882.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1176,H2B1A,RNA Polymerase I Promoter Opening,4880.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1177,H2B1A,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,4872.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1178,H2B1A,SIRT1 negatively regulates rRNA expression,4864.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1179,H2B1A,Senescence-Associated Secretory Phenotype (SASP),4856.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1180,H2B1A,Transcriptional regulation by RUNX1,4852.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1181,H2B1A,Transcriptional regulation by small RNAs,4904.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1182,H2B1A,Transcriptional regulation of granulopoiesis,4898.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1183,H2B1A,Ub-specific processing proteases,4868.5,0.0019514727806336,0.5,0.0,1.0,0.0010687970866103,True,0,40,40,94,6.554588851677638,0.0002583162126950481
1184,H4,Activation of anterior HOX genes in hindbrain development during early embryogenesis,4218.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1185,H4,Amyloid fiber formation,4216.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1186,H4,Assembly of the ORC complex at the origin of replication,4172.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1187,H4,B-WICH complex positively regulates rRNA expression,4162.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1188,H4,DNA Damage/Telomere Stress Induced Senescence,4156.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1189,H4,DNA methylation,4204.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1190,H4,Defective pyroptosis,4222.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1191,H4,Deposition of new CENPA-containing nucleosomes at the centromere,4186.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1192,H4,Depurination,4182.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1193,H4,Depyrimidination,4184.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1194,H4,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,4160.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1195,H4,Estrogen-dependent gene expression,4188.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1196,H4,Formation of the beta-catenin:TCF transactivating complex,4148.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1197,H4,G2/M DNA damage checkpoint,4176.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1198,H4,HATs acetylate histones,4212.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1199,H4,HCMV Early Events,4190.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1200,H4,HCMV Late Events,4192.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1201,H4,HDACs deacetylate histones,4206.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1202,H4,HDMs demethylate histones,4210.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1203,H4,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),4168.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1204,H4,Inhibition of DNA recombination at telomere,4142.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1205,H4,Meiotic recombination,4198.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1206,H4,Meiotic synapsis,4196.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1207,H4,Mitotic Prophase,4174.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1208,H4,NoRC negatively regulates rRNA expression,4166.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1209,H4,Nonhomologous End-Joining (NHEJ),4220.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1210,H4,Oxidative Stress Induced Senescence,4152.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1211,H4,PKMTs methylate histone lysines,4208.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1212,H4,PRC2 methylates histones and DNA,4202.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1213,H4,Packaging Of Telomere Ends,4140.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1214,H4,Pre-NOTCH Transcription and Translation,4144.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1215,H4,RHO GTPase Effectors,4146.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1216,H4,RMTs methylate histone arginines,4214.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1217,H4,RNA Polymerase I Promoter Escape,4180.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1218,H4,RNA Polymerase I Promoter Opening,4178.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1219,H4,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,4170.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1220,H4,SIRT1 negatively regulates rRNA expression,4164.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1221,H4,SUMO E3 ligases SUMOylate target proteins,4158.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1222,H4,Senescence-Associated Secretory Phenotype (SASP),4154.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1223,H4,Transcriptional regulation by RUNX1,4150.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1224,H4,Transcriptional regulation by small RNAs,4200.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1225,H4,Transcriptional regulation of granulopoiesis,4194.5,0.0009713598776999,0.5,0.0,1.0,0.00053200158241445,True,0,42,42,95,6.569855608330948,0.00012831947238608847
1226,HATs acetylate histones,Chromatin modifying enzymes,6108.5,0.0021732370594419997,0.5,2.0,3.0,0.0409745441977034,True,5,2,7,8,3.0,0.0005433092648604999
1227,HATs acetylate histones,HATs acetylate histones,5900.5,0.0027255109647551998,0.5,1.0,2.0,0.03410384729496735,False,5,2,7,8,3.0,0.0006813777411887999
1228,HBA,Cytoprotection by HMOX1,4400.5,0.0024925907403201,0.5,0.0,1.0,0.0013651605842542498,True,0,5,5,14,3.807354922057604,0.0005184952600198786
1229,HBA,Erythrocytes take up carbon dioxide and release oxygen,4402.5,0.0024925907403201,0.5,0.0,1.0,0.0013651605842542498,True,0,5,5,14,3.807354922057604,0.0005184952600198786
1230,HBA,Erythrocytes take up oxygen and release carbon dioxide,4404.5,0.0024925907403201,0.5,0.0,1.0,0.0013651605842542498,True,0,5,5,14,3.807354922057604,0.0005184952600198786
1231,HBA,Heme signaling,4408.5,0.0024925907403201,0.5,0.0,1.0,0.0013651605842542498,True,0,5,5,14,3.807354922057604,0.0005184952600198786
1232,HBA,Scavenging of heme from plasma,4406.5,0.0024925907403201,0.5,0.0,1.0,0.0013651605842542498,True,0,5,5,14,3.807354922057604,0.0005184952600198786
1233,HBB,Chaperone Mediated Autophagy,4396.5,0.0355107818946717,0.5,0.0,1.0,0.01944880841225765,True,0,8,8,20,4.321928094887363,0.006672540714855953
1234,HBB,Cytoprotection by HMOX1,4384.5,0.0355107818946717,0.5,0.0,1.0,0.01944880841225765,True,0,8,8,20,4.321928094887363,0.006672540714855953
1235,HBB,Erythrocytes take up carbon dioxide and release oxygen,4386.5,0.0355107818946717,0.5,0.0,1.0,0.01944880841225765,True,0,8,8,20,4.321928094887363,0.006672540714855953
1236,HBB,Erythrocytes take up oxygen and release carbon dioxide,4388.5,0.0355107818946717,0.5,0.0,1.0,0.01944880841225765,True,0,8,8,20,4.321928094887363,0.006672540714855953
1237,HBB,Heme signaling,4394.5,0.0355107818946717,0.5,0.0,1.0,0.01944880841225765,True,0,8,8,20,4.321928094887363,0.006672540714855953
1238,HBB,Late endosomal microautophagy,4398.5,0.0355107818946717,0.5,0.0,1.0,0.01944880841225765,True,0,8,8,20,4.321928094887363,0.006672540714855953
1239,HBB,Neutrophil degranulation,4390.5,0.0355107818946717,0.5,0.0,1.0,0.01944880841225765,True,0,8,8,20,4.321928094887363,0.006672540714855953
1240,HBB,Scavenging of heme from plasma,4392.5,0.0355107818946717,0.5,0.0,1.0,0.01944880841225765,True,0,8,8,20,4.321928094887363,0.006672540714855953
1241,HCMV Early Events,HCMV Infection,5718.5,5.314702150894875e-06,0.5,1.0,2.0,6.650194877811703e-05,True,8,1,9,13,3.700439718141092,1.1306819084144552e-06
1242,HCMV Infection,Infectious disease,6110.5,0.0034093494731802,0.5,2.0,3.0,0.0642803968703281,True,2,1,3,15,3.9068905956085187,0.0006948085364347513
1243,HCMV Late Events,HCMV Infection,5720.5,0.0033077003663954004,0.5,1.0,2.0,0.041388682581648156,True,4,1,5,9,3.169925001442312,0.0007932277835335931
1244,HDACs deacetylate histones,Chromatin modifying enzymes,6120.5,0.0011224235864517999,0.5,2.0,3.0,0.02116234611949095,True,4,2,6,7,2.807354922057604,0.0002948040330963444
1245,HDACs deacetylate histones,HDACs deacetylate histones,5894.5,0.0012073948215253,0.5,1.0,2.0,0.015107922569570349,False,4,2,6,7,2.807354922057604,0.0003171216884799353
1246,HDL assembly,Plasma lipoprotein assembly,5670.5,0.004545481473551299,0.5,1.0,2.0,0.05687682348767135,True,2,1,3,7,2.807354922057604,0.0011938685955484262
1247,HDL clearance,Plasma lipoprotein clearance,5680.5,0.0017163425121638999,0.5,1.0,2.0,0.0214762969944448,True,1,1,2,6,2.584962500721156,0.0004787616360892584
1248,HDL remodeling,Plasma lipoprotein remodeling,5678.5,0.0013395020589036999,0.5,1.0,2.0,0.0167609575814902,True,6,1,7,11,3.4594316186372973,0.00030037506423588167
1249,HDMs demethylate histones,Chromatin modifying enzymes,6062.5,0.00016488562519251378,0.5,2.0,3.0,0.0031087788180600004,True,2,2,4,5,2.321928094887362,4.9635519036755255e-05
1250,HDMs demethylate histones,HDMs demethylate histones,5898.5,0.0004830768491513,0.5,1.0,2.0,0.006044657059990801,False,2,2,4,5,2.321928094887362,0.00014542062180538553
1251,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),Homology Directed Repair,5572.5,0.0009557172571258001,0.5,1.0,2.0,0.0119587247366344,True,2,1,3,7,2.807354922057604,0.00025101869321111334
1252,HEMO,Scavenging of heme from plasma,1422.5,0.0016024226381063,0.5,0.0,1.0,0.0008776267156389999,True,0,1,1,5,2.321928094887362,0.00048237727980100483
1253,HEP2,Common Pathway of Fibrin Clot Formation,1876.5,0.0105790464777542,0.5,0.0,1.0,0.005794010639937,True,0,4,4,10,3.321928094887362,0.0024477608709568112
1254,HEP2,Intrinsic Pathway of Fibrin Clot Formation,1874.5,0.0105790464777542,0.5,0.0,1.0,0.005794010639937,True,0,4,4,10,3.321928094887362,0.0024477608709568112
1255,HEP2,Post-translational protein phosphorylation,1880.5,0.0105790464777542,0.5,0.0,1.0,0.005794010639937,True,0,4,4,10,3.321928094887362,0.0024477608709568112
1256,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1878.5,0.0105790464777542,0.5,0.0,1.0,0.005794010639937,True,0,4,4,10,3.321928094887362,0.0024477608709568112
1257,HGFA,MET Receptor Activation,4526.5,0.0112542794052428,0.5,0.0,1.0,0.0061638272178802,True,0,1,1,6,2.584962500721156,0.0031393018484792722
1258,HGFL,Signaling by MST1,3180.5,0.0015219958529806002,0.5,0.0,1.0,0.0008335779774343,True,0,1,1,5,2.321928094887362,0.00045816640502334747
1259,HIV Infection,Infectious disease,6466.5,0.0010360735937913,0.5,2.0,3.0,0.01953429013941905,True,2,1,3,18,4.169925001442312,0.00020040398912987226
1260,HIV Life Cycle,HIV Infection,5222.5,0.0009921962688712,0.5,1.0,2.0,0.0124151803011584,True,2,1,3,7,2.807354922057604,0.00026059988868465893
1261,HPPD,Tyrosine catabolism,3618.5,0.0014152615464074,0.5,0.0,1.0,0.00077512094075975,True,0,1,1,6,2.584962500721156,0.00039477722462165333
1262,HPT,Neutrophil degranulation,176.5,0.0031688993747657,0.5,0.0,1.0,0.0017355663133621002,True,0,2,2,8,3.0,0.000792224843691425
1263,HPT,Scavenging of heme from plasma,178.5,0.0031688993747657,0.5,0.0,1.0,0.0017355663133621002,True,0,2,2,8,3.0,0.000792224843691425
1264,HPTR,Scavenging of heme from plasma,180.5,0.0016068172706367998,0.5,0.0,1.0,0.0008800336005784001,True,0,1,1,5,2.321928094887362,0.000483700196012606
1265,HRG,Dissolution of Fibrin Clot,1528.5,0.005100337612383,0.5,0.0,1.0,0.0027933907328566,True,0,2,2,7,2.807354922057604,0.0013396013024251049
1266,HRG,Platelet degranulation ,1526.5,0.005100337612383,0.5,0.0,1.0,0.0027933907328566,True,0,2,2,7,2.807354922057604,0.0013396013024251049
1267,HS71L,HSF1-dependent transactivation,3628.5,0.0011391742521338,0.5,0.0,1.0,0.000623911403687,True,0,3,3,8,3.0,0.00028479356303345
1268,HS71L,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,3630.5,0.0011391742521338,0.5,0.0,1.0,0.000623911403687,True,0,3,3,8,3.0,0.00028479356303345
1269,HS71L,Regulation of HSF1-mediated heat shock response,3626.5,0.0011391742521338,0.5,0.0,1.0,0.000623911403687,True,0,3,3,8,3.0,0.00028479356303345
1270,HS90A,Aggrephagy,2232.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1271,HS90A,Anchoring of the basal body to the plasma membrane,2248.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1272,HS90A,Chaperone Mediated Autophagy,2250.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1273,HS90A,Constitutive Signaling by Overexpressed ERBB2,2186.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1274,HS90A,Downregulation of ERBB2 signaling,2182.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1275,HS90A,Drug resistance in ERBB2 KD mutants,2190.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1276,HS90A,Drug resistance in ERBB2 TMD/JMD mutants,2196.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1277,HS90A,Drug-mediated inhibition of ERBB2 signaling,2184.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1278,HS90A,Estrogen-dependent gene expression,2228.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1279,HS90A,Extra-nuclear estrogen signaling,2226.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1280,HS90A,G2/M Transition,2218.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1281,HS90A,HSF1 activation,2210.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1282,HS90A,HSF1-dependent transactivation,2212.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1283,HS90A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,2246.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1284,HS90A,Influenza Viral RNA Transcription and Replication,2202.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1285,HS90A,Interleukin-4 and Interleukin-13 signaling,2216.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1286,HS90A,Mitotic Prometaphase,2224.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1287,HS90A,Neutrophil degranulation,2238.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1288,HS90A,PIWI-interacting RNA (piRNA) biogenesis,2242.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1289,HS90A,Potential therapeutics for SARS,2234.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1290,HS90A,RHO GTPase cycle,2206.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1291,HS90A,Regulation of actin dynamics for phagocytic cup formation,2208.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1292,HS90A,Regulation of necroptotic cell death,2220.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1293,HS90A,SARS-CoV-2 Infection,2236.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1294,HS90A,Scavenging by Class F Receptors,2244.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1295,HS90A,Semaphorin interactions,2214.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1296,HS90A,Signaling by EGFRvIII in Cancer,2198.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1297,HS90A,Signaling by ERBB2 ECD mutants,2192.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1298,HS90A,Signaling by ERBB2 KD Mutants,2188.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1299,HS90A,Signaling by ERBB2 TMD/JMD mutants,2194.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1300,HS90A,Signaling by Ligand-Responsive EGFR Variants in Cancer,2200.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1301,HS90A,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",2230.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1302,HS90A,Uptake and function of diphtheria toxin,2222.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1303,HS90A,VEGFA-VEGFR2 Pathway,2204.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1304,HS90A,eNOS activation,2240.5,0.0147746038406869,0.5,0.0,1.0,0.0080918646150014,True,0,35,35,84,6.392317422778761,0.00199864305003466
1305,HS90B,Aryl hydrocarbon receptor signalling,2326.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1306,HS90B,Cell recruitment (pro-inflammatory response),2340.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1307,HS90B,Chaperone Mediated Autophagy,2350.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1308,HS90B,Estrogen-dependent gene expression,2338.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1309,HS90B,G2/M Transition,2334.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1310,HS90B,HSF1 activation,2328.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1311,HS90B,HSF1-dependent transactivation,2330.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1312,HS90B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,2348.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1313,HS90B,Inflammasomes,2320.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1314,HS90B,Neutrophil degranulation,2346.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1315,HS90B,Potential therapeutics for SARS,2342.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1316,HS90B,RHO GTPase cycle,2322.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1317,HS90B,Regulation of actin dynamics for phagocytic cup formation,2324.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1318,HS90B,SARS-CoV-2 Infection,2344.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1319,HS90B,Semaphorin interactions,2332.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1320,HS90B,Uptake and function of diphtheria toxin,2336.5,0.0249562090248587,0.5,0.0,1.0,0.0136682016594391,True,0,16,16,45,5.491853096329675,0.003844235021117205
1321,HSF1 activation,Cellular response to heat stress,5410.5,4.235071285015716e-05,0.5,1.0,2.0,0.00052992714487365,True,3,1,4,8,3.0,1.058767821253929e-05
1322,HSF1-dependent transactivation,Cellular response to heat stress,5412.5,0.0019472585631476,0.5,1.0,2.0,0.024365709600940852,True,5,1,6,10,3.321928094887362,0.00045055320690113183
1323,HSP72,HSF1-dependent transactivation,3884.5,0.0088567665126883,0.5,0.0,1.0,0.00485073957448455,True,0,4,4,12,3.584962500721156,0.0019316987895310472
1324,HSP72,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,3888.5,0.0088567665126883,0.5,0.0,1.0,0.00485073957448455,True,0,4,4,12,3.584962500721156,0.0019316987895310472
1325,HSP72,Meiotic synapsis,3886.5,0.0088567665126883,0.5,0.0,1.0,0.00485073957448455,True,0,4,4,12,3.584962500721156,0.0019316987895310472
1326,HSP72,Regulation of HSF1-mediated heat shock response,3882.5,0.0088567665126883,0.5,0.0,1.0,0.00485073957448455,True,0,4,4,12,3.584962500721156,0.0019316987895310472
1327,HSP76,Neutrophil degranulation,2816.5,0.0011170950671127002,0.5,0.0,1.0,0.0006118189118729,True,0,2,2,9,3.169925001442312,0.000267893323435389
1328,HSP76,Regulation of HSF1-mediated heat shock response,2814.5,0.0011170950671127002,0.5,0.0,1.0,0.0006118189118729,True,0,2,2,9,3.169925001442312,0.000267893323435389
1329,HSP7C,AUF1 (hnRNP D0) binds and destabilizes mRNA,2580.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1330,HSP7C,Chaperone Mediated Autophagy,2584.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1331,HSP7C,"GABA synthesis, release, reuptake and degradation",2558.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1332,HSP7C,Golgi Associated Vesicle Biogenesis,2562.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1333,HSP7C,HSF1-dependent transactivation,2566.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1334,HSP7C,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,2578.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1335,HSP7C,Interleukin-4 and Interleukin-13 signaling,2570.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1336,HSP7C,L1CAM interactions,2568.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1337,HSP7C,Late endosomal microautophagy,2586.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1338,HSP7C,Lipophagy,2574.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1339,HSP7C,Lysosome Vesicle Biogenesis,2560.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1340,HSP7C,Neutrophil degranulation,2576.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1341,HSP7C,Protein methylation,2582.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1342,HSP7C,Regulation of HSF1-mediated heat shock response,2564.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1343,HSP7C,mRNA Splicing - Major Pathway,2572.5,0.036579795349578295,0.5,0.0,1.0,0.020034293630135203,True,0,15,15,42,5.392317422778761,0.0057224622824936225
1344,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,Cellular responses to stress,6446.5,0.0016855141183617,0.5,2.0,3.0,0.03177894120598075,True,11,2,13,14,3.807354922057604,0.0003506115412090856
1345,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,5884.5,0.0023892018339267997,0.5,1.0,2.0,0.0298956693092642,False,11,2,13,14,3.807354922057604,0.0004969888582522619
1346,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,2946.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1347,HV102,CD22 mediated BCR regulation,2944.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1348,HV102,FCERI mediated Ca+2 mobilization,2934.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1349,HV102,FCERI mediated MAPK activation,2932.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1350,HV102,FCERI mediated NF-kB activation,2936.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1351,HV102,FCGR activation,2924.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1352,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,2948.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1353,HV102,Initial triggering of complement,2920.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1354,HV102,Leishmania parasite growth and survival,2940.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1355,HV102,Parasite infection,2938.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1356,HV102,Potential therapeutics for SARS,2942.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1357,HV102,Regulation of Complement cascade,2922.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1358,HV102,Regulation of actin dynamics for phagocytic cup formation,2926.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1359,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,2930.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1360,HV102,Role of phospholipids in phagocytosis,2928.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1361,HV102,Scavenging of heme from plasma,2950.5,0.0034808018024186,0.5,0.0,1.0,0.0019063913483256,True,0,16,16,31,4.954196310386875,0.0005845964125076747
1362,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,710.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1363,HV146,CD22 mediated BCR regulation,708.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1364,HV146,FCERI mediated Ca+2 mobilization,698.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1365,HV146,FCERI mediated MAPK activation,696.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1366,HV146,FCERI mediated NF-kB activation,700.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1367,HV146,FCGR activation,688.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1368,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,712.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1369,HV146,Initial triggering of complement,684.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1370,HV146,Leishmania parasite growth and survival,704.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1371,HV146,Parasite infection,702.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1372,HV146,Potential therapeutics for SARS,706.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1373,HV146,Regulation of Complement cascade,686.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1374,HV146,Regulation of actin dynamics for phagocytic cup formation,690.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1375,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,694.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1376,HV146,Role of phospholipids in phagocytosis,692.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1377,HV146,Scavenging of heme from plasma,714.5,0.007731540044250199,0.5,0.0,1.0,0.0042344671964231004,True,0,16,16,31,4.954196310386875,0.0012985027098892951
1378,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,678.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1379,HV169,CD22 mediated BCR regulation,676.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1380,HV169,FCERI mediated Ca+2 mobilization,666.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1381,HV169,FCERI mediated MAPK activation,664.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1382,HV169,FCERI mediated NF-kB activation,668.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1383,HV169,FCGR activation,656.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1384,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,680.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1385,HV169,Initial triggering of complement,652.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1386,HV169,Leishmania parasite growth and survival,672.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1387,HV169,Parasite infection,670.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1388,HV169,Potential therapeutics for SARS,674.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1389,HV169,Regulation of Complement cascade,654.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1390,HV169,Regulation of actin dynamics for phagocytic cup formation,658.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1391,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,662.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1392,HV169,Role of phospholipids in phagocytosis,660.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1393,HV169,Scavenging of heme from plasma,682.5,0.009741199212115,0.5,0.0,1.0,0.00533513223516175,True,0,16,16,31,4.954196310386875,0.0016360225132520134
1394,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,870.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1395,HV307,CD22 mediated BCR regulation,868.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1396,HV307,FCERI mediated Ca+2 mobilization,858.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1397,HV307,FCERI mediated MAPK activation,856.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1398,HV307,FCERI mediated NF-kB activation,860.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1399,HV307,FCGR activation,848.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1400,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,872.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1401,HV307,Initial triggering of complement,844.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1402,HV307,Leishmania parasite growth and survival,864.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1403,HV307,Parasite infection,862.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1404,HV307,Potential therapeutics for SARS,866.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1405,HV307,Regulation of Complement cascade,846.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1406,HV307,Regulation of actin dynamics for phagocytic cup formation,850.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1407,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,854.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1408,HV307,Role of phospholipids in phagocytosis,852.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1409,HV307,Scavenging of heme from plasma,874.5,0.0124624432560982,0.5,0.0,1.0,0.00682552335669225,True,0,16,16,31,4.954196310386875,0.0020930521276831147
1410,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,806.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1411,HV313,CD22 mediated BCR regulation,804.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1412,HV313,FCERI mediated Ca+2 mobilization,794.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1413,HV313,FCERI mediated MAPK activation,792.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1414,HV313,FCERI mediated NF-kB activation,796.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1415,HV313,FCGR activation,784.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1416,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,808.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1417,HV313,Initial triggering of complement,780.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1418,HV313,Leishmania parasite growth and survival,800.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1419,HV313,Parasite infection,798.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1420,HV313,Potential therapeutics for SARS,802.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1421,HV313,Regulation of Complement cascade,782.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1422,HV313,Regulation of actin dynamics for phagocytic cup formation,786.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1423,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,790.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1424,HV313,Role of phospholipids in phagocytosis,788.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1425,HV313,Scavenging of heme from plasma,810.5,0.0046949241620661,0.5,0.0,1.0,0.00257135088742735,True,0,16,16,31,4.954196310386875,0.0007885067803149148
1426,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,774.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1427,HV323,CD22 mediated BCR regulation,772.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1428,HV323,FCERI mediated Ca+2 mobilization,762.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1429,HV323,FCERI mediated MAPK activation,760.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1430,HV323,FCERI mediated NF-kB activation,764.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1431,HV323,FCGR activation,752.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1432,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,776.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1433,HV323,Initial triggering of complement,748.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1434,HV323,Leishmania parasite growth and survival,768.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1435,HV323,Parasite infection,766.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1436,HV323,Potential therapeutics for SARS,770.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1437,HV323,Regulation of Complement cascade,750.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1438,HV323,Regulation of actin dynamics for phagocytic cup formation,754.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1439,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,758.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1440,HV323,Role of phospholipids in phagocytosis,756.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1441,HV323,Scavenging of heme from plasma,778.5,0.0285268348499704,0.5,0.0,1.0,0.015623788494739851,True,0,16,16,31,4.954196310386875,0.00479104708056172
1442,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,742.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1443,HV348,CD22 mediated BCR regulation,740.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1444,HV348,FCERI mediated Ca+2 mobilization,730.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1445,HV348,FCERI mediated MAPK activation,728.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1446,HV348,FCERI mediated NF-kB activation,732.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1447,HV348,FCGR activation,720.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1448,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,744.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1449,HV348,Initial triggering of complement,716.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1450,HV348,Leishmania parasite growth and survival,736.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1451,HV348,Parasite infection,734.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1452,HV348,Potential therapeutics for SARS,738.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1453,HV348,Regulation of Complement cascade,718.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1454,HV348,Regulation of actin dynamics for phagocytic cup formation,722.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1455,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,726.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1456,HV348,Role of phospholipids in phagocytosis,724.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1457,HV348,Scavenging of heme from plasma,746.5,0.009065177990264399,0.5,0.0,1.0,0.00496488391831555,True,0,16,16,31,4.954196310386875,0.0015224855744931573
1458,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,838.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1459,HV353,CD22 mediated BCR regulation,836.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1460,HV353,FCERI mediated Ca+2 mobilization,826.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1461,HV353,FCERI mediated MAPK activation,824.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1462,HV353,FCERI mediated NF-kB activation,828.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1463,HV353,FCGR activation,816.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1464,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,840.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1465,HV353,Initial triggering of complement,812.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1466,HV353,Leishmania parasite growth and survival,832.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1467,HV353,Parasite infection,830.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1468,HV353,Potential therapeutics for SARS,834.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1469,HV353,Regulation of Complement cascade,814.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1470,HV353,Regulation of actin dynamics for phagocytic cup formation,818.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1471,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,822.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1472,HV353,Role of phospholipids in phagocytosis,820.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1473,HV353,Scavenging of heme from plasma,842.5,0.0259589999358684,0.5,0.0,1.0,0.01421741762330125,True,0,16,16,31,4.954196310386875,0.004359782342175028
1474,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1980.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1475,HV434,CD22 mediated BCR regulation,1978.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1476,HV434,FCERI mediated Ca+2 mobilization,1968.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1477,HV434,FCERI mediated MAPK activation,1966.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1478,HV434,FCERI mediated NF-kB activation,1970.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1479,HV434,FCGR activation,1958.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1480,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1982.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1481,HV434,Initial triggering of complement,1954.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1482,HV434,Leishmania parasite growth and survival,1974.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1483,HV434,Parasite infection,1972.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1484,HV434,Potential therapeutics for SARS,1976.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1485,HV434,Regulation of Complement cascade,1956.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1486,HV434,Regulation of actin dynamics for phagocytic cup formation,1960.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1487,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,1964.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1488,HV434,Role of phospholipids in phagocytosis,1962.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1489,HV434,Scavenging of heme from plasma,1984.5,0.005859871421339801,0.5,0.0,1.0,0.00320937784282365,True,0,16,16,31,4.954196310386875,0.0009841582500592855
1490,HYOU1,IRE1alpha activates chaperones,5150.5,0.0129405064348764,0.5,0.0,1.0,0.007087352544249701,True,0,2,2,9,3.169925001442312,0.003103294766788487
1491,HYOU1,Scavenging by Class F Receptors,5152.5,0.0129405064348764,0.5,0.0,1.0,0.007087352544249701,True,0,2,2,9,3.169925001442312,0.003103294766788487
1492,Hedgehog 'off' state,Signaling by Hedgehog,6416.5,0.00027832945317560003,0.5,2.0,3.0,0.0052476661168297,True,3,1,4,16,4.0,5.5665890635120006e-05
1493,Hedgehog 'on' state,Hedgehog 'on' state,5944.5,0.00027496355835689997,0.5,1.0,2.0,0.0034405714477576,False,10,2,12,13,3.700439718141092,5.849741191142033e-05
1494,Hedgehog 'on' state,Signaling by Hedgehog,6340.5,0.00018574135183502225,0.5,2.0,3.0,0.00350199588077245,True,10,2,12,13,3.700439718141092,3.9515739584567705e-05
1495,Hedgehog ligand biogenesis,Hedgehog ligand biogenesis,5942.5,0.0004717991862146466,0.5,1.0,2.0,0.00590354161425985,False,11,2,13,14,3.807354922057604,9.814111790454429e-05
1496,Hedgehog ligand biogenesis,Signaling by Hedgehog,6318.5,0.00038530619374939996,0.5,2.0,3.0,0.00726462195959975,True,11,2,13,14,3.807354922057604,8.014931287504864e-05
1497,Heme biosynthesis,Heme biosynthesis,5838.5,0.0005294042366539,0.5,1.0,2.0,0.00662434364698215,False,2,2,4,5,2.321928094887362,0.0001593665550644168
1498,Heme biosynthesis,Metabolism of porphyrins,6344.5,0.00019867088680573585,0.5,2.0,3.0,0.00374577131236265,True,2,2,4,5,2.321928094887362,5.9805896193689965e-05
1499,Heme degradation,Heme degradation,5840.5,0.0002293545550882119,0.5,1.0,2.0,0.0028698738784329,False,4,2,6,7,2.807354922057604,6.023986725258125e-05
1500,Heme degradation,Metabolism of porphyrins,6520.5,8.768501772725965e-05,0.5,2.0,3.0,0.0016532267470463,True,4,2,6,7,2.807354922057604,2.303042913579282e-05
1501,Heme signaling,Cellular responses to stress,6494.5,0.0042468685499207,0.5,2.0,3.0,0.08007110975055726,True,5,2,7,8,3.0,0.001061717137480175
1502,Heme signaling,Heme signaling,5886.5,0.0053385116308292,0.5,1.0,2.0,0.06679987268242556,False,5,2,7,8,3.0,0.0013346279077073
1503,Hemostasis,root,6898.5,0.0086674016630115,0.5,4.0,5.0,0.7223316949658143,True,7,1,8,109,6.768184324776926,0.001115756436850563
1504,Heparan sulfate/heparin (HS-GAG) metabolism,Glycosaminoglycan metabolism,5228.5,0.0050343067437259,0.5,1.0,2.0,0.06299340954567285,True,2,1,3,7,2.807354922057604,0.0013222583254742155
1505,Hereditary fructose intolerance,Diseases of carbohydrate metabolism,5550.5,0.0032742160242112,0.5,1.0,2.0,0.0409696987993816,True,1,1,2,6,2.584962500721156,0.0009133194624916032
1506,Hh mutants abrogate ligand secretion,Diseases of signal transduction by growth factor receptors and second messengers,6332.5,0.000618204529728,0.5,2.0,3.0,0.011655722838200901,True,1,1,2,14,3.807354922057604,0.00012859556653316566
1507,Hh mutants are degraded by ERAD,Hh mutants abrogate ligand secretion,5512.5,0.0010715782749351,0.5,1.0,2.0,0.0134084736130478,True,9,1,10,14,3.807354922057604,0.00022290392373951288
1508,Homology Directed Repair,DNA Double-Strand Break Repair,6216.5,0.0009065219819049,0.5,2.0,3.0,0.01709170421716045,True,1,1,2,7,2.807354922057604,0.00023809757704831716
1509,Host Interactions of HIV factors,HIV Infection,5224.5,0.00014378205873984525,0.5,1.0,2.0,0.0017991200323275,True,11,1,12,16,4.0,2.875641174796905e-05
1510,Hyaluronan metabolism,Glycosaminoglycan metabolism,5232.5,0.0058962182563032,0.5,1.0,2.0,0.0737783592255045,True,1,1,2,6,2.584962500721156,0.0016447084886151832
1511,IBP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2834.5,5.819955983886777e-06,0.5,0.0,1.0,3.187516659985749e-06,True,0,1,1,4,2.0,1.939985327962259e-06
1512,IBP3,Post-translational protein phosphorylation,2832.5,0.0032224636063531,0.5,0.0,1.0,0.0017649027690049002,True,0,3,3,10,3.321928094887362,0.000745607871210334
1513,IBP3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2830.5,0.0032224636063531,0.5,0.0,1.0,0.0017649027690049002,True,0,3,3,10,3.321928094887362,0.000745607871210334
1514,IBP3,Transcriptional Regulation by TP53,2828.5,0.0032224636063531,0.5,0.0,1.0,0.0017649027690049002,True,0,3,3,10,3.321928094887362,0.000745607871210334
1515,IBP4,Post-translational protein phosphorylation,2904.5,0.0035762685445298002,0.5,0.0,1.0,0.0019586772817238502,True,0,2,2,6,2.584962500721156,0.0009975748822506213
1516,IBP4,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2902.5,0.0035762685445298002,0.5,0.0,1.0,0.0019586772817238502,True,0,2,2,6,2.584962500721156,0.0009975748822506213
1517,IBP6,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2974.5,0.0037836024072612,0.5,0.0,1.0,0.00207223142946395,True,0,1,1,4,2.0,0.0012612008024204
1518,IC1,Defective SERPING1 causes hereditary angioedema,1850.5,0.00048690849200329995,0.5,0.0,1.0,0.0002666736543104,True,0,4,4,16,4.0,9.738169840065999e-05
1519,IC1,Intrinsic Pathway of Fibrin Clot Formation,1852.5,0.00048690849200329995,0.5,0.0,1.0,0.0002666736543104,True,0,4,4,16,4.0,9.738169840065999e-05
1520,IC1,Platelet degranulation ,1848.5,0.00048690849200329995,0.5,0.0,1.0,0.0002666736543104,True,0,4,4,16,4.0,9.738169840065999e-05
1521,IC1,Regulation of Complement cascade,1846.5,0.00048690849200329995,0.5,0.0,1.0,0.0002666736543104,True,0,4,4,16,4.0,9.738169840065999e-05
1522,ICAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1868.5,0.0125476771147612,0.5,0.0,1.0,0.00687220486858605,True,0,5,5,13,3.700439718141092,0.0026694687874272956
1523,ICAM1,Integrin cell surface interactions,1870.5,0.0125476771147612,0.5,0.0,1.0,0.00687220486858605,True,0,5,5,13,3.700439718141092,0.0026694687874272956
1524,ICAM1,Interferon gamma signaling,1866.5,0.0125476771147612,0.5,0.0,1.0,0.00687220486858605,True,0,5,5,13,3.700439718141092,0.0026694687874272956
1525,ICAM1,Interleukin-10 signaling,1862.5,0.0125476771147612,0.5,0.0,1.0,0.00687220486858605,True,0,5,5,13,3.700439718141092,0.0026694687874272956
1526,ICAM1,Interleukin-4 and Interleukin-13 signaling,1864.5,0.0125476771147612,0.5,0.0,1.0,0.00687220486858605,True,0,5,5,13,3.700439718141092,0.0026694687874272956
1527,ICAM2,CD209 (DC-SIGN) signaling,2640.5,0.0025434612719338998,0.5,0.0,1.0,0.0013930217343162,True,0,3,3,10,3.321928094887362,0.0005885015243411141
1528,ICAM2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,2642.5,0.0025434612719338998,0.5,0.0,1.0,0.0013930217343162,True,0,3,3,10,3.321928094887362,0.0005885015243411141
1529,ICAM2,Integrin cell surface interactions,2644.5,0.0025434612719338998,0.5,0.0,1.0,0.0013930217343162,True,0,3,3,10,3.321928094887362,0.0005885015243411141
1530,IDHC,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,86.5,0.0078266235517555,0.5,0.0,1.0,0.0042865432370498,True,0,4,4,16,4.0,0.0015653247103511
1531,IDHC,KEAP1-NFE2L2 pathway,82.5,0.0078266235517555,0.5,0.0,1.0,0.0042865432370498,True,0,4,4,16,4.0,0.0015653247103511
1532,IDHC,NADPH regeneration,80.5,0.0078266235517555,0.5,0.0,1.0,0.0042865432370498,True,0,4,4,16,4.0,0.0015653247103511
1533,IDHC,Neutrophil degranulation,84.5,0.0078266235517555,0.5,0.0,1.0,0.0042865432370498,True,0,4,4,16,4.0,0.0015653247103511
1534,IGF1,IGF1R signaling cascade,1752.5,0.0051151337669358005,0.5,0.0,1.0,0.0028014944005254998,True,0,4,4,14,3.807354922057604,0.001064022492590679
1535,IGF1,Platelet degranulation ,1754.5,0.0051151337669358005,0.5,0.0,1.0,0.0028014944005254998,True,0,4,4,14,3.807354922057604,0.001064022492590679
1536,IGF1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1758.5,0.0051151337669358005,0.5,0.0,1.0,0.0028014944005254998,True,0,4,4,14,3.807354922057604,0.001064022492590679
1537,IGF1,"Synthesis, secretion, and deacylation of Ghrelin",1756.5,0.0051151337669358005,0.5,0.0,1.0,0.0028014944005254998,True,0,4,4,14,3.807354922057604,0.001064022492590679
1538,IGF1R signaling cascade,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),5376.5,0.0026646308260334997,0.5,1.0,2.0,0.03334206464903045,True,2,1,3,7,2.807354922057604,0.0006998640475034717
1539,IGF2,IGF1R signaling cascade,356.5,0.0093942475330476,0.5,0.0,1.0,0.00514511116622245,True,0,3,3,12,3.584962500721156,0.0020489257069321734
1540,IGF2,Platelet degranulation ,358.5,0.0093942475330476,0.5,0.0,1.0,0.00514511116622245,True,0,3,3,12,3.584962500721156,0.0020489257069321734
1541,IGF2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),360.5,0.0093942475330476,0.5,0.0,1.0,0.00514511116622245,True,0,3,3,12,3.584962500721156,0.0020489257069321734
1542,IGHA1,Scavenging of heme from plasma,976.5,0.0037457447550632,0.5,0.0,1.0,0.00205149726971725,True,0,1,1,5,2.321928094887362,0.0011275815273750554
1543,IGHA2,Scavenging of heme from plasma,978.5,0.0010599603972562001,0.5,0.0,1.0,0.0005805269721169,True,0,1,1,5,2.321928094887362,0.00031907987379002574
1544,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,984.5,0.0121810857159417,0.5,0.0,1.0,0.00667142737226485,True,0,3,3,11,3.4594316186372973,0.0027315332440648495
1545,IGHD,CD22 mediated BCR regulation,982.5,0.0121810857159417,0.5,0.0,1.0,0.00667142737226485,True,0,3,3,11,3.4594316186372973,0.0027315332440648495
1546,IGHD,Potential therapeutics for SARS,980.5,0.0121810857159417,0.5,0.0,1.0,0.00667142737226485,True,0,3,3,11,3.4594316186372973,0.0027315332440648495
1547,IGHG1,FCGR activation,914.5,0.018967037524581398,0.5,0.0,1.0,0.010388007790361701,True,0,8,8,19,4.247927513443585,0.0036141957898605972
1548,IGHG1,Initial triggering of complement,910.5,0.018967037524581398,0.5,0.0,1.0,0.010388007790361701,True,0,8,8,19,4.247927513443585,0.0036141957898605972
1549,IGHG1,Interleukin-4 and Interleukin-13 signaling,920.5,0.018967037524581398,0.5,0.0,1.0,0.010388007790361701,True,0,8,8,19,4.247927513443585,0.0036141957898605972
1550,IGHG1,Leishmania parasite growth and survival,924.5,0.018967037524581398,0.5,0.0,1.0,0.010388007790361701,True,0,8,8,19,4.247927513443585,0.0036141957898605972
1551,IGHG1,Parasite infection,922.5,0.018967037524581398,0.5,0.0,1.0,0.010388007790361701,True,0,8,8,19,4.247927513443585,0.0036141957898605972
1552,IGHG1,Regulation of Complement cascade,912.5,0.018967037524581398,0.5,0.0,1.0,0.010388007790361701,True,0,8,8,19,4.247927513443585,0.0036141957898605972
1553,IGHG1,Regulation of actin dynamics for phagocytic cup formation,916.5,0.018967037524581398,0.5,0.0,1.0,0.010388007790361701,True,0,8,8,19,4.247927513443585,0.0036141957898605972
1554,IGHG1,Role of phospholipids in phagocytosis,918.5,0.018967037524581398,0.5,0.0,1.0,0.010388007790361701,True,0,8,8,19,4.247927513443585,0.0036141957898605972
1555,IGHG2,FCGR activation,930.5,0.0111722490205269,0.5,0.0,1.0,0.006118900208357951,True,0,7,7,16,4.0,0.00223444980410538
1556,IGHG2,Initial triggering of complement,926.5,0.0111722490205269,0.5,0.0,1.0,0.006118900208357951,True,0,7,7,16,4.0,0.00223444980410538
1557,IGHG2,Leishmania parasite growth and survival,938.5,0.0111722490205269,0.5,0.0,1.0,0.006118900208357951,True,0,7,7,16,4.0,0.00223444980410538
1558,IGHG2,Parasite infection,936.5,0.0111722490205269,0.5,0.0,1.0,0.006118900208357951,True,0,7,7,16,4.0,0.00223444980410538
1559,IGHG2,Regulation of Complement cascade,928.5,0.0111722490205269,0.5,0.0,1.0,0.006118900208357951,True,0,7,7,16,4.0,0.00223444980410538
1560,IGHG2,Regulation of actin dynamics for phagocytic cup formation,932.5,0.0111722490205269,0.5,0.0,1.0,0.006118900208357951,True,0,7,7,16,4.0,0.00223444980410538
1561,IGHG2,Role of phospholipids in phagocytosis,934.5,0.0111722490205269,0.5,0.0,1.0,0.006118900208357951,True,0,7,7,16,4.0,0.00223444980410538
1562,IGHG3,FCGR activation,944.5,0.0017049105258534,0.5,0.0,1.0,0.0009337580421551001,True,0,7,7,16,4.0,0.00034098210517068
1563,IGHG3,Initial triggering of complement,940.5,0.0017049105258534,0.5,0.0,1.0,0.0009337580421551001,True,0,7,7,16,4.0,0.00034098210517068
1564,IGHG3,Leishmania parasite growth and survival,952.5,0.0017049105258534,0.5,0.0,1.0,0.0009337580421551001,True,0,7,7,16,4.0,0.00034098210517068
1565,IGHG3,Parasite infection,950.5,0.0017049105258534,0.5,0.0,1.0,0.0009337580421551001,True,0,7,7,16,4.0,0.00034098210517068
1566,IGHG3,Regulation of Complement cascade,942.5,0.0017049105258534,0.5,0.0,1.0,0.0009337580421551001,True,0,7,7,16,4.0,0.00034098210517068
1567,IGHG3,Regulation of actin dynamics for phagocytic cup formation,946.5,0.0017049105258534,0.5,0.0,1.0,0.0009337580421551001,True,0,7,7,16,4.0,0.00034098210517068
1568,IGHG3,Role of phospholipids in phagocytosis,948.5,0.0017049105258534,0.5,0.0,1.0,0.0009337580421551001,True,0,7,7,16,4.0,0.00034098210517068
1569,IGHG4,FCGR activation,958.5,0.0067417906607063,0.5,0.0,1.0,0.00369239391305265,True,0,8,8,19,4.247927513443585,0.0012846577326832151
1570,IGHG4,Initial triggering of complement,954.5,0.0067417906607063,0.5,0.0,1.0,0.00369239391305265,True,0,8,8,19,4.247927513443585,0.0012846577326832151
1571,IGHG4,Interleukin-4 and Interleukin-13 signaling,964.5,0.0067417906607063,0.5,0.0,1.0,0.00369239391305265,True,0,8,8,19,4.247927513443585,0.0012846577326832151
1572,IGHG4,Leishmania parasite growth and survival,968.5,0.0067417906607063,0.5,0.0,1.0,0.00369239391305265,True,0,8,8,19,4.247927513443585,0.0012846577326832151
1573,IGHG4,Parasite infection,966.5,0.0067417906607063,0.5,0.0,1.0,0.00369239391305265,True,0,8,8,19,4.247927513443585,0.0012846577326832151
1574,IGHG4,Regulation of Complement cascade,956.5,0.0067417906607063,0.5,0.0,1.0,0.00369239391305265,True,0,8,8,19,4.247927513443585,0.0012846577326832151
1575,IGHG4,Regulation of actin dynamics for phagocytic cup formation,960.5,0.0067417906607063,0.5,0.0,1.0,0.00369239391305265,True,0,8,8,19,4.247927513443585,0.0012846577326832151
1576,IGHG4,Role of phospholipids in phagocytosis,962.5,0.0067417906607063,0.5,0.0,1.0,0.00369239391305265,True,0,8,8,19,4.247927513443585,0.0012846577326832151
1577,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,974.5,0.0122146030985023,0.5,0.0,1.0,0.00668978442094465,True,0,3,3,11,3.4594316186372973,0.0027390493101080017
1578,IGHM,CD22 mediated BCR regulation,972.5,0.0122146030985023,0.5,0.0,1.0,0.00668978442094465,True,0,3,3,11,3.4594316186372973,0.0027390493101080017
1579,IGHM,Potential therapeutics for SARS,970.5,0.0122146030985023,0.5,0.0,1.0,0.00668978442094465,True,0,3,3,11,3.4594316186372973,0.0027390493101080017
1580,IGJ,Scavenging of heme from plasma,362.5,0.0024298139932464003,0.5,0.0,1.0,0.0013307785498004499,True,0,1,1,5,2.321928094887362,0.0007314468958512447
1581,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,904.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1582,IGKC,CD22 mediated BCR regulation,902.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1583,IGKC,FCERI mediated Ca+2 mobilization,892.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1584,IGKC,FCERI mediated MAPK activation,890.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1585,IGKC,FCERI mediated NF-kB activation,894.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1586,IGKC,FCGR activation,882.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1587,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,906.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1588,IGKC,Initial triggering of complement,878.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1589,IGKC,Leishmania parasite growth and survival,898.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1590,IGKC,Parasite infection,896.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1591,IGKC,Potential therapeutics for SARS,900.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1592,IGKC,Regulation of Complement cascade,880.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1593,IGKC,Regulation of actin dynamics for phagocytic cup formation,884.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1594,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,888.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1595,IGKC,Role of phospholipids in phagocytosis,886.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1596,IGKC,Scavenging of heme from plasma,908.5,0.0006354840389203,0.5,0.0,1.0,0.00034804661183374997,True,0,16,16,31,4.954196310386875,0.0001067287683833537
1597,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,26.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1598,IGLC7,CD22 mediated BCR regulation,24.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1599,IGLC7,FCERI mediated Ca+2 mobilization,14.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1600,IGLC7,FCERI mediated MAPK activation,12.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1601,IGLC7,FCERI mediated NF-kB activation,16.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1602,IGLC7,FCGR activation,4.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1603,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,28.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1604,IGLC7,Initial triggering of complement,0.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1605,IGLC7,Leishmania parasite growth and survival,20.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1606,IGLC7,Parasite infection,18.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1607,IGLC7,Potential therapeutics for SARS,22.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1608,IGLC7,Regulation of Complement cascade,2.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1609,IGLC7,Regulation of actin dynamics for phagocytic cup formation,6.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1610,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,10.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1611,IGLC7,Role of phospholipids in phagocytosis,8.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1612,IGLC7,Scavenging of heme from plasma,30.5,0.0147244950105213,0.5,0.0,1.0,0.0080644206392381,True,0,16,16,31,4.954196310386875,0.002472960957776109
1613,IL1R2,Interleukin-1 family signaling,3232.5,0.0010180777324253999,0.5,0.0,1.0,0.0005575883635978,True,0,2,2,7,2.807354922057604,0.0002673976430532516
1614,IL1R2,Interleukin-10 signaling,3234.5,0.0010180777324253999,0.5,0.0,1.0,0.0005575883635978,True,0,2,2,7,2.807354922057604,0.0002673976430532516
1615,ILEU,Neutrophil degranulation,3566.5,0.0006002006344983,0.5,0.0,1.0,0.00032872233520215,True,0,1,1,5,2.321928094887362,0.00018067839440054202
1616,ILK,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,4674.5,0.0002498618707277,0.5,0.0,1.0,0.00013684620259065,True,0,1,1,6,2.584962500721156,6.969720622668645e-05
1617,IPSP,Common Pathway of Fibrin Clot Formation,1844.5,0.004590310283840699,0.5,0.0,1.0,0.00251405518267765,True,0,2,2,6,2.584962500721156,0.0012804346720271986
1618,IPSP,Intrinsic Pathway of Fibrin Clot Formation,1842.5,0.004590310283840699,0.5,0.0,1.0,0.00251405518267765,True,0,2,2,6,2.584962500721156,0.0012804346720271986
1619,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,5522.5,0.0078164070528792,0.5,1.0,2.0,0.09780534951934505,True,7,1,8,12,3.584962500721156,0.0017047919261389333
1620,IRE1alpha activates chaperones,Unfolded Protein Response (UPR),5436.5,0.0038970132963362,0.5,1.0,2.0,0.04876265334586235,True,3,1,4,8,3.0,0.00097425332408405
1621,ITA2B,ECM proteoglycans,2376.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1622,ITA2B,GRB2:SOS provides linkage to MAPK signaling for Integrins ,2378.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1623,ITA2B,Integrin cell surface interactions,2374.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1624,ITA2B,L1CAM interactions,2356.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1625,ITA2B,Paradoxical activation of RAF signaling by kinase inactive BRAF,2368.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1626,ITA2B,Platelet degranulation ,2372.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1627,ITA2B,RAF/MAP kinase cascade,2358.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1628,ITA2B,Signaling by BRAF and RAF1 fusions,2366.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1629,ITA2B,Signaling by RAF1 mutants,2370.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1630,ITA2B,Signaling by RAS mutants,2360.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1631,ITA2B,Signaling by high-kinase activity BRAF mutants,2364.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1632,ITA2B,Signaling by moderate kinase activity BRAF mutants,2362.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1633,ITA2B,Transcriptional regulation by RUNX1,2354.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1634,ITA2B,p130Cas linkage to MAPK signaling for integrins,2380.5,0.0030704779246244996,0.5,0.0,1.0,0.0016816621235549501,True,0,14,14,33,5.044394119358453,0.0005079877096019671
1635,ITB3,ECM proteoglycans,1802.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1636,ITB3,GRB2:SOS provides linkage to MAPK signaling for Integrins ,1810.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1637,ITB3,Integrin cell surface interactions,1800.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1638,ITB3,L1CAM interactions,1782.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1639,ITB3,Molecules associated with elastic fibres,1804.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1640,ITB3,PECAM1 interactions,1806.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1641,ITB3,Paradoxical activation of RAF signaling by kinase inactive BRAF,1794.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1642,ITB3,Platelet degranulation ,1798.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1643,ITB3,RAF/MAP kinase cascade,1784.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1644,ITB3,Signaling by BRAF and RAF1 fusions,1792.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1645,ITB3,Signaling by RAF1 mutants,1796.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1646,ITB3,Signaling by RAS mutants,1786.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1647,ITB3,Signaling by high-kinase activity BRAF mutants,1790.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1648,ITB3,Signaling by moderate kinase activity BRAF mutants,1788.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1649,ITB3,Syndecan interactions,1808.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1650,ITB3,TGF-beta receptor signaling activates SMADs,1778.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1651,ITB3,VEGFA-VEGFR2 Pathway,1780.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1652,ITB3,p130Cas linkage to MAPK signaling for integrins,1812.5,0.0046371151858627,0.5,0.0,1.0,0.00253968963856995,True,0,18,18,41,5.357552004618084,0.0007293869059182418
1653,ITIH2,Post-translational protein phosphorylation,2882.5,0.0202730432764223,0.5,0.0,1.0,0.01110329070720085,True,0,2,2,6,2.584962500721156,0.005655022408838069
1654,ITIH2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2880.5,0.0202730432764223,0.5,0.0,1.0,0.01110329070720085,True,0,2,2,6,2.584962500721156,0.005655022408838069
1655,ITIH3,Platelet degranulation ,4546.5,0.0022512530771296004,0.5,0.0,1.0,0.0012329829828717,True,0,1,1,6,2.584962500721156,0.000627971164740701
1656,ITIH4,Platelet degranulation ,4728.5,0.0019474342339176002,0.5,0.0,1.0,0.0010665852253909,True,0,1,1,6,2.584962500721156,0.0005432230416708269
1657,Immune System,root,6890.5,0.0180721684782422,0.5,4.0,5.0,1.5061145884475728,True,3,1,4,280,8.129283016944967,0.0019795824540326155
1658,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,6144.5,0.000788104879323,0.5,2.0,3.0,0.014859050037798749,True,40,2,42,43,5.426264754702098,0.00012263809684254662
1659,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,5782.5,0.0010458063555159,0.5,1.0,2.0,0.013085994042891649,False,40,2,42,43,5.426264754702098,0.00016273938211940045
1660,Infection with Mycobacterium tuberculosis,Infectious disease,6490.5,0.0062776018216251,0.5,2.0,3.0,0.1183588657197846,True,3,1,4,12,3.584962500721156,0.0013691719006726256
1661,Infectious disease,Disease,6694.5,0.0185467063779307,0.5,3.0,4.0,0.6354855154648371,True,7,1,8,106,6.727920454563199,0.002399960828657236
1662,Inflammasomes,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",5268.5,0.00039052354248100005,0.5,1.0,2.0,0.00488655354173505,True,1,1,2,6,2.584962500721156,0.0001089337872857643
1663,Influenza Infection,Infectious disease,6086.5,0.002563087524193,0.5,2.0,3.0,0.04832484453840095,True,2,1,3,8,3.0,0.00064077188104825
1664,Influenza Viral RNA Transcription and Replication,Influenza Infection,5266.5,0.0004011675330817,0.5,1.0,2.0,0.0050197399551273995,True,1,1,2,6,2.584962500721156,0.00011190285337740647
1665,Inhibition of DNA recombination at telomere,Telomere Maintenance,5212.5,0.0003403184599058916,0.5,1.0,2.0,0.0042583460269932,True,3,1,4,8,3.0,8.50796149764729e-05
1666,Initial triggering of complement,Complement cascade,5246.5,0.0082574381200257,0.5,1.0,2.0,0.10332389498138915,True,48,1,49,53,5.727920454563199,0.0012273388450104385
1667,Innate Immune System,Immune System,6656.5,0.018015771321192902,0.5,3.0,4.0,0.6172935232407689,True,12,1,13,217,7.7615512324444795,0.0020562307795998006
1668,Inositol phosphate metabolism,Metabolism,6620.5,7.754411168844406e-05,0.5,3.0,4.0,0.00265697632687115,True,1,1,2,5,2.321928094887362,2.334310360533959e-05
1669,Insulin effects increased synthesis of Xylulose-5-Phosphate,Insulin effects increased synthesis of Xylulose-5-Phosphate,5830.5,0.0015824013911151,0.5,1.0,2.0,0.01980031491334775,False,3,2,5,6,2.584962500721156,0.00044139970524009157
1670,Insulin effects increased synthesis of Xylulose-5-Phosphate,Integration of energy metabolism,6372.5,0.0014651241458313998,0.5,2.0,3.0,0.02762367492661305,True,3,2,5,6,2.584962500721156,0.0004086860449828062
1671,Integration of energy metabolism,Metabolism,6700.5,0.0010099531967118999,0.5,3.0,4.0,0.0346050999422522,True,3,1,4,13,3.700439718141092,0.00021486355687406014
1672,Integrin cell surface interactions,Extracellular matrix organization,6794.5,0.0155726178608655,0.5,3.0,4.0,0.5335811591984247,True,25,2,27,27,4.754887502163468,0.0027059812819992045
1673,Integrin cell surface interactions,Integrin cell surface interactions,5924.5,0.02140364972658645,0.5,1.5,2.5,0.3277578475467962,False,25,2,27,27,4.754887502163468,0.003719212533440498
1674,Integrin signaling,Signal Transduction,6676.5,0.0005956041293003001,0.5,3.0,4.0,0.02040781739941805,True,2,1,3,14,3.807354922057604,0.00012389435333086965
1675,Interaction With Cumulus Cells And The Zona Pellucida,Fertilization,6432.5,0.004930405182336299,0.5,2.0,3.0,0.09295861405386116,True,2,2,4,5,2.321928094887362,0.0014841998506603666
1676,Interaction With Cumulus Cells And The Zona Pellucida,Interaction With Cumulus Cells And The Zona Pellucida,5774.5,0.005883988206747,0.5,1.0,2.0,0.07362532673072769,False,2,2,4,5,2.321928094887362,0.001771256944363966
1677,Interferon Signaling,Cytokine Signaling in Immune system,6426.5,0.00038795525138209997,0.5,2.0,3.0,0.007314567697723099,True,3,1,4,15,3.9068905956085187,7.906335872442423e-05
1678,Interferon alpha/beta signaling,Interferon Signaling,5716.5,0.00031188631082160184,0.5,1.0,2.0,0.0039025794631523,True,2,1,3,7,2.807354922057604,8.191679452175934e-05
1679,Interferon gamma signaling,Interferon Signaling,5714.5,0.0014217617143875,0.5,1.0,2.0,0.01779025842284945,True,6,1,7,11,3.4594316186372973,0.0003188212839603892
1680,Interleukin-1 family signaling,Signaling by Interleukins,5478.5,0.0010820544959310998,0.5,1.0,2.0,0.013539560754394199,True,12,1,13,17,4.087462841250339,0.0002126903978850811
1681,Interleukin-10 signaling,Signaling by Interleukins,5486.5,0.0031023511582478,0.5,1.0,2.0,0.0388191834574944,True,3,1,4,8,3.0,0.00077558778956195
1682,Interleukin-12 family signaling,Signaling by Interleukins,5480.5,0.0026073833660373,0.5,1.0,2.0,0.0326257370836749,True,8,1,9,13,3.700439718141092,0.0005547105212251196
1683,"Interleukin-3, Interleukin-5 and GM-CSF signaling",Signaling by Interleukins,5484.5,0.0006971419828507,0.5,1.0,2.0,0.00872321705306025,True,1,1,2,6,2.584962500721156,0.0001944628382334437
1684,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,5488.5,0.0037566675456924,0.5,1.0,2.0,0.0470065312423941,True,16,1,17,21,4.392317422778761,0.0006966703276448662
1685,Intra-Golgi and retrograde Golgi-to-ER traffic,Membrane Trafficking,6272.5,0.0027196985471524,0.5,2.0,3.0,0.0512776127392818,True,2,1,3,12,3.584962500721156,0.000593177926040753
1686,Intra-Golgi traffic,Intra-Golgi and retrograde Golgi-to-ER traffic,5598.5,0.0022832934690289,0.5,1.0,2.0,0.0285704562573098,True,1,1,2,6,2.584962500721156,0.0006369086060369082
1687,Intracellular oxygen transport,Intracellular oxygen transport,6196.5,0.0008257137751061501,0.5,1.5,2.5,0.012313285152239551,False,2,2,4,4,2.0,0.00027523792503538337
1688,Intracellular oxygen transport,Transport of small molecules,6770.5,3.4116446547764074e-05,0.5,3.0,4.0,0.0011689680732764,True,2,2,4,4,2.0,1.1372148849254691e-05
1689,Intracellular signaling by second messengers,Signal Transduction,6842.5,0.0006089649026309,0.5,3.0,4.0,0.02086561177832285,True,1,1,2,14,3.807354922057604,0.0001266735892198814
1690,Intraflagellar transport,Cilium Assembly,6128.5,0.0032861737760734003,0.5,2.0,3.0,0.06195802342134765,True,6,2,8,9,3.169925001442312,0.0007880654388116727
1691,Intraflagellar transport,Intraflagellar transport,5950.5,0.0037449999565557,0.5,1.0,2.0,0.046860536717564696,False,6,2,8,9,3.169925001442312,0.0008980976768791676
1692,Intrinsic Pathway for Apoptosis,Apoptosis,6424.5,0.0015899062649078,0.5,2.0,3.0,0.02997633610131635,True,1,1,2,11,3.4594316186372973,0.00035652666099040664
1693,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),6448.5,0.0073519248490547,0.5,2.0,3.0,0.13861431653623835,True,18,2,20,21,4.392317422778761,0.0013634072834803775
1694,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,5790.5,0.008976855663627499,0.5,1.0,2.0,0.1123258422733237,False,18,2,20,21,4.392317422778761,0.001664749116160443
1695,Ion channel transport,Transport of small molecules,6618.5,5.390509613212528e-06,0.5,3.0,4.0,0.00018470076089875,True,1,1,2,5,2.321928094887362,1.6227050854920163e-06
1696,Iron uptake and transport,Transport of small molecules,6702.5,0.0015202690926902,0.5,3.0,4.0,0.05209059594339255,True,1,1,2,6,2.584962500721156,0.00042406833889737495
1697,K1C10,Formation of the cornified envelope,2658.5,0.0002989039615253,0.5,0.0,1.0,0.00016370593862490002,True,0,1,1,5,2.321928094887362,8.997905824190787e-05
1698,K1C14,Formation of the cornified envelope,1030.5,0.0039741629504167,0.5,0.0,1.0,0.0021765990411307997,True,0,2,2,8,3.0,0.000993540737604175
1699,K1C14,Type I hemidesmosome assembly,1028.5,0.0039741629504167,0.5,0.0,1.0,0.0021765990411307997,True,0,2,2,8,3.0,0.000993540737604175
1700,K1C16,Formation of the cornified envelope,2430.5,0.0005612812942325,0.5,0.0,1.0,0.00030740670225995004,True,0,1,1,5,2.321928094887362,0.00016896250556908322
1701,K1C20,Formation of the cornified envelope,3690.5,0.0013645838232247,0.5,0.0,1.0,0.0007473653894494001,True,0,1,1,5,2.321928094887362,0.0004107806623884703
1702,K1C9,Formation of the cornified envelope,3642.5,0.0003888132389084,0.5,0.0,1.0,0.000212948118521,True,0,1,1,5,2.321928094887362,0.00011704444762269415
1703,K22E,Formation of the cornified envelope,3692.5,0.000101857558021329,0.5,0.0,1.0,5.578610285667882e-05,True,0,1,1,5,2.321928094887362,3.066218024950438e-05
1704,K2C1,Formation of the cornified envelope,1570.5,0.0030342301950309,0.5,0.0,1.0,0.00166180969816085,True,0,2,2,8,3.0,0.000758557548757725
1705,K2C1,Neutrophil degranulation,1568.5,0.0030342301950309,0.5,0.0,1.0,0.00166180969816085,True,0,2,2,8,3.0,0.000758557548757725
1706,K2C1B,Formation of the cornified envelope,4816.5,0.0002575612322154,0.5,0.0,1.0,0.00014106304599655,True,0,1,1,5,2.321928094887362,7.753365661701153e-05
1707,K2C5,Formation of the cornified envelope,2662.5,0.0044125014878242,0.5,0.0,1.0,0.0024166715424638503,True,0,2,2,8,3.0,0.00110312537195605
1708,K2C5,Type I hemidesmosome assembly,2660.5,0.0044125014878242,0.5,0.0,1.0,0.0024166715424638503,True,0,2,2,8,3.0,0.00110312537195605
1709,K2C6A,Formation of the cornified envelope,1032.5,0.00017994631146158206,0.5,0.0,1.0,9.855433052665695e-05,True,0,1,1,5,2.321928094887362,5.416923735902946e-05
1710,K2C6B,Formation of the cornified envelope,1566.5,0.0006943762492681,0.5,0.0,1.0,0.00038030113440175003,True,0,1,1,5,2.321928094887362,0.00020902807930634767
1711,K2C75,Formation of the cornified envelope,106.5,0.00045527686828610004,0.5,0.0,1.0,0.0002493494120206,True,0,1,1,5,2.321928094887362,0.00013705199368607563
1712,K2C78,Formation of the cornified envelope,4824.5,0.0006104447510814,0.5,0.0,1.0,0.00033433290895325,True,0,1,1,5,2.321928094887362,0.00018376218077113392
1713,K2C8,Formation of the cornified envelope,1882.5,0.00014966757454217466,0.5,0.0,1.0,8.197104731267013e-05,True,0,1,1,5,2.321928094887362,4.5054429315469425e-05
1714,KAIN,Platelet degranulation ,3526.5,0.0014937221949562,0.5,0.0,1.0,0.0008180928507012001,True,0,1,1,6,2.584962500721156,0.00041666326904555364
1715,KEAP1-NFE2L2 pathway,Cellular response to chemical stress,5760.5,0.0019479895206044,0.5,1.0,2.0,0.02437485594516925,True,12,1,13,17,4.087462841250339,0.00038289999974243453
1716,KLKB1,Activation of Matrix Metalloproteinases,1438.5,0.0044477446804277,0.5,0.0,1.0,0.0024359737955884503,True,0,4,4,13,3.700439718141092,0.0009462401279739575
1717,KLKB1,Defective SERPING1 causes hereditary angioedema,1434.5,0.0044477446804277,0.5,0.0,1.0,0.0024359737955884503,True,0,4,4,13,3.700439718141092,0.0009462401279739575
1718,KLKB1,Defective factor XII causes hereditary angioedema,1432.5,0.0044477446804277,0.5,0.0,1.0,0.0024359737955884503,True,0,4,4,13,3.700439718141092,0.0009462401279739575
1719,KLKB1,Intrinsic Pathway of Fibrin Clot Formation,1436.5,0.0044477446804277,0.5,0.0,1.0,0.0024359737955884503,True,0,4,4,13,3.700439718141092,0.0009462401279739575
1720,KNG1,Class A/1 (Rhodopsin-like receptors),342.5,0.0446727466915404,0.5,0.0,1.0,0.02446670124668395,True,0,7,7,19,4.247927513443585,0.008512454979056491
1721,KNG1,G alpha (i) signalling events,346.5,0.0446727466915404,0.5,0.0,1.0,0.02446670124668395,True,0,7,7,19,4.247927513443585,0.008512454979056491
1722,KNG1,G alpha (q) signalling events,344.5,0.0446727466915404,0.5,0.0,1.0,0.02446670124668395,True,0,7,7,19,4.247927513443585,0.008512454979056491
1723,KNG1,Intrinsic Pathway of Fibrin Clot Formation,350.5,0.0446727466915404,0.5,0.0,1.0,0.02446670124668395,True,0,7,7,19,4.247927513443585,0.008512454979056491
1724,KNG1,Platelet degranulation ,348.5,0.0446727466915404,0.5,0.0,1.0,0.02446670124668395,True,0,7,7,19,4.247927513443585,0.008512454979056491
1725,KNG1,Post-translational protein phosphorylation,354.5,0.0446727466915404,0.5,0.0,1.0,0.02446670124668395,True,0,7,7,19,4.247927513443585,0.008512454979056491
1726,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),352.5,0.0446727466915404,0.5,0.0,1.0,0.02446670124668395,True,0,7,7,19,4.247927513443585,0.008512454979056491
1727,KPYM,Neutrophil degranulation,2706.5,0.0023119660551768,0.5,0.0,1.0,0.001266234716998,True,0,1,1,5,2.321928094887362,0.0006959711315651439
1728,KRT81,Formation of the cornified envelope,4726.5,0.0001040685882023543,0.5,0.0,1.0,5.699705626547811e-05,True,0,1,1,5,2.321928094887362,3.1327766655311365e-05
1729,KSRP (KHSRP) binds and destabilizes mRNA,KSRP (KHSRP) binds and destabilizes mRNA,5938.5,0.00013258411271201706,0.5,1.0,2.0,0.0016590020704895,False,2,2,4,5,2.321928094887362,3.9911794874811294e-05
1730,KSRP (KHSRP) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,6070.5,0.00011921468853120247,0.5,2.0,3.0,0.0022476919869437,True,2,2,4,5,2.321928094887362,3.588719717163075e-05
1731,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,454.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1732,KV105,CD22 mediated BCR regulation,452.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1733,KV105,FCERI mediated Ca+2 mobilization,442.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1734,KV105,FCERI mediated MAPK activation,440.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1735,KV105,FCERI mediated NF-kB activation,444.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1736,KV105,FCGR activation,432.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1737,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,456.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1738,KV105,Initial triggering of complement,428.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1739,KV105,Leishmania parasite growth and survival,448.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1740,KV105,Parasite infection,446.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1741,KV105,Potential therapeutics for SARS,450.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1742,KV105,Regulation of Complement cascade,430.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1743,KV105,Regulation of actin dynamics for phagocytic cup formation,434.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1744,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,438.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1745,KV105,Role of phospholipids in phagocytosis,436.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1746,KV105,Scavenging of heme from plasma,458.5,0.0108053194607613,0.5,0.0,1.0,0.0059179375055416,True,0,16,16,31,4.954196310386875,0.0018147402096756232
1747,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1634.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1748,KV116,CD22 mediated BCR regulation,1632.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1749,KV116,FCERI mediated Ca+2 mobilization,1622.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1750,KV116,FCERI mediated MAPK activation,1620.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1751,KV116,FCERI mediated NF-kB activation,1624.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1752,KV116,FCGR activation,1612.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1753,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1636.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1754,KV116,Initial triggering of complement,1608.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1755,KV116,Leishmania parasite growth and survival,1628.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1756,KV116,Parasite infection,1626.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1757,KV116,Potential therapeutics for SARS,1630.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1758,KV116,Regulation of Complement cascade,1610.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1759,KV116,Regulation of actin dynamics for phagocytic cup formation,1614.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1760,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,1618.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1761,KV116,Role of phospholipids in phagocytosis,1616.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1762,KV116,Scavenging of heme from plasma,1638.5,0.0080563521860018,0.5,0.0,1.0,0.00441236271935575,True,0,16,16,31,4.954196310386875,0.001353054512486898
1763,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1916.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1764,KV230,CD22 mediated BCR regulation,1914.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1765,KV230,FCERI mediated Ca+2 mobilization,1904.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1766,KV230,FCERI mediated MAPK activation,1902.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1767,KV230,FCERI mediated NF-kB activation,1906.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1768,KV230,FCGR activation,1894.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1769,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1918.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1770,KV230,Initial triggering of complement,1890.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1771,KV230,Leishmania parasite growth and survival,1910.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1772,KV230,Parasite infection,1908.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1773,KV230,Potential therapeutics for SARS,1912.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1774,KV230,Regulation of Complement cascade,1892.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1775,KV230,Regulation of actin dynamics for phagocytic cup formation,1896.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1776,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,1900.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1777,KV230,Role of phospholipids in phagocytosis,1898.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1778,KV230,Scavenging of heme from plasma,1920.5,0.0073559971202429,0.5,0.0,1.0,0.0040287870623932995,True,0,16,16,31,4.954196310386875,0.001235430734356312
1779,KV311,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1666.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1780,KV311,CD22 mediated BCR regulation,1664.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1781,KV311,FCERI mediated Ca+2 mobilization,1654.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1782,KV311,FCERI mediated MAPK activation,1652.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1783,KV311,FCERI mediated NF-kB activation,1656.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1784,KV311,FCGR activation,1644.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1785,KV311,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1668.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1786,KV311,Initial triggering of complement,1640.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1787,KV311,Leishmania parasite growth and survival,1660.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1788,KV311,Parasite infection,1658.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1789,KV311,Potential therapeutics for SARS,1662.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1790,KV311,Regulation of Complement cascade,1642.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1791,KV311,Regulation of actin dynamics for phagocytic cup formation,1646.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1792,KV311,Role of LAT2/NTAL/LAB on calcium mobilization,1650.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1793,KV311,Role of phospholipids in phagocytosis,1648.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1794,KV311,Scavenging of heme from plasma,1670.5,0.0215137481883119,0.5,0.0,1.0,0.011782809175677849,True,0,16,16,31,4.954196310386875,0.003613207739016257
1795,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,550.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1796,KV320,CD22 mediated BCR regulation,548.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1797,KV320,FCERI mediated Ca+2 mobilization,538.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1798,KV320,FCERI mediated MAPK activation,536.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1799,KV320,FCERI mediated NF-kB activation,540.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1800,KV320,FCGR activation,528.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1801,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,552.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1802,KV320,Initial triggering of complement,524.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1803,KV320,Leishmania parasite growth and survival,544.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1804,KV320,Parasite infection,542.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1805,KV320,Potential therapeutics for SARS,546.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1806,KV320,Regulation of Complement cascade,526.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1807,KV320,Regulation of actin dynamics for phagocytic cup formation,530.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1808,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,534.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1809,KV320,Role of phospholipids in phagocytosis,532.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1810,KV320,Scavenging of heme from plasma,554.5,0.012907442186491001,0.5,0.0,1.0,0.0070692436714558,True,0,16,16,31,4.954196310386875,0.0021677891546797753
1811,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1948.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1812,KV401,CD22 mediated BCR regulation,1946.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1813,KV401,FCERI mediated Ca+2 mobilization,1936.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1814,KV401,FCERI mediated MAPK activation,1934.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1815,KV401,FCERI mediated NF-kB activation,1938.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1816,KV401,FCGR activation,1926.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1817,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1950.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1818,KV401,Initial triggering of complement,1922.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1819,KV401,Leishmania parasite growth and survival,1942.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1820,KV401,Parasite infection,1940.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1821,KV401,Potential therapeutics for SARS,1944.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1822,KV401,Regulation of Complement cascade,1924.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1823,KV401,Regulation of actin dynamics for phagocytic cup formation,1928.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1824,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,1932.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1825,KV401,Role of phospholipids in phagocytosis,1930.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1826,KV401,Scavenging of heme from plasma,1952.5,0.0098886858522399,0.5,0.0,1.0,0.0054159088121367,True,0,16,16,31,4.954196310386875,0.001660792714373467
1827,KVD12,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,486.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1828,KVD12,CD22 mediated BCR regulation,484.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1829,KVD12,FCERI mediated Ca+2 mobilization,474.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1830,KVD12,FCERI mediated MAPK activation,472.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1831,KVD12,FCERI mediated NF-kB activation,476.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1832,KVD12,FCGR activation,464.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1833,KVD12,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,488.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1834,KVD12,Initial triggering of complement,460.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1835,KVD12,Leishmania parasite growth and survival,480.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1836,KVD12,Parasite infection,478.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1837,KVD12,Potential therapeutics for SARS,482.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1838,KVD12,Regulation of Complement cascade,462.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1839,KVD12,Regulation of actin dynamics for phagocytic cup formation,466.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1840,KVD12,Role of LAT2/NTAL/LAB on calcium mobilization,470.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1841,KVD12,Role of phospholipids in phagocytosis,468.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1842,KVD12,Scavenging of heme from plasma,490.5,0.0040576359328236,0.5,0.0,1.0,0.0022223161432561502,True,0,16,16,31,4.954196310386875,0.0006814750003699416
1843,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,422.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1844,KVD16,CD22 mediated BCR regulation,420.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1845,KVD16,FCERI mediated Ca+2 mobilization,410.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1846,KVD16,FCERI mediated MAPK activation,408.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1847,KVD16,FCERI mediated NF-kB activation,412.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1848,KVD16,FCGR activation,400.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1849,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,424.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1850,KVD16,Initial triggering of complement,396.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1851,KVD16,Leishmania parasite growth and survival,416.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1852,KVD16,Parasite infection,414.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1853,KVD16,Potential therapeutics for SARS,418.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1854,KVD16,Regulation of Complement cascade,398.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1855,KVD16,Regulation of actin dynamics for phagocytic cup formation,402.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1856,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,406.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1857,KVD16,Role of phospholipids in phagocytosis,404.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1858,KVD16,Scavenging of heme from plasma,426.5,0.0070970905944704,0.5,0.0,1.0,0.0038869872160433,True,0,16,16,31,4.954196310386875,0.0011919476994888107
1859,KVD33,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,390.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1860,KVD33,CD22 mediated BCR regulation,388.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1861,KVD33,FCERI mediated Ca+2 mobilization,378.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1862,KVD33,FCERI mediated MAPK activation,376.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1863,KVD33,FCERI mediated NF-kB activation,380.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1864,KVD33,FCGR activation,368.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1865,KVD33,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,392.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1866,KVD33,Initial triggering of complement,364.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1867,KVD33,Leishmania parasite growth and survival,384.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1868,KVD33,Parasite infection,382.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1869,KVD33,Potential therapeutics for SARS,386.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1870,KVD33,Regulation of Complement cascade,366.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1871,KVD33,Regulation of actin dynamics for phagocytic cup formation,370.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1872,KVD33,Role of LAT2/NTAL/LAB on calcium mobilization,374.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1873,KVD33,Role of phospholipids in phagocytosis,372.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1874,KVD33,Scavenging of heme from plasma,394.5,0.0014104323399436,0.5,0.0,1.0,0.0007724760451453499,True,0,16,16,31,4.954196310386875,0.00023688038929505113
1875,KVD40,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,518.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1876,KVD40,CD22 mediated BCR regulation,516.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1877,KVD40,FCERI mediated Ca+2 mobilization,506.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1878,KVD40,FCERI mediated MAPK activation,504.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1879,KVD40,FCERI mediated NF-kB activation,508.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1880,KVD40,FCGR activation,496.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1881,KVD40,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,520.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1882,KVD40,Initial triggering of complement,492.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1883,KVD40,Leishmania parasite growth and survival,512.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1884,KVD40,Parasite infection,510.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1885,KVD40,Potential therapeutics for SARS,514.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1886,KVD40,Regulation of Complement cascade,494.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1887,KVD40,Regulation of actin dynamics for phagocytic cup formation,498.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1888,KVD40,Role of LAT2/NTAL/LAB on calcium mobilization,502.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1889,KVD40,Role of phospholipids in phagocytosis,500.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1890,KVD40,Scavenging of heme from plasma,522.5,0.017202107958274197,0.5,0.0,1.0,0.0094213780749685,True,0,16,16,31,4.954196310386875,0.0028890730270793655
1891,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,5226.5,0.0008451674047214,0.5,1.0,2.0,0.0105754335543082,True,2,1,3,7,2.807354922057604,0.00022198282587866728
1892,Keratinization,Developmental Biology,6760.5,0.0032895354444332,0.5,3.0,4.0,0.1127128496536223,True,1,1,2,20,4.321928094887363,0.0006181097124542834
1893,Ketone body metabolism,Metabolism of lipids,6438.5,0.00040088138093350003,0.5,2.0,3.0,0.0075582789230174505,True,2,1,3,7,2.807354922057604,0.00010529130830725184
1894,Kinesins,Factors involved in megakaryocyte development and platelet production,6552.5,0.0013274704847413,0.5,2.0,3.0,0.02502833172840515,True,6,2,8,9,3.169925001442312,0.00031834397124220424
1895,Kinesins,Kinesins,6042.5,0.0011805535401518,0.5,1.0,2.0,0.0147720622582372,False,6,2,8,9,3.169925001442312,0.0002831114563795428
1896,L1CAM interactions,Axon guidance,5422.5,0.0033439367745517,0.5,1.0,2.0,0.0418421024894244,True,12,1,13,17,4.087462841250339,0.0006572896704892424
1897,LAMC1,ECM proteoglycans,2550.5,0.022309339253071,0.5,0.0,1.0,0.012218544390940101,True,0,7,7,18,4.169925001442312,0.004315215258799134
1898,LAMC1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,2556.5,0.022309339253071,0.5,0.0,1.0,0.012218544390940101,True,0,7,7,18,4.169925001442312,0.004315215258799134
1899,LAMC1,L1CAM interactions,2544.5,0.022309339253071,0.5,0.0,1.0,0.012218544390940101,True,0,7,7,18,4.169925001442312,0.004315215258799134
1900,LAMC1,Laminin interactions,2548.5,0.022309339253071,0.5,0.0,1.0,0.012218544390940101,True,0,7,7,18,4.169925001442312,0.004315215258799134
1901,LAMC1,MET promotes cell motility,2546.5,0.022309339253071,0.5,0.0,1.0,0.012218544390940101,True,0,7,7,18,4.169925001442312,0.004315215258799134
1902,LAMC1,Post-translational protein phosphorylation,2554.5,0.022309339253071,0.5,0.0,1.0,0.012218544390940101,True,0,7,7,18,4.169925001442312,0.004315215258799134
1903,LAMC1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2552.5,0.022309339253071,0.5,0.0,1.0,0.012218544390940101,True,0,7,7,18,4.169925001442312,0.004315215258799134
1904,LBP,Interleukin-4 and Interleukin-13 signaling,2862.5,0.0045010570305156995,0.5,0.0,1.0,0.0024651722989034,True,0,3,3,10,3.321928094887362,0.0010414465330508943
1905,LBP,Regulation of TLR by endogenous ligand,2860.5,0.0045010570305156995,0.5,0.0,1.0,0.0024651722989034,True,0,3,3,10,3.321928094887362,0.0010414465330508943
1906,LBP,Toll Like Receptor 4 (TLR4) Cascade,2858.5,0.0045010570305156995,0.5,0.0,1.0,0.0024651722989034,True,0,3,3,10,3.321928094887362,0.0010414465330508943
1907,LCAT,HDL remodeling,1524.5,0.0007593768031668999,0.5,0.0,1.0,0.00041590111987145,True,0,1,1,6,2.584962500721156,0.0002118228023345133
1908,LDH6A,Pyruvate metabolism,4770.5,0.0002968945777438,0.5,0.0,1.0,0.00016260542441175,True,0,1,1,6,2.584962500721156,8.281664806370394e-05
1909,LDHA,Pyruvate metabolism,114.5,0.0013735795799562,0.5,0.0,1.0,0.00075229225221775,True,0,1,1,6,2.584962500721156,0.00038315033411922406
1910,LDHB,Pyruvate metabolism,2062.5,0.0010252614991324,0.5,0.0,1.0,0.00056152282223005,True,0,1,1,6,2.584962500721156,0.000285989462630685
1911,LDL clearance,Plasma lipoprotein clearance,5684.5,0.0023730956621376004,0.5,1.0,2.0,0.029694135567405154,True,2,1,3,7,2.807354922057604,0.0006232924722592216
1912,LDL remodeling,Plasma lipoprotein remodeling,5676.5,0.0010374501379995,0.5,1.0,2.0,0.0129814341384091,True,4,1,5,9,3.169925001442312,0.00024879347653510844
1913,LG3BP,Platelet degranulation ,4644.5,0.00796454605357,0.5,0.0,1.0,0.0043620816558176,True,0,1,1,6,2.584962500721156,0.002221653936956897
1914,LIRA3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,4826.5,0.0031863729880771,0.5,0.0,1.0,0.00174513639150265,True,0,2,2,7,2.807354922057604,0.0008368993837735234
1915,LIRA3,Neutrophil degranulation,4828.5,0.0031863729880771,0.5,0.0,1.0,0.00174513639150265,True,0,2,2,7,2.807354922057604,0.0008368993837735234
1916,LKHA4,Arachidonic acid metabolism,2452.5,0.0027036678713307,0.5,0.0,1.0,0.0014807648729294,True,0,4,4,12,3.584962500721156,0.0005896815668406117
1917,LKHA4,Biosynthesis of DHA-derived SPMs,2454.5,0.0027036678713307,0.5,0.0,1.0,0.0014807648729294,True,0,4,4,12,3.584962500721156,0.0005896815668406117
1918,LKHA4,Biosynthesis of EPA-derived SPMs,2456.5,0.0027036678713307,0.5,0.0,1.0,0.0014807648729294,True,0,4,4,12,3.584962500721156,0.0005896815668406117
1919,LKHA4,Neutrophil degranulation,2458.5,0.0027036678713307,0.5,0.0,1.0,0.0014807648729294,True,0,4,4,12,3.584962500721156,0.0005896815668406117
1920,LMAN2,COPII-mediated vesicle transport,4660.5,0.0039510479656953,0.5,0.0,1.0,0.00216393925485425,True,0,2,2,7,2.807354922057604,0.00103774091109952
1921,LMAN2,Cargo concentration in the ER,4662.5,0.0039510479656953,0.5,0.0,1.0,0.00216393925485425,True,0,2,2,7,2.807354922057604,0.00103774091109952
1922,LRP1,Retinoid metabolism and transport,4642.5,0.0035630485956226997,0.5,0.0,1.0,0.0019514368820538,True,0,2,2,11,3.4594316186372973,0.0007989916429554957
1923,LRP1,Scavenging of heme from plasma,4640.5,0.0035630485956226997,0.5,0.0,1.0,0.0019514368820538,True,0,2,2,11,3.4594316186372973,0.0007989916429554957
1924,LUM,Diseases associated with glycosaminoglycan metabolism,3872.5,0.0108376444965182,0.5,0.0,1.0,0.0059356415208803495,True,0,4,4,13,3.700439718141092,0.0023056660964485723
1925,LUM,ECM proteoglycans,3876.5,0.0108376444965182,0.5,0.0,1.0,0.0059356415208803495,True,0,4,4,13,3.700439718141092,0.0023056660964485723
1926,LUM,Integrin cell surface interactions,3874.5,0.0108376444965182,0.5,0.0,1.0,0.0059356415208803495,True,0,4,4,13,3.700439718141092,0.0023056660964485723
1927,LUM,Keratan sulfate/keratin metabolism,3870.5,0.0108376444965182,0.5,0.0,1.0,0.0059356415208803495,True,0,4,4,13,3.700439718141092,0.0023056660964485723
1928,LV147,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,582.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1929,LV147,CD22 mediated BCR regulation,580.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1930,LV147,FCERI mediated Ca+2 mobilization,570.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1931,LV147,FCERI mediated MAPK activation,568.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1932,LV147,FCERI mediated NF-kB activation,572.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1933,LV147,FCGR activation,560.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1934,LV147,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,584.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1935,LV147,Initial triggering of complement,556.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1936,LV147,Leishmania parasite growth and survival,576.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1937,LV147,Parasite infection,574.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1938,LV147,Potential therapeutics for SARS,578.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1939,LV147,Regulation of Complement cascade,558.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1940,LV147,Regulation of actin dynamics for phagocytic cup formation,562.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1941,LV147,Role of LAT2/NTAL/LAB on calcium mobilization,566.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1942,LV147,Role of phospholipids in phagocytosis,564.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1943,LV147,Scavenging of heme from plasma,586.5,0.0131555559224201,0.5,0.0,1.0,0.0072051324426140005,True,0,16,16,31,4.954196310386875,0.0022094595536715374
1944,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,614.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1945,LV319,CD22 mediated BCR regulation,612.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1946,LV319,FCERI mediated Ca+2 mobilization,602.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1947,LV319,FCERI mediated MAPK activation,600.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1948,LV319,FCERI mediated NF-kB activation,604.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1949,LV319,FCGR activation,592.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1950,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,616.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1951,LV319,Initial triggering of complement,588.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1952,LV319,Leishmania parasite growth and survival,608.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1953,LV319,Parasite infection,606.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1954,LV319,Potential therapeutics for SARS,610.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1955,LV319,Regulation of Complement cascade,590.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1956,LV319,Regulation of actin dynamics for phagocytic cup formation,594.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1957,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,598.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1958,LV319,Role of phospholipids in phagocytosis,596.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1959,LV319,Scavenging of heme from plasma,618.5,0.0114482998155027,0.5,0.0,1.0,0.006270089755224599,True,0,16,16,31,4.954196310386875,0.0019227279751478073
1960,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,4476.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1961,LV321,CD22 mediated BCR regulation,4474.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1962,LV321,FCERI mediated Ca+2 mobilization,4464.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1963,LV321,FCERI mediated MAPK activation,4462.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1964,LV321,FCERI mediated NF-kB activation,4466.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1965,LV321,FCGR activation,4454.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1966,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,4478.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1967,LV321,Initial triggering of complement,4450.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1968,LV321,Leishmania parasite growth and survival,4470.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1969,LV321,Parasite infection,4468.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1970,LV321,Potential therapeutics for SARS,4472.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1971,LV321,Regulation of Complement cascade,4452.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1972,LV321,Regulation of actin dynamics for phagocytic cup formation,4456.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1973,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,4460.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1974,LV321,Role of phospholipids in phagocytosis,4458.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1975,LV321,Scavenging of heme from plasma,4480.5,0.015852669549651,0.5,0.0,1.0,0.0086823076385219,True,0,16,16,31,4.954196310386875,0.0026624364940733658
1976,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,646.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1977,LV325,CD22 mediated BCR regulation,644.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1978,LV325,FCERI mediated Ca+2 mobilization,634.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1979,LV325,FCERI mediated MAPK activation,632.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1980,LV325,FCERI mediated NF-kB activation,636.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1981,LV325,FCGR activation,624.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1982,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,648.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1983,LV325,Initial triggering of complement,620.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1984,LV325,Leishmania parasite growth and survival,640.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1985,LV325,Parasite infection,638.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1986,LV325,Potential therapeutics for SARS,642.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1987,LV325,Regulation of Complement cascade,622.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1988,LV325,Regulation of actin dynamics for phagocytic cup formation,626.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1989,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,630.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1990,LV325,Role of phospholipids in phagocytosis,628.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1991,LV325,Scavenging of heme from plasma,650.5,0.011483879055820202,0.5,0.0,1.0,0.00628957605745365,True,0,16,16,31,4.954196310386875,0.0019287034651153507
1992,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1556.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
1993,LV743,CD22 mediated BCR regulation,1554.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
1994,LV743,FCERI mediated Ca+2 mobilization,1544.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
1995,LV743,FCERI mediated MAPK activation,1542.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
1996,LV743,FCERI mediated NF-kB activation,1546.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
1997,LV743,FCGR activation,1534.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
1998,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1558.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
1999,LV743,Initial triggering of complement,1530.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
2000,LV743,Leishmania parasite growth and survival,1550.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
2001,LV743,Parasite infection,1548.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
2002,LV743,Potential therapeutics for SARS,1552.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
2003,LV743,Regulation of Complement cascade,1532.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
2004,LV743,Regulation of actin dynamics for phagocytic cup formation,1536.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
2005,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,1540.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
2006,LV743,Role of phospholipids in phagocytosis,1538.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
2007,LV743,Scavenging of heme from plasma,1560.5,0.018274814332443802,0.5,0.0,1.0,0.0100088858582584,True,0,16,16,31,4.954196310386875,0.003069232752800586
2008,LYAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,2686.5,0.0037476903159358,0.5,0.0,1.0,0.0020525628289262497,True,0,2,2,7,2.807354922057604,0.0009843291189439308
2009,LYAM1,Neutrophil degranulation,2688.5,0.0037476903159358,0.5,0.0,1.0,0.0020525628289262497,True,0,2,2,7,2.807354922057604,0.0009843291189439308
2010,LYSC,Amyloid fiber formation,4060.5,0.0111983551712858,0.5,0.0,1.0,0.00613319821863545,True,0,2,2,7,2.807354922057604,0.002941242778919567
2011,LYSC,Neutrophil degranulation,4058.5,0.0111983551712858,0.5,0.0,1.0,0.00613319821863545,True,0,2,2,7,2.807354922057604,0.002941242778919567
2012,Lactose synthesis,Lactose synthesis,5994.5,0.0015375511679132999,0.5,1.0,2.0,0.01923911182776105,False,2,2,4,5,2.321928094887362,0.0004628490214100899
2013,Lactose synthesis,Metabolism of carbohydrates,6404.5,0.0006092715748747,0.5,2.0,3.0,0.0114872995399407,True,2,2,4,5,2.321928094887362,0.00018340901954271794
2014,Laminin interactions,Extracellular matrix organization,6808.5,0.0004398890249355,0.5,3.0,4.0,0.01507238525602285,True,5,2,7,7,2.807354922057604,0.00011553664786727351
2015,Laminin interactions,Laminin interactions,6042.5,0.0006095767260443,0.5,1.5,2.5,0.009125303196653174,False,5,2,7,7,2.807354922057604,0.0001601050436650301
2016,Late endosomal microautophagy,Autophagy,6824.5,0.004899713427452,0.5,3.0,4.0,0.1678840894779819,True,6,2,8,8,3.0,0.001224928356863
2017,Late endosomal microautophagy,Late endosomal microautophagy,6050.5,0.00624035665790635,0.5,1.5,2.5,0.09537330162630532,False,6,2,8,8,3.0,0.0015600891644765875
2018,Latent infection - Other responses of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,5170.5,0.0046657311885503,0.5,1.0,2.0,0.058381487372946905,True,1,1,2,6,2.584962500721156,0.0013014728013505678
2019,Leishmania infection,Infectious disease,6194.5,0.011998907294698,0.5,2.0,3.0,0.2262292349261572,True,3,1,4,44,5.459431618637297,0.001857579428517788
2020,Leishmania parasite growth and survival,Leishmania infection,5740.5,0.0052498798963166,0.5,1.0,2.0,0.06569083911830015,True,33,1,34,38,5.247927513443585,0.0008402594116241747
2021,Lipophagy,Selective autophagy,5742.5,0.0019273949982917,0.5,1.0,2.0,0.0241171602495194,True,1,1,2,6,2.584962500721156,0.0005376332382567412
2022,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,Cell-extracellular matrix interactions,5474.5,9.571585237124058e-05,0.5,1.0,2.0,0.0011976759056148,True,1,1,2,6,2.584962500721156,2.669926180594253e-05
2023,Lysosome Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,5324.5,0.0065655558878853,0.5,1.0,2.0,0.08215366524020551,True,3,1,4,8,3.0,0.001641388971971325
2024,M Phase,"Cell Cycle, Mitotic",6396.5,0.0012588230173614001,0.5,2.0,3.0,0.0237340418698757,True,3,1,4,29,4.857980995127572,0.00021489025287184057
2025,MA1A1,Intra-Golgi traffic,3624.5,0.0024809332474058,0.5,0.0,1.0,0.0013587759220710502,True,0,1,1,6,2.584962500721156,0.0006920388279951972
2026,MAPK family signaling cascades,Signal Transduction,6726.5,0.0018160992405802,0.5,3.0,4.0,0.0622269387630337,True,2,1,3,28,4.807354922057604,0.0003127239965448397
2027,MAPK1/MAPK3 signaling,MAPK family signaling cascades,6324.5,0.0004122591477193,0.5,2.0,3.0,0.00777279707970485,True,1,1,2,27,4.754887502163468,7.16363521553318e-05
2028,MAPK6/MAPK4 signaling,MAPK family signaling cascades,6534.5,0.0023763647304018,0.5,2.0,3.0,0.044804344400750346,True,10,2,12,13,3.700439718141092,0.0005055622181963847
2029,MAPK6/MAPK4 signaling,MAPK6/MAPK4 signaling,5958.5,0.003226331493647,0.5,1.0,2.0,0.040370527950586446,False,10,2,12,13,3.700439718141092,0.0006863892927283267
2030,MASP1,Initial triggering of complement,3760.5,0.0023597903295667,0.5,0.0,1.0,0.0012924274703095002,True,0,3,3,13,3.700439718141092,0.0005020360798287056
2031,MASP1,SARS-CoV-2 Infection,3762.5,0.0023597903295667,0.5,0.0,1.0,0.0012924274703095002,True,0,3,3,13,3.700439718141092,0.0005020360798287056
2032,MASP1,Scavenging by Class A Receptors,3764.5,0.0023597903295667,0.5,0.0,1.0,0.0012924274703095002,True,0,3,3,13,3.700439718141092,0.0005020360798287056
2033,MDHC,Gluconeogenesis,3738.5,0.00012504895547757087,0.5,0.0,1.0,6.848773942657495e-05,True,0,1,1,6,2.584962500721156,3.488152399151061e-05
2034,MDHM,Citric acid cycle (TCA cycle),3742.5,0.0027314594583814997,0.5,0.0,1.0,0.00149598597545615,True,0,2,2,9,3.169925001442312,0.0006550380300453199
2035,MDHM,Gluconeogenesis,3740.5,0.0027314594583814997,0.5,0.0,1.0,0.00149598597545615,True,0,2,2,9,3.169925001442312,0.0006550380300453199
2036,MET Receptor Activation,Signaling by MET,5594.5,0.0097123750989514,0.5,1.0,2.0,0.12152926975137836,True,1,1,2,6,2.584962500721156,0.0027091985193701874
2037,MET promotes cell motility,Signaling by MET,5596.5,0.0063568229354263005,0.5,1.0,2.0,0.07954182590873965,True,5,1,6,10,3.321928094887362,0.0014708303321719128
2038,MFAP4,Molecules associated with elastic fibres,3890.5,0.00034023086687170003,0.5,0.0,1.0,0.00018634016466744999,True,0,1,1,5,2.321928094887362,0.00010241969637914042
2039,MHC class II antigen presentation,Adaptive Immune System,6258.5,0.000508060510526,0.5,2.0,3.0,0.009579050639326351,True,8,2,10,11,3.4594316186372973,0.00011392943181428398
2040,MHC class II antigen presentation,MHC class II antigen presentation,5784.5,0.001193540723713,0.5,1.0,2.0,0.01493456863986225,False,8,2,10,11,3.4594316186372973,0.00026764413624481576
2041,MINP1,Synthesis of IPs in the ER lumen,5122.5,0.0014769165541179,0.5,0.0,1.0,0.0008088886126791,True,0,1,1,5,2.321928094887362,0.0004445961838821735
2042,ML12A,EPH-Ephrin signaling,2864.5,0.0035857263164178,0.5,0.0,1.0,0.00196385718437995,True,0,2,2,8,3.0,0.00089643157910445
2043,ML12A,Smooth Muscle Contraction,2866.5,0.0035857263164178,0.5,0.0,1.0,0.00196385718437995,True,0,2,2,8,3.0,0.00089643157910445
2044,MMP14,Activation of Matrix Metalloproteinases,3868.5,0.0022414373174819,0.5,0.0,1.0,0.0012276070148242,True,0,2,2,6,2.584962500721156,0.0006252331278307679
2045,MMP14,Collagen degradation,3866.5,0.0022414373174819,0.5,0.0,1.0,0.0012276070148242,True,0,2,2,6,2.584962500721156,0.0006252331278307679
2046,MMP8,Activation of Matrix Metalloproteinases,2912.5,0.0041312556196744996,0.5,0.0,1.0,0.0022626367193893998,True,0,3,3,9,3.169925001442312,0.0009907266001775961
2047,MMP8,Collagen degradation,2910.5,0.0041312556196744996,0.5,0.0,1.0,0.0022626367193893998,True,0,3,3,9,3.169925001442312,0.0009907266001775961
2048,MMP8,Neutrophil degranulation,2914.5,0.0041312556196744996,0.5,0.0,1.0,0.0022626367193893998,True,0,3,3,9,3.169925001442312,0.0009907266001775961
2049,MMP9,Activation of Matrix Metalloproteinases,2736.5,0.0165223148095935,0.5,0.0,1.0,0.00904906392125965,True,0,7,7,22,4.459431618637297,0.0030263800270324765
2050,MMP9,Collagen degradation,2734.5,0.0165223148095935,0.5,0.0,1.0,0.00904906392125965,True,0,7,7,22,4.459431618637297,0.0030263800270324765
2051,MMP9,EPH-Ephrin signaling,2728.5,0.0165223148095935,0.5,0.0,1.0,0.00904906392125965,True,0,7,7,22,4.459431618637297,0.0030263800270324765
2052,MMP9,Extra-nuclear estrogen signaling,2732.5,0.0165223148095935,0.5,0.0,1.0,0.00904906392125965,True,0,7,7,22,4.459431618637297,0.0030263800270324765
2053,MMP9,Interleukin-4 and Interleukin-13 signaling,2730.5,0.0165223148095935,0.5,0.0,1.0,0.00904906392125965,True,0,7,7,22,4.459431618637297,0.0030263800270324765
2054,MMP9,Neutrophil degranulation,2738.5,0.0165223148095935,0.5,0.0,1.0,0.00904906392125965,True,0,7,7,22,4.459431618637297,0.0030263800270324765
2055,MMP9,Signaling by SCF-KIT,2740.5,0.0165223148095935,0.5,0.0,1.0,0.00904906392125965,True,0,7,7,22,4.459431618637297,0.0030263800270324765
2056,MMRN1,Platelet degranulation ,4672.5,0.0005769569489912001,0.5,0.0,1.0,0.00031599206112485,True,0,1,1,6,2.584962500721156,0.000160938070865494
2057,MRC1,Antigen processing-Cross presentation,2916.5,0.0055745709563373,0.5,0.0,1.0,0.0030531223680718,True,0,2,2,10,3.321928094887362,0.0012898342670096146
2058,MRC1,Modulation by Mtb of host immune system,2918.5,0.0055745709563373,0.5,0.0,1.0,0.0030531223680718,True,0,2,2,10,3.321928094887362,0.0012898342670096146
2059,MT1A,Metallothioneins bind metals,1672.5,0.0022810778739716,0.5,0.0,1.0,0.0012493176488172501,True,0,1,1,5,2.321928094887362,0.0006866728625108742
2060,MT1E,Metallothioneins bind metals,1674.5,0.0066203257603202,0.5,0.0,1.0,0.0036258691155015,True,0,1,1,5,2.321928094887362,0.001992916634923333
2061,MTOR signalling,Signal Transduction,6816.5,4.2630999286104016e-05,0.5,3.0,4.0,0.0014607112445769,True,1,1,2,5,2.321928094887362,1.2833209530247078e-05
2062,MUC18,RHO GTPase cycle,3750.5,0.0006252376771427,0.5,0.0,1.0,0.00034243480841789997,True,0,1,1,6,2.584962500721156,0.00017440563939425486
2063,MYG,Intracellular oxygen transport,998.5,0.0010427670548303,0.5,0.0,1.0,0.0005711103948137,True,0,1,1,4,2.0,0.0003475890182767667
2064,MYH10,EPH-Ephrin signaling,3676.5,0.000557042345038,0.5,0.0,1.0,0.0003050850831247,True,0,3,3,11,3.4594316186372973,0.00012491330570244729
2065,MYH10,RHO GTPase Effectors,3674.5,0.000557042345038,0.5,0.0,1.0,0.0003050850831247,True,0,3,3,11,3.4594316186372973,0.00012491330570244729
2066,MYH10,Semaphorin interactions,3678.5,0.000557042345038,0.5,0.0,1.0,0.0003050850831247,True,0,3,3,11,3.4594316186372973,0.00012491330570244729
2067,MYH11,EPH-Ephrin signaling,3682.5,0.000721683025111,0.5,0.0,1.0,0.00039525671193035004,True,0,4,4,13,3.700439718141092,0.0001535352155088179
2068,MYH11,RHO GTPase Effectors,3680.5,0.000721683025111,0.5,0.0,1.0,0.00039525671193035004,True,0,4,4,13,3.700439718141092,0.0001535352155088179
2069,MYH11,Semaphorin interactions,3684.5,0.000721683025111,0.5,0.0,1.0,0.00039525671193035004,True,0,4,4,13,3.700439718141092,0.0001535352155088179
2070,MYH11,Smooth Muscle Contraction,3686.5,0.000721683025111,0.5,0.0,1.0,0.00039525671193035004,True,0,4,4,13,3.700439718141092,0.0001535352155088179
2071,MYH9,EPH-Ephrin signaling,3658.5,0.015328011968348,0.5,0.0,1.0,0.008394959282998,True,0,10,10,30,4.906890595608519,0.0025949375090413254
2072,MYH9,Leishmania parasite growth and survival,3664.5,0.015328011968348,0.5,0.0,1.0,0.008394959282998,True,0,10,10,30,4.906890595608519,0.0025949375090413254
2073,MYH9,Parasite infection,3662.5,0.015328011968348,0.5,0.0,1.0,0.008394959282998,True,0,10,10,30,4.906890595608519,0.0025949375090413254
2074,MYH9,RHO GTPase Effectors,3654.5,0.015328011968348,0.5,0.0,1.0,0.008394959282998,True,0,10,10,30,4.906890595608519,0.0025949375090413254
2075,MYH9,Regulation of actin dynamics for phagocytic cup formation,3656.5,0.015328011968348,0.5,0.0,1.0,0.008394959282998,True,0,10,10,30,4.906890595608519,0.0025949375090413254
2076,MYH9,Semaphorin interactions,3660.5,0.015328011968348,0.5,0.0,1.0,0.008394959282998,True,0,10,10,30,4.906890595608519,0.0025949375090413254
2077,MYH9,Sensory processing of sound by inner hair cells of the cochlea,3670.5,0.015328011968348,0.5,0.0,1.0,0.008394959282998,True,0,10,10,30,4.906890595608519,0.0025949375090413254
2078,MYH9,Sensory processing of sound by outer hair cells of the cochlea,3672.5,0.015328011968348,0.5,0.0,1.0,0.008394959282998,True,0,10,10,30,4.906890595608519,0.0025949375090413254
2079,MYH9,Signaling by ALK fusions and activated point mutants,3666.5,0.015328011968348,0.5,0.0,1.0,0.008394959282998,True,0,10,10,30,4.906890595608519,0.0025949375090413254
2080,MYH9,Translocation of SLC2A4 (GLUT4) to the plasma membrane,3668.5,0.015328011968348,0.5,0.0,1.0,0.008394959282998,True,0,10,10,30,4.906890595608519,0.0025949375090413254
2081,MYL6,EPH-Ephrin signaling,3904.5,0.0007805008272019,0.5,0.0,1.0,0.00042747048203230003,True,0,4,4,13,3.700439718141092,0.00016604847078233965
2082,MYL6,RHO GTPase Effectors,3902.5,0.0007805008272019,0.5,0.0,1.0,0.00042747048203230003,True,0,4,4,13,3.700439718141092,0.00016604847078233965
2083,MYL6,Semaphorin interactions,3906.5,0.0007805008272019,0.5,0.0,1.0,0.00042747048203230003,True,0,4,4,13,3.700439718141092,0.00016604847078233965
2084,MYL6,Smooth Muscle Contraction,3908.5,0.0007805008272019,0.5,0.0,1.0,0.00042747048203230003,True,0,4,4,13,3.700439718141092,0.00016604847078233965
2085,Macroautophagy,Autophagy,6764.5,0.0011882308151493,0.5,3.0,4.0,0.04071361548889185,True,1,1,2,14,3.807354922057604,0.00024716935496011256
2086,Meiosis,Cell Cycle,6680.5,0.0005928195265247,0.5,3.0,4.0,0.0203124055945352,True,2,2,4,10,3.321928094887362,0.00013716552277349956
2087,Meiosis,Reproduction,6678.5,0.0005928195265247,0.5,3.0,4.0,0.0203124055945352,True,2,2,4,10,3.321928094887362,0.00013716552277349956
2088,Meiotic recombination,Meiosis,6158.5,0.0008686882710608,0.5,2.0,3.0,0.01637838164132525,True,4,2,6,8,3.0,0.0002171720677652
2089,Meiotic recombination,Meiotic recombination,5816.5,0.0018741104989382002,0.5,1.0,2.0,0.02345042052524885,False,4,2,6,8,3.0,0.00046852762473455006
2090,Meiotic synapsis,Meiosis,6292.5,0.0014198801975089002,0.5,2.0,3.0,0.02677063859899925,True,5,2,7,9,3.169925001442312,0.000340504972395855
2091,Meiotic synapsis,Meiotic synapsis,5814.5,0.0021093763870141,0.5,1.0,2.0,0.02639426189092535,False,5,2,7,9,3.169925001442312,0.0005058547542904247
2092,Membrane Trafficking,Vesicle-mediated transport,6718.5,0.019020399225206097,0.5,3.0,4.0,0.651716157018585,True,8,1,9,48,5.584962500721156,0.0028884597631532553
2093,Metabolic disorders of biological oxidation enzymes,Diseases of metabolism,6604.5,0.0004800326577917,0.5,2.0,3.0,0.009050609213373601,True,3,1,4,10,3.321928094887362,0.0001110690986181737
2094,Metabolism,root,6866.5,0.0086677305859531,0.5,4.0,5.0,0.7223591070409887,True,12,1,13,222,7.794415866350106,0.0009855948044392875
2095,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,5888.5,0.0067399656936086,0.5,1.0,2.0,0.0843360249731316,False,7,2,9,10,3.321928094887362,0.001559481218945235
2096,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,6298.5,0.0045037505841121,0.5,2.0,3.0,0.08491440294668781,True,7,2,9,10,3.321928094887362,0.0010420697626690794
2097,Metabolism of RNA,root,6888.5,0.0025513422062735,0.5,4.0,5.0,0.212626045491826,True,2,1,3,22,4.459431618637297,0.0004673274407474543
2098,Metabolism of amine-derived hormones,Metabolism of amino acids and derivatives,6528.5,1.0281260555452875e-05,0.5,2.0,3.0,0.0001938444603671,True,1,1,2,6,2.584962500721156,2.8678851043447965e-06
2099,Metabolism of amino acids and derivatives,Metabolism,6632.5,0.0005192219820277,0.5,3.0,4.0,0.017790654694474953,True,14,1,15,49,5.614709844115208,7.849505031420645e-05
2100,Metabolism of carbohydrates,Metabolism,6716.5,0.0057144049936736,0.5,3.0,4.0,0.19579873261490205,True,8,1,9,48,5.584962500721156,0.000867796132938917
2101,Metabolism of cofactors,Metabolism of vitamins and cofactors,6176.5,0.0005628832833894,0.5,2.0,3.0,0.010612687591161,True,2,1,3,8,3.0,0.00014072082084735
2102,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,6346.5,0.006660217196484301,0.5,2.0,3.0,0.1255727545681145,True,1,1,2,18,4.169925001442312,0.00128826185962586
2103,Metabolism of folate and pterines,Metabolism of water-soluble vitamins and cofactors,5308.5,0.0003260527526361,0.5,1.0,2.0,0.00407984169933695,True,1,1,2,6,2.584962500721156,9.095011525797293e-05
2104,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",Selenoamino acid metabolism,5378.5,0.00016722912369003,0.5,1.0,2.0,0.00209250910062235,True,2,1,3,7,2.807354922057604,4.3922651581863704e-05
2105,Metabolism of lipids,Metabolism,6684.5,0.0023676803173876,0.5,3.0,4.0,0.0811263475191216,True,8,1,9,45,5.491853096329675,0.00036471563392680975
2106,Metabolism of nitric oxide: NOS3 activation and regulation,Metabolism,6832.5,0.0005987387028717,0.5,3.0,4.0,0.0205152206256962,True,1,1,2,5,2.321928094887362,0.0001802383091293256
2107,Metabolism of nucleotides,Metabolism,6640.5,0.00016747305281897282,0.5,3.0,4.0,0.00573830722978565,True,2,1,3,8,3.0,4.1868263204743204e-05
2108,Metabolism of polyamines,Metabolism of amino acids and derivatives,6610.5,0.00023840336657455553,0.5,2.0,3.0,0.00449489356816925,True,1,1,2,14,3.807354922057604,4.959138038273157e-05
2109,Metabolism of porphyrins,Metabolism,6698.5,0.00021870392226077095,0.5,3.0,4.0,0.00749368496702345,True,2,1,3,8,3.0,5.467598056519274e-05
2110,Metabolism of proteins,root,6884.5,0.0208093147903773,0.5,4.0,5.0,1.7342253431909969,True,7,1,8,140,7.129283016944966,0.0025597970629146045
2111,Metabolism of steroid hormones,Metabolism of steroids,5304.5,0.0014556897044948,0.5,1.0,2.0,0.01821479349484445,True,1,1,2,6,2.584962500721156,0.00040605437412580226
2112,Metabolism of steroids,Metabolism of lipids,6378.5,0.0029959729109567,0.5,2.0,3.0,0.056486531886511496,True,3,1,4,11,3.4594316186372973,0.000671828422805192
2113,Metabolism of vitamins and cofactors,Metabolism,6708.5,0.0052556442490174,0.5,3.0,4.0,0.1800797255657674,True,3,1,4,39,5.285402218862249,0.00083616673460378
2114,Metabolism of water-soluble vitamins and cofactors,Metabolism of vitamins and cofactors,6248.5,0.0013324352117628,0.5,2.0,3.0,0.02512193745167065,True,6,1,7,19,4.247927513443585,0.00025389741156856845
2115,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",5462.5,0.0022541649251727,0.5,1.0,2.0,0.02820597582613865,True,1,1,2,6,2.584962500721156,0.0006287834042111316
2116,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,5592.5,0.0083296456911096,0.5,1.0,2.0,0.10422741582927164,True,4,1,5,9,3.169925001442312,0.0019975528788236012
2117,Metalloprotease DUBs,Deubiquitination,5570.5,0.0003372422617969,0.5,1.0,2.0,0.00421985409211845,True,1,1,2,6,2.584962500721156,9.407134990367678e-05
2118,Metallothioneins bind metals,Metallothioneins bind metals,5954.5,0.007194621005653301,0.5,1.0,2.0,0.0900250482551247,False,3,2,5,6,2.584962500721156,0.002006888776160426
2119,Metallothioneins bind metals,Response to metal ions,6068.5,0.00567273111709,0.5,2.0,3.0,0.10695454086291295,True,3,2,5,6,2.584962500721156,0.0015823683276879092
2120,Methionine salvage pathway,Sulfur amino acid metabolism,5218.5,0.00044325155543290006,0.5,1.0,2.0,0.0055463300479153006,True,1,1,2,6,2.584962500721156,0.0001236418945368982
2121,Methylation,Phase II - Conjugation of compounds,5204.5,0.001200853265777,0.5,1.0,2.0,0.01502606921392415,True,2,1,3,7,2.807354922057604,0.00031540355190422443
2122,Miscellaneous transport and binding events,Miscellaneous transport and binding events,5983.5,0.0005551850655739714,0.5,1.5,2.5,0.0093970172816174,False,2,2,4,4,2.0,0.00018506168852465714
2123,Miscellaneous transport and binding events,Transport of small molecules,6690.5,0.0005241062157239,0.5,3.0,4.0,0.017958008385466448,True,2,2,4,4,2.0,0.00017470207190796666
2124,Mitochondrial Fatty Acid Beta-Oxidation,Fatty acid metabolism,5688.5,0.00010791223081783009,0.5,1.0,2.0,0.00135028707961955,True,1,1,2,6,2.584962500721156,3.010135553611016e-05
2125,Mitochondrial biogenesis,Organelle biogenesis and maintenance,6804.5,0.0003528721479254012,0.5,3.0,4.0,0.01209083350154315,True,2,1,3,8,3.0,8.82180369813503e-05
2126,Mitochondrial protein import,Mitochondrial protein import,6262.5,0.000558411297217,0.5,1.5,2.5,0.008661120821392925,False,4,2,6,6,2.584962500721156,0.00015576489213057855
2127,Mitochondrial protein import,Protein localization,6846.5,0.00025792050937838677,0.5,3.0,4.0,0.0088374045780076,True,4,2,6,6,2.584962500721156,7.194510662984707e-05
2128,Mitotic G1 phase and G1/S transition,"Cell Cycle, Mitotic",6056.5,0.0008728512461695,0.5,2.0,3.0,0.01645687101129115,True,1,1,2,14,3.807354922057604,0.00018156580080338849
2129,Mitotic G2-G2/M phases,"Cell Cycle, Mitotic",6558.5,0.0016467292436502,0.5,2.0,3.0,0.031047685240983648,True,1,1,2,24,4.584962500721156,0.0002948505461652727
2130,Mitotic Metaphase and Anaphase,M Phase,5392.5,0.0010257877334339,0.5,1.0,2.0,0.0128355044872192,True,15,1,16,20,4.321928094887363,0.00019274738687644944
2131,Mitotic Prometaphase,M Phase,5606.5,0.0006122434037335,0.5,1.0,2.0,0.0076608958167056,True,9,1,10,14,3.807354922057604,0.00012735556530772078
2132,Mitotic Prophase,M Phase,5604.5,0.0008068331998895,0.5,1.0,2.0,0.01009576427956675,True,3,1,4,8,3.0,0.000201708299972375
2133,Modulation by Mtb of host immune system,Infection with Mycobacterium tuberculosis,5722.5,0.0054863266331033,0.5,1.0,2.0,0.06864945623965595,True,2,1,3,7,2.807354922057604,0.0014409811392467535
2134,Molecules associated with elastic fibres,Elastic fibre formation,6350.5,0.006435906462818,0.5,2.0,3.0,0.12134356565809895,True,9,2,11,12,3.584962500721156,0.0014036988223580266
2135,Molecules associated with elastic fibres,Molecules associated with elastic fibres,5820.5,0.0069631429038506006,0.5,1.0,2.0,0.08712860280394386,False,9,2,11,12,3.584962500721156,0.0015186913530384136
2136,Muscle contraction,root,6880.5,0.0036751315274989,0.5,4.0,5.0,0.3062814080498363,True,3,1,4,16,4.0,0.0007350263054997799
2137,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,5520.5,0.0085989820643977,0.5,1.0,2.0,0.10759757528354469,True,7,1,8,12,3.584962500721156,0.0018754748949517451
2138,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,Asparagine N-linked glycosylation,5472.5,0.0097981369516428,0.5,1.0,2.0,0.1226023929806514,True,4,1,5,9,3.169925001442312,0.0023497153901458124
2139,NADPH regeneration,Metabolism of cofactors,5692.5,0.0008125875983889,0.5,1.0,2.0,0.010167768072703049,True,1,1,2,6,2.584962500721156,0.00022666557829417706
2140,NCAM signaling for neurite out-growth,Axon guidance,5424.5,0.0054831892157934,0.5,1.0,2.0,0.06861019827950754,True,2,1,3,7,2.807354922057604,0.0014401570980490904
2141,NGAL,Interleukin-4 and Interleukin-13 signaling,4420.5,0.0107308928152282,0.5,0.0,1.0,0.0058771749682921,True,0,3,3,10,3.321928094887362,0.002482894805196399
2142,NGAL,Metal sequestration by antimicrobial proteins,4422.5,0.0107308928152282,0.5,0.0,1.0,0.0058771749682921,True,0,3,3,10,3.321928094887362,0.002482894805196399
2143,NGAL,Neutrophil degranulation,4424.5,0.0107308928152282,0.5,0.0,1.0,0.0058771749682921,True,0,3,3,10,3.321928094887362,0.002482894805196399
2144,NID1,Laminin interactions,2702.5,0.0001953509043989349,0.5,0.0,1.0,0.00010699123224281522,True,0,1,1,4,2.0,6.51169681329783e-05
2145,NIK-->noncanonical NF-kB signaling,TNFR2 non-canonical NF-kB pathway,5556.5,0.0020268190978478,0.5,1.0,2.0,0.025361236810776948,True,9,1,10,14,3.807354922057604,0.000421607959201876
2146,NOTCH4 Activation and Transmission of Signal to the Nucleus,Signaling by NOTCH4,5704.5,0.00016219382235919792,0.5,1.0,2.0,0.00202950324598,True,1,1,2,6,2.584962500721156,4.524282257529076e-05
2147,NOTCH4 Intracellular Domain Regulates Transcription,Signaling by NOTCH4,5702.5,0.0027311861406948,0.5,1.0,2.0,0.0341748597899158,True,1,1,2,6,2.584962500721156,0.0007618451072069486
2148,NPC2,LDL clearance,4082.5,0.0026601384341276,0.5,0.0,1.0,0.0014569243479033,True,0,2,2,9,3.169925001442312,0.0006379343593008267
2149,NPC2,Neutrophil degranulation,4084.5,0.0026601384341276,0.5,0.0,1.0,0.0014569243479033,True,0,2,2,9,3.169925001442312,0.0006379343593008267
2150,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,6588.5,0.0059090276396912,0.5,2.0,3.0,0.11140971167229155,True,1,1,2,9,3.169925001442312,0.0014170584932936107
2151,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,5712.5,0.006894359840775801,0.5,1.0,2.0,0.0862679322324755,True,4,1,5,9,3.169925001442312,0.0016533534388247148
2152,NRP1,L1CAM interactions,50.5,0.0010307362627887,0.5,0.0,1.0,0.00056452128139565,True,0,5,5,16,4.0,0.00020614725255774002
2153,NRP1,Neurophilin interactions with VEGF and VEGFR,46.5,0.0010307362627887,0.5,0.0,1.0,0.00056452128139565,True,0,5,5,16,4.0,0.00020614725255774002
2154,NRP1,SARS-CoV-2 Infection,54.5,0.0010307362627887,0.5,0.0,1.0,0.00056452128139565,True,0,5,5,16,4.0,0.00020614725255774002
2155,NRP1,Semaphorin interactions,48.5,0.0010307362627887,0.5,0.0,1.0,0.00056452128139565,True,0,5,5,16,4.0,0.00020614725255774002
2156,NRP1,Signaling by ROBO receptors,52.5,0.0010307362627887,0.5,0.0,1.0,0.00056452128139565,True,0,5,5,16,4.0,0.00020614725255774002
2157,NUCB1,Post-translational protein phosphorylation,4514.5,0.0055657006173186,0.5,0.0,1.0,0.0030482641950065,True,0,2,2,6,2.584962500721156,0.001552512924807162
2158,NUCB1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4512.5,0.0055657006173186,0.5,0.0,1.0,0.0030482641950065,True,0,2,2,6,2.584962500721156,0.001552512924807162
2159,Neddylation,Neddylation,5968.5,5.9485056626283595e-05,0.5,1.0,2.0,0.00074432622497165,False,10,2,12,13,3.700439718141092,1.2655211042640168e-05
2160,Neddylation,Post-translational protein modification,6088.5,7.698472688440086e-05,0.5,2.0,3.0,0.0014514818254952,True,10,2,12,13,3.700439718141092,1.637819682853978e-05
2161,Negative epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,6464.5,0.0008578468523548,0.5,2.0,3.0,0.016173975873437,True,2,1,3,9,3.169925001442312,0.00020572236960091227
2162,Negative regulation of NOTCH4 signaling,Signaling by NOTCH4,5706.5,0.000316262032771,0.5,1.0,2.0,0.003957332115077299,True,10,1,11,15,3.9068905956085187,6.445263586150516e-05
2163,Nephrin family interactions,Cell-Cell communication,6722.5,0.0004649245062938,0.5,3.0,4.0,0.01593020256609865,True,3,2,5,5,2.321928094887362,0.0001399562221137012
2164,Nephrin family interactions,Nephrin family interactions,6053.5,0.00069915108102915,0.5,1.5,2.5,0.01050424535546305,False,3,2,5,5,2.321928094887362,0.0002104654468906728
2165,Nervous system development,Developmental Biology,6802.5,0.0064556492886233,0.5,3.0,4.0,0.2211967738230156,True,2,1,3,48,5.584962500721156,0.000980362346469901
2166,Netrin-1 signaling,Axon guidance,5460.5,9.66662663984441e-05,0.5,1.0,2.0,0.00120956827195265,True,1,1,2,6,2.584962500721156,2.6964373094278834e-05
2167,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,5652.5,0.0020987726644412,0.5,1.0,2.0,0.0262615793444021,True,3,1,4,8,3.0,0.0005246931661103
2168,Neuronal System,root,6900.5,0.001902678298799,0.5,4.0,5.0,0.15856711088069098,True,1,1,2,16,4.0,0.0003805356597598
2169,Neurophilin interactions with VEGF and VEGFR,Signaling by VEGF,5296.5,3.6023952097429465e-05,0.5,1.0,2.0,0.00045076148185745,True,1,1,2,6,2.584962500721156,1.0048627312052172e-05
2170,Neurotransmitter clearance,Transmission across Chemical Synapses,6244.5,7.321235010389556e-05,0.5,2.0,3.0,0.0013803568562004,True,1,1,2,6,2.584962500721156,2.042206859602243e-05
2171,Neurotransmitter receptors and postsynaptic signal transmission,Transmission across Chemical Synapses,6354.5,0.0053179568289317,0.5,2.0,3.0,0.10026557212515255,True,1,1,2,10,3.321928094887362,0.001230459348738956
2172,Neurotransmitter release cycle,Transmission across Chemical Synapses,6592.5,0.0013527096870979,0.5,2.0,3.0,0.02550419551325415,True,1,1,2,6,2.584962500721156,0.0003773288247299064
2173,Neutrophil degranulation,Innate Immune System,6470.5,0.0118449143564557,0.5,2.0,3.0,0.22332582849530674,True,87,2,89,90,6.491853096329675,0.0015810393242038647
2174,Neutrophil degranulation,Neutrophil degranulation,5834.5,0.0185907518343118,0.5,1.0,2.0,0.2326228622283042,False,87,2,89,90,6.491853096329675,0.0024814624092695534
2175,Nicotinate metabolism,Metabolism of water-soluble vitamins and cofactors,5312.5,0.0001376638400625747,0.5,1.0,2.0,0.0017225638202319,True,1,1,2,6,2.584962500721156,3.840035705670061e-05
2176,NoRC negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,5504.5,0.0003101903838136508,0.5,1.0,2.0,0.00388135862183105,True,3,1,4,8,3.0,7.75475959534127e-05
2177,Non-integrin membrane-ECM interactions,Extracellular matrix organization,6616.5,0.0057387879252423,0.5,3.0,4.0,0.196634190917887,True,1,1,2,12,3.584962500721156,0.0012516542772900894
2178,Nonhomologous End-Joining (NHEJ),DNA Double-Strand Break Repair,6476.5,0.0015137852754603,0.5,2.0,3.0,0.0285411393136792,True,3,2,5,6,2.584962500721156,0.0004222597238202031
2179,Nonhomologous End-Joining (NHEJ),Nonhomologous End-Joining (NHEJ),5960.5,0.0016519167453261,0.5,1.0,2.0,0.02067014851714695,False,3,2,5,6,2.584962500721156,0.0004607905229116896
2180,Nuclear signaling by ERBB4,Signaling by ERBB4,5192.5,1.784656079963165e-05,0.5,1.0,2.0,0.0002233109285273,True,2,1,3,7,2.807354922057604,4.6873908960362575e-06
2181,Nucleosome assembly,Chromosome Maintenance,6320.5,0.0008684277414733,0.5,2.0,3.0,0.01637346957659935,True,1,1,2,8,3.0,0.000217106935368325
2182,Nucleotide Excision Repair,DNA Repair,6818.5,0.0068478912769685,0.5,3.0,4.0,0.23463657801634286,True,1,1,2,6,2.584962500721156,0.0019101709642962705
2183,Nucleotide catabolism,Metabolism of nucleotides,6240.5,0.0002720423308900523,0.5,2.0,3.0,0.00512912775082285,True,1,1,2,6,2.584962500721156,7.588428912027054e-05
2184,Nucleotide salvage,Metabolism of nucleotides,6428.5,0.0005033766057822,0.5,2.0,3.0,0.0094907395822774,True,1,1,2,6,2.584962500721156,0.00014041335318875443
2185,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",Innate Immune System,6496.5,6.799419516074305e-05,0.5,2.0,3.0,0.0012819729641074,True,1,1,2,6,2.584962500721156,1.8966501085315464e-05
2186,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,5494.5,0.0023603624427722,0.5,1.0,2.0,0.029534806995836,True,2,1,3,7,2.807354922057604,0.0006199480981133726
2187,O-linked glycosylation,Post-translational protein modification,6196.5,0.00119154191124,0.5,2.0,3.0,0.022465513595674898,True,1,1,2,7,2.807354922057604,0.00031295792896451495
2188,O2/CO2 exchange in erythrocytes,Transport of small molecules,6664.5,0.002979353507038,0.5,3.0,4.0,0.10208475621445315,True,2,1,3,10,3.321928094887362,0.0006893574908297145
2189,OLFM4,Neutrophil degranulation,4768.5,0.0020881876907,0.5,0.0,1.0,0.00114367412257275,True,0,1,1,5,2.321928094887362,0.0006286071314769999
2190,OSTP,Integrin cell surface interactions,2510.5,0.0342935791752078,0.5,0.0,1.0,0.0187821617988446,True,0,5,5,15,3.9068905956085187,0.006988861582913475
2191,OSTP,Post-translational protein phosphorylation,2514.5,0.0342935791752078,0.5,0.0,1.0,0.0187821617988446,True,0,5,5,15,3.9068905956085187,0.006988861582913475
2192,OSTP,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2512.5,0.0342935791752078,0.5,0.0,1.0,0.0187821617988446,True,0,5,5,15,3.9068905956085187,0.006988861582913475
2193,OSTP,Signaling by PDGF,2516.5,0.0342935791752078,0.5,0.0,1.0,0.0187821617988446,True,0,5,5,15,3.9068905956085187,0.006988861582913475
2194,OSTP,Transcriptional regulation by RUNX3,2508.5,0.0342935791752078,0.5,0.0,1.0,0.0187821617988446,True,0,5,5,15,3.9068905956085187,0.006988861582913475
2195,OTC,Mitochondrial protein import,138.5,0.0004944839451689,0.5,0.0,1.0,0.0002708226346875,True,0,2,2,7,2.807354922057604,0.00012987597828196867
2196,OTC,Urea cycle,136.5,0.0004944839451689,0.5,0.0,1.0,0.0002708226346875,True,0,2,2,7,2.807354922057604,0.00012987597828196867
2197,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,6264.5,0.0049540469878897,0.5,2.0,3.0,0.0934043602748524,True,7,1,8,24,4.584962500721156,0.000887033169381175
2198,Orc1 removal from chromatin,Switching of origins to a post-replicative state,5608.5,0.0012215730147669,0.5,1.0,2.0,0.01528533184932795,True,9,1,10,14,3.807354922057604,0.0002541050191992175
2199,Organelle biogenesis and maintenance,root,6904.5,0.0013578883457932,0.5,4.0,5.0,0.11316491706817215,True,2,1,3,20,4.321928094887363,0.0002551496979257739
2200,Other interleukin signaling,Signaling by Interleukins,5482.5,0.0013189717111903,0.5,1.0,2.0,0.0165040648915005,True,2,1,3,7,2.807354922057604,0.0003464273066713438
2201,Oxidative Stress Induced Senescence,Cellular Senescence,5394.5,0.0005357524245548,0.5,1.0,2.0,0.006703777424198001,True,3,1,4,8,3.0,0.0001339381061387
2202,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,Cellular response to hypoxia,5190.5,0.0005423391716128,0.5,1.0,2.0,0.006786196250883799,True,9,1,10,14,3.807354922057604,0.00011281446458724802
2203,P01891,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",994.5,0.0031766289242939,0.5,0.0,1.0,0.00173979969037795,True,0,6,6,16,4.0,0.00063532578485878
2204,P01891,Antigen processing-Cross presentation,986.5,0.0031766289242939,0.5,0.0,1.0,0.00173979969037795,True,0,6,6,16,4.0,0.00063532578485878
2205,P01891,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,996.5,0.0031766289242939,0.5,0.0,1.0,0.00173979969037795,True,0,6,6,16,4.0,0.00063532578485878
2206,P01891,Interferon alpha/beta signaling,990.5,0.0031766289242939,0.5,0.0,1.0,0.00173979969037795,True,0,6,6,16,4.0,0.00063532578485878
2207,P01891,Interferon gamma signaling,988.5,0.0031766289242939,0.5,0.0,1.0,0.00173979969037795,True,0,6,6,16,4.0,0.00063532578485878
2208,P01891,SARS-CoV-2 Infection,992.5,0.0031766289242939,0.5,0.0,1.0,0.00173979969037795,True,0,6,6,16,4.0,0.00063532578485878
2209,P30443,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",3562.5,0.006112491572807599,0.5,0.0,1.0,0.0033477347210681997,True,0,6,6,16,4.0,0.0012224983145615199
2210,P30443,Antigen processing-Cross presentation,3554.5,0.006112491572807599,0.5,0.0,1.0,0.0033477347210681997,True,0,6,6,16,4.0,0.0012224983145615199
2211,P30443,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,3564.5,0.006112491572807599,0.5,0.0,1.0,0.0033477347210681997,True,0,6,6,16,4.0,0.0012224983145615199
2212,P30443,Interferon alpha/beta signaling,3558.5,0.006112491572807599,0.5,0.0,1.0,0.0033477347210681997,True,0,6,6,16,4.0,0.0012224983145615199
2213,P30443,Interferon gamma signaling,3556.5,0.006112491572807599,0.5,0.0,1.0,0.0033477347210681997,True,0,6,6,16,4.0,0.0012224983145615199
2214,P30443,SARS-CoV-2 Infection,3560.5,0.006112491572807599,0.5,0.0,1.0,0.0033477347210681997,True,0,6,6,16,4.0,0.0012224983145615199
2215,PA2GA,Glycerophospholipid biosynthesis,2704.5,0.0013821889387222999,0.5,0.0,1.0,0.0007570074896826,True,0,1,1,6,2.584962500721156,0.00038555185401360737
2216,PAI1,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",1840.5,0.0140036560079735,0.5,0.0,1.0,0.00766962618784525,True,0,5,5,18,4.169925001442312,0.0027086768191157016
2217,PAI1,Dissolution of Fibrin Clot,1836.5,0.0140036560079735,0.5,0.0,1.0,0.00766962618784525,True,0,5,5,18,4.169925001442312,0.0027086768191157016
2218,PAI1,ECM proteoglycans,1838.5,0.0140036560079735,0.5,0.0,1.0,0.00766962618784525,True,0,5,5,18,4.169925001442312,0.0027086768191157016
2219,PAI1,Platelet degranulation ,1834.5,0.0140036560079735,0.5,0.0,1.0,0.00766962618784525,True,0,5,5,18,4.169925001442312,0.0027086768191157016
2220,PAI1,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,1832.5,0.0140036560079735,0.5,0.0,1.0,0.00766962618784525,True,0,5,5,18,4.169925001442312,0.0027086768191157016
2221,PAK4,RHO GTPase cycle,108.5,0.0011451210635767,0.5,0.0,1.0,0.00062716839748565,True,0,2,2,10,3.321928094887362,0.00026495606554197983
2222,PAK4,Signaling by ROBO receptors,110.5,0.0011451210635767,0.5,0.0,1.0,0.00062716839748565,True,0,2,2,10,3.321928094887362,0.00026495606554197983
2223,PARK7,Aggrephagy,5022.5,0.0018557215032349002,0.5,0.0,1.0,0.0010163553168154,True,0,4,4,12,3.584962500721156,0.0004047408245853742
2224,PARK7,Chaperone Mediated Autophagy,5024.5,0.0018557215032349002,0.5,0.0,1.0,0.0010163553168154,True,0,4,4,12,3.584962500721156,0.0004047408245853742
2225,PARK7,Late endosomal microautophagy,5026.5,0.0018557215032349002,0.5,0.0,1.0,0.0010163553168154,True,0,4,4,12,3.584962500721156,0.0004047408245853742
2226,PARK7,SUMO E3 ligases SUMOylate target proteins,5020.5,0.0018557215032349002,0.5,0.0,1.0,0.0010163553168154,True,0,4,4,12,3.584962500721156,0.0004047408245853742
2227,PCOC1,Crosslinking of collagen fibrils,4740.5,0.0084407031719293,0.5,0.0,1.0,0.0046228669180675,True,0,1,1,6,2.584962500721156,0.002354474606144794
2228,PCP/CE pathway,Beta-catenin independent WNT signaling,5440.5,0.0010963130786788,0.5,1.0,2.0,0.013717975934137351,True,10,1,11,15,3.9068905956085187,0.00022342317549528385
2229,PDIA1,Chylomicron assembly,2078.5,0.0094248839916405,0.5,0.0,1.0,0.00516189036909585,True,0,8,8,24,4.584962500721156,0.0016875465126978948
2230,PDIA1,Detoxification of Reactive Oxygen Species,2082.5,0.0094248839916405,0.5,0.0,1.0,0.00516189036909585,True,0,8,8,24,4.584962500721156,0.0016875465126978948
2231,PDIA1,Hedgehog ligand biogenesis,2086.5,0.0094248839916405,0.5,0.0,1.0,0.00516189036909585,True,0,8,8,24,4.584962500721156,0.0016875465126978948
2232,PDIA1,Interleukin-12 family signaling,2074.5,0.0094248839916405,0.5,0.0,1.0,0.00516189036909585,True,0,8,8,24,4.584962500721156,0.0016875465126978948
2233,PDIA1,LDL remodeling,2080.5,0.0094248839916405,0.5,0.0,1.0,0.00516189036909585,True,0,8,8,24,4.584962500721156,0.0016875465126978948
2234,PDIA1,Post-translational protein phosphorylation,2088.5,0.0094248839916405,0.5,0.0,1.0,0.00516189036909585,True,0,8,8,24,4.584962500721156,0.0016875465126978948
2235,PDIA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2084.5,0.0094248839916405,0.5,0.0,1.0,0.00516189036909585,True,0,8,8,24,4.584962500721156,0.0016875465126978948
2236,PDIA1,VLDL assembly,2076.5,0.0094248839916405,0.5,0.0,1.0,0.00516189036909585,True,0,8,8,24,4.584962500721156,0.0016875465126978948
2237,PDIA3,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",3552.5,0.0006595738261865999,0.5,0.0,1.0,0.00036124028519825,True,0,3,3,11,3.4594316186372973,0.00014790535713790157
2238,PDIA3,Antigen processing-Cross presentation,3548.5,0.0006595738261865999,0.5,0.0,1.0,0.00036124028519825,True,0,3,3,11,3.4594316186372973,0.00014790535713790157
2239,PDIA3,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,3550.5,0.0006595738261865999,0.5,0.0,1.0,0.00036124028519825,True,0,3,3,11,3.4594316186372973,0.00014790535713790157
2240,PEBP1,Paradoxical activation of RAF signaling by kinase inactive BRAF,3546.5,0.0006198675624259,0.5,0.0,1.0,0.0003394936641596,True,0,6,6,14,3.807354922057604,0.0001289415016107422
2241,PEBP1,RAF/MAP kinase cascade,3536.5,0.0006198675624259,0.5,0.0,1.0,0.0003394936641596,True,0,6,6,14,3.807354922057604,0.0001289415016107422
2242,PEBP1,Signaling by BRAF and RAF1 fusions,3544.5,0.0006198675624259,0.5,0.0,1.0,0.0003394936641596,True,0,6,6,14,3.807354922057604,0.0001289415016107422
2243,PEBP1,Signaling by RAS mutants,3538.5,0.0006198675624259,0.5,0.0,1.0,0.0003394936641596,True,0,6,6,14,3.807354922057604,0.0001289415016107422
2244,PEBP1,Signaling by high-kinase activity BRAF mutants,3542.5,0.0006198675624259,0.5,0.0,1.0,0.0003394936641596,True,0,6,6,14,3.807354922057604,0.0001289415016107422
2245,PEBP1,Signaling by moderate kinase activity BRAF mutants,3540.5,0.0006198675624259,0.5,0.0,1.0,0.0003394936641596,True,0,6,6,14,3.807354922057604,0.0001289415016107422
2246,PECAM1 interactions,Cell surface interactions at the vascular wall,6236.5,0.00014541764602686756,0.5,2.0,3.0,0.00274172655871395,True,2,2,4,5,2.321928094887362,4.3775073352934295e-05
2247,PECAM1 interactions,PECAM1 interactions,5850.5,0.00023248426940172194,0.5,1.0,2.0,0.0029090354523197,False,2,2,4,5,2.321928094887362,6.998473860994419e-05
2248,PERK regulates gene expression,Unfolded Protein Response (UPR),5438.5,0.0004347498729421,0.5,1.0,2.0,0.0054399499653672995,True,1,1,2,6,2.584962500721156,0.00012127041017992381
2249,PERM,Events associated with phagocytolytic activity of PMN cells,1858.5,0.0096988237517894,0.5,0.0,1.0,0.00531192372875095,True,0,2,2,7,2.807354922057604,0.002547391548815175
2250,PERM,Neutrophil degranulation,1860.5,0.0096988237517894,0.5,0.0,1.0,0.00531192372875095,True,0,2,2,7,2.807354922057604,0.002547391548815175
2251,PGBM,Amyloid fiber formation,4498.5,0.00801811542177,0.5,0.0,1.0,0.004391420924718449,True,0,9,9,25,4.643856189774724,0.0014206803207170388
2252,PGBM,Chondroitin sulfate/dermatan sulfate metabolism,4484.5,0.00801811542177,0.5,0.0,1.0,0.004391420924718449,True,0,9,9,25,4.643856189774724,0.0014206803207170388
2253,PGBM,Diseases associated with glycosaminoglycan metabolism,4486.5,0.00801811542177,0.5,0.0,1.0,0.004391420924718449,True,0,9,9,25,4.643856189774724,0.0014206803207170388
2254,PGBM,ECM proteoglycans,4494.5,0.00801811542177,0.5,0.0,1.0,0.004391420924718449,True,0,9,9,25,4.643856189774724,0.0014206803207170388
2255,PGBM,Heparan sulfate/heparin (HS-GAG) metabolism,4482.5,0.00801811542177,0.5,0.0,1.0,0.004391420924718449,True,0,9,9,25,4.643856189774724,0.0014206803207170388
2256,PGBM,Integrin cell surface interactions,4490.5,0.00801811542177,0.5,0.0,1.0,0.004391420924718449,True,0,9,9,25,4.643856189774724,0.0014206803207170388
2257,PGBM,Laminin interactions,4492.5,0.00801811542177,0.5,0.0,1.0,0.004391420924718449,True,0,9,9,25,4.643856189774724,0.0014206803207170388
2258,PGBM,Retinoid metabolism and transport,4496.5,0.00801811542177,0.5,0.0,1.0,0.004391420924718449,True,0,9,9,25,4.643856189774724,0.0014206803207170388
2259,PGBM,SARS-CoV-2 Infection,4488.5,0.00801811542177,0.5,0.0,1.0,0.004391420924718449,True,0,9,9,25,4.643856189774724,0.0014206803207170388
2260,PGK1,Gluconeogenesis,148.5,0.00015917874232655282,0.5,0.0,1.0,8.71801942293363e-05,True,0,3,3,11,3.4594316186372973,3.569484991345025e-05
2261,PGK1,Glycolysis,146.5,0.00015917874232655282,0.5,0.0,1.0,8.71801942293363e-05,True,0,3,3,11,3.4594316186372973,3.569484991345025e-05
2262,PGK1,Response of Mtb to phagocytosis,150.5,0.00015917874232655282,0.5,0.0,1.0,8.71801942293363e-05,True,0,3,3,11,3.4594316186372973,3.569484991345025e-05
2263,PGM1,Diseases associated with glycosylation precursor biosynthesis,3696.5,0.0025221953306052,0.5,0.0,1.0,0.0013813746458393502,True,0,5,5,15,3.9068905956085187,0.0005140109161721416
2264,PGM1,Galactose catabolism,3704.5,0.0025221953306052,0.5,0.0,1.0,0.0013813746458393502,True,0,5,5,15,3.9068905956085187,0.0005140109161721416
2265,PGM1,Glycogen breakdown (glycogenolysis),3700.5,0.0025221953306052,0.5,0.0,1.0,0.0013813746458393502,True,0,5,5,15,3.9068905956085187,0.0005140109161721416
2266,PGM1,Glycogen synthesis,3698.5,0.0025221953306052,0.5,0.0,1.0,0.0013813746458393502,True,0,5,5,15,3.9068905956085187,0.0005140109161721416
2267,PGM1,Neutrophil degranulation,3702.5,0.0025221953306052,0.5,0.0,1.0,0.0013813746458393502,True,0,5,5,15,3.9068905956085187,0.0005140109161721416
2268,PGRP1,Neutrophil degranulation,76.5,0.0002365711236033,0.5,0.0,1.0,0.00012956702762785001,True,0,1,1,5,2.321928094887362,7.121500431252456e-05
2269,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,4418.5,0.0014406859839486,0.5,0.0,1.0,0.0007890455852859,True,0,1,1,5,2.321928094887362,0.0004336896955012056
2270,PIGR,Neutrophil degranulation,876.5,0.0009253881034653,0.5,0.0,1.0,0.000506823420128,True,0,1,1,5,2.321928094887362,0.00027856957677365905
2271,PIP3 activates AKT signaling,Intracellular signaling by second messengers,6276.5,0.0006678249572608,0.5,2.0,3.0,0.012591273974797,True,1,1,2,14,3.807354922057604,0.00013891733980293743
2272,PIWI-interacting RNA (piRNA) biogenesis,Gene Silencing by RNA,6278.5,7.592792645957927e-05,0.5,2.0,3.0,0.00143155674851075,True,2,2,4,5,2.321928094887362,2.285658337290223e-05
2273,PIWI-interacting RNA (piRNA) biogenesis,PIWI-interacting RNA (piRNA) biogenesis,5856.5,0.0001806692279419346,0.5,1.0,2.0,0.0022606828005137,False,2,2,4,5,2.321928094887362,5.43868569039754e-05
2274,PKMTs methylate histone lysines,Chromatin modifying enzymes,6524.5,0.0014624015234887,0.5,2.0,3.0,0.02757234218818465,True,2,2,4,5,2.321928094887362,0.0004402267242748029
2275,PKMTs methylate histone lysines,PKMTs methylate histone lysines,5896.5,0.0011370939978474,0.5,1.0,2.0,0.014228260522186651,False,2,2,4,5,2.321928094887362,0.0003422994012415419
2276,PLEK,Platelet degranulation ,2384.5,0.0024144393034387,0.5,0.0,1.0,0.0013223580256522,True,0,1,1,6,2.584962500721156,0.0006734908113970531
2277,PLF4,Class A/1 (Rhodopsin-like receptors),1388.5,0.0077165213240980995,0.5,0.0,1.0,0.004226241632376,True,0,5,5,18,4.169925001442312,0.001492578968156276
2278,PLF4,Common Pathway of Fibrin Clot Formation,1394.5,0.0077165213240980995,0.5,0.0,1.0,0.004226241632376,True,0,5,5,18,4.169925001442312,0.001492578968156276
2279,PLF4,G alpha (i) signalling events,1390.5,0.0077165213240980995,0.5,0.0,1.0,0.004226241632376,True,0,5,5,18,4.169925001442312,0.001492578968156276
2280,PLF4,Platelet degranulation ,1392.5,0.0077165213240980995,0.5,0.0,1.0,0.004226241632376,True,0,5,5,18,4.169925001442312,0.001492578968156276
2281,PLF4,Transcriptional regulation by RUNX1,1386.5,0.0077165213240980995,0.5,0.0,1.0,0.004226241632376,True,0,5,5,18,4.169925001442312,0.001492578968156276
2282,PLMN,Activation of Matrix Metalloproteinases,218.5,0.011008399302282399,0.5,0.0,1.0,0.006029161779393199,True,0,5,5,15,3.9068905956085187,0.002243457254199737
2283,PLMN,Dissolution of Fibrin Clot,216.5,0.011008399302282399,0.5,0.0,1.0,0.006029161779393199,True,0,5,5,15,3.9068905956085187,0.002243457254199737
2284,PLMN,Platelet degranulation ,214.5,0.011008399302282399,0.5,0.0,1.0,0.006029161779393199,True,0,5,5,15,3.9068905956085187,0.002243457254199737
2285,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),220.5,0.011008399302282399,0.5,0.0,1.0,0.006029161779393199,True,0,5,5,15,3.9068905956085187,0.002243457254199737
2286,PLMN,Signaling by PDGF,222.5,0.011008399302282399,0.5,0.0,1.0,0.006029161779393199,True,0,5,5,15,3.9068905956085187,0.002243457254199737
2287,PLSI,Sensory processing of sound by inner hair cells of the cochlea,4730.5,0.0056890797039593,0.5,0.0,1.0,0.00311583736828305,True,0,2,2,6,2.584962500721156,0.001586928650666465
2288,PLSI,Sensory processing of sound by outer hair cells of the cochlea,4732.5,0.0056890797039593,0.5,0.0,1.0,0.00311583736828305,True,0,2,2,6,2.584962500721156,0.001586928650666465
2289,PLSL,Interleukin-12 family signaling,2670.5,0.000629344822176,0.5,0.0,1.0,0.0003446842400726,True,0,1,1,6,2.584962500721156,0.00017555129852805997
2290,PON1,Arachidonic acid metabolism,3188.5,0.013207294797861601,0.5,0.0,1.0,0.00723346917366415,True,0,2,2,8,3.0,0.0033018236994654003
2291,PON1,Atorvastatin ADME,3190.5,0.013207294797861601,0.5,0.0,1.0,0.00723346917366415,True,0,2,2,8,3.0,0.0033018236994654003
2292,PON3,Arachidonic acid metabolism,4742.5,0.0028581686657868,0.5,0.0,1.0,0.0015653830139726,True,0,2,2,8,3.0,0.0007145421664467
2293,PON3,Atorvastatin ADME,4744.5,0.0028581686657868,0.5,0.0,1.0,0.0015653830139726,True,0,2,2,8,3.0,0.0007145421664467
2294,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,5452.5,0.0037538400813432998,0.5,1.0,2.0,0.04697115167003505,True,5,1,6,10,3.321928094887362,0.0008685568105086978
2295,PPIA,Basigin interactions,4264.5,0.0010504805067455,0.5,0.0,1.0,0.0005753349553694,True,0,7,7,22,4.459431618637297,0.00019241572751994748
2296,PPIA,Downstream signaling events of B Cell Receptor (BCR),4252.5,0.0010504805067455,0.5,0.0,1.0,0.0005753349553694,True,0,7,7,22,4.459431618637297,0.00019241572751994748
2297,PPIA,HIV Life Cycle,4254.5,0.0010504805067455,0.5,0.0,1.0,0.0005753349553694,True,0,7,7,22,4.459431618637297,0.00019241572751994748
2298,PPIA,Host Interactions of HIV factors,4256.5,0.0010504805067455,0.5,0.0,1.0,0.0005753349553694,True,0,7,7,22,4.459431618637297,0.00019241572751994748
2299,PPIA,Interleukin-12 family signaling,4258.5,0.0010504805067455,0.5,0.0,1.0,0.0005753349553694,True,0,7,7,22,4.459431618637297,0.00019241572751994748
2300,PPIA,Neutrophil degranulation,4262.5,0.0010504805067455,0.5,0.0,1.0,0.0005753349553694,True,0,7,7,22,4.459431618637297,0.00019241572751994748
2301,PPIA,Platelet degranulation ,4260.5,0.0010504805067455,0.5,0.0,1.0,0.0005753349553694,True,0,7,7,22,4.459431618637297,0.00019241572751994748
2302,PRC2 methylates histones and DNA,Epigenetic regulation of gene expression,6478.5,0.00025386645485370196,0.5,2.0,3.0,0.00478643700167215,True,4,2,6,7,2.807354922057604,6.66779063288655e-05
2303,PRC2 methylates histones and DNA,PRC2 methylates histones and DNA,5862.5,0.0005145019635387,0.5,1.0,2.0,0.0064378740810031,False,4,2,6,7,2.807354922057604,0.00013513370149916267
2304,PRDX2,Detoxification of Reactive Oxygen Species,3616.5,0.0025586418540733003,0.5,0.0,1.0,0.001401335948137,True,0,3,3,14,3.807354922057604,0.0005322348558733359
2305,PRDX2,Neurodegenerative Diseases,3614.5,0.0025586418540733003,0.5,0.0,1.0,0.001401335948137,True,0,3,3,14,3.807354922057604,0.0005322348558733359
2306,PRDX2,Transcriptional Regulation by TP53,3612.5,0.0025586418540733003,0.5,0.0,1.0,0.001401335948137,True,0,3,3,14,3.807354922057604,0.0005322348558733359
2307,PRDX6,Detoxification of Reactive Oxygen Species,3528.5,0.0004499462480027,0.5,0.0,1.0,0.0002464298983665,True,0,2,2,9,3.169925001442312,0.00010790271955660367
2308,PRDX6,Neutrophil degranulation,3530.5,0.0004499462480027,0.5,0.0,1.0,0.0002464298983665,True,0,2,2,9,3.169925001442312,0.00010790271955660367
2309,PRG2,Neutrophil degranulation,2668.5,0.0043481880078578,0.5,0.0,1.0,0.0023814478587415,True,0,1,1,5,2.321928094887362,0.0013089350171516085
2310,PROC,Common Pathway of Fibrin Clot Formation,1464.5,0.0097048071144818,0.5,0.0,1.0,0.00531520074120905,True,0,5,5,12,3.584962500721156,0.0021166600845602024
2311,PROC,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",1460.5,0.0097048071144818,0.5,0.0,1.0,0.00531520074120905,True,0,5,5,12,3.584962500721156,0.0021166600845602024
2312,PROC,Intrinsic Pathway of Fibrin Clot Formation,1462.5,0.0097048071144818,0.5,0.0,1.0,0.00531520074120905,True,0,5,5,12,3.584962500721156,0.0021166600845602024
2313,PROC,Post-translational protein phosphorylation,1468.5,0.0097048071144818,0.5,0.0,1.0,0.00531520074120905,True,0,5,5,12,3.584962500721156,0.0021166600845602024
2314,PROC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1466.5,0.0097048071144818,0.5,0.0,1.0,0.00531520074120905,True,0,5,5,12,3.584962500721156,0.0021166600845602024
2315,PROF1,PCP/CE pathway,2170.5,0.0071245037507665,0.5,0.0,1.0,0.0039020010568074502,True,0,4,4,17,4.087462841250339,0.0014004040860995301
2316,PROF1,Platelet degranulation ,2172.5,0.0071245037507665,0.5,0.0,1.0,0.0039020010568074502,True,0,4,4,17,4.087462841250339,0.0014004040860995301
2317,PROF1,RHO GTPase Effectors,2166.5,0.0071245037507665,0.5,0.0,1.0,0.0039020010568074502,True,0,4,4,17,4.087462841250339,0.0014004040860995301
2318,PROF1,Signaling by ROBO receptors,2168.5,0.0071245037507665,0.5,0.0,1.0,0.0039020010568074502,True,0,4,4,17,4.087462841250339,0.0014004040860995301
2319,PROP,Activation of C3 and C5,3222.5,0.0046043172957521,0.5,0.0,1.0,0.00252172664685155,True,0,6,6,17,4.087462841250339,0.0009050321229708486
2320,PROP,Diseases associated with O-glycosylation of proteins,3226.5,0.0046043172957521,0.5,0.0,1.0,0.00252172664685155,True,0,6,6,17,4.087462841250339,0.0009050321229708486
2321,PROP,Initial triggering of complement,3220.5,0.0046043172957521,0.5,0.0,1.0,0.00252172664685155,True,0,6,6,17,4.087462841250339,0.0009050321229708486
2322,PROP,Neutrophil degranulation,3230.5,0.0046043172957521,0.5,0.0,1.0,0.00252172664685155,True,0,6,6,17,4.087462841250339,0.0009050321229708486
2323,PROP,O-glycosylation of TSR domain-containing proteins,3228.5,0.0046043172957521,0.5,0.0,1.0,0.00252172664685155,True,0,6,6,17,4.087462841250339,0.0009050321229708486
2324,PROP,Regulation of Complement cascade,3224.5,0.0046043172957521,0.5,0.0,1.0,0.00252172664685155,True,0,6,6,17,4.087462841250339,0.0009050321229708486
2325,PROS,Common Pathway of Fibrin Clot Formation,2072.5,0.0051514833673228,0.5,0.0,1.0,0.0028214026192712,True,0,5,5,17,4.087462841250339,0.0010125839791012069
2326,PROS,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",2064.5,0.0051514833673228,0.5,0.0,1.0,0.0028214026192712,True,0,5,5,17,4.087462841250339,0.0010125839791012069
2327,PROS,Intrinsic Pathway of Fibrin Clot Formation,2070.5,0.0051514833673228,0.5,0.0,1.0,0.0028214026192712,True,0,5,5,17,4.087462841250339,0.0010125839791012069
2328,PROS,Platelet degranulation ,2068.5,0.0051514833673228,0.5,0.0,1.0,0.0028214026192712,True,0,5,5,17,4.087462841250339,0.0010125839791012069
2329,PROS,Regulation of Complement cascade,2066.5,0.0051514833673228,0.5,0.0,1.0,0.0028214026192712,True,0,5,5,17,4.087462841250339,0.0010125839791012069
2330,PROZ,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",2908.5,0.0025556222698143,0.5,0.0,1.0,0.0013996821598337,True,0,1,1,6,2.584962500721156,0.0007128728039136273
2331,PRTN3,Common Pathway of Fibrin Clot Formation,2968.5,0.0024586161978704,0.5,0.0,1.0,0.00134655315485545,True,0,3,3,11,3.4594316186372973,0.0005513294984937336
2332,PRTN3,Neutrophil degranulation,2970.5,0.0024586161978704,0.5,0.0,1.0,0.00134655315485545,True,0,3,3,11,3.4594316186372973,0.0005513294984937336
2333,PRTN3,Other interleukin signaling,2966.5,0.0024586161978704,0.5,0.0,1.0,0.00134655315485545,True,0,3,3,11,3.4594316186372973,0.0005513294984937336
2334,PSA1,APC/C-mediated degradation of cell cycle proteins,3006.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2335,PSA1,AUF1 (hnRNP D0) binds and destabilizes mRNA,3076.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2336,PSA1,Antigen processing-Cross presentation,2998.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2337,PSA1,Antigen processing: Ubiquitination & Proteasome degradation,3072.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2338,PSA1,CDK-mediated phosphorylation and removal of Cdc6,3058.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2339,PSA1,CLEC7A (Dectin-1) signaling,3038.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2340,PSA1,Cyclin A:Cdk2-associated events at S phase entry,3060.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2341,PSA1,Defective CFTR causes cystic fibrosis,3046.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2342,PSA1,Degradation of AXIN,3008.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2343,PSA1,Degradation of DVL,3010.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2344,PSA1,Degradation of GLI1 by the proteasome,3040.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2345,PSA1,Degradation of GLI2 by the proteasome,3042.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2346,PSA1,Degradation of beta-catenin by the destruction complex,3074.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2347,PSA1,Downstream TCR signaling,3012.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2348,PSA1,Downstream signaling events of B Cell Receptor (BCR),2994.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2349,PSA1,FCERI mediated NF-kB activation,3020.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2350,PSA1,G1/S Transition,3034.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2351,PSA1,G2/M Transition,3032.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2352,PSA1,GLI3 is processed to GLI3R by the proteasome,3044.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2353,PSA1,Hedgehog 'on' state,3080.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2354,PSA1,Hedgehog ligand biogenesis,3078.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2355,PSA1,Hh mutants are degraded by ERAD,3036.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2356,PSA1,Host Interactions of HIV factors,3002.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2357,PSA1,Interleukin-1 family signaling,3030.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2358,PSA1,KEAP1-NFE2L2 pathway,3070.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2359,PSA1,MAPK6/MAPK4 signaling,3082.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2360,PSA1,Mitotic Metaphase and Anaphase,3022.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2361,PSA1,NIK-->noncanonical NF-kB signaling,3048.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2362,PSA1,Neddylation,3084.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2363,PSA1,Negative regulation of NOTCH4 signaling,3068.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2364,PSA1,Orc1 removal from chromatin,3056.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2365,PSA1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,2996.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2366,PSA1,PCP/CE pathway,3028.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2367,PSA1,PTEN Regulation,3000.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2368,PSA1,RAF/MAP kinase cascade,3050.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2369,PSA1,Regulation of activated PAK-2p34 by proteasome mediated degradation,3004.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2370,PSA1,Regulation of ornithine decarboxylase (ODC),3024.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2371,PSA1,Signaling by ROBO receptors,3026.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2372,PSA1,Transcriptional regulation by RUNX1,3018.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2373,PSA1,Transcriptional regulation by RUNX2,3016.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2374,PSA1,Transcriptional regulation by RUNX3,3014.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2375,PSA1,UCH proteinases,3052.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2376,PSA1,Ub-specific processing proteases,3054.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2377,PSA1,Ubiquitin-dependent degradation of Cyclin D,3062.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2378,PSA1,p53-Dependent G1/S DNA damage checkpoint,3064.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2379,PSA1,p53-Independent G1/S DNA damage checkpoint,3066.5,0.017587421165287498,0.5,0.0,1.0,0.009632409270061301,True,0,46,46,111,6.794415866350106,0.0022564129842257397
2380,PSA3,APC/C-mediated degradation of cell cycle proteins,3098.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2381,PSA3,AUF1 (hnRNP D0) binds and destabilizes mRNA,3168.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2382,PSA3,Antigen processing-Cross presentation,3090.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2383,PSA3,Antigen processing: Ubiquitination & Proteasome degradation,3164.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2384,PSA3,CDK-mediated phosphorylation and removal of Cdc6,3150.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2385,PSA3,CLEC7A (Dectin-1) signaling,3130.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2386,PSA3,Cyclin A:Cdk2-associated events at S phase entry,3152.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2387,PSA3,Defective CFTR causes cystic fibrosis,3138.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2388,PSA3,Degradation of AXIN,3100.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2389,PSA3,Degradation of DVL,3102.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2390,PSA3,Degradation of GLI1 by the proteasome,3132.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2391,PSA3,Degradation of GLI2 by the proteasome,3134.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2392,PSA3,Degradation of beta-catenin by the destruction complex,3166.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2393,PSA3,Downstream TCR signaling,3104.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2394,PSA3,Downstream signaling events of B Cell Receptor (BCR),3086.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2395,PSA3,FCERI mediated NF-kB activation,3112.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2396,PSA3,G1/S Transition,3126.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2397,PSA3,G2/M Transition,3124.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2398,PSA3,GLI3 is processed to GLI3R by the proteasome,3136.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2399,PSA3,Hedgehog 'on' state,3172.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2400,PSA3,Hedgehog ligand biogenesis,3170.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2401,PSA3,Hh mutants are degraded by ERAD,3128.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2402,PSA3,Host Interactions of HIV factors,3094.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2403,PSA3,Interleukin-1 family signaling,3122.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2404,PSA3,KEAP1-NFE2L2 pathway,3162.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2405,PSA3,MAPK6/MAPK4 signaling,3174.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2406,PSA3,Mitotic Metaphase and Anaphase,3114.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2407,PSA3,NIK-->noncanonical NF-kB signaling,3140.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2408,PSA3,Neddylation,3176.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2409,PSA3,Negative regulation of NOTCH4 signaling,3160.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2410,PSA3,Orc1 removal from chromatin,3148.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2411,PSA3,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,3088.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2412,PSA3,PCP/CE pathway,3120.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2413,PSA3,PTEN Regulation,3092.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2414,PSA3,RAF/MAP kinase cascade,3142.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2415,PSA3,Regulation of activated PAK-2p34 by proteasome mediated degradation,3096.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2416,PSA3,Regulation of ornithine decarboxylase (ODC),3116.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2417,PSA3,Signaling by ROBO receptors,3118.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2418,PSA3,Transcriptional regulation by RUNX1,3110.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2419,PSA3,Transcriptional regulation by RUNX2,3108.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2420,PSA3,Transcriptional regulation by RUNX3,3106.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2421,PSA3,UCH proteinases,3144.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2422,PSA3,Ub-specific processing proteases,3146.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2423,PSA3,Ubiquitin-dependent degradation of Cyclin D,3154.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2424,PSA3,p53-Dependent G1/S DNA damage checkpoint,3156.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2425,PSA3,p53-Independent G1/S DNA damage checkpoint,3158.5,0.0102929992147432,0.5,0.0,1.0,0.00563734615331285,True,0,46,46,111,6.794415866350106,0.0013205606925824841
2426,PSA5,APC/C-mediated degradation of cell cycle proteins,3248.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2427,PSA5,AUF1 (hnRNP D0) binds and destabilizes mRNA,3320.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2428,PSA5,Antigen processing-Cross presentation,3240.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2429,PSA5,Antigen processing: Ubiquitination & Proteasome degradation,3314.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2430,PSA5,CDK-mediated phosphorylation and removal of Cdc6,3300.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2431,PSA5,CLEC7A (Dectin-1) signaling,3280.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2432,PSA5,Cyclin A:Cdk2-associated events at S phase entry,3302.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2433,PSA5,Defective CFTR causes cystic fibrosis,3288.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2434,PSA5,Degradation of AXIN,3250.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2435,PSA5,Degradation of DVL,3252.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2436,PSA5,Degradation of GLI1 by the proteasome,3282.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2437,PSA5,Degradation of GLI2 by the proteasome,3284.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2438,PSA5,Degradation of beta-catenin by the destruction complex,3318.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2439,PSA5,Downstream TCR signaling,3254.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2440,PSA5,Downstream signaling events of B Cell Receptor (BCR),3236.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2441,PSA5,FCERI mediated NF-kB activation,3262.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2442,PSA5,G1/S Transition,3276.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2443,PSA5,G2/M Transition,3274.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2444,PSA5,GLI3 is processed to GLI3R by the proteasome,3286.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2445,PSA5,Hedgehog 'on' state,3324.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2446,PSA5,Hedgehog ligand biogenesis,3322.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2447,PSA5,Hh mutants are degraded by ERAD,3278.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2448,PSA5,Host Interactions of HIV factors,3244.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2449,PSA5,Interleukin-1 family signaling,3272.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2450,PSA5,KEAP1-NFE2L2 pathway,3312.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2451,PSA5,MAPK6/MAPK4 signaling,3326.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2452,PSA5,Mitotic Metaphase and Anaphase,3264.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2453,PSA5,NIK-->noncanonical NF-kB signaling,3290.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2454,PSA5,Neddylation,3328.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2455,PSA5,Negative regulation of NOTCH4 signaling,3310.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2456,PSA5,Neutrophil degranulation,3316.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2457,PSA5,Orc1 removal from chromatin,3298.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2458,PSA5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,3238.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2459,PSA5,PCP/CE pathway,3270.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2460,PSA5,PTEN Regulation,3242.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2461,PSA5,RAF/MAP kinase cascade,3292.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2462,PSA5,Regulation of activated PAK-2p34 by proteasome mediated degradation,3246.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2463,PSA5,Regulation of ornithine decarboxylase (ODC),3266.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2464,PSA5,Signaling by ROBO receptors,3268.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2465,PSA5,Transcriptional regulation by RUNX1,3260.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2466,PSA5,Transcriptional regulation by RUNX2,3258.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2467,PSA5,Transcriptional regulation by RUNX3,3256.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2468,PSA5,UCH proteinases,3294.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2469,PSA5,Ub-specific processing proteases,3296.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2470,PSA5,Ubiquitin-dependent degradation of Cyclin D,3304.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2471,PSA5,p53-Dependent G1/S DNA damage checkpoint,3306.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2472,PSA5,p53-Independent G1/S DNA damage checkpoint,3308.5,0.020920358029747198,0.5,0.0,1.0,0.0114578168524484,True,0,47,47,112,6.807354922057604,0.0026795705124974265
2473,PSA6,APC/C-mediated degradation of cell cycle proteins,3970.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2474,PSA6,AUF1 (hnRNP D0) binds and destabilizes mRNA,4040.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2475,PSA6,Antigen processing-Cross presentation,3962.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2476,PSA6,Antigen processing: Ubiquitination & Proteasome degradation,4036.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2477,PSA6,CDK-mediated phosphorylation and removal of Cdc6,4022.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2478,PSA6,CLEC7A (Dectin-1) signaling,4002.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2479,PSA6,Cyclin A:Cdk2-associated events at S phase entry,4024.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2480,PSA6,Defective CFTR causes cystic fibrosis,4010.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2481,PSA6,Degradation of AXIN,3972.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2482,PSA6,Degradation of DVL,3974.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2483,PSA6,Degradation of GLI1 by the proteasome,4004.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2484,PSA6,Degradation of GLI2 by the proteasome,4006.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2485,PSA6,Degradation of beta-catenin by the destruction complex,4038.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2486,PSA6,Downstream TCR signaling,3976.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2487,PSA6,Downstream signaling events of B Cell Receptor (BCR),3958.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2488,PSA6,FCERI mediated NF-kB activation,3984.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2489,PSA6,G1/S Transition,3998.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2490,PSA6,G2/M Transition,3996.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2491,PSA6,GLI3 is processed to GLI3R by the proteasome,4008.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2492,PSA6,Hedgehog 'on' state,4044.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2493,PSA6,Hedgehog ligand biogenesis,4042.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2494,PSA6,Hh mutants are degraded by ERAD,4000.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2495,PSA6,Host Interactions of HIV factors,3966.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2496,PSA6,Interleukin-1 family signaling,3994.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2497,PSA6,KEAP1-NFE2L2 pathway,4034.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2498,PSA6,MAPK6/MAPK4 signaling,4046.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2499,PSA6,Mitotic Metaphase and Anaphase,3986.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2500,PSA6,NIK-->noncanonical NF-kB signaling,4012.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2501,PSA6,Neddylation,4048.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2502,PSA6,Negative regulation of NOTCH4 signaling,4032.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2503,PSA6,Orc1 removal from chromatin,4020.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2504,PSA6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,3960.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2505,PSA6,PCP/CE pathway,3992.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2506,PSA6,PTEN Regulation,3964.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2507,PSA6,RAF/MAP kinase cascade,4014.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2508,PSA6,Regulation of activated PAK-2p34 by proteasome mediated degradation,3968.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2509,PSA6,Regulation of ornithine decarboxylase (ODC),3988.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2510,PSA6,Signaling by ROBO receptors,3990.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2511,PSA6,Transcriptional regulation by RUNX1,3982.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2512,PSA6,Transcriptional regulation by RUNX2,3980.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2513,PSA6,Transcriptional regulation by RUNX3,3978.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2514,PSA6,UCH proteinases,4016.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2515,PSA6,Ub-specific processing proteases,4018.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2516,PSA6,Ubiquitin-dependent degradation of Cyclin D,4026.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2517,PSA6,p53-Dependent G1/S DNA damage checkpoint,4028.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2518,PSA6,p53-Independent G1/S DNA damage checkpoint,4030.5,0.0214859295434313,0.5,0.0,1.0,0.011767573253918199,True,0,46,46,111,6.794415866350106,0.0027565798273851308
2519,PSB2,APC/C-mediated degradation of cell cycle proteins,3778.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2520,PSB2,AUF1 (hnRNP D0) binds and destabilizes mRNA,3848.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2521,PSB2,Antigen processing-Cross presentation,3770.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2522,PSB2,Antigen processing: Ubiquitination & Proteasome degradation,3844.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2523,PSB2,CDK-mediated phosphorylation and removal of Cdc6,3830.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2524,PSB2,CLEC7A (Dectin-1) signaling,3810.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2525,PSB2,Cyclin A:Cdk2-associated events at S phase entry,3832.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2526,PSB2,Defective CFTR causes cystic fibrosis,3818.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2527,PSB2,Degradation of AXIN,3780.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2528,PSB2,Degradation of DVL,3782.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2529,PSB2,Degradation of GLI1 by the proteasome,3812.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2530,PSB2,Degradation of GLI2 by the proteasome,3814.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2531,PSB2,Degradation of beta-catenin by the destruction complex,3846.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2532,PSB2,Downstream TCR signaling,3784.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2533,PSB2,Downstream signaling events of B Cell Receptor (BCR),3766.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2534,PSB2,FCERI mediated NF-kB activation,3792.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2535,PSB2,G1/S Transition,3806.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2536,PSB2,G2/M Transition,3804.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2537,PSB2,GLI3 is processed to GLI3R by the proteasome,3816.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2538,PSB2,Hedgehog 'on' state,3852.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2539,PSB2,Hedgehog ligand biogenesis,3850.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2540,PSB2,Hh mutants are degraded by ERAD,3808.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2541,PSB2,Host Interactions of HIV factors,3774.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2542,PSB2,Interleukin-1 family signaling,3802.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2543,PSB2,KEAP1-NFE2L2 pathway,3842.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2544,PSB2,MAPK6/MAPK4 signaling,3854.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2545,PSB2,Mitotic Metaphase and Anaphase,3794.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2546,PSB2,NIK-->noncanonical NF-kB signaling,3820.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2547,PSB2,Neddylation,3856.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2548,PSB2,Negative regulation of NOTCH4 signaling,3840.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2549,PSB2,Orc1 removal from chromatin,3828.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2550,PSB2,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,3768.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2551,PSB2,PCP/CE pathway,3800.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2552,PSB2,PTEN Regulation,3772.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2553,PSB2,RAF/MAP kinase cascade,3822.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2554,PSB2,Regulation of activated PAK-2p34 by proteasome mediated degradation,3776.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2555,PSB2,Regulation of ornithine decarboxylase (ODC),3796.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2556,PSB2,Signaling by ROBO receptors,3798.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2557,PSB2,Transcriptional regulation by RUNX1,3790.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2558,PSB2,Transcriptional regulation by RUNX2,3788.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2559,PSB2,Transcriptional regulation by RUNX3,3786.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2560,PSB2,UCH proteinases,3824.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2561,PSB2,Ub-specific processing proteases,3826.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2562,PSB2,Ubiquitin-dependent degradation of Cyclin D,3834.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2563,PSB2,p53-Dependent G1/S DNA damage checkpoint,3836.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2564,PSB2,p53-Independent G1/S DNA damage checkpoint,3838.5,0.0138985869683901,0.5,0.0,1.0,0.0076120811969471,True,0,46,46,111,6.794415866350106,0.001783146704859924
2565,PSB5,APC/C-mediated degradation of cell cycle proteins,3434.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2566,PSB5,AUF1 (hnRNP D0) binds and destabilizes mRNA,3504.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2567,PSB5,Antigen processing-Cross presentation,3426.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2568,PSB5,Antigen processing: Ubiquitination & Proteasome degradation,3500.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2569,PSB5,CDK-mediated phosphorylation and removal of Cdc6,3486.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2570,PSB5,CLEC7A (Dectin-1) signaling,3466.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2571,PSB5,Cyclin A:Cdk2-associated events at S phase entry,3488.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2572,PSB5,Defective CFTR causes cystic fibrosis,3474.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2573,PSB5,Degradation of AXIN,3436.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2574,PSB5,Degradation of DVL,3438.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2575,PSB5,Degradation of GLI1 by the proteasome,3468.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2576,PSB5,Degradation of GLI2 by the proteasome,3470.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2577,PSB5,Degradation of beta-catenin by the destruction complex,3502.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2578,PSB5,Downstream TCR signaling,3440.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2579,PSB5,Downstream signaling events of B Cell Receptor (BCR),3422.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2580,PSB5,FCERI mediated NF-kB activation,3448.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2581,PSB5,G1/S Transition,3462.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2582,PSB5,G2/M Transition,3460.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2583,PSB5,GLI3 is processed to GLI3R by the proteasome,3472.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2584,PSB5,Hedgehog 'on' state,3508.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2585,PSB5,Hedgehog ligand biogenesis,3506.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2586,PSB5,Hh mutants are degraded by ERAD,3464.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2587,PSB5,Host Interactions of HIV factors,3430.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2588,PSB5,Interleukin-1 family signaling,3458.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2589,PSB5,KEAP1-NFE2L2 pathway,3498.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2590,PSB5,MAPK6/MAPK4 signaling,3510.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2591,PSB5,Mitotic Metaphase and Anaphase,3450.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2592,PSB5,NIK-->noncanonical NF-kB signaling,3476.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2593,PSB5,Neddylation,3512.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2594,PSB5,Negative regulation of NOTCH4 signaling,3496.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2595,PSB5,Orc1 removal from chromatin,3484.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2596,PSB5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,3424.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2597,PSB5,PCP/CE pathway,3456.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2598,PSB5,PTEN Regulation,3428.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2599,PSB5,RAF/MAP kinase cascade,3478.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2600,PSB5,Regulation of activated PAK-2p34 by proteasome mediated degradation,3432.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2601,PSB5,Regulation of ornithine decarboxylase (ODC),3452.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2602,PSB5,Signaling by ROBO receptors,3454.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2603,PSB5,Transcriptional regulation by RUNX1,3446.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2604,PSB5,Transcriptional regulation by RUNX2,3444.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2605,PSB5,Transcriptional regulation by RUNX3,3442.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2606,PSB5,UCH proteinases,3480.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2607,PSB5,Ub-specific processing proteases,3482.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2608,PSB5,Ubiquitin-dependent degradation of Cyclin D,3490.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2609,PSB5,p53-Dependent G1/S DNA damage checkpoint,3492.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2610,PSB5,p53-Independent G1/S DNA damage checkpoint,3494.5,0.0108048516688489,0.5,0.0,1.0,0.0059176813017974,True,0,46,46,111,6.794415866350106,0.0013862298155651904
2611,PSB6,APC/C-mediated degradation of cell cycle proteins,3342.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2612,PSB6,AUF1 (hnRNP D0) binds and destabilizes mRNA,3412.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2613,PSB6,Antigen processing-Cross presentation,3334.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2614,PSB6,Antigen processing: Ubiquitination & Proteasome degradation,3408.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2615,PSB6,CDK-mediated phosphorylation and removal of Cdc6,3394.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2616,PSB6,CLEC7A (Dectin-1) signaling,3374.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2617,PSB6,Cyclin A:Cdk2-associated events at S phase entry,3396.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2618,PSB6,Defective CFTR causes cystic fibrosis,3382.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2619,PSB6,Degradation of AXIN,3344.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2620,PSB6,Degradation of DVL,3346.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2621,PSB6,Degradation of GLI1 by the proteasome,3376.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2622,PSB6,Degradation of GLI2 by the proteasome,3378.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2623,PSB6,Degradation of beta-catenin by the destruction complex,3410.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2624,PSB6,Downstream TCR signaling,3348.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2625,PSB6,Downstream signaling events of B Cell Receptor (BCR),3330.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2626,PSB6,FCERI mediated NF-kB activation,3356.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2627,PSB6,G1/S Transition,3370.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2628,PSB6,G2/M Transition,3368.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2629,PSB6,GLI3 is processed to GLI3R by the proteasome,3380.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2630,PSB6,Hedgehog 'on' state,3416.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2631,PSB6,Hedgehog ligand biogenesis,3414.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2632,PSB6,Hh mutants are degraded by ERAD,3372.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2633,PSB6,Host Interactions of HIV factors,3338.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2634,PSB6,Interleukin-1 family signaling,3366.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2635,PSB6,KEAP1-NFE2L2 pathway,3406.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2636,PSB6,MAPK6/MAPK4 signaling,3418.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2637,PSB6,Mitotic Metaphase and Anaphase,3358.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2638,PSB6,NIK-->noncanonical NF-kB signaling,3384.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2639,PSB6,Neddylation,3420.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2640,PSB6,Negative regulation of NOTCH4 signaling,3404.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2641,PSB6,Orc1 removal from chromatin,3392.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2642,PSB6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,3332.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2643,PSB6,PCP/CE pathway,3364.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2644,PSB6,PTEN Regulation,3336.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2645,PSB6,RAF/MAP kinase cascade,3386.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2646,PSB6,Regulation of activated PAK-2p34 by proteasome mediated degradation,3340.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2647,PSB6,Regulation of ornithine decarboxylase (ODC),3360.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2648,PSB6,Signaling by ROBO receptors,3362.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2649,PSB6,Transcriptional regulation by RUNX1,3354.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2650,PSB6,Transcriptional regulation by RUNX2,3352.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2651,PSB6,Transcriptional regulation by RUNX3,3350.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2652,PSB6,UCH proteinases,3388.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2653,PSB6,Ub-specific processing proteases,3390.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2654,PSB6,Ubiquitin-dependent degradation of Cyclin D,3398.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2655,PSB6,p53-Dependent G1/S DNA damage checkpoint,3400.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2656,PSB6,p53-Independent G1/S DNA damage checkpoint,3402.5,0.0145046986198657,0.5,0.0,1.0,0.007944040921769601,True,0,46,46,111,6.794415866350106,0.0018609089980026715
2657,PSB7,APC/C-mediated degradation of cell cycle proteins,4938.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2658,PSB7,AUF1 (hnRNP D0) binds and destabilizes mRNA,5010.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2659,PSB7,Antigen processing-Cross presentation,4930.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2660,PSB7,Antigen processing: Ubiquitination & Proteasome degradation,5004.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2661,PSB7,CDK-mediated phosphorylation and removal of Cdc6,4990.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2662,PSB7,CLEC7A (Dectin-1) signaling,4970.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2663,PSB7,Cyclin A:Cdk2-associated events at S phase entry,4992.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2664,PSB7,Defective CFTR causes cystic fibrosis,4978.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2665,PSB7,Degradation of AXIN,4940.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2666,PSB7,Degradation of DVL,4942.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2667,PSB7,Degradation of GLI1 by the proteasome,4972.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2668,PSB7,Degradation of GLI2 by the proteasome,4974.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2669,PSB7,Degradation of beta-catenin by the destruction complex,5008.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2670,PSB7,Downstream TCR signaling,4944.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2671,PSB7,Downstream signaling events of B Cell Receptor (BCR),4926.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2672,PSB7,FCERI mediated NF-kB activation,4952.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2673,PSB7,G1/S Transition,4966.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2674,PSB7,G2/M Transition,4964.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2675,PSB7,GLI3 is processed to GLI3R by the proteasome,4976.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2676,PSB7,Hedgehog 'on' state,5014.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2677,PSB7,Hedgehog ligand biogenesis,5012.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2678,PSB7,Hh mutants are degraded by ERAD,4968.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2679,PSB7,Host Interactions of HIV factors,4934.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2680,PSB7,Interleukin-1 family signaling,4962.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2681,PSB7,KEAP1-NFE2L2 pathway,5002.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2682,PSB7,MAPK6/MAPK4 signaling,5016.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2683,PSB7,Mitotic Metaphase and Anaphase,4954.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2684,PSB7,NIK-->noncanonical NF-kB signaling,4980.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2685,PSB7,Neddylation,5018.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2686,PSB7,Negative regulation of NOTCH4 signaling,5000.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2687,PSB7,Neutrophil degranulation,5006.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2688,PSB7,Orc1 removal from chromatin,4988.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2689,PSB7,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,4928.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2690,PSB7,PCP/CE pathway,4960.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2691,PSB7,PTEN Regulation,4932.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2692,PSB7,RAF/MAP kinase cascade,4982.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2693,PSB7,Regulation of activated PAK-2p34 by proteasome mediated degradation,4936.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2694,PSB7,Regulation of ornithine decarboxylase (ODC),4956.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2695,PSB7,Signaling by ROBO receptors,4958.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2696,PSB7,Transcriptional regulation by RUNX1,4950.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2697,PSB7,Transcriptional regulation by RUNX2,4948.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2698,PSB7,Transcriptional regulation by RUNX3,4946.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2699,PSB7,UCH proteinases,4984.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2700,PSB7,Ub-specific processing proteases,4986.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2701,PSB7,Ubiquitin-dependent degradation of Cyclin D,4994.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2702,PSB7,p53-Dependent G1/S DNA damage checkpoint,4996.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2703,PSB7,p53-Independent G1/S DNA damage checkpoint,4998.5,0.0022170924120412,0.5,0.0,1.0,0.00121427361644575,True,0,47,47,112,6.807354922057604,0.0002839748460489987
2704,PSME1,APC/C-mediated degradation of cell cycle proteins,4560.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2705,PSME1,AUF1 (hnRNP D0) binds and destabilizes mRNA,4630.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2706,PSME1,Antigen processing-Cross presentation,4552.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2707,PSME1,Antigen processing: Ubiquitination & Proteasome degradation,4626.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2708,PSME1,CDK-mediated phosphorylation and removal of Cdc6,4612.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2709,PSME1,CLEC7A (Dectin-1) signaling,4592.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2710,PSME1,Cyclin A:Cdk2-associated events at S phase entry,4614.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2711,PSME1,Defective CFTR causes cystic fibrosis,4600.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2712,PSME1,Degradation of AXIN,4562.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2713,PSME1,Degradation of DVL,4564.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2714,PSME1,Degradation of GLI1 by the proteasome,4594.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2715,PSME1,Degradation of GLI2 by the proteasome,4596.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2716,PSME1,Degradation of beta-catenin by the destruction complex,4628.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2717,PSME1,Downstream TCR signaling,4566.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2718,PSME1,Downstream signaling events of B Cell Receptor (BCR),4548.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2719,PSME1,FCERI mediated NF-kB activation,4574.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2720,PSME1,G1/S Transition,4588.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2721,PSME1,G2/M Transition,4586.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2722,PSME1,GLI3 is processed to GLI3R by the proteasome,4598.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2723,PSME1,Hedgehog 'on' state,4634.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2724,PSME1,Hedgehog ligand biogenesis,4632.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2725,PSME1,Hh mutants are degraded by ERAD,4590.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2726,PSME1,Host Interactions of HIV factors,4556.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2727,PSME1,Interleukin-1 family signaling,4584.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2728,PSME1,KEAP1-NFE2L2 pathway,4624.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2729,PSME1,MAPK6/MAPK4 signaling,4636.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2730,PSME1,Mitotic Metaphase and Anaphase,4576.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2731,PSME1,NIK-->noncanonical NF-kB signaling,4602.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2732,PSME1,Neddylation,4638.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2733,PSME1,Negative regulation of NOTCH4 signaling,4622.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2734,PSME1,Orc1 removal from chromatin,4610.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2735,PSME1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,4550.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2736,PSME1,PCP/CE pathway,4582.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2737,PSME1,PTEN Regulation,4554.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2738,PSME1,RAF/MAP kinase cascade,4604.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2739,PSME1,Regulation of activated PAK-2p34 by proteasome mediated degradation,4558.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2740,PSME1,Regulation of ornithine decarboxylase (ODC),4578.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2741,PSME1,Signaling by ROBO receptors,4580.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2742,PSME1,Transcriptional regulation by RUNX1,4572.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2743,PSME1,Transcriptional regulation by RUNX2,4570.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2744,PSME1,Transcriptional regulation by RUNX3,4568.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2745,PSME1,UCH proteinases,4606.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2746,PSME1,Ub-specific processing proteases,4608.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2747,PSME1,Ubiquitin-dependent degradation of Cyclin D,4616.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2748,PSME1,p53-Dependent G1/S DNA damage checkpoint,4618.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2749,PSME1,p53-Independent G1/S DNA damage checkpoint,4620.5,0.004894299404861,0.5,0.0,1.0,0.00268054619917145,True,0,46,46,111,6.794415866350106,0.0006279238224881701
2750,PSPB,Defective CSF2RA causes SMDP4,2258.5,0.0095458548370662,0.5,0.0,1.0,0.00522814457896185,True,0,4,4,10,3.321928094887362,0.002208702835282822
2751,PSPB,Defective CSF2RB causes SMDP5,2256.5,0.0095458548370662,0.5,0.0,1.0,0.00522814457896185,True,0,4,4,10,3.321928094887362,0.002208702835282822
2752,PSPB,Defective pro-SFTPB causes SMDP1 and RDS,2254.5,0.0095458548370662,0.5,0.0,1.0,0.00522814457896185,True,0,4,4,10,3.321928094887362,0.002208702835282822
2753,PSPB,Surfactant metabolism,2260.5,0.0095458548370662,0.5,0.0,1.0,0.00522814457896185,True,0,4,4,10,3.321928094887362,0.002208702835282822
2754,PTEN Regulation,PIP3 activates AKT signaling,5196.5,0.000911463051628,0.5,1.0,2.0,0.0114049795174904,True,9,1,10,14,3.807354922057604,0.000189597619981402
2755,PTGDS,Arachidonic acid metabolism,3744.5,0.0042741325518026,0.5,0.0,1.0,0.0023408886172983498,True,0,2,2,8,3.0,0.00106853313795065
2756,PTGDS,Transcriptional regulation of testis differentiation,3746.5,0.0042741325518026,0.5,0.0,1.0,0.0023408886172983498,True,0,2,2,8,3.0,0.00106853313795065
2757,PTX3,Neutrophil degranulation,3178.5,0.0015981496048164,0.5,0.0,1.0,0.0008752864290736,True,0,1,1,5,2.321928094887362,0.00048109096860827414
2758,PVR,Adherens junctions interactions,2746.5,0.0013149054568875,0.5,0.0,1.0,0.00072015717330845,True,0,2,2,9,3.169925001442312,0.0003153307209200872
2759,PVR,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,2748.5,0.0013149054568875,0.5,0.0,1.0,0.00072015717330845,True,0,2,2,9,3.169925001442312,0.0003153307209200872
2760,PYGB,Glycogen breakdown (glycogenolysis),2588.5,0.002487881138296,0.5,0.0,1.0,0.0013625811944864498,True,0,2,2,9,3.169925001442312,0.0005966249123030943
2761,PYGB,Neutrophil degranulation,2590.5,0.002487881138296,0.5,0.0,1.0,0.0013625811944864498,True,0,2,2,9,3.169925001442312,0.0005966249123030943
2762,PYGL,Glycogen breakdown (glycogenolysis),2034.5,0.0027448023247785003,0.5,0.0,1.0,0.00150329369548875,True,0,2,2,9,3.169925001442312,0.0006582378157470736
2763,PYGL,Neutrophil degranulation,2036.5,0.0027448023247785003,0.5,0.0,1.0,0.00150329369548875,True,0,2,2,9,3.169925001442312,0.0006582378157470736
2764,Packaging Of Telomere Ends,Telomere Maintenance,5210.5,0.000892708518886988,0.5,1.0,2.0,0.011170307293103301,True,3,1,4,8,3.0,0.000223177129721747
2765,Paracetamol ADME,Drug ADME,6778.5,4.165901941064837e-08,0.5,3.0,4.0,1.4274072649059265e-06,True,2,2,4,4,2.0,1.3886339803549455e-08
2766,Paracetamol ADME,Paracetamol ADME,6046.5,4.754129698573021e-06,0.5,1.5,2.5,6.418016004197515e-05,False,2,2,4,4,2.0,1.5847098995243404e-06
2767,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,5586.5,0.0019682561468526002,0.5,1.0,2.0,0.024628448734078198,True,13,1,14,18,4.169925001442312,0.00038071270788328526
2768,Parasite infection,Leishmania infection,5736.5,0.0107756486539784,0.5,1.0,2.0,0.1348338278406072,True,34,1,35,39,5.285402218862249,0.0017143928548663274
2769,Pentose phosphate pathway,Metabolism of carbohydrates,6154.5,0.00018801164687681646,0.5,2.0,3.0,0.0035448003710274,True,3,2,5,6,2.584962500721156,5.244452259653923e-05
2770,Pentose phosphate pathway,Pentose phosphate pathway,6000.5,0.00016274131407802243,0.5,1.0,2.0,0.00203635391516375,False,3,2,5,6,2.584962500721156,4.539554152805926e-05
2771,Pentose phosphate pathway disease,Diseases of carbohydrate metabolism,5554.5,0.0001236336987406083,0.5,1.0,2.0,0.0015470070885369,True,1,1,2,6,2.584962500721156,3.448674810844966e-05
2772,Peptide hormone metabolism,Metabolism of proteins,6704.5,0.0010038175838822999,0.5,3.0,4.0,0.0343948689178159,True,2,1,3,13,3.700439718141092,0.00021355822945843134
2773,Peroxisomal lipid metabolism,Fatty acid metabolism,5450.5,0.0002336106557555,0.5,1.0,2.0,0.00292312972994425,True,1,1,2,6,2.584962500721156,6.516404445193125e-05
2774,Peroxisomal protein import,Protein localization,6786.5,0.00037443803569832586,0.5,3.0,4.0,0.012829768438485201,True,1,1,2,5,2.321928094887362,0.00011271708026269667
2775,Phase I - Functionalization of compounds,Biological oxidations,6454.5,0.0013752202925166,0.5,2.0,3.0,0.02592861391373945,True,2,1,3,11,3.4594316186372973,0.0003083846575355351
2776,Phase II - Conjugation of compounds,Biological oxidations,6406.5,0.0025030839214689,0.5,2.0,3.0,0.047193527427294046,True,3,1,4,11,3.4594316186372973,0.0005613011108877114
2777,Phenylalanine and tyrosine metabolism,Metabolism of amino acids and derivatives,6164.5,0.000345101812605,0.5,2.0,3.0,0.0065066024030187505,True,1,1,2,7,2.807354922057604,9.064083062119594e-05
2778,Phospholipid metabolism,Metabolism of lipids,6412.5,0.000831138137267,0.5,2.0,3.0,0.015670405670602648,True,1,1,2,7,2.807354922057604,0.0002182980453048567
2779,Physiological factors,Cardiac conduction,6188.5,0.0025897323547478,0.5,2.0,3.0,0.04882721025247175,True,2,2,4,5,2.321928094887362,0.0007795871195206022
2780,Physiological factors,Physiological factors,5946.5,0.0030596642685535,0.5,1.0,2.0,0.038285049789917,False,2,2,4,5,2.321928094887362,0.0009210507214958983
2781,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",6116.5,0.0075620243039988995,0.5,2.0,3.0,0.14257556382176595,True,3,1,4,17,4.087462841250339,0.001486403840178298
2782,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,6622.5,0.012494466497166599,0.5,3.0,4.0,0.4281111870007357,True,3,1,4,32,5.0,0.0020824110828610997
2783,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",6394.5,0.0039193949744584,0.5,2.0,3.0,0.07389687282915874,True,4,1,5,13,3.700439718141092,0.0008338358131329091
2784,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",6414.5,0.01062576736232,0.5,2.0,3.0,0.20033984444093372,True,4,1,5,20,4.321928094887363,0.001996601076314409
2785,Platelet Adhesion to exposed collagen,Hemostasis,6636.5,3.6229354101311026e-05,0.5,3.0,4.0,0.0012413648707689001,True,6,2,8,8,3.0,9.057338525327756e-06
2786,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,5996.5,0.0005518935893643965,0.5,1.5,2.5,0.008377268686053225,False,6,2,8,8,3.0,0.00013797339734109913
2787,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",6390.5,0.0,0.5,2.0,3.0,0.0,True,0,1,1,4,2.0,0.0
2788,"Platelet activation, signaling and aggregation",Hemostasis,6836.5,0.010700206133248201,0.5,3.0,4.0,0.3666325368831309,True,5,1,6,78,6.285402218862249,0.0014687186529722222
2789,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,5644.5,0.0190116016398056,0.5,1.0,2.0,0.23788888305385955,True,63,1,64,68,6.087462841250339,0.002682426993359962
2790,Platelet homeostasis,Hemostasis,6736.5,0.0019544574542402,0.5,3.0,4.0,0.06696765331012655,True,1,1,2,5,2.321928094887362,0.0005883503189753631
2791,Platelet sensitization by LDL,Platelet homeostasis,6124.5,0.0045334318952871995,0.5,2.0,3.0,0.0854740189311951,True,2,2,4,5,2.321928094887362,0.0013646989837812597
2792,Platelet sensitization by LDL,Platelet sensitization by LDL,5928.5,0.0071855425219023005,0.5,1.0,2.0,0.08991145075817294,False,2,2,4,5,2.321928094887362,0.002163063834211602
2793,Positive epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,6584.5,0.0008586470365561,0.5,2.0,3.0,0.01618906266886155,True,2,1,3,10,3.321928094887362,0.00019867221705327287
2794,Post-chaperonin tubulin folding pathway,Post-chaperonin tubulin folding pathway,5914.5,0.0010158555892291,0.5,1.0,2.0,0.01271122528465835,False,6,2,8,9,3.169925001442312,0.00024361483453005302
2795,Post-chaperonin tubulin folding pathway,Protein folding,6228.5,0.0005027486154308,0.5,2.0,3.0,0.0094788993560588,True,6,2,8,9,3.169925001442312,0.0001205653855301731
2796,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,5962.5,0.0012408843409851,0.5,1.0,2.0,0.01552697113418985,False,4,2,6,7,2.807354922057604,0.0003259176951946708
2797,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,6122.5,0.0004814451755427,0.5,2.0,3.0,0.0090772410392784,True,4,2,6,7,2.807354922057604,0.00012645135150219017
2798,Post-translational protein modification,Metabolism of proteins,6724.5,0.0150540629430057,0.5,3.0,4.0,0.5158133608326103,True,12,1,13,102,6.672425341971495,0.0019620996323878766
2799,Post-translational protein phosphorylation,Post-translational protein modification,6544.5,0.0176415661358885,0.5,2.0,3.0,0.3326167884957958,True,42,2,44,45,5.491853096329675,0.0027174931216269486
2800,Post-translational protein phosphorylation,Post-translational protein phosphorylation,5972.5,0.0225894543532907,0.5,1.0,2.0,0.28265793522882776,False,42,2,44,45,5.491853096329675,0.003479661972952252
2801,Potential therapeutics for SARS,SARS-CoV Infections,5748.5,0.0138076625495518,0.5,1.0,2.0,0.17277289329585838,True,31,1,32,36,5.169925001442312,0.0022378979560244336
2802,Pre-NOTCH Expression and Processing,Signaling by NOTCH,6328.5,0.0041792064440057996,0.5,2.0,3.0,0.07879539804792796,True,2,1,3,10,3.321928094887362,0.0009669773194398132
2803,Pre-NOTCH Processing in Golgi,Pre-NOTCH Expression and Processing,5290.5,0.004588657415925099,0.5,1.0,2.0,0.05741707658684215,True,1,1,2,6,2.584962500721156,0.001279973616182049
2804,Pre-NOTCH Transcription and Translation,Pre-NOTCH Expression and Processing,5288.5,0.0033501303292114,0.5,1.0,2.0,0.0419196013676366,True,3,1,4,8,3.0,0.00083753258230285
2805,Processing and activation of SUMO,SUMOylation,5404.5,0.0005245277451127,0.5,1.0,2.0,0.0065633249517696,True,1,1,2,6,2.584962500721156,0.00014631331429748156
2806,Processing of Capped Intron-Containing Pre-mRNA,Metabolism of RNA,6714.5,0.00026202130572112266,0.5,3.0,4.0,0.00897791452217765,True,1,1,2,6,2.584962500721156,7.30889948412052e-05
2807,Programmed Cell Death,root,6868.5,0.0051089743257003994,0.5,4.0,5.0,0.42577628540844653,True,2,1,3,34,5.087462841250339,0.0008392616856862879
2808,Protein folding,Metabolism of proteins,6844.5,0.0020064667681727,0.5,3.0,4.0,0.06874970371842545,True,2,1,3,12,3.584962500721156,0.00043761901386480447
2809,Protein localization,root,6858.5,0.0003680287514855107,0.5,4.0,5.0,0.030671110234935,True,2,1,3,9,3.169925001442312,8.82578826617302e-05
2810,Protein methylation,Post-translational protein modification,6232.5,0.0013313093951012,0.5,2.0,3.0,0.0251007111319905,True,2,2,4,5,2.321928094887362,0.00040076406143473166
2811,Protein methylation,Protein methylation,5966.5,0.0010702331854162,0.5,1.0,2.0,0.013391642740545849,False,2,2,4,5,2.321928094887362,0.0003221722911652875
2812,Protein ubiquitination,Post-translational protein modification,6388.5,0.00012790107133428666,0.5,2.0,3.0,0.00241146637802395,True,1,1,2,6,2.584962500721156,3.5677101589921206e-05
2813,Pyrimidine catabolism,Nucleotide catabolism,5658.5,5.9118861155928155e-05,0.5,1.0,2.0,0.0007397440843885999,True,1,1,2,6,2.584962500721156,1.649078927437476e-05
2814,Pyrimidine salvage,Nucleotide salvage,5660.5,0.0006109172242532,0.5,1.0,2.0,0.00764430156224665,True,1,1,2,6,2.584962500721156,0.00017041105008219946
2815,Pyroptosis,Pyroptosis,5940.5,0.0027695582952965998,0.5,1.0,2.0,0.0346550039235633,False,2,2,4,5,2.321928094887362,0.0008337201216242786
2816,Pyroptosis,Regulated Necrosis,6560.5,0.002266847814828,0.5,2.0,3.0,0.04273949570967785,True,2,2,4,5,2.321928094887362,0.0006823891878685782
2817,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,5626.5,0.0008836123306025,0.5,1.0,2.0,0.01105648826238635,True,3,1,4,8,3.0,0.000220903082650625
2818,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,6252.5,0.0005696334834827,0.5,2.0,3.0,0.01073995689704,True,2,1,3,11,3.4594316186372973,0.00012773679073853974
2819,QSOX1,Neutrophil degranulation,40.5,0.0074367354092255,0.5,0.0,1.0,0.0040730064073408,True,0,4,4,13,3.700439718141092,0.0015821361096332801
2820,QSOX1,Platelet degranulation ,38.5,0.0074367354092255,0.5,0.0,1.0,0.0040730064073408,True,0,4,4,13,3.700439718141092,0.0015821361096332801
2821,QSOX1,Post-translational protein phosphorylation,44.5,0.0074367354092255,0.5,0.0,1.0,0.0040730064073408,True,0,4,4,13,3.700439718141092,0.0015821361096332801
2822,QSOX1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),42.5,0.0074367354092255,0.5,0.0,1.0,0.0040730064073408,True,0,4,4,13,3.700439718141092,0.0015821361096332801
2823,RA biosynthesis pathway,Signaling by Retinoic Acid,5510.5,0.0076891742859432,0.5,1.0,2.0,0.09621330791297794,True,2,1,3,7,2.807354922057604,0.002019558051022926
2824,RAB GEFs exchange GTP for GDP on RABs,Rab regulation of trafficking,5700.5,0.0005319563362883,0.5,1.0,2.0,0.0066562776282943,True,3,1,4,8,3.0,0.000132989084072075
2825,RAB geranylgeranylation,Post-translational protein modification,6536.5,0.0002680468948784,0.5,2.0,3.0,0.0050537971886391,True,3,2,5,6,2.584962500721156,7.476979043001964e-05
2826,RAB geranylgeranylation,RAB geranylgeranylation,5964.5,0.0003734274566171,0.5,1.0,2.0,0.00467263317627695,False,3,2,5,6,2.584962500721156,0.00010416495473578338
2827,RAB10,Neutrophil degranulation,4052.5,0.0002270621242724971,0.5,0.0,1.0,0.00012435906834591215,True,0,4,4,13,3.700439718141092,4.830657085041706e-05
2828,RAB10,RAB GEFs exchange GTP for GDP on RABs,4050.5,0.0002270621242724971,0.5,0.0,1.0,0.00012435906834591215,True,0,4,4,13,3.700439718141092,4.830657085041706e-05
2829,RAB10,RAB geranylgeranylation,4056.5,0.0002270621242724971,0.5,0.0,1.0,0.00012435906834591215,True,0,4,4,13,3.700439718141092,4.830657085041706e-05
2830,RAB10,Translocation of SLC2A4 (GLUT4) to the plasma membrane,4054.5,0.0002270621242724971,0.5,0.0,1.0,0.00012435906834591215,True,0,4,4,13,3.700439718141092,4.830657085041706e-05
2831,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,5558.5,0.00046329291437700003,0.5,1.0,2.0,0.00579710410600955,True,22,1,23,27,4.754887502163468,8.050425211662811e-05
2832,RAP1A,GRB2:SOS provides linkage to MAPK signaling for Integrins ,4248.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2833,RAP1A,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,4226.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2834,RAP1A,MET promotes cell motility,4242.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2835,RAP1A,Neutrophil degranulation,4246.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2836,RAP1A,Paradoxical activation of RAF signaling by kinase inactive BRAF,4238.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2837,RAP1A,RAF/MAP kinase cascade,4228.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2838,RAP1A,Rap1 signalling,4244.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2839,RAP1A,Signaling by BRAF and RAF1 fusions,4236.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2840,RAP1A,Signaling by NTRK1 (TRKA),4224.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2841,RAP1A,Signaling by RAF1 mutants,4240.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2842,RAP1A,Signaling by RAS mutants,4230.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2843,RAP1A,Signaling by high-kinase activity BRAF mutants,4234.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2844,RAP1A,Signaling by moderate kinase activity BRAF mutants,4232.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2845,RAP1A,p130Cas linkage to MAPK signaling for integrins,4250.5,0.0105119258753936,0.5,0.0,1.0,0.0057572495306012494,True,0,14,14,32,5.0,0.0017519876458989333
2846,RARR2,Platelet degranulation ,5028.5,0.0011451421758344,0.5,0.0,1.0,0.0006271799604036,True,0,1,1,6,2.584962500721156,0.0003194293317165916
2847,RB27B,Platelet degranulation ,32.5,5.999714721275582e-05,0.5,0.0,1.0,3.285968258553022e-05,True,0,3,3,13,3.700439718141092,1.2764156293973962e-05
2848,RB27B,RAB GEFs exchange GTP for GDP on RABs,34.5,5.999714721275582e-05,0.5,0.0,1.0,3.285968258553022e-05,True,0,3,3,13,3.700439718141092,1.2764156293973962e-05
2849,RB27B,RAB geranylgeranylation,36.5,5.999714721275582e-05,0.5,0.0,1.0,3.285968258553022e-05,True,0,3,3,13,3.700439718141092,1.2764156293973962e-05
2850,RET4,Retinoid cycle disease events,1324.5,0.0091483111615336,0.5,0.0,1.0,0.0050104149101566995,True,0,4,4,14,3.807354922057604,0.0019029822656859328
2851,RET4,Retinoid metabolism and transport,1330.5,0.0091483111615336,0.5,0.0,1.0,0.0050104149101566995,True,0,4,4,14,3.807354922057604,0.0019029822656859328
2852,RET4,Retinoid metabolism disease events,1326.5,0.0091483111615336,0.5,0.0,1.0,0.0050104149101566995,True,0,4,4,14,3.807354922057604,0.0019029822656859328
2853,RET4,The canonical retinoid cycle in rods (twilight vision),1328.5,0.0091483111615336,0.5,0.0,1.0,0.0050104149101566995,True,0,4,4,14,3.807354922057604,0.0019029822656859328
2854,RETN,FOXO-mediated transcription,5096.5,0.0028950805979104,0.5,0.0,1.0,0.0015855992147346,True,0,2,2,9,3.169925001442312,0.0006942764190984339
2855,RETN,Neutrophil degranulation,5098.5,0.0028950805979104,0.5,0.0,1.0,0.0015855992147346,True,0,2,2,9,3.169925001442312,0.0006942764190984339
2856,RHO GTPase Effectors,Signaling by Rho GTPases,5300.5,0.0085816906204125,0.5,1.0,2.0,0.1073812104357034,True,24,1,25,29,4.857980995127572,0.0014649570607262806
2857,RHO GTPase cycle,Signaling by Rho GTPases,5302.5,0.0013920504144027,0.5,1.0,2.0,0.0174184860650347,True,12,1,13,17,4.087462841250339,0.00027362370160537186
2858,RIDA,Threonine catabolism,3878.5,0.00016082855396841288,0.5,0.0,1.0,8.808377530602129e-05,True,0,1,1,5,2.321928094887362,4.84142189037557e-05
2859,RIPK1-mediated regulated necrosis,Regulated Necrosis,6542.5,0.000712491069622,0.5,2.0,3.0,0.0134334156947395,True,1,1,2,6,2.584962500721156,0.00019874435771048492
2860,RMTs methylate histone arginines,Chromatin modifying enzymes,6380.5,0.0019251510171753,0.5,2.0,3.0,0.0362970919798124,True,3,2,5,6,2.584962500721156,0.0005370072955541471
2861,RMTs methylate histone arginines,RMTs methylate histone arginines,5902.5,0.0022031734026802,0.5,1.0,2.0,0.0275679277247334,False,3,2,5,6,2.584962500721156,0.0006145596787238379
2862,RNA Polymerase I Promoter Clearance,RNA Polymerase I Transcription,6166.5,0.0005525004453374,0.5,2.0,3.0,0.01041692797312405,True,2,1,3,9,3.169925001442312,0.00013249649457635298
2863,RNA Polymerase I Promoter Escape,RNA Polymerase I Promoter Clearance,5634.5,0.0006031370830122,0.5,1.0,2.0,0.00754695000055955,True,3,1,4,8,3.0,0.00015078427075305
2864,RNA Polymerase I Promoter Opening,RNA Polymerase I Promoter Clearance,5632.5,0.00024882513453166304,0.5,1.0,2.0,0.00311350587135865,True,3,1,4,8,3.0,6.220628363291576e-05
2865,RNA Polymerase I Transcription,Gene expression (Transcription),6768.5,0.00026826905689749997,0.5,3.0,4.0,0.00919198786199205,True,1,1,2,9,3.169925001442312,6.433426423849587e-05
2866,RNA Polymerase II Transcription,Gene expression (Transcription),6624.5,0.0095735510018166,0.5,3.0,4.0,0.32802875449938296,True,1,1,2,49,5.614709844115208,0.0014473123126230141
2867,RNAS1,Chaperone Mediated Autophagy,2276.5,0.020318315072791103,0.5,0.0,1.0,0.01112808550041795,True,0,2,2,5,2.321928094887362,0.006116422298261709
2868,RNAS1,Late endosomal microautophagy,2278.5,0.020318315072791103,0.5,0.0,1.0,0.01112808550041795,True,0,2,2,5,2.321928094887362,0.006116422298261709
2869,ROS and RNS production in phagocytes,Innate Immune System,6106.5,0.0031367146668879,0.5,2.0,3.0,0.05914009849757565,True,1,1,2,6,2.584962500721156,0.0008749644288488133
2870,Rab regulation of trafficking,Membrane Trafficking,6554.5,0.00020382380251542329,0.5,2.0,3.0,0.0038429251739599997,True,1,1,2,8,3.0,5.095595062885582e-05
2871,Rap1 signalling,Adaptive Immune System,6250.5,0.0010624393913593,0.5,2.0,3.0,0.0200313949228407,True,4,2,6,7,2.807354922057604,0.0002790492121457191
2872,Rap1 signalling,Rap1 signalling,5786.5,0.0009409318970125,0.5,1.0,2.0,0.011773718082826248,False,4,2,6,7,2.807354922057604,0.0002471353252519976
2873,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,DNA Double Strand Break Response,5574.5,0.00013462269084891392,0.5,1.0,2.0,0.0016845104461215,True,2,1,3,7,2.807354922057604,3.5358587156923094e-05
2874,Regulated Necrosis,Programmed Cell Death,6670.5,0.0017117973115192001,0.5,3.0,4.0,0.0586531308964157,True,2,1,3,8,3.0,0.00042794932787980003
2875,Regulation of Apoptosis,Apoptosis,6156.5,0.0006816819798119999,0.5,2.0,3.0,0.01285253639920805,True,1,1,2,14,3.807354922057604,0.00014179980277391962
2876,Regulation of Complement cascade,Complement cascade,5252.5,0.0068274812517392005,0.5,1.0,2.0,0.0854310920152454,True,65,1,66,70,6.129283016944966,0.0009576673047642463
2877,Regulation of HSF1-mediated heat shock response,Cellular response to heat stress,5408.5,0.0043390370943218,0.5,1.0,2.0,0.054293620677192955,True,7,1,8,12,3.584962500721156,0.0009463626133560143
2878,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,6814.5,0.014307652775424999,0.5,3.0,4.0,0.4902383158393054,True,49,2,51,51,5.672425341971495,0.0021442956709347804
2879,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),6079.5,0.02363042801411445,0.5,1.5,2.5,0.3626268352056116,False,49,2,51,51,5.672425341971495,0.0035415050454700764
2880,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,5274.5,0.0023705556095361003,0.5,1.0,2.0,0.029662352328532,True,9,1,10,14,3.807354922057604,0.0004931101713874445
2881,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,5344.5,0.0069862862099601,0.5,1.0,2.0,0.08741819099040354,True,36,1,37,41,5.357552004618084,0.0010988956448779825
2882,Regulation of activated PAK-2p34 by proteasome mediated degradation,Regulation of Apoptosis,5278.5,0.0009533587206550999,0.5,1.0,2.0,0.0119292127777108,True,9,1,10,14,3.807354922057604,0.0001983125307184624
2883,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,Cell-extracellular matrix interactions,5476.5,5.985866630857492e-05,0.5,1.0,2.0,0.0007490011383063,True,1,1,2,6,2.584962500721156,1.669715270286193e-05
2884,Regulation of insulin secretion,Integration of energy metabolism,6574.5,0.0005683445911363,0.5,2.0,3.0,0.0107156559234373,True,2,1,3,8,3.0,0.000142086147784075
2885,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,6294.5,0.0021436781263693,0.5,2.0,3.0,0.040417235548672395,True,1,1,2,10,3.321928094887362,0.0004960004144689891
2886,Regulation of mRNA stability by proteins that bind AU-rich elements,Metabolism of RNA,6820.5,0.0035505995046136002,0.5,3.0,4.0,0.1216579650542982,True,4,1,5,19,4.247927513443585,0.0006765717505659235
2887,Regulation of mitotic cell cycle,"Cell Cycle, Mitotic",6084.5,0.0008885251106595,0.5,2.0,3.0,0.01675238845173875,True,1,1,2,14,3.807354922057604,0.00018482619341931195
2888,Regulation of necroptotic cell death,RIPK1-mediated regulated necrosis,5496.5,0.0006904322561858872,0.5,1.0,2.0,0.00863925940382255,True,1,1,2,6,2.584962500721156,0.0001925912073130469
2889,Regulation of ornithine decarboxylase (ODC),Metabolism of polyamines,5414.5,0.00016579923738318364,0.5,1.0,2.0,0.00207461718057905,True,9,1,10,14,3.807354922057604,3.4488661659335034e-05
2890,Reproduction,root,6894.5,0.0019918035528298,0.5,4.0,5.0,0.16599471125175702,True,2,1,3,12,3.584962500721156,0.00043442090366420985
2891,Respiratory electron transport,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",5234.5,0.0002734746705597,0.5,1.0,2.0,0.0034219412522712,True,1,1,2,6,2.584962500721156,7.628383016689504e-05
2892,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",The citric acid (TCA) cycle and respiratory electron transport,6508.5,0.00017632496066445857,0.5,2.0,3.0,0.00332445780018155,True,1,1,2,6,2.584962500721156,4.918460391956368e-05
2893,Response of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,5724.5,0.0010744576595547,0.5,1.0,2.0,0.013444502854772049,True,2,1,3,7,2.807354922057604,0.00028220580469919313
2894,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",6614.5,0.016123537248683498,0.5,2.0,3.0,0.3039956394766738,True,1,1,2,68,6.087462841250339,0.0022749378176406855
2895,Response to metal ions,Cellular responses to stimuli,6644.5,0.0036681458843886,0.5,3.0,4.0,0.1256855816143559,True,1,1,2,6,2.584962500721156,0.0010232034180694249
2896,Retinoid cycle disease events,Diseases associated with visual transduction,5388.5,0.00160054824336,0.5,1.0,2.0,0.02002738333679065,True,2,1,3,7,2.807354922057604,0.0004203832519231009
2897,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,5880.5,0.0335240047541482,0.5,1.0,2.0,0.41948007314433194,True,14,3,17,20,4.321928094887363,0.006299221664861243
2898,Retinoid metabolism and transport,Retinoid metabolism and transport,5882.5,0.0335240047541482,0.5,1.0,2.0,0.41948007314433194,False,14,3,17,20,4.321928094887363,0.006299221664861243
2899,Retinoid metabolism and transport,Visual phototransduction,6112.5,0.0211706364520308,0.5,2.0,3.0,0.399154420466188,True,14,3,17,20,4.321928094887363,0.0039780012195897345
2900,Retinoid metabolism disease events,Diseases associated with visual transduction,5390.5,0.0003590973862875,0.5,1.0,2.0,0.0044933234847847,True,1,1,2,6,2.584962500721156,0.00010016768270665689
2901,Reversible hydration of carbon dioxide,Metabolism,6746.5,0.0010702744672274,0.5,3.0,4.0,0.03667195175442045,True,4,2,6,6,2.584962500721156,0.00029854551254360456
2902,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,6080.5,0.0026048657367311,0.5,1.5,2.5,0.039306223745896374,False,4,2,6,6,2.584962500721156,0.0007266089216294736
2903,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,5380.5,0.0014873281703863001,0.5,1.0,2.0,0.0186106801463241,True,26,1,27,31,4.954196310386875,0.00024979495012479033
2904,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,5346.5,0.0005728403929170999,0.5,1.0,2.0,0.0071678527575437,True,31,1,32,36,5.169925001442312,9.28439799159941e-05
2905,S Phase,"Cell Cycle, Mitotic",6066.5,0.00018113055835952788,0.5,2.0,3.0,0.00341506327476425,True,2,1,3,15,3.9068905956085187,3.691351067040966e-05
2906,S10A8,Antigen processing-Cross presentation,1814.5,0.014378064868088299,0.5,0.0,1.0,0.007874685209351001,True,0,9,9,23,4.523561956057013,0.002603042200390572
2907,S10A8,IRAK4 deficiency (TLR2/4),1826.5,0.014378064868088299,0.5,0.0,1.0,0.007874685209351001,True,0,9,9,23,4.523561956057013,0.002603042200390572
2908,S10A8,Metal sequestration by antimicrobial proteins,1828.5,0.014378064868088299,0.5,0.0,1.0,0.007874685209351001,True,0,9,9,23,4.523561956057013,0.002603042200390572
2909,S10A8,MyD88 deficiency (TLR2/4),1824.5,0.014378064868088299,0.5,0.0,1.0,0.007874685209351001,True,0,9,9,23,4.523561956057013,0.002603042200390572
2910,S10A8,Neutrophil degranulation,1830.5,0.014378064868088299,0.5,0.0,1.0,0.007874685209351001,True,0,9,9,23,4.523561956057013,0.002603042200390572
2911,S10A8,RHO GTPase Effectors,1822.5,0.014378064868088299,0.5,0.0,1.0,0.007874685209351001,True,0,9,9,23,4.523561956057013,0.002603042200390572
2912,S10A8,Regulation of TLR by endogenous ligand,1820.5,0.014378064868088299,0.5,0.0,1.0,0.007874685209351001,True,0,9,9,23,4.523561956057013,0.002603042200390572
2913,S10A8,Toll Like Receptor 2 (TLR2) Cascade,1818.5,0.014378064868088299,0.5,0.0,1.0,0.007874685209351001,True,0,9,9,23,4.523561956057013,0.002603042200390572
2914,S10A8,Toll Like Receptor 4 (TLR4) Cascade,1816.5,0.014378064868088299,0.5,0.0,1.0,0.007874685209351001,True,0,9,9,23,4.523561956057013,0.002603042200390572
2915,S10A9,Antigen processing-Cross presentation,2000.5,0.0048064621430199995,0.5,0.0,1.0,0.0026324388361156,True,0,9,9,23,4.523561956057013,0.0008701743876972977
2916,S10A9,IRAK4 deficiency (TLR2/4),2012.5,0.0048064621430199995,0.5,0.0,1.0,0.0026324388361156,True,0,9,9,23,4.523561956057013,0.0008701743876972977
2917,S10A9,Metal sequestration by antimicrobial proteins,2014.5,0.0048064621430199995,0.5,0.0,1.0,0.0026324388361156,True,0,9,9,23,4.523561956057013,0.0008701743876972977
2918,S10A9,MyD88 deficiency (TLR2/4),2010.5,0.0048064621430199995,0.5,0.0,1.0,0.0026324388361156,True,0,9,9,23,4.523561956057013,0.0008701743876972977
2919,S10A9,Neutrophil degranulation,2016.5,0.0048064621430199995,0.5,0.0,1.0,0.0026324388361156,True,0,9,9,23,4.523561956057013,0.0008701743876972977
2920,S10A9,RHO GTPase Effectors,2008.5,0.0048064621430199995,0.5,0.0,1.0,0.0026324388361156,True,0,9,9,23,4.523561956057013,0.0008701743876972977
2921,S10A9,Regulation of TLR by endogenous ligand,2006.5,0.0048064621430199995,0.5,0.0,1.0,0.0026324388361156,True,0,9,9,23,4.523561956057013,0.0008701743876972977
2922,S10A9,Toll Like Receptor 2 (TLR2) Cascade,2004.5,0.0048064621430199995,0.5,0.0,1.0,0.0026324388361156,True,0,9,9,23,4.523561956057013,0.0008701743876972977
2923,S10A9,Toll Like Receptor 4 (TLR4) Cascade,2002.5,0.0048064621430199995,0.5,0.0,1.0,0.0026324388361156,True,0,9,9,23,4.523561956057013,0.0008701743876972977
2924,S10AC,Advanced glycosylation endproduct receptor signaling,4446.5,0.0082887675047929,0.5,0.0,1.0,0.00453965366498035,True,0,11,11,19,4.247927513443585,0.0015794363553154292
2925,S10AC,Interleukin-1 family signaling,4442.5,0.0082887675047929,0.5,0.0,1.0,0.00453965366498035,True,0,11,11,19,4.247927513443585,0.0015794363553154292
2926,S10AC,Neutrophil degranulation,4444.5,0.0082887675047929,0.5,0.0,1.0,0.00453965366498035,True,0,11,11,19,4.247927513443585,0.0015794363553154292
2927,S10AC,TRAF6 mediated NF-kB activation,4440.5,0.0082887675047929,0.5,0.0,1.0,0.00453965366498035,True,0,11,11,19,4.247927513443585,0.0015794363553154292
2928,S10AC,Toll Like Receptor 10 (TLR10) Cascade,4430.5,0.0082887675047929,0.5,0.0,1.0,0.00453965366498035,True,0,11,11,19,4.247927513443585,0.0015794363553154292
2929,S10AC,Toll Like Receptor 2 (TLR2) Cascade,4438.5,0.0082887675047929,0.5,0.0,1.0,0.00453965366498035,True,0,11,11,19,4.247927513443585,0.0015794363553154292
2930,S10AC,Toll Like Receptor 3 (TLR3) Cascade,4432.5,0.0082887675047929,0.5,0.0,1.0,0.00453965366498035,True,0,11,11,19,4.247927513443585,0.0015794363553154292
2931,S10AC,Toll Like Receptor 4 (TLR4) Cascade,4426.5,0.0082887675047929,0.5,0.0,1.0,0.00453965366498035,True,0,11,11,19,4.247927513443585,0.0015794363553154292
2932,S10AC,Toll Like Receptor 5 (TLR5) Cascade,4434.5,0.0082887675047929,0.5,0.0,1.0,0.00453965366498035,True,0,11,11,19,4.247927513443585,0.0015794363553154292
2933,S10AC,Toll Like Receptor 7/8 (TLR7/8) Cascade,4436.5,0.0082887675047929,0.5,0.0,1.0,0.00453965366498035,True,0,11,11,19,4.247927513443585,0.0015794363553154292
2934,S10AC,Toll Like Receptor 9 (TLR9) Cascade,4428.5,0.0082887675047929,0.5,0.0,1.0,0.00453965366498035,True,0,11,11,19,4.247927513443585,0.0015794363553154292
2935,SAA1,Advanced glycosylation endproduct receptor signaling,2502.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2936,SAA1,Amyloid fiber formation,2506.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2937,SAA1,Class A/1 (Rhodopsin-like receptors),2492.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2938,SAA1,G alpha (i) signalling events,2496.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2939,SAA1,G alpha (q) signalling events,2494.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2940,SAA1,Interleukin-1 family signaling,2498.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2941,SAA1,Interleukin-4 and Interleukin-13 signaling,2500.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2942,SAA1,Scavenging by Class B Receptors,2504.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2943,SAA1,TRAF6 mediated NF-kB activation,2490.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2944,SAA1,Toll Like Receptor 10 (TLR10) Cascade,2480.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2945,SAA1,Toll Like Receptor 2 (TLR2) Cascade,2488.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2946,SAA1,Toll Like Receptor 3 (TLR3) Cascade,2482.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2947,SAA1,Toll Like Receptor 4 (TLR4) Cascade,2476.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2948,SAA1,Toll Like Receptor 5 (TLR5) Cascade,2484.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2949,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,2486.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2950,SAA1,Toll Like Receptor 9 (TLR9) Cascade,2478.5,0.0024248611890553,0.5,0.0,1.0,0.00132806596126605,True,0,16,16,31,4.954196310386875,0.0004072524758421585
2951,SAE1,Processing and activation of SUMO,5100.5,0.0011306616718772,0.5,0.0,1.0,0.000619249170594,True,0,1,1,6,2.584962500721156,0.0003153900972882574
2952,SAHH,Defective AHCY causes HMAHCHD,2964.5,0.0007946737472048001,0.5,0.0,1.0,0.00043523281198029997,True,0,3,3,13,3.700439718141092,0.00016906370358028415
2953,SAHH,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",2962.5,0.0007946737472048001,0.5,0.0,1.0,0.00043523281198029997,True,0,3,3,13,3.700439718141092,0.00016906370358028415
2954,SAHH,Methylation,2960.5,0.0007946737472048001,0.5,0.0,1.0,0.00043523281198029997,True,0,3,3,13,3.700439718141092,0.00016906370358028415
2955,SAMP,Amyloid fiber formation,1258.5,0.0023460054940741,0.5,0.0,1.0,0.0012848776893644,True,0,1,1,4,2.0,0.0007820018313580334
2956,SAP,Class A/1 (Rhodopsin-like receptors),2156.5,0.0082219061607182,0.5,0.0,1.0,0.0045030345481456,True,0,5,5,19,4.247927513443585,0.0015666958317652427
2957,SAP,G alpha (i) signalling events,2158.5,0.0082219061607182,0.5,0.0,1.0,0.0045030345481456,True,0,5,5,19,4.247927513443585,0.0015666958317652427
2958,SAP,Glycosphingolipid metabolism,2160.5,0.0082219061607182,0.5,0.0,1.0,0.0045030345481456,True,0,5,5,19,4.247927513443585,0.0015666958317652427
2959,SAP,Neutrophil degranulation,2164.5,0.0082219061607182,0.5,0.0,1.0,0.0045030345481456,True,0,5,5,19,4.247927513443585,0.0015666958317652427
2960,SAP,Platelet degranulation ,2162.5,0.0082219061607182,0.5,0.0,1.0,0.0045030345481456,True,0,5,5,19,4.247927513443585,0.0015666958317652427
2961,SARS-CoV Infections,Infectious disease,6168.5,0.0127626746340546,0.5,2.0,3.0,0.24062942125983838,True,3,1,4,54,5.754887502163468,0.0018893985473432307
2962,SARS-CoV-1 Infection,SARS-CoV Infections,5746.5,0.0023646717585330997,0.5,1.0,2.0,0.029588728718607953,True,3,1,4,8,3.0,0.0005911679396332749
2963,SARS-CoV-2 Infection,SARS-CoV Infections,5750.5,0.005945026095089,0.5,1.0,2.0,0.0743890832703798,True,18,1,19,23,4.523561956057013,0.0010763029621800148
2964,SEPP1,Platelet degranulation ,3862.5,0.0009453410179403,0.5,0.0,1.0,0.0005177513803189,True,0,1,1,6,2.584962500721156,0.00026369620818910485
2965,SIRT1 negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,5502.5,0.00020812983893191844,0.5,1.0,2.0,0.0026042926762174,True,3,1,4,8,3.0,5.203245973297961e-05
2966,SLC transporter disorders,Disorders of transmembrane transporters,6266.5,1.8187714779147905e-05,0.5,2.0,3.0,0.00034291395862015003,True,4,1,5,11,3.4594316186372973,4.078482715854642e-06
2967,SLC-mediated transmembrane transport,Transport of small molecules,6646.5,0.0007421471717143,0.5,3.0,4.0,0.0254289774344462,True,3,1,4,14,3.807354922057604,0.0001543774453409095
2968,SODE,Detoxification of Reactive Oxygen Species,2352.5,0.000536430797559,0.5,0.0,1.0,0.00029379639792515,True,0,1,1,6,2.584962500721156,0.00014963358680909237
2969,SODM,Detoxification of Reactive Oxygen Species,1520.5,0.0006885090430106999,0.5,0.0,1.0,0.00037708773936155,True,0,5,5,21,4.392317422778761,0.00012768332963898453
2970,SODM,FOXO-mediated transcription,1514.5,0.0006885090430106999,0.5,0.0,1.0,0.00037708773936155,True,0,5,5,21,4.392317422778761,0.00012768332963898453
2971,SODM,Interleukin-12 family signaling,1516.5,0.0006885090430106999,0.5,0.0,1.0,0.00037708773936155,True,0,5,5,21,4.392317422778761,0.00012768332963898453
2972,SODM,Neurodegenerative Diseases,1518.5,0.0006885090430106999,0.5,0.0,1.0,0.00037708773936155,True,0,5,5,21,4.392317422778761,0.00012768332963898453
2973,SODM,Transcriptional activation of mitochondrial biogenesis,1522.5,0.0006885090430106999,0.5,0.0,1.0,0.00037708773936155,True,0,5,5,21,4.392317422778761,0.00012768332963898453
2974,SPP24,Platelet degranulation ,4666.5,0.0010044768253933,0.5,0.0,1.0,0.0005501393179561999,True,0,3,3,10,3.321928094887362,0.0002324140530198892
2975,SPP24,Post-translational protein phosphorylation,4670.5,0.0010044768253933,0.5,0.0,1.0,0.0005501393179561999,True,0,3,3,10,3.321928094887362,0.0002324140530198892
2976,SPP24,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4668.5,0.0010044768253933,0.5,0.0,1.0,0.0005501393179561999,True,0,3,3,10,3.321928094887362,0.0002324140530198892
2977,STOM,Neutrophil degranulation,3184.5,0.0006333629261355,0.5,0.0,1.0,0.00034688490505145,True,0,3,3,12,3.584962500721156,0.00013813917257466776
2978,STOM,RHO GTPase cycle,3182.5,0.0006333629261355,0.5,0.0,1.0,0.00034688490505145,True,0,3,3,12,3.584962500721156,0.00013813917257466776
2979,STOM,Stimuli-sensing channels,3186.5,0.0006333629261355,0.5,0.0,1.0,0.00034688490505145,True,0,3,3,12,3.584962500721156,0.00013813917257466776
2980,SUMO E3 ligases SUMOylate target proteins,SUMOylation,5402.5,0.0012055292421892,0.5,1.0,2.0,0.015084578898010051,True,2,1,3,7,2.807354922057604,0.00031663169493473367
2981,SUMOylation,Post-translational protein modification,6440.5,0.0009368592868598,0.5,2.0,3.0,0.01766368840881275,True,2,1,3,9,3.169925001442312,0.00022467053640910927
2982,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,6398.5,0.006694324198691299,0.5,2.0,3.0,0.1262158132088237,True,10,2,12,13,3.700439718141092,0.001424191054478354
2983,Scavenging by Class A Receptors,Scavenging by Class A Receptors,5872.5,0.0107402181072821,0.5,1.0,2.0,0.13439049153789778,False,10,2,12,13,3.700439718141092,0.0022849390166266377
2984,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,6540.5,0.0038017397485296998,0.5,2.0,3.0,0.07167858318884605,True,5,2,7,8,3.0,0.0009504349371324249
2985,Scavenging by Class B Receptors,Scavenging by Class B Receptors,5870.5,0.0067115825987366,0.5,1.0,2.0,0.08398087221616721,False,5,2,7,8,3.0,0.00167789564968415
2986,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,6612.5,0.0107612866612249,0.5,2.0,3.0,0.2028949460477722,True,5,2,7,8,3.0,0.002690321665306225
2987,Scavenging by Class F Receptors,Scavenging by Class F Receptors,5874.5,0.0139187968473143,0.5,1.0,2.0,0.174163497541864,False,5,2,7,8,3.0,0.003479699211828575
2988,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,6064.5,0.0004081839387122,0.5,2.0,3.0,0.0076959624652522506,True,2,2,4,5,2.321928094887362,0.00012287560930064034
2989,Scavenging by Class H Receptors,Scavenging by Class H Receptors,5876.5,0.0024989103933824,0.5,1.0,2.0,0.0312684335384344,False,2,2,4,5,2.321928094887362,0.0007522469848845815
2990,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,6136.5,0.0099085933729215,0.5,2.0,3.0,0.18681813625986715,True,41,2,43,44,5.459431618637297,0.0015339729496218195
2991,Scavenging of heme from plasma,Scavenging of heme from plasma,5868.5,0.011871594242962101,0.5,1.0,2.0,0.14854720543975064,False,41,2,43,44,5.459431618637297,0.0018378697916251912
2992,Selective autophagy,Macroautophagy,6516.5,0.0011101259306629,0.5,2.0,3.0,0.020930484234722997,True,2,1,3,14,3.807354922057604,0.0002309223988371038
2993,Selenoamino acid metabolism,Metabolism of amino acids and derivatives,6556.5,0.00014175901270589995,0.5,2.0,3.0,0.0026727461260170997,True,1,1,2,7,2.807354922057604,3.7232938774536235e-05
2994,Semaphorin interactions,Axon guidance,5420.5,0.0059241519763422006,0.5,1.0,2.0,0.0741278890329084,True,8,1,9,13,3.700439718141092,0.00126033995361716
2995,Senescence-Associated Secretory Phenotype (SASP),Cellular Senescence,5396.5,0.0006704429086745,0.5,1.0,2.0,0.008389136155790851,True,3,1,4,8,3.0,0.000167610727168625
2996,Sensory Perception,root,6852.5,0.0062858224205343,0.5,4.0,5.0,0.5238535076383106,True,2,1,3,26,4.700439718141092,0.001102690797787105
2997,Sensory processing of sound,Sensory Perception,6840.5,0.0055418660175638994,0.5,3.0,4.0,0.18988684627041857,True,2,1,3,10,3.321928094887362,0.0012822670567147257
2998,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound,6608.5,0.001265985157907,0.5,2.0,3.0,0.0238690779641023,True,5,2,7,8,3.0,0.00031649628947675
2999,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound by inner hair cells of the cochlea,6030.5,0.0006607034395603999,0.5,1.0,2.0,0.00826726786331385,False,5,2,7,8,3.0,0.00016517585989009998
3000,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,6360.5,0.006639875064175101,0.5,2.0,3.0,0.1251892208915865,True,6,2,8,9,3.169925001442312,0.0015923248168440611
3001,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,6032.5,0.0075483641394846,0.5,1.0,2.0,0.09445137490500041,False,6,2,8,9,3.169925001442312,0.0018101918228442331
3002,Serotonin clearance from the synaptic cleft,Neurotransmitter clearance,5162.5,0.00015168475599659293,0.5,1.0,2.0,0.00189800511624305,True,1,1,2,6,2.584962500721156,4.231139264806252e-05
3003,Signal Transduction,root,6870.5,0.0090753403596539,0.5,4.0,5.0,0.7563288560118281,True,14,1,15,181,7.499845887083206,0.001067706459648315
3004,Signaling by ALK fusions and activated point mutants,Signaling by ALK in cancer,5754.5,0.0009925590973621,0.5,1.0,2.0,0.012419720311310299,True,5,1,6,10,3.321928094887362,0.00022965655040310616
3005,Signaling by ALK in cancer,Diseases of signal transduction by growth factor receptors and second messengers,6514.5,0.0002374433871173,0.5,2.0,3.0,0.00447679396852875,True,2,1,3,11,3.4594316186372973,5.324521316235753e-05
3006,Signaling by Activin,Signaling by TGFB family members,6334.5,0.0001030802576820944,0.5,2.0,3.0,0.0019434909578570502,True,1,1,2,6,2.584962500721156,2.8753510716320916e-05
3007,Signaling by BMP,Signaling by BMP,6016.5,0.0046207896347493,0.5,1.0,2.0,0.057819141483368544,False,2,2,4,5,2.321928094887362,0.0013909962837127512
3008,Signaling by BMP,Signaling by TGFB family members,6310.5,0.0029706778569113003,0.5,2.0,3.0,0.0560096150653729,True,2,2,4,5,2.321928094887362,0.0008942631423850937
3009,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,5584.5,0.0014134410514231,0.5,1.0,2.0,0.0176861434063254,True,13,1,14,18,4.169925001442312,0.00027339681930178415
3010,Signaling by EGFR in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,6460.5,0.0001435818830572233,0.5,2.0,3.0,0.0027071148026658,True,2,1,3,7,2.807354922057604,3.77117148247444e-05
3011,Signaling by EGFRvIII in Cancer,Signaling by EGFR in Cancer,5236.5,1.0775113833467562e-05,0.5,1.0,2.0,0.000134827135724,True,1,1,2,6,2.584962500721156,3.0056419924336795e-06
3012,Signaling by ERBB2,Signaling by Receptor Tyrosine Kinases,6518.5,0.0004146244688951,0.5,2.0,3.0,0.0078173932072347,True,2,1,3,7,2.807354922057604,0.00010890092397034132
3013,Signaling by ERBB2 ECD mutants,Signaling by ERBB2 in Cancer,5184.5,7.992632076370751e-05,0.5,1.0,2.0,0.0010001042275824,True,1,1,2,6,2.584962500721156,2.2294883348885636e-05
3014,Signaling by ERBB2 KD Mutants,Signaling by ERBB2 in Cancer,5180.5,3.8862174702781486e-05,0.5,1.0,2.0,0.00048627567041649997,True,1,1,2,6,2.584962500721156,1.084032948600269e-05
3015,Signaling by ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,5186.5,6.090306854894337e-05,0.5,1.0,2.0,0.0007620695628991499,True,1,1,2,6,2.584962500721156,1.6988481340234947e-05
3016,Signaling by ERBB2 in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,6132.5,0.0002551638660179,0.5,2.0,3.0,0.0048108985903717,True,6,1,7,11,3.4594316186372973,5.721892111799494e-05
3017,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,6316.5,3.3166802931246746e-05,0.5,2.0,3.0,0.0006253319796376,True,1,1,2,7,2.807354922057604,8.711245368562186e-06
3018,Signaling by GPCR,Signal Transduction,6734.5,0.0068909844131345,0.5,3.0,4.0,0.23611312394808026,True,2,1,3,20,4.321928094887363,0.0012948285452699913
3019,Signaling by Hedgehog,Signal Transduction,6828.5,0.0004058424259381,0.5,3.0,4.0,0.01390581044361405,True,3,1,4,19,4.247927513443585,7.733384748521314e-05
3020,Signaling by Hippo,Signal Transduction,6796.5,0.0010204060380033,0.5,3.0,4.0,0.03496325675461305,True,3,2,5,5,2.321928094887362,0.0003071728251956336
3021,Signaling by Hippo,Signaling by Hippo,6006.5,0.0006035749579595619,0.5,1.5,2.5,0.0099668351948994,False,3,2,5,5,2.321928094887362,0.00018169416697745455
3022,Signaling by Interleukins,Cytokine Signaling in Immune system,6386.5,0.0054943873907675,0.5,2.0,3.0,0.10359202094598301,True,6,1,7,48,5.584962500721156,0.0008343840060085048
3023,Signaling by Ligand-Responsive EGFR Variants in Cancer,Signaling by EGFR in Cancer,5238.5,0.00021486428288085258,0.5,1.0,2.0,0.00268855960855445,True,1,1,2,6,2.584962500721156,5.993487598200265e-05
3024,Signaling by MET,Signaling by Receptor Tyrosine Kinases,6418.5,0.008756443894905,0.5,2.0,3.0,0.16509533363037915,True,2,1,3,12,3.584962500721156,0.0019098179960092853
3025,Signaling by MRAS-complex mutants,Oncogenic MAPK signaling,5590.5,0.00033831686783820003,0.5,1.0,2.0,0.00423330045164695,True,1,1,2,6,2.584962500721156,9.437110367825151e-05
3026,Signaling by MST1,Signaling by MST1,6014.5,0.0011736378123435999,0.5,1.0,2.0,0.0146855269523248,False,2,2,4,5,2.321928094887362,0.00035330018556087826
3027,Signaling by MST1,Signaling by Receptor Tyrosine Kinases,6308.5,0.0010740049292577,0.5,2.0,3.0,0.020249453344827202,True,2,2,4,5,2.321928094887362,0.00032330769919753987
3028,Signaling by NOTCH,Signal Transduction,6692.5,0.0023550198648762,0.5,3.0,4.0,0.0806925489768694,True,2,1,3,25,4.643856189774724,0.0004172714161538905
3029,Signaling by NOTCH4,Signaling by NOTCH,6302.5,0.0016179621100416,0.5,2.0,3.0,0.030505305300257298,True,3,1,4,18,4.169925001442312,0.00031295659213435764
3030,Signaling by NTRK1 (TRKA),Signaling by NTRKs,5244.5,0.0011519260280811999,0.5,1.0,2.0,0.014413851151139849,True,2,1,3,7,2.807354922057604,0.0003025528356727683
3031,Signaling by NTRKs,Signaling by Receptor Tyrosine Kinases,6148.5,0.0003443350721455,0.5,2.0,3.0,0.00649214616102185,True,1,1,2,7,2.807354922057604,9.043944659601407e-05
3032,Signaling by Nuclear Receptors,Signal Transduction,6848.5,0.0055861821322923,0.5,3.0,4.0,0.1914052964166411,True,3,1,4,23,4.523561956057013,0.00101133691931646
3033,Signaling by PDGF,Signaling by PDGF,6012.5,0.0118680763883224,0.5,1.0,2.0,0.14850318713309515,False,6,2,8,9,3.169925001442312,0.002846112672102596
3034,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,6512.5,0.009619813588639,0.5,2.0,3.0,0.18137343800061456,True,6,2,8,9,3.169925001442312,0.0023069512246171467
3035,Signaling by RAF1 mutants,Oncogenic MAPK signaling,5588.5,0.002123923478181,0.5,1.0,2.0,0.026576287126617748,True,12,1,13,17,4.087462841250339,0.00041748186560887113
3036,Signaling by RAS mutants,Oncogenic MAPK signaling,5578.5,0.0029379759952863,0.5,1.0,2.0,0.036762385473845555,True,13,1,14,18,4.169925001442312,0.0005682821306821008
3037,Signaling by ROBO receptors,Axon guidance,5426.5,0.0040173422211695,0.5,1.0,2.0,0.05026830837009475,True,14,1,15,19,4.247927513443585,0.0007655102344455594
3038,Signaling by Receptor Tyrosine Kinases,Signal Transduction,6776.5,0.0117625301020867,0.5,3.0,4.0,0.4030320722600038,True,9,1,10,44,5.459431618637297,0.001820985312105241
3039,Signaling by Retinoic Acid,Signaling by Nuclear Receptors,6102.5,0.005448486765126799,0.5,2.0,3.0,0.10272660352368734,True,1,1,2,7,2.807354922057604,0.0014310425155168566
3040,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",6212.5,0.007775720631336601,0.5,2.0,3.0,0.14660462709001,True,2,1,3,40,5.321928094887363,0.001229960308726849
3041,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,6790.5,0.0052792420938203004,0.5,3.0,4.0,0.18088828360636325,True,1,1,2,40,5.321928094887363,0.0008350683548725747
3042,Signaling by SCF-KIT,Signaling by Receptor Tyrosine Kinases,6182.5,0.0022882093171066,0.5,2.0,3.0,0.043142248743656755,True,2,2,4,5,2.321928094887362,0.0006888196408068812
3043,Signaling by SCF-KIT,Signaling by SCF-KIT,6010.5,0.0033742446363146,0.5,1.0,2.0,0.0422213395215863,False,2,2,4,5,2.321928094887362,0.0010157488482389959
3044,Signaling by TGF-beta Receptor Complex,Signaling by TGFB family members,6172.5,0.0022830984416017,0.5,2.0,3.0,0.04304588751451605,True,2,1,3,10,3.321928094887362,0.0005282592378856322
3045,Signaling by TGFB family members,Signal Transduction,6710.5,0.0030974025160677,0.5,3.0,4.0,0.10612959489495175,True,3,1,4,15,3.9068905956085187,0.0006312352916202692
3046,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),Signaling by Receptor Tyrosine Kinases,6078.5,0.0017904870839747999,0.5,2.0,3.0,0.033758117568905455,True,1,1,2,7,2.807354922057604,0.0004702706000960817
3047,Signaling by VEGF,Signaling by Receptor Tyrosine Kinases,6270.5,0.0034133137441717002,0.5,2.0,3.0,0.06435513984245135,True,2,1,3,11,3.4594316186372973,0.000765414527247473
3048,Signaling by WNT,Signal Transduction,6650.5,0.0016482931015589998,0.5,3.0,4.0,0.056477218646639654,True,3,1,4,25,4.643856189774724,0.00029205086843731075
3049,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,5582.5,5.950462244842824e-05,0.5,1.0,2.0,0.00074457104872005,True,13,1,14,18,4.169925001442312,1.1509765118802993e-05
3050,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,5580.5,0.00015510916651048206,0.5,1.0,2.0,0.0019408541727139999,True,13,1,14,18,4.169925001442312,3.0002208246194965e-05
3051,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,6370.5,0.0053553072138540995,0.5,2.0,3.0,0.10096978200007431,True,3,1,4,45,5.491853096329675,0.0008249273565481404
3052,Smooth Muscle Contraction,Muscle contraction,6720.5,0.0031731841204331,0.5,3.0,4.0,0.1087261805598991,True,10,2,12,12,3.584962500721156,0.000692085075926793
3053,Smooth Muscle Contraction,Smooth Muscle Contraction,6033.5,0.0052870757618178,0.5,1.5,2.5,0.08065351014878773,False,10,2,12,12,3.584962500721156,0.0011531339157051363
3054,Sphingolipid metabolism,Metabolism of lipids,6052.5,0.0007057012222263,0.5,2.0,3.0,0.01330539887255095,True,1,1,2,6,2.584962500721156,0.0001968503776774067
3055,Stimuli-sensing channels,Ion channel transport,6498.5,3.144533723243143e-05,0.5,2.0,3.0,0.0005928752018303,True,2,2,4,5,2.321928094887362,9.46598973073126e-06
3056,Stimuli-sensing channels,Stimuli-sensing channels,6044.5,1.7606031259522284e-05,0.5,1.0,2.0,0.00022030122399415,False,2,2,4,5,2.321928094887362,5.299943513713911e-06
3057,Striated Muscle Contraction,Muscle contraction,6686.5,0.001691705083904,0.5,3.0,4.0,0.0579646895439343,True,3,2,5,5,2.321928094887362,0.0005092539740723561
3058,Striated Muscle Contraction,Striated Muscle Contraction,6064.5,0.00255041410403415,0.5,1.5,2.5,0.03867809473100435,False,3,2,5,5,2.321928094887362,0.0007677511466787567
3059,Sulfur amino acid metabolism,Metabolism of amino acids and derivatives,6306.5,0.0004379721645208,0.5,2.0,3.0,0.00825759423462705,True,2,1,3,8,3.0,0.0001094930411302
3060,Surfactant metabolism,Metabolism of proteins,6810.5,0.001485733345191,0.5,3.0,4.0,0.05090726091590925,True,3,2,5,5,2.321928094887362,0.00044725030246067906
3061,Surfactant metabolism,Surfactant metabolism,6209.5,0.0034925280349224,0.5,1.5,2.5,0.053407026513658154,False,3,2,5,5,2.321928094887362,0.0010513556992090228
3062,Switching of origins to a post-replicative state,Synthesis of DNA,6532.5,0.0023555390286632,0.5,2.0,3.0,0.0444116934321723,True,2,1,3,15,3.9068905956085187,0.00048004718726994206
3063,Syndecan interactions,Non-integrin membrane-ECM interactions,6420.5,0.0081042156749196,0.5,2.0,3.0,0.15279812292772305,True,9,2,11,12,3.584962500721156,0.0017675642218763863
3064,Syndecan interactions,Syndecan interactions,5892.5,0.0089754796175063,0.5,1.0,2.0,0.11230862404621089,False,9,2,11,12,3.584962500721156,0.0019575906272067812
3065,Synthesis of DNA,DNA Replication,6750.5,0.0021399143339723,0.5,3.0,4.0,0.0733221595179409,True,1,1,2,15,3.9068905956085187,0.0004361039424615341
3066,Synthesis of IPs in the ER lumen,Inositol phosphate metabolism,6434.5,0.00022898644140203618,0.5,2.0,3.0,0.004317345419423,True,2,2,4,5,2.321928094887362,6.893178746236544e-05
3067,Synthesis of IPs in the ER lumen,Synthesis of IPs in the ER lumen,5812.5,0.0009327513069152,0.5,1.0,2.0,0.01167135577386205,False,2,2,4,5,2.321928094887362,0.00028078612187625544
3068,Synthesis of Ketone Bodies,Ketone body metabolism,5642.5,0.00031373371785039996,0.5,1.0,2.0,0.003925695747775749,True,1,1,2,6,2.584962500721156,8.751380740727102e-05
3069,"Synthesis, secretion, and deacylation of Ghrelin",Peptide hormone metabolism,6096.5,0.0001508254010532994,0.5,2.0,3.0,0.0028436851998011,True,3,2,5,6,2.584962500721156,4.207168164882035e-05
3070,"Synthesis, secretion, and deacylation of Ghrelin","Synthesis, secretion, and deacylation of Ghrelin",5890.5,0.00014217988247273197,0.5,1.0,2.0,0.0017790722778111001,False,3,2,5,6,2.584962500721156,3.966007522927531e-05
3071,TAGL2,Platelet degranulation ,3708.5,0.0009793129934708,0.5,0.0,1.0,0.0005363574038482501,True,0,1,1,6,2.584962500721156,0.00027317245111317066
3072,TALDO,Insulin effects increased synthesis of Xylulose-5-Phosphate,3716.5,0.0059174921757749,0.5,0.0,1.0,0.0032409360049869,True,0,5,5,19,4.247927513443585,0.0011275864921182876
3073,TALDO,Interleukin-12 family signaling,3710.5,0.0059174921757749,0.5,0.0,1.0,0.0032409360049869,True,0,5,5,19,4.247927513443585,0.0011275864921182876
3074,TALDO,KEAP1-NFE2L2 pathway,3714.5,0.0059174921757749,0.5,0.0,1.0,0.0032409360049869,True,0,5,5,19,4.247927513443585,0.0011275864921182876
3075,TALDO,Pentose phosphate pathway,3718.5,0.0059174921757749,0.5,0.0,1.0,0.0032409360049869,True,0,5,5,19,4.247927513443585,0.0011275864921182876
3076,TALDO,Pentose phosphate pathway disease,3712.5,0.0059174921757749,0.5,0.0,1.0,0.0032409360049869,True,0,5,5,19,4.247927513443585,0.0011275864921182876
3077,TBA1A,Activation of NMDA receptors and postsynaptic events,4772.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3078,TBA1A,Aggrephagy,4794.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3079,TBA1A,Anchoring of the basal body to the plasma membrane,4804.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3080,TBA1A,COPI-mediated anterograde transport,4778.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3081,TBA1A,Carboxyterminal post-translational modifications of tubulin,4808.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3082,TBA1A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,4784.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3083,TBA1A,G2/M Transition,4786.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3084,TBA1A,Gap junction trafficking,4774.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3085,TBA1A,Golgi-to-ER retrograde transport,4788.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3086,TBA1A,HCMV Early Events,4792.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3087,TBA1A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,4800.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3088,TBA1A,Intraflagellar transport,4806.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3089,TBA1A,Kinesins,4810.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3090,TBA1A,L1CAM interactions,4782.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3091,TBA1A,MHC class II antigen presentation,4796.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3092,TBA1A,Mitotic Metaphase and Anaphase,4780.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3093,TBA1A,Mitotic Prometaphase,4790.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3094,TBA1A,Post-chaperonin tubulin folding pathway,4802.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3095,TBA1A,RHO GTPase Effectors,4776.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3096,TBA1A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,4798.5,0.0010835259770962,0.5,0.0,1.0,0.0005934335436700499,True,0,20,20,58,5.857980995127572,0.00015799489352128838
3097,TBA1B,Activation of NMDA receptors and postsynaptic events,4302.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3098,TBA1B,Aggrephagy,4326.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3099,TBA1B,COPI-mediated anterograde transport,4310.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3100,TBA1B,Carboxyterminal post-translational modifications of tubulin,4338.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3101,TBA1B,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,4316.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3102,TBA1B,G2/M Transition,4318.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3103,TBA1B,Gap junction trafficking,4304.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3104,TBA1B,Golgi-to-ER retrograde transport,4320.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3105,TBA1B,HCMV Early Events,4324.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3106,TBA1B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,4332.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3107,TBA1B,Intraflagellar transport,4336.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3108,TBA1B,Kinesins,4340.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3109,TBA1B,L1CAM interactions,4314.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3110,TBA1B,MHC class II antigen presentation,4328.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3111,TBA1B,Mitotic Metaphase and Anaphase,4312.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3112,TBA1B,Mitotic Prometaphase,4322.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3113,TBA1B,Post-chaperonin tubulin folding pathway,4334.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3114,TBA1B,RHO GTPase Effectors,4306.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3115,TBA1B,RHO GTPase cycle,4308.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3116,TBA1B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,4330.5,0.008997416046925399,0.5,0.0,1.0,0.00492777155459595,True,0,20,20,58,5.857980995127572,0.0013119628143206934
3117,TBA4A,Activation of NMDA receptors and postsynaptic events,4342.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3118,TBA4A,Aggrephagy,4366.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3119,TBA4A,Anchoring of the basal body to the plasma membrane,4376.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3120,TBA4A,COPI-mediated anterograde transport,4348.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3121,TBA4A,Carboxyterminal post-translational modifications of tubulin,4380.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3122,TBA4A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,4354.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3123,TBA4A,G2/M Transition,4356.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3124,TBA4A,Gap junction trafficking,4344.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3125,TBA4A,Golgi-to-ER retrograde transport,4358.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3126,TBA4A,HCMV Early Events,4364.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3127,TBA4A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,4372.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3128,TBA4A,Intraflagellar transport,4378.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3129,TBA4A,Kinesins,4382.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3130,TBA4A,L1CAM interactions,4352.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3131,TBA4A,MHC class II antigen presentation,4368.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3132,TBA4A,Mitotic Metaphase and Anaphase,4350.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3133,TBA4A,Mitotic Prometaphase,4360.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3134,TBA4A,Platelet degranulation ,4362.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3135,TBA4A,Post-chaperonin tubulin folding pathway,4374.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3136,TBA4A,RHO GTPase Effectors,4346.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3137,TBA4A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,4370.5,0.0002618482004548,0.5,0.0,1.0,0.00014341096455845,True,0,21,21,61,5.930737337562887,3.778071332117109e-05
3138,TBB1,Activation of NMDA receptors and postsynaptic events,5058.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3139,TBB1,Aggrephagy,5080.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3140,TBB1,COPI-mediated anterograde transport,5064.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3141,TBB1,Carboxyterminal post-translational modifications of tubulin,5092.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3142,TBB1,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,5070.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3143,TBB1,G2/M Transition,5072.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3144,TBB1,Gap junction trafficking,5060.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3145,TBB1,Golgi-to-ER retrograde transport,5074.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3146,TBB1,HCMV Early Events,5078.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3147,TBB1,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,5086.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3148,TBB1,Intraflagellar transport,5090.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3149,TBB1,Kinesins,5094.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3150,TBB1,L1CAM interactions,5068.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3151,TBB1,MHC class II antigen presentation,5082.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3152,TBB1,Mitotic Metaphase and Anaphase,5066.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3153,TBB1,Mitotic Prometaphase,5076.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3154,TBB1,Post-chaperonin tubulin folding pathway,5088.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3155,TBB1,RHO GTPase Effectors,5062.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3156,TBB1,Translocation of SLC2A4 (GLUT4) to the plasma membrane,5084.5,0.0272304290470662,0.5,0.0,1.0,0.014913763349137351,True,0,19,19,57,5.832890014164741,0.003985199379854919
3157,TBB2A,Activation of NMDA receptors and postsynaptic events,4680.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3158,TBB2A,Aggrephagy,4702.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3159,TBB2A,COPI-mediated anterograde transport,4686.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3160,TBB2A,Carboxyterminal post-translational modifications of tubulin,4714.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3161,TBB2A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,4692.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3162,TBB2A,G2/M Transition,4694.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3163,TBB2A,Gap junction trafficking,4682.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3164,TBB2A,Golgi-to-ER retrograde transport,4696.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3165,TBB2A,HCMV Early Events,4700.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3166,TBB2A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,4708.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3167,TBB2A,Intraflagellar transport,4712.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3168,TBB2A,Kinesins,4716.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3169,TBB2A,L1CAM interactions,4690.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3170,TBB2A,MHC class II antigen presentation,4704.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3171,TBB2A,Mitotic Metaphase and Anaphase,4688.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3172,TBB2A,Mitotic Prometaphase,4698.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3173,TBB2A,Post-chaperonin tubulin folding pathway,4710.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3174,TBB2A,RHO GTPase Effectors,4684.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3175,TBB2A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,4706.5,0.0063312165631184,0.5,0.0,1.0,0.0034675276460492998,True,0,19,19,57,5.832890014164741,0.0009265796097981439
3176,TBB5,Anchoring of the basal body to the plasma membrane,2140.5,0.0005219689788312001,0.5,0.0,1.0,0.0002858758417807,True,0,5,5,18,4.169925001442312,0.00010096258237509838
3177,TBB5,G2/M Transition,2132.5,0.0005219689788312001,0.5,0.0,1.0,0.0002858758417807,True,0,5,5,18,4.169925001442312,0.00010096258237509838
3178,TBB5,Mitotic Prometaphase,2134.5,0.0005219689788312001,0.5,0.0,1.0,0.0002858758417807,True,0,5,5,18,4.169925001442312,0.00010096258237509838
3179,TBB5,Neutrophil degranulation,2138.5,0.0005219689788312001,0.5,0.0,1.0,0.0002858758417807,True,0,5,5,18,4.169925001442312,0.00010096258237509838
3180,TBB5,Potential therapeutics for SARS,2136.5,0.0005219689788312001,0.5,0.0,1.0,0.0002858758417807,True,0,5,5,18,4.169925001442312,0.00010096258237509838
3181,TCF dependent signaling in response to WNT,Signaling by WNT,6384.5,0.0013312514078795,0.5,2.0,3.0,0.025099617832038602,True,4,1,5,21,4.392317422778761,0.0002468792735115882
3182,TCR signaling,Adaptive Immune System,6468.5,4.124791112415332e-05,0.5,2.0,3.0,0.0007776944305622,True,1,1,2,14,3.807354922057604,8.580167637487172e-06
3183,TENA,ECM proteoglycans,2984.5,0.010396146899142901,0.5,0.0,1.0,0.0056938388421533,True,0,5,5,11,3.4594316186372973,0.0023312717377914926
3184,TENA,Integrin cell surface interactions,2982.5,0.010396146899142901,0.5,0.0,1.0,0.0056938388421533,True,0,5,5,11,3.4594316186372973,0.0023312717377914926
3185,TENA,Post-translational protein phosphorylation,2990.5,0.010396146899142901,0.5,0.0,1.0,0.0056938388421533,True,0,5,5,11,3.4594316186372973,0.0023312717377914926
3186,TENA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2988.5,0.010396146899142901,0.5,0.0,1.0,0.0056938388421533,True,0,5,5,11,3.4594316186372973,0.0023312717377914926
3187,TENA,Syndecan interactions,2986.5,0.010396146899142901,0.5,0.0,1.0,0.0056938388421533,True,0,5,5,11,3.4594316186372973,0.0023312717377914926
3188,TENX,ECM proteoglycans,2898.5,0.0052146993108864,0.5,0.0,1.0,0.0028560251961159498,True,0,1,1,4,2.0,0.0017382331036287998
3189,TETN,Platelet degranulation ,1872.5,0.0020201180085928,0.5,0.0,1.0,0.0011063932142020999,True,0,1,1,6,2.584962500721156,0.0005634976678797701
3190,TFR1,Cargo recognition for clathrin-mediated endocytosis,1400.5,0.0084499574977828,0.5,0.0,1.0,0.004627935395890501,True,0,4,4,15,3.9068905956085187,0.0017220594861734216
3191,TFR1,Golgi Associated Vesicle Biogenesis,1398.5,0.0084499574977828,0.5,0.0,1.0,0.004627935395890501,True,0,4,4,15,3.9068905956085187,0.0017220594861734216
3192,TFR1,RHO GTPase cycle,1396.5,0.0084499574977828,0.5,0.0,1.0,0.004627935395890501,True,0,4,4,15,3.9068905956085187,0.0017220594861734216
3193,TFR1,Transferrin endocytosis and recycling,1402.5,0.0084499574977828,0.5,0.0,1.0,0.004627935395890501,True,0,4,4,15,3.9068905956085187,0.0017220594861734216
3194,TGF-beta receptor signaling activates SMADs,Signaling by TGF-beta Receptor Complex,5280.5,0.00020309098761167396,0.5,1.0,2.0,0.0025412424011719502,True,2,1,3,7,2.807354922057604,5.33417534664506e-05
3195,THIK,Neutrophil degranulation,2440.5,0.0018706701052975,0.5,0.0,1.0,0.0010245424780671,True,0,4,4,13,3.700439718141092,0.00039797768240229736
3196,THIK,Peroxisomal lipid metabolism,2438.5,0.0018706701052975,0.5,0.0,1.0,0.0010245424780671,True,0,4,4,13,3.700439718141092,0.00039797768240229736
3197,THIK,TYSND1 cleaves peroxisomal proteins,2442.5,0.0018706701052975,0.5,0.0,1.0,0.0010245424780671,True,0,4,4,13,3.700439718141092,0.00039797768240229736
3198,THIK,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,2436.5,0.0018706701052975,0.5,0.0,1.0,0.0010245424780671,True,0,4,4,13,3.700439718141092,0.00039797768240229736
3199,THIL,Branched-chain amino acid catabolism,2980.5,0.0016091010809685,0.5,0.0,1.0,0.0008812844147599,True,0,3,3,9,3.169925001442312,0.0003858824991845026
3200,THIL,Synthesis of Ketone Bodies,2978.5,0.0016091010809685,0.5,0.0,1.0,0.0008812844147599,True,0,3,3,9,3.169925001442312,0.0003858824991845026
3201,THIL,Utilization of Ketone Bodies,2976.5,0.0016091010809685,0.5,0.0,1.0,0.0008812844147599,True,0,3,3,9,3.169925001442312,0.0003858824991845026
3202,THIM,Mitochondrial Fatty Acid Beta-Oxidation,3748.5,0.0003356820443005,0.5,0.0,1.0,0.000183848831783,True,0,1,1,6,2.584962500721156,9.363613823937455e-05
3203,THRB,Class A/1 (Rhodopsin-like receptors),156.5,0.0402018377843411,0.5,0.0,1.0,0.0220180406955677,True,0,10,10,28,4.807354922057604,0.006922572896594581
3204,THRB,Common Pathway of Fibrin Clot Formation,166.5,0.0402018377843411,0.5,0.0,1.0,0.0220180406955677,True,0,10,10,28,4.807354922057604,0.006922572896594581
3205,THRB,Defective factor VIII causes hemophilia A,162.5,0.0402018377843411,0.5,0.0,1.0,0.0220180406955677,True,0,10,10,28,4.807354922057604,0.006922572896594581
3206,THRB,Defective factor XII causes hereditary angioedema,160.5,0.0402018377843411,0.5,0.0,1.0,0.0220180406955677,True,0,10,10,28,4.807354922057604,0.006922572896594581
3207,THRB,G alpha (q) signalling events,158.5,0.0402018377843411,0.5,0.0,1.0,0.0220180406955677,True,0,10,10,28,4.807354922057604,0.006922572896594581
3208,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",152.5,0.0402018377843411,0.5,0.0,1.0,0.0220180406955677,True,0,10,10,28,4.807354922057604,0.006922572896594581
3209,THRB,Intrinsic Pathway of Fibrin Clot Formation,164.5,0.0402018377843411,0.5,0.0,1.0,0.0220180406955677,True,0,10,10,28,4.807354922057604,0.006922572896594581
3210,THRB,Regulation of Complement cascade,154.5,0.0402018377843411,0.5,0.0,1.0,0.0220180406955677,True,0,10,10,28,4.807354922057604,0.006922572896594581
3211,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),168.5,0.0402018377843411,0.5,0.0,1.0,0.0220180406955677,True,0,10,10,28,4.807354922057604,0.006922572896594581
3212,THRB,Thrombin signalling through proteinase activated receptors (PARs),170.5,0.0402018377843411,0.5,0.0,1.0,0.0220180406955677,True,0,10,10,28,4.807354922057604,0.006922572896594581
3213,TIMP1,Activation of Matrix Metalloproteinases,328.5,0.0055074329472568,0.5,0.0,1.0,0.00301635172529455,True,0,6,6,18,4.169925001442312,0.0010652829481511493
3214,TIMP1,Interleukin-10 signaling,322.5,0.0055074329472568,0.5,0.0,1.0,0.00301635172529455,True,0,6,6,18,4.169925001442312,0.0010652829481511493
3215,TIMP1,Interleukin-4 and Interleukin-13 signaling,324.5,0.0055074329472568,0.5,0.0,1.0,0.00301635172529455,True,0,6,6,18,4.169925001442312,0.0010652829481511493
3216,TIMP1,Platelet degranulation ,326.5,0.0055074329472568,0.5,0.0,1.0,0.00301635172529455,True,0,6,6,18,4.169925001442312,0.0010652829481511493
3217,TIMP1,Post-translational protein phosphorylation,332.5,0.0055074329472568,0.5,0.0,1.0,0.00301635172529455,True,0,6,6,18,4.169925001442312,0.0010652829481511493
3218,TIMP1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),330.5,0.0055074329472568,0.5,0.0,1.0,0.00301635172529455,True,0,6,6,18,4.169925001442312,0.0010652829481511493
3219,TIMP2,Activation of Matrix Metalloproteinases,2774.5,0.0025146259141194003,0.5,0.0,1.0,0.0013772289716759,True,0,2,2,8,3.0,0.0006286564785298501
3220,TIMP2,Neutrophil degranulation,2776.5,0.0025146259141194003,0.5,0.0,1.0,0.0013772289716759,True,0,2,2,8,3.0,0.0006286564785298501
3221,TKFC,Fructose catabolism,4760.5,0.0034830000690008,0.5,0.0,1.0,0.001907595311272,True,0,2,2,10,3.321928094887362,0.0008058903324007231
3222,TKFC,SARS-CoV-2 Infection,4762.5,0.0034830000690008,0.5,0.0,1.0,0.001907595311272,True,0,2,2,10,3.321928094887362,0.0008058903324007231
3223,TKT,Insulin effects increased synthesis of Xylulose-5-Phosphate,3522.5,0.0026228969306111,0.5,0.0,1.0,0.00143652764503635,True,0,3,3,11,3.4594316186372973,0.0005881684382487737
3224,TKT,KEAP1-NFE2L2 pathway,3520.5,0.0026228969306111,0.5,0.0,1.0,0.00143652764503635,True,0,3,3,11,3.4594316186372973,0.0005881684382487737
3225,TKT,Pentose phosphate pathway,3524.5,0.0026228969306111,0.5,0.0,1.0,0.00143652764503635,True,0,3,3,11,3.4594316186372973,0.0005881684382487737
3226,TLN1,GRB2:SOS provides linkage to MAPK signaling for Integrins ,5144.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3227,TLN1,IRE1alpha activates chaperones,5126.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3228,TLN1,Paradoxical activation of RAF signaling by kinase inactive BRAF,5138.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3229,TLN1,Platelet degranulation ,5142.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3230,TLN1,RAF/MAP kinase cascade,5128.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3231,TLN1,Semaphorin interactions,5124.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3232,TLN1,Signaling by BRAF and RAF1 fusions,5136.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3233,TLN1,Signaling by RAF1 mutants,5140.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3234,TLN1,Signaling by RAS mutants,5130.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3235,TLN1,Signaling by high-kinase activity BRAF mutants,5134.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3236,TLN1,Signaling by moderate kinase activity BRAF mutants,5132.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3237,TLN1,Smooth Muscle Contraction,5148.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3238,TLN1,p130Cas linkage to MAPK signaling for integrins,5146.5,0.0190684453981365,0.5,0.0,1.0,0.0104435476066946,True,0,13,13,32,5.0,0.00317807423302275
3239,TNFR2 non-canonical NF-kB pathway,Cytokine Signaling in Immune system,6570.5,0.0009942044593311,0.5,2.0,3.0,0.0187448830689804,True,1,1,2,14,3.807354922057604,0.00020680904061595037
3240,TPIS,Gluconeogenesis,3900.5,0.0003783422324872,0.5,0.0,1.0,0.0002072132800605,True,0,2,2,7,2.807354922057604,9.937141144769686e-05
3241,TPIS,Glycolysis,3898.5,0.0003783422324872,0.5,0.0,1.0,0.0002072132800605,True,0,2,2,7,2.807354922057604,9.937141144769686e-05
3242,TPM3,RHO GTPase cycle,2046.5,0.0069156803969567,0.5,0.0,1.0,0.00378763113354595,True,0,4,4,13,3.700439718141092,0.0014712837120888936
3243,TPM3,Signaling by ALK fusions and activated point mutants,2048.5,0.0069156803969567,0.5,0.0,1.0,0.00378763113354595,True,0,4,4,13,3.700439718141092,0.0014712837120888936
3244,TPM3,Smooth Muscle Contraction,2052.5,0.0069156803969567,0.5,0.0,1.0,0.00378763113354595,True,0,4,4,13,3.700439718141092,0.0014712837120888936
3245,TPM3,Striated Muscle Contraction,2050.5,0.0069156803969567,0.5,0.0,1.0,0.00378763113354595,True,0,4,4,13,3.700439718141092,0.0014712837120888936
3246,TPM4,RHO GTPase cycle,4294.5,0.0048639764846774,0.5,0.0,1.0,0.0026639387173396003,True,0,4,4,13,3.700439718141092,0.001034791801691477
3247,TPM4,Signaling by ALK fusions and activated point mutants,4296.5,0.0048639764846774,0.5,0.0,1.0,0.0026639387173396003,True,0,4,4,13,3.700439718141092,0.001034791801691477
3248,TPM4,Smooth Muscle Contraction,4300.5,0.0048639764846774,0.5,0.0,1.0,0.0026639387173396003,True,0,4,4,13,3.700439718141092,0.001034791801691477
3249,TPM4,Striated Muscle Contraction,4298.5,0.0048639764846774,0.5,0.0,1.0,0.0026639387173396003,True,0,4,4,13,3.700439718141092,0.001034791801691477
3250,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,5276.5,0.0007836483332703,0.5,1.0,2.0,0.009805656053637899,True,2,1,3,7,2.807354922057604,0.00020582487036611597
3251,TRAP1,Respiratory electron transport,4664.5,0.0004614607233047451,0.5,0.0,1.0,0.00025273623160303275,True,0,1,1,6,2.584962500721156,0.00012872121346092658
3252,TRFE,Cargo recognition for clathrin-mediated endocytosis,1406.5,0.013889217064559301,0.5,0.0,1.0,0.00760694941852025,True,0,5,5,17,4.087462841250339,0.0027300871766457496
3253,TRFE,Platelet degranulation ,1404.5,0.013889217064559301,0.5,0.0,1.0,0.00760694941852025,True,0,5,5,17,4.087462841250339,0.0027300871766457496
3254,TRFE,Post-translational protein phosphorylation,1410.5,0.013889217064559301,0.5,0.0,1.0,0.00760694941852025,True,0,5,5,17,4.087462841250339,0.0027300871766457496
3255,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1408.5,0.013889217064559301,0.5,0.0,1.0,0.00760694941852025,True,0,5,5,17,4.087462841250339,0.0027300871766457496
3256,TRFE,Transferrin endocytosis and recycling,1412.5,0.013889217064559301,0.5,0.0,1.0,0.00760694941852025,True,0,5,5,17,4.087462841250339,0.0027300871766457496
3257,TRFL,Amyloid fiber formation,1420.5,0.0205961056396383,0.5,0.0,1.0,0.01128022789844705,True,0,4,4,13,3.700439718141092,0.004381740193401215
3258,TRFL,Latent infection - Other responses of Mtb to phagocytosis,1414.5,0.0205961056396383,0.5,0.0,1.0,0.01128022789844705,True,0,4,4,13,3.700439718141092,0.004381740193401215
3259,TRFL,Metal sequestration by antimicrobial proteins,1416.5,0.0205961056396383,0.5,0.0,1.0,0.01128022789844705,True,0,4,4,13,3.700439718141092,0.004381740193401215
3260,TRFL,Neutrophil degranulation,1418.5,0.0205961056396383,0.5,0.0,1.0,0.01128022789844705,True,0,4,4,13,3.700439718141092,0.004381740193401215
3261,TRY1,Activation of Matrix Metalloproteinases,2146.5,0.00017772261969538559,0.5,0.0,1.0,9.73364425270111e-05,True,0,2,2,9,3.169925001442312,4.2620099794100394e-05
3262,TRY1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",2144.5,0.00017772261969538559,0.5,0.0,1.0,9.73364425270111e-05,True,0,2,2,9,3.169925001442312,4.2620099794100394e-05
3263,TRY2,Activation of Matrix Metalloproteinases,2152.5,0.0045197086954172,0.5,0.0,1.0,0.0024753875810764,True,0,4,4,11,3.4594316186372973,0.001013516762209782
3264,TRY2,Collagen degradation,2150.5,0.0045197086954172,0.5,0.0,1.0,0.0024753875810764,True,0,4,4,11,3.4594316186372973,0.001013516762209782
3265,TRY2,Defensins,2148.5,0.0045197086954172,0.5,0.0,1.0,0.0024753875810764,True,0,4,4,11,3.4594316186372973,0.001013516762209782
3266,TRY2,Neutrophil degranulation,2154.5,0.0045197086954172,0.5,0.0,1.0,0.0024753875810764,True,0,4,4,11,3.4594316186372973,0.001013516762209782
3267,TRY3,"Cobalamin (Cbl, vitamin B12) transport and metabolism",3634.5,0.0005371657810376,0.5,0.0,1.0,0.00029419893912815,True,0,3,3,11,3.4594316186372973,0.00012045610897869219
3268,TRY3,Defensins,3632.5,0.0005371657810376,0.5,0.0,1.0,0.00029419893912815,True,0,3,3,11,3.4594316186372973,0.00012045610897869219
3269,TRY3,Neutrophil degranulation,3636.5,0.0005371657810376,0.5,0.0,1.0,0.00029419893912815,True,0,3,3,11,3.4594316186372973,0.00012045610897869219
3270,TSP1,Diseases associated with O-glycosylation of proteins,2264.5,0.0070382776860745,0.5,0.0,1.0,0.0038547761261564497,True,0,7,7,25,4.643856189774724,0.001247068927593535
3271,TSP1,Integrin cell surface interactions,2270.5,0.0070382776860745,0.5,0.0,1.0,0.0038547761261564497,True,0,7,7,25,4.643856189774724,0.001247068927593535
3272,TSP1,O-glycosylation of TSR domain-containing proteins,2266.5,0.0070382776860745,0.5,0.0,1.0,0.0038547761261564497,True,0,7,7,25,4.643856189774724,0.001247068927593535
3273,TSP1,Platelet degranulation ,2268.5,0.0070382776860745,0.5,0.0,1.0,0.0038547761261564497,True,0,7,7,25,4.643856189774724,0.001247068927593535
3274,TSP1,Signaling by PDGF,2274.5,0.0070382776860745,0.5,0.0,1.0,0.0038547761261564497,True,0,7,7,25,4.643856189774724,0.001247068927593535
3275,TSP1,Syndecan interactions,2272.5,0.0070382776860745,0.5,0.0,1.0,0.0038547761261564497,True,0,7,7,25,4.643856189774724,0.001247068927593535
3276,TSP1,Transcriptional regulation by RUNX1,2262.5,0.0070382776860745,0.5,0.0,1.0,0.0038547761261564497,True,0,7,7,25,4.643856189774724,0.001247068927593535
3277,TTHY,Amyloid fiber formation,1354.5,0.0037170143660004004,0.5,0.0,1.0,0.0020357619971414,True,0,5,5,18,4.169925001442312,0.0007189687210091874
3278,TTHY,Neutrophil degranulation,1348.5,0.0037170143660004004,0.5,0.0,1.0,0.0020357619971414,True,0,5,5,18,4.169925001442312,0.0007189687210091874
3279,TTHY,Retinoid cycle disease events,1346.5,0.0037170143660004004,0.5,0.0,1.0,0.0020357619971414,True,0,5,5,18,4.169925001442312,0.0007189687210091874
3280,TTHY,Retinoid metabolism and transport,1352.5,0.0037170143660004004,0.5,0.0,1.0,0.0020357619971414,True,0,5,5,18,4.169925001442312,0.0007189687210091874
3281,TTHY,The canonical retinoid cycle in rods (twilight vision),1350.5,0.0037170143660004004,0.5,0.0,1.0,0.0020357619971414,True,0,5,5,18,4.169925001442312,0.0007189687210091874
3282,TXND5,Golgi Associated Vesicle Biogenesis,4836.5,0.0003879081483167,0.5,0.0,1.0,0.00021245241179265002,True,0,3,3,10,3.321928094887362,8.975349422762891e-05
3283,TXND5,Lysosome Vesicle Biogenesis,4834.5,0.0003879081483167,0.5,0.0,1.0,0.00021245241179265002,True,0,3,3,10,3.321928094887362,8.975349422762891e-05
3284,TXND5,Neutrophil degranulation,4838.5,0.0003879081483167,0.5,0.0,1.0,0.00021245241179265002,True,0,3,3,10,3.321928094887362,8.975349422762891e-05
3285,TYPH,Pyrimidine catabolism,2884.5,0.0015263268632487001,0.5,0.0,1.0,0.0008359500172611001,True,0,2,2,8,3.0,0.00038158171581217503
3286,TYPH,Pyrimidine salvage,2886.5,0.0015263268632487001,0.5,0.0,1.0,0.0008359500172611001,True,0,2,2,8,3.0,0.00038158171581217503
3287,TYSND1 cleaves peroxisomal proteins,Peroxisomal protein import,6410.5,0.0005979530688832,0.5,2.0,3.0,0.01127389869534095,True,2,2,4,5,2.321928094887362,0.00018000180973317393
3288,TYSND1 cleaves peroxisomal proteins,TYSND1 cleaves peroxisomal proteins,6018.5,0.0005075434752041697,0.5,1.0,2.0,0.0063508037200188504,False,2,2,4,5,2.321928094887362,0.00015278581013999316
3289,Telomere Maintenance,Chromosome Maintenance,6170.5,0.0007252171942916,0.5,2.0,3.0,0.01367335599737465,True,2,1,3,9,3.169925001442312,0.0001739161241606884
3290,Terminal pathway of complement,Complement cascade,5248.5,0.00015696670054547393,0.5,1.0,2.0,0.0019640971748129503,True,8,1,9,13,3.700439718141092,3.339404608034211e-05
3291,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",Metabolism of cofactors,5690.5,6.237188484372355e-05,0.5,1.0,2.0,0.00078044860714785,True,1,1,2,6,2.584962500721156,1.739819728412131e-05
3292,The canonical retinoid cycle in rods (twilight vision),The canonical retinoid cycle in rods (twilight vision),5878.5,0.000987916460065,0.5,1.0,2.0,0.01236162779380585,False,3,2,5,6,2.584962500721156,0.00027557232742776787
3293,The canonical retinoid cycle in rods (twilight vision),Visual phototransduction,6314.5,0.0009111341234914,0.5,2.0,3.0,0.01717866224065855,True,3,2,5,6,2.584962500721156,0.0002541544362899514
3294,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,6728.5,0.00033949209801339996,0.5,3.0,4.0,0.01163237862864305,True,2,1,3,14,3.807354922057604,7.061931218261152e-05
3295,Threonine catabolism,Metabolism of amino acids and derivatives,6296.5,2.650323556292906e-05,0.5,2.0,3.0,0.00049969606041695,True,2,2,4,5,2.321928094887362,7.978268886590008e-06
3296,Threonine catabolism,Threonine catabolism,5986.5,2.013652644609003e-05,0.5,1.0,2.0,0.0002519648725867884,False,2,2,4,5,2.321928094887362,6.061698468754125e-06
3297,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",6082.5,0.0022635884871088,0.5,2.0,3.0,0.042678043845924205,True,2,2,4,5,2.321928094887362,0.0006814080324593999
3298,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),6008.5,0.0033822332651775996,0.5,1.0,2.0,0.04232129985282815,False,2,2,4,5,2.321928094887362,0.0010181536651509859
3299,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,5256.5,0.00048453272210490005,0.5,1.0,2.0,0.0060628741464508005,True,2,1,3,7,2.807354922057604,0.0001272622941711577
3300,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,5272.5,0.0012256618211643,0.5,1.0,2.0,0.01533649437657465,True,9,1,10,14,3.807354922057604,0.0002549555506169498
3301,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,5258.5,0.0002964585445337,0.5,1.0,2.0,0.0037095344919948,True,2,1,3,7,2.807354922057604,7.786469887957945e-05
3302,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,5242.5,0.0019565315056373003,0.5,1.0,2.0,0.02448174032645655,True,10,1,11,15,3.9068905956085187,0.0003987314303254126
3303,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,5260.5,0.0014693066537443,0.5,1.0,2.0,0.0183851800256018,True,2,1,3,7,2.807354922057604,0.0003859127094329951
3304,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,5262.5,0.0020503084684572,0.5,1.0,2.0,0.025655155242468503,True,3,1,4,8,3.0,0.0005125771171143
3305,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,5254.5,0.0004695220882066,0.5,1.0,2.0,0.0058750486807348,True,3,1,4,8,3.0,0.00011738052205165
3306,Toll-like Receptor Cascades,Innate Immune System,6246.5,0.0043360976165314,0.5,2.0,3.0,0.08175344823161575,True,9,1,10,26,4.700439718141092,0.0007606602000775825
3307,Trafficking and processing of endosomal TLR,Toll-like Receptor Cascades,5270.5,0.00048034249262790004,0.5,1.0,2.0,0.00601044252975145,True,2,1,3,7,2.807354922057604,0.0001261617323473245
3308,Transcriptional Regulation by TP53,Generic Transcription Pathway,5358.5,0.0010790104833208,0.5,1.0,2.0,0.0135014715510966,True,9,1,10,14,3.807354922057604,0.00022444993157671227
3309,Transcriptional Regulation by VENTX,Generic Transcription Pathway,5360.5,0.0020850134396223,0.5,1.0,2.0,0.0260894125440509,True,1,1,2,6,2.584962500721156,0.0005815997905704386
3310,Transcriptional activation of mitochondrial biogenesis,Mitochondrial biogenesis,6204.5,9.039733077507353e-05,0.5,2.0,3.0,0.0017043651124504498,True,3,2,5,6,2.584962500721156,2.5215697725398543e-05
3311,Transcriptional activation of mitochondrial biogenesis,Transcriptional activation of mitochondrial biogenesis,5822.5,0.00013218375832292425,0.5,1.0,2.0,0.00165399250526385,False,3,2,5,6,2.584962500721156,3.687172691383354e-05
3312,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Generic Transcription Pathway,5282.5,0.0081443294801814,0.5,1.0,2.0,0.10190858613439815,True,2,2,4,10,3.321928094887362,0.001884420402508723
3313,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Signaling by TGF-beta Receptor Complex,5284.5,0.0081443294801814,0.5,1.0,2.0,0.10190858613439815,True,2,2,4,10,3.321928094887362,0.001884420402508723
3314,Transcriptional regulation by RUNX1,Generic Transcription Pathway,5368.5,0.003332408701099,0.5,1.0,2.0,0.041697853700217447,True,16,1,17,21,4.392317422778761,0.0006179919392396875
3315,Transcriptional regulation by RUNX2,Generic Transcription Pathway,5366.5,0.0039528302568582994,0.5,1.0,2.0,0.04946108131872025,True,10,1,11,15,3.9068905956085187,0.0008055672283372148
3316,Transcriptional regulation by RUNX3,Generic Transcription Pathway,5364.5,0.0028573699639705998,0.5,1.0,2.0,0.0357537761456892,True,11,1,12,16,4.0,0.00057147399279412
3317,Transcriptional regulation by small RNAs,Gene Silencing by RNA,6506.5,0.0013915746111888001,0.5,2.0,3.0,0.02623696074150205,True,4,2,6,7,2.807354922057604,0.00036549642459830176
3318,Transcriptional regulation by small RNAs,Transcriptional regulation by small RNAs,5854.5,0.0011624300197251,0.5,1.0,2.0,0.0145452857817991,False,4,2,6,7,2.807354922057604,0.00030531170419407323
3319,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,5362.5,0.001466825474254,0.5,1.0,2.0,0.0183541334557868,True,2,1,3,7,2.807354922057604,0.000385261028793524
3320,Transcriptional regulation of granulopoiesis,Developmental Biology,6730.5,0.0006695501286256,0.5,3.0,4.0,0.02294150777765825,True,4,2,6,6,2.584962500721156,0.00018676628513991772
3321,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,6090.5,0.00154612664685635,0.5,1.5,2.5,0.02439958501695135,False,4,2,6,6,2.584962500721156,0.0004312811212238145
3322,Transcriptional regulation of testis differentiation,Developmental Biology,6834.5,0.0021859472009755,0.5,3.0,4.0,0.07489943257223511,True,2,2,4,4,2.0,0.0007286490669918332
3323,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,5936.5,0.002916868671573,0.5,1.5,2.5,0.04476753260555548,False,2,2,4,4,2.0,0.0009722895571909999
3324,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,6798.5,6.462098791844785e-07,0.5,3.0,4.0,2.2141776000760398e-05,True,3,2,5,5,2.321928094887362,1.945285571289254e-07
3325,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,6066.5,8.563928692549053e-05,0.5,1.5,2.5,0.0010871098971176945,False,3,2,5,5,2.321928094887362,2.5779994171846855e-05
3326,Transferrin endocytosis and recycling,Iron uptake and transport,6562.5,0.0017643526424518,0.5,2.0,3.0,0.033265374807770004,True,3,2,5,6,2.584962500721156,0.0004921537232528598
3327,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,6020.5,0.0020880856702233004,0.5,1.0,2.0,0.02612785483418555,False,3,2,5,6,2.584962500721156,0.0005824567676240011
3328,Translation,Metabolism of proteins,6666.5,3.7302895703889712e-06,0.5,3.0,4.0,0.0001278148767854,True,1,1,2,5,2.321928094887362,1.1229290531995863e-06
3329,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Membrane Trafficking,6546.5,0.0056936435316232,0.5,2.0,3.0,0.10734882672779356,True,15,2,17,18,4.169925001442312,0.0011013009918006123
3330,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Translocation of SLC2A4 (GLUT4) to the plasma membrane,5844.5,0.0068590557010294005,0.5,1.0,2.0,0.0858261776380658,False,15,2,17,18,4.169925001442312,0.0013267224764606552
3331,Transmission across Chemical Synapses,Neuronal System,6780.5,0.0035960494268724,0.5,3.0,4.0,0.12321526405315684,True,3,1,4,16,4.0,0.00071920988537448
3332,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,6526.5,0.0012262358320233,0.5,2.0,3.0,0.02311963808906815,True,1,1,2,6,2.584962500721156,0.0003420498350475434
3333,Transport of fatty acids,"Transport of vitamins, nucleosides, and related molecules",5468.5,0.0009828330815996999,0.5,1.0,2.0,0.01229802035829765,True,1,1,2,6,2.584962500721156,0.00027415435486479757
3334,Transport of inorganic cations/anions and amino acids/oligopeptides,SLC-mediated transmembrane transport,6080.5,0.0004557993012375,0.5,2.0,3.0,0.00859370979926,True,2,1,3,8,3.0,0.000113949825309375
3335,Transport of small molecules,root,6856.5,0.0078600746392804,0.5,4.0,5.0,0.6550499512418506,True,8,1,9,64,6.0,0.0011228678056114856
3336,"Transport of vitamins, nucleosides, and related molecules",SLC-mediated transmembrane transport,6210.5,0.00019897020210120375,0.5,2.0,3.0,0.0037514146487616002,True,1,1,2,6,2.584962500721156,5.55013342709104e-05
3337,Triglyceride catabolism,Triglyceride metabolism,5694.5,0.0009865479656157,0.5,1.0,2.0,0.012344504059458649,True,1,1,2,6,2.584962500721156,0.00027519059555497293
3338,Triglyceride metabolism,Metabolism of lipids,6098.5,0.0004174743543107,0.5,2.0,3.0,0.0078711253831207,True,1,1,2,6,2.584962500721156,0.00011645152612523012
3339,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",Regulation of mRNA stability by proteins that bind AU-rich elements,6218.5,0.0005238881217545,0.5,2.0,3.0,0.00987746684431825,True,2,2,4,5,2.321928094887362,0.0001577060390201684
3340,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA","Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",5936.5,0.0008581726935775,0.5,1.0,2.0,0.010738166484356451,False,2,2,4,5,2.321928094887362,0.0002583357222265819
3341,Tryptophan catabolism,Metabolism of amino acids and derivatives,6538.5,0.00016050777682211897,0.5,2.0,3.0,0.00302623819472505,True,2,2,4,5,2.321928094887362,4.831765536079774e-05
3342,Tryptophan catabolism,Tryptophan catabolism,5984.5,0.0004412898921459,0.5,1.0,2.0,0.00552178409449545,False,2,2,4,5,2.321928094887362,0.00013284149431923902
3343,Type I hemidesmosome assembly,Cell junction organization,6222.5,0.0042484831301315,0.5,2.0,3.0,0.08010155129301125,True,3,2,5,6,2.584962500721156,0.0011850843988680131
3344,Type I hemidesmosome assembly,Type I hemidesmosome assembly,5930.5,0.0053858926778583005,0.5,1.0,2.0,0.06739274352882856,False,3,2,5,6,2.584962500721156,0.0015023567685226462
3345,Tyrosine catabolism,Phenylalanine and tyrosine metabolism,5664.5,0.0008058752757490999,0.5,1.0,2.0,0.01008377794048065,True,2,1,3,7,2.807354922057604,0.00021166276647347122
3346,UCH proteinases,Deubiquitination,5566.5,0.0005948795267937,0.5,1.0,2.0,0.0074436246278317,True,11,1,12,16,4.0,0.00011897590535874
3347,UGPA,Glucuronidation,4756.5,0.0091023339835576,0.5,0.0,1.0,0.00498523378830915,True,0,2,2,9,3.169925001442312,0.002182853164123874
3348,UGPA,Glycogen synthesis,4758.5,0.0091023339835576,0.5,0.0,1.0,0.00498523378830915,True,0,2,2,9,3.169925001442312,0.002182853164123874
3349,URP2,Platelet degranulation ,4818.5,0.0035832887592247,0.5,0.0,1.0,0.0019625221649770498,True,0,1,1,6,2.584962500721156,0.00099953312161672
3350,UTS2,Class A/1 (Rhodopsin-like receptors),88.5,0.0023626385584324,0.5,0.0,1.0,0.0012939874094199501,True,0,2,2,8,3.0,0.0005906596396081
3351,UTS2,G alpha (q) signalling events,90.5,0.0023626385584324,0.5,0.0,1.0,0.0012939874094199501,True,0,2,2,8,3.0,0.0005906596396081
3352,Ub-specific processing proteases,Deubiquitination,5568.5,0.0011379840932534,0.5,1.0,2.0,0.014239398132050201,True,11,1,12,16,4.0,0.00022759681865068
3353,Ubiquitin-dependent degradation of Cyclin D,S Phase,5614.5,8.604940953508159e-05,0.5,1.0,2.0,0.00107672137832325,True,9,1,10,14,3.807354922057604,1.7899533304741194e-05
3354,Unfolded Protein Response (UPR),Cellular responses to stress,6352.5,0.0074519494057663,0.5,2.0,3.0,0.14050019484023069,True,3,1,4,12,3.584962500721156,0.0016253021490566615
3355,Uptake and actions of bacterial toxins,Infectious disease,6474.5,0.00013597389136354884,0.5,2.0,3.0,0.0025636725626424,True,1,1,2,7,2.807354922057604,3.571347934383397e-05
3356,Uptake and function of diphtheria toxin,Uptake and actions of bacterial toxins,5506.5,7.171465495445074e-05,0.5,1.0,2.0,0.00089735307360885,True,2,1,3,7,2.807354922057604,1.8835820779139253e-05
3357,Urea cycle,Metabolism of amino acids and derivatives,6606.5,0.0008603739971028001,0.5,2.0,3.0,0.0162216230473715,True,5,2,7,8,3.0,0.00021509349927570002
3358,Urea cycle,Urea cycle,5980.5,0.0018254243307817,0.5,1.0,2.0,0.0228412189239125,False,5,2,7,8,3.0,0.000456356082695425
3359,Utilization of Ketone Bodies,Ketone body metabolism,5640.5,0.0002559534213691,0.5,1.0,2.0,0.0032027008916409,True,1,1,2,6,2.584962500721156,7.13964013061816e-05
3360,VCAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,2872.5,0.0075904319847228,0.5,0.0,1.0,0.00415718408777975,True,0,4,4,12,3.584962500721156,0.0016555057938922994
3361,VCAM1,Integrin cell surface interactions,2874.5,0.0075904319847228,0.5,0.0,1.0,0.00415718408777975,True,0,4,4,12,3.584962500721156,0.0016555057938922994
3362,VCAM1,Interferon gamma signaling,2870.5,0.0075904319847228,0.5,0.0,1.0,0.00415718408777975,True,0,4,4,12,3.584962500721156,0.0016555057938922994
3363,VCAM1,Interleukin-4 and Interleukin-13 signaling,2868.5,0.0075904319847228,0.5,0.0,1.0,0.00415718408777975,True,0,4,4,12,3.584962500721156,0.0016555057938922994
3364,VEGFA-VEGFR2 Pathway,Signaling by VEGF,5298.5,0.0041401501693869,0.5,1.0,2.0,0.05180498298515605,True,4,1,5,9,3.169925001442312,0.0009928596240831398
3365,VINC,Neutrophil degranulation,2854.5,0.0208368997862515,0.5,0.0,1.0,0.011412107822639201,True,0,11,11,26,4.700439718141092,0.0036553144698539845
3366,VINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,2846.5,0.0208368997862515,0.5,0.0,1.0,0.011412107822639201,True,0,11,11,26,4.700439718141092,0.0036553144698539845
3367,VINC,Platelet degranulation ,2850.5,0.0208368997862515,0.5,0.0,1.0,0.011412107822639201,True,0,11,11,26,4.700439718141092,0.0036553144698539845
3368,VINC,RAF/MAP kinase cascade,2836.5,0.0208368997862515,0.5,0.0,1.0,0.011412107822639201,True,0,11,11,26,4.700439718141092,0.0036553144698539845
3369,VINC,Signaling by ALK fusions and activated point mutants,2852.5,0.0208368997862515,0.5,0.0,1.0,0.011412107822639201,True,0,11,11,26,4.700439718141092,0.0036553144698539845
3370,VINC,Signaling by BRAF and RAF1 fusions,2844.5,0.0208368997862515,0.5,0.0,1.0,0.011412107822639201,True,0,11,11,26,4.700439718141092,0.0036553144698539845
3371,VINC,Signaling by RAF1 mutants,2848.5,0.0208368997862515,0.5,0.0,1.0,0.011412107822639201,True,0,11,11,26,4.700439718141092,0.0036553144698539845
3372,VINC,Signaling by RAS mutants,2838.5,0.0208368997862515,0.5,0.0,1.0,0.011412107822639201,True,0,11,11,26,4.700439718141092,0.0036553144698539845
3373,VINC,Signaling by high-kinase activity BRAF mutants,2842.5,0.0208368997862515,0.5,0.0,1.0,0.011412107822639201,True,0,11,11,26,4.700439718141092,0.0036553144698539845
3374,VINC,Signaling by moderate kinase activity BRAF mutants,2840.5,0.0208368997862515,0.5,0.0,1.0,0.011412107822639201,True,0,11,11,26,4.700439718141092,0.0036553144698539845
3375,VINC,Smooth Muscle Contraction,2856.5,0.0208368997862515,0.5,0.0,1.0,0.011412107822639201,True,0,11,11,26,4.700439718141092,0.0036553144698539845
3376,VLDL assembly,Plasma lipoprotein assembly,5666.5,0.0031449409352786,0.5,1.0,2.0,0.03935210197111225,True,3,1,4,8,3.0,0.00078623523381965
3377,VLDL clearance,Plasma lipoprotein clearance,5686.5,0.0029557635678493,0.5,1.0,2.0,0.03698495829277075,True,2,1,3,7,2.807354922057604,0.0007763299267754949
3378,VNN1,Neutrophil degranulation,96.5,0.0010792307777203,0.5,0.0,1.0,0.00059108111701825,True,0,3,3,12,3.584962500721156,0.00023538486466368066
3379,VNN1,Post-translational modification: synthesis of GPI-anchored proteins,98.5,0.0010792307777203,0.5,0.0,1.0,0.00059108111701825,True,0,3,3,12,3.584962500721156,0.00023538486466368066
3380,VNN1,Vitamin B5 (pantothenate) metabolism,94.5,0.0010792307777203,0.5,0.0,1.0,0.00059108111701825,True,0,3,3,12,3.584962500721156,0.00023538486466368066
3381,VTDB,Vitamin D (calciferol) metabolism,1376.5,0.0044100576208131,0.5,0.0,1.0,0.002415333067253,True,0,1,1,6,2.584962500721156,0.0012301544632408196
3382,VTNC,ECM proteoglycans,1446.5,0.0147939134214542,0.5,0.0,1.0,0.0081024402294156,True,0,5,5,13,3.700439718141092,0.003147346697024513
3383,VTNC,Integrin cell surface interactions,1444.5,0.0147939134214542,0.5,0.0,1.0,0.0081024402294156,True,0,5,5,13,3.700439718141092,0.003147346697024513
3384,VTNC,Molecules associated with elastic fibres,1448.5,0.0147939134214542,0.5,0.0,1.0,0.0081024402294156,True,0,5,5,13,3.700439718141092,0.003147346697024513
3385,VTNC,Regulation of Complement cascade,1442.5,0.0147939134214542,0.5,0.0,1.0,0.0081024402294156,True,0,5,5,13,3.700439718141092,0.003147346697024513
3386,VTNC,Syndecan interactions,1450.5,0.0147939134214542,0.5,0.0,1.0,0.0081024402294156,True,0,5,5,13,3.700439718141092,0.003147346697024513
3387,VWF,Defective factor VIII causes hemophilia A,1588.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3388,VWF,GP1b-IX-V activation signalling,1600.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3389,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,1596.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3390,VWF,Integrin cell surface interactions,1594.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3391,VWF,Intrinsic Pathway of Fibrin Clot Formation,1592.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3392,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,1582.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3393,VWF,Platelet Adhesion to exposed collagen,1590.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3394,VWF,Platelet degranulation ,1586.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3395,VWF,RAF/MAP kinase cascade,1572.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3396,VWF,Signaling by BRAF and RAF1 fusions,1580.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3397,VWF,Signaling by RAF1 mutants,1584.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3398,VWF,Signaling by RAS mutants,1574.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3399,VWF,Signaling by high-kinase activity BRAF mutants,1578.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3400,VWF,Signaling by moderate kinase activity BRAF mutants,1576.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3401,VWF,p130Cas linkage to MAPK signaling for integrins,1598.5,0.011245868924233501,0.5,0.0,1.0,0.0061592209032603,True,0,15,15,31,4.954196310386875,0.0018887299541359595
3402,Vesicle-mediated transport,root,6872.5,0.0181619529204613,0.5,4.0,5.0,1.5135971248351956,True,2,1,3,105,6.714245517666122,0.0023543394981232124
3403,Virus Assembly and Release,Influenza Infection,5264.5,0.004526062568042,0.5,1.0,2.0,0.0566338380817469,True,1,1,2,6,2.584962500721156,0.0012625132249309528
3404,Visual phototransduction,Sensory Perception,6642.5,0.0142622082448401,0.5,3.0,4.0,0.4886812015811002,True,2,1,3,18,4.169925001442312,0.0027586876484400084
3405,Vitamin B5 (pantothenate) metabolism,Metabolism of water-soluble vitamins and cofactors,5316.5,0.0008740350488822999,0.5,1.0,2.0,0.0109366493927168,True,1,1,2,6,2.584962500721156,0.000243805911137558
3406,Vitamin C (ascorbate) metabolism,Metabolism of water-soluble vitamins and cofactors,5314.5,0.00030299497527900004,0.5,1.0,2.0,0.0037913237193640003,True,1,1,2,6,2.584962500721156,8.451831092181554e-05
3407,Vitamin D (calciferol) metabolism,Metabolism of steroids,5662.5,0.0035286118306714995,0.5,1.0,2.0,0.044152909525075154,True,1,1,2,6,2.584962500721156,0.0009842813781069338
3408,YAP1- and WWTR1 (TAZ)-stimulated gene expression,Generic Transcription Pathway,5356.5,0.0002251632423731,0.5,1.0,2.0,0.0028174287073631,True,1,1,2,6,2.584962500721156,6.280769807991181e-05
3409,ZA2G,Miscellaneous transport and binding events,2992.5,0.0006992101309394999,0.5,0.0,1.0,0.00038294859056855,True,0,1,1,4,2.0,0.00023307004364649998
3410,ZPI,Post-translational protein phosphorylation,5120.5,0.0128207962617092,0.5,0.0,1.0,0.00702178878871675,True,0,2,2,6,2.584962500721156,0.003576270674834158
3411,ZPI,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),5118.5,0.0128207962617092,0.5,0.0,1.0,0.00702178878871675,True,0,2,2,6,2.584962500721156,0.003576270674834158
3412,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,Fatty acid metabolism,5348.5,0.00016750785823948952,0.5,1.0,2.0,0.0020959968578293,True,1,1,2,6,2.584962500721156,4.6725135397035086e-05
3413,eNOS activation,Metabolism of nitric oxide: NOS3 activation and regulation,6284.5,0.000844751414924,0.5,2.0,3.0,0.01592707249146955,True,2,2,4,5,2.321928094887362,0.00025429551477171373
3414,eNOS activation,eNOS activation,5848.5,0.0009625894314463999,0.5,1.0,2.0,0.01204471506529015,False,2,2,4,5,2.321928094887362,0.0002897682923745039
3415,mRNA Splicing,Processing of Capped Intron-Containing Pre-mRNA,6564.5,0.001018588257369,0.5,2.0,3.0,0.0192046189298583,True,1,1,2,6,2.584962500721156,0.00028412800891616005
3416,mRNA Splicing - Major Pathway,mRNA Splicing,5630.5,0.0015425454228459,0.5,1.0,2.0,0.0193016040759225,True,1,1,2,6,2.584962500721156,0.000430282164049303
3417,mTORC1-mediated signalling,MTOR signalling,6230.5,2.9700758202545263e-05,0.5,2.0,3.0,0.0005599826417408,True,2,2,4,5,2.321928094887362,8.940819112929154e-06
3418,mTORC1-mediated signalling,mTORC1-mediated signalling,5832.5,5.9553169458567144e-05,0.5,1.0,2.0,0.00074517850906115,False,2,2,4,5,2.321928094887362,1.7927290343888807e-05
3419,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,6214.5,0.0006425969828747001,0.5,2.0,3.0,0.012115621883825051,True,10,2,12,13,3.700439718141092,0.00013670997213189053
3420,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,5906.5,0.00036338731549179996,0.5,1.0,2.0,0.00454700262692835,False,10,2,12,13,3.700439718141092,7.730921728223134e-05
3421,p53-Dependent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,5618.5,0.0020434617870019,0.5,1.0,2.0,0.02556948390162645,True,9,1,10,14,3.807354922057604,0.00042506988149052134
3422,p53-Independent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,5620.5,0.0012488455978121,0.5,1.0,2.0,0.0156265889638799,True,9,1,10,14,3.807354922057604,0.0002597781145889639
3423,p75 NTR receptor-mediated signalling,Death Receptor Signalling,6504.5,0.0008725585216316999,0.5,2.0,3.0,0.0164513519380447,True,1,1,2,6,2.584962500721156,0.00024339404427694148
3424,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,6568.5,0.0007381841402614,0.5,2.0,3.0,0.0139178367816688,True,2,2,4,5,2.321928094887362,0.00022221556854210893
3425,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",5858.5,0.0012458689687223,0.5,1.0,2.0,0.01558934291892055,False,2,2,4,5,2.321928094887362,0.00037504393025236275
3426,trans-Golgi Network Vesicle Budding,Membrane Trafficking,6590.5,0.0073607525173335995,0.5,2.0,3.0,0.13878075474530727,True,2,1,3,10,3.321928094887362,0.0017031177649718477
